<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Hormone therapy for preventing cardiovascular disease in post‐menopausal women - Boardman, HMP - 2015 | Cochrane Library</title> <meta content="Hormone therapy for preventing cardiovascular disease in post‐menopausal women - Boardman, HMP - 2015 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002229.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Hormone therapy for preventing cardiovascular disease in post‐menopausal women - Boardman, HMP - 2015 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002229.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD002229.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Hormone therapy for preventing cardiovascular disease in post‐menopausal women" name="citation_title"/> <meta content="Henry MP Boardman" name="citation_author"/> <meta content="University of Oxford, John Radcliffe Hospital" name="citation_author_institution"/> <meta content="Harry.Boardman@cochrane.nhs.uk" name="citation_author_email"/> <meta content="Louise Hartley" name="citation_author"/> <meta content="Warwick Medical School, University of Warwick" name="citation_author_institution"/> <meta content="Anne Eisinga" name="citation_author"/> <meta content="UK Cochrane Centre" name="citation_author_institution"/> <meta content="Caroline Main" name="citation_author"/> <meta content="University of Birmingham" name="citation_author_institution"/> <meta content="Marta Roqué i Figuls" name="citation_author"/> <meta content="CIBER Epidemiología y Salud Pública (CIBERESP)" name="citation_author_institution"/> <meta content="Xavier Bonfill Cosp" name="citation_author"/> <meta content="CIBER Epidemiología y Salud Pública (CIBERESP) ‐ Universitat Autònoma de Barcelona" name="citation_author_institution"/> <meta content="Rafael Gabriel Sanchez" name="citation_author"/> <meta content="Hospital Universitario de la Paz, Universidad Autónoma de Madrid" name="citation_author_institution"/> <meta content="Beatrice Knight" name="citation_author"/> <meta content="University of Exeter Medical School" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="3" name="citation_issue"/> <meta content="10.1002/14651858.CD002229.pub4" name="citation_doi"/> <meta content="2015" name="citation_date"/> <meta content="2015/03/10" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002229.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002229.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002229.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Cardiovascular Diseases [mortality, *prevention &amp; control]; Cause of Death; Estrogen Replacement Therapy [adverse effects, methods]; Hormone Replacement Therapy [adverse effects, *methods]; Postmenopause; Primary Prevention; Secondary Prevention; Stroke [chemically induced]; Venous Thromboembolism [chemically induced]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002229.pub4&amp;doi=10.1002/14651858.CD002229.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002229.pub4&amp;doi=10.1002/14651858.CD002229.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002229.pub4&amp;doi=10.1002/14651858.CD002229.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002229.pub4&amp;doi=10.1002/14651858.CD002229.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002229.pub4&amp;doi=10.1002/14651858.CD002229.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002229.pub4&amp;doi=10.1002/14651858.CD002229.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002229.pub4&amp;doi=10.1002/14651858.CD002229.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002229.pub4&amp;doi=10.1002/14651858.CD002229.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002229.pub4&amp;doi=10.1002/14651858.CD002229.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002229.pub4&amp;doi=10.1002/14651858.CD002229.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002229.pub4&amp;doi=10.1002/14651858.CD002229.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002229.pub4&amp;doi=10.1002/14651858.CD002229.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002229.pub4&amp;doi=10.1002/14651858.CD002229.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002229.pub4&amp;doi=10.1002/14651858.CD002229.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002229.pub4&amp;doi=10.1002/14651858.CD002229.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002229.pub4&amp;doi=10.1002/14651858.CD002229.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002229.pub4&amp;doi=10.1002/14651858.CD002229.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002229.pub4&amp;doi=10.1002/14651858.CD002229.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002229.pub4&amp;doi=10.1002/14651858.CD002229.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002229.pub4&amp;doi=10.1002/14651858.CD002229.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002229.pub4&amp;doi=10.1002/14651858.CD002229.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002229.pub4&amp;doi=10.1002/14651858.CD002229.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002229.pub4&amp;doi=10.1002/14651858.CD002229.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="z6k50IFd";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD002229\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD002229\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002229\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002229\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANT","ru","hr","fr","th","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD002229.pub4",title:"Hormone therapy for preventing cardiovascular disease in post\\u2010menopausal women",firstPublishedDate:"Mar 10, 2015 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Heart Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=z6k50IFd&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002229.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002229.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD002229.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD002229.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002229.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD002229.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD002229.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD002229.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD002229.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD002229.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>16161 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD002229.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002229.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002229.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002229.pub4/full#CD002229-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002229.pub4/full#CD002229-sec-0107"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002229.pub4/full#CD002229-sec-0043"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002229.pub4/full#CD002229-sec-0044"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002229.pub4/full#CD002229-sec-0049"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002229.pub4/full#CD002229-sec-0050"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002229.pub4/full#CD002229-sec-0073"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002229.pub4/full#CD002229-sec-0101"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002229.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002229.pub4/appendices#CD002229-sec-0112"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002229.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002229.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/table_n/CD002229StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/table_n/CD002229StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002229.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002229.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002229.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002229.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002229.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD002229.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2015 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Hormone therapy for preventing cardiovascular disease in post‐menopausal women</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002229.pub4/information#CD002229-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Henry MP Boardman</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002229.pub4/information#CD002229-cr-0003">Louise Hartley</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002229.pub4/information#CD002229-cr-0004">Anne Eisinga</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002229.pub4/information#CD002229-cr-0005">Caroline Main</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002229.pub4/information#CD002229-cr-0006">Marta Roqué i Figuls</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002229.pub4/information#CD002229-cr-0007">Xavier Bonfill Cosp</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002229.pub4/information#CD002229-cr-0008">Rafael Gabriel Sanchez</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002229.pub4/information#CD002229-cr-0009">Beatrice Knight</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/information/en#CD002229-sec-0132">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 10 March 2015 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD002229.pub4">https://doi.org/10.1002/14651858.CD002229.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD002229-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002229-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD002229-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002229-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD002229-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD002229-abs-0010">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD002229-abs-0016">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD002229-abs-0002">繁體中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD002229-abs-0001" lang="en"> <section id="CD002229-sec-0001"> <h3 class="title" id="CD002229-sec-0001">Background</h3> <p>Evidence from systematic reviews of observational studies suggests that hormone therapy may have beneficial effects in reducing the incidence of cardiovascular disease events in post‐menopausal women, however the results of randomised controlled trials (RCTs) have had mixed results. This is an updated version of a Cochrane review published in 2013. </p> </section> <section id="CD002229-sec-0002"> <h3 class="title" id="CD002229-sec-0002">Objectives</h3> <p>To assess the effects of hormone therapy for the prevention of cardiovascular disease in post‐menopausal women, and whether there are differential effects between use in primary or secondary prevention.<br/> <br/> Secondary aims were to undertake exploratory analyses to (i) assess the impact of time since menopause that treatment was commenced (≥ 10 years versus &lt; 10 years), and where these data were not available, use age of trial participants at baseline as a proxy (≥ 60 years of age versus &lt; 60 years of age); and (ii) assess the effects of length of time on treatment. </p> </section> <section id="CD002229-sec-0003"> <h3 class="title" id="CD002229-sec-0003">Search methods</h3> <p>We searched the following databases on 25 February 2014: Cochrane Central Register of Controlled Trials (CENTRAL) in <i>The Cochrane Library</i>, MEDLINE, EMBASE and LILACS. We also searched research and trials registers, and conducted reference checking of relevant studies and related systematic reviews to identify additional studies. </p> </section> <section id="CD002229-sec-0004"> <h3 class="title" id="CD002229-sec-0004">Selection criteria</h3> <p>RCTs of women comparing orally administered hormone therapy with placebo or a no treatment control, with a minimum of six months follow‐up. </p> </section> <section id="CD002229-sec-0005"> <h3 class="title" id="CD002229-sec-0005">Data collection and analysis</h3> <p>Two authors independently assessed study quality and extracted data. We calculated risk ratios (RRs) with 95% confidence intervals (CIs) for each outcome. We combined results using random effects meta‐analyses, and undertook further analyses to assess the effects of treatment as primary or secondary prevention, and whether treatment was commenced more than or less than 10 years after menopause. </p> </section> <section id="CD002229-sec-0006"> <h3 class="title" id="CD002229-sec-0006">Main results</h3> <p>We identified six new trials through this update. Therefore the review includes 19 trials with a total of 40,410 post‐menopausal women. On the whole, study quality was good and generally at low risk of bias; the findings are dominated by the three largest trials. We found high quality evidence that hormone therapy in both primary and secondary prevention conferred no protective effects for all‐cause mortality, cardiovascular death, non‐fatal myocardial infarction, angina, or revascularisation. However, there was an increased risk of stroke in those in the hormone therapy arm for combined primary and secondary prevention (RR 1.24, 95% CI 1.10 to 1.41). Venous thromboembolic events were increased (RR 1.92, 95% CI 1.36 to 2.69), as were pulmonary emboli (RR 1.81, 95% CI 1.32 to 2.48) on hormone therapy relative to placebo. </p> <p>The absolute risk increase for stroke was 6 per 1000 women (number needed to treat for an additional harmful outcome (NNTH) = 165; mean length of follow‐up: 4.21 years (range: 2.0 to 7.1)); for venous thromboembolism 8 per 1000 women (NNTH = 118; mean length of follow‐up: 5.95 years (range: 1.0 to 7.1)); and for pulmonary embolism 4 per 1000 (NNTH = 242; mean length of follow‐up: 3.13 years (range: 1.0 to 7.1)). </p> <p>We performed subgroup analyses according to when treatment was started in relation to the menopause. Those who started hormone therapy less than 10 years after the menopause had lower mortality (RR 0.70, 95% CI 0.52 to 0.95, moderate quality evidence) and coronary heart disease (composite of death from cardiovascular causes and non‐fatal myocardial infarction) (RR 0.52, 95% CI 0.29 to 0.96; moderate quality evidence), though they were still at increased risk of venous thromboembolism (RR 1.74, 95% CI 1.11 to 2.73, high quality evidence) compared to placebo or no treatment. There was no strong evidence of effect on risk of stroke in this group. In those who started treatment more than 10 years after the menopause there was high quality evidence that it had little effect on death or coronary heart disease between groups but there was an increased risk of stroke (RR 1.21, 95% CI 1.06 to 1.38, high quality evidence) and venous thromboembolism (RR 1.96, 95% CI 1.37 to 2.80, high quality evidence). </p> </section> <section id="CD002229-sec-0007"> <h3 class="title" id="CD002229-sec-0007">Authors' conclusions</h3> <p>Our review findings provide strong evidence that treatment with hormone therapy in post‐menopausal women overall, for either primary or secondary prevention of cardiovascular disease events has little if any benefit and causes an increase in the risk of stroke and venous thromboembolic events. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD002229-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002229-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD002229-abs-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD002229-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002229-abs-0015">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD002229-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD002229-abs-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD002229-abs-0007">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD002229-abs-0011">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD002229-abs-0017">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD002229-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD002229-abs-0004" lang="en"> <h3>Hormone therapy for preventing cardiovascular disease in both healthy post‐menopausal women and post‐menopausal women with pre‐existing cardiovascular disease </h3> <p>Hormone therapy is used for controlling menopausal symptoms. It has also been used for the prevention of cardiovascular disease in post‐menopausal women. The present review assessed the effects of using hormone therapy for six months or more. Nineteen randomised controlled trials (involving 40,410 women) compared oral hormone therapy (oestrogen, with or without progestogen) with placebo. Most participants were from the Unites States (US), and the mean age in most studies was over 60 years. The length of time women were on treatment varied across the trials from 7 months to 10.1 years. The studies were generally well conducted with overall low risk of bias.<br/> <br/> Overall, results showed no evidence that hormone therapy provides any protective effects against death from any cause, death specifically from cardiovascular disease, non‐fatal heart attack or angina, either in healthy women or women with pre‐existing heart disease. Rather, in post‐menopausal women hormone therapy increased the risk of stroke and obstruction of a vein by a blood clot (venous thromboembolism). </p> <p>We are confident that the results of are review are close to the true effects for most of the outcomes we looked at. The studies were large, well‐designed and the results were generally consistent across the studies. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD002229-sec-0107" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD002229-sec-0107"></div> <h3 class="title" id="CD002229-sec-0108">Implications for practice</h3> <section id="CD002229-sec-0108"> <p>Our review findings provide strong evidence that treatment with hormone therapy in post‐menopausal women for either primary or secondary prevention of cardiovascular disease events has little if any benefit overall, and causes an increase in the risk of stroke, or venous thromboembolic events. </p> </section> <h3 class="title" id="CD002229-sec-0109">Implications for research</h3> <section id="CD002229-sec-0109"> <p>Currently there is a lack of evidence regarding factors that may modulate the risks involved in hormone therapy treatment, such as different oestrogen and progestogen preparations, different durations, doses and routes of administration (for example, skin patches and creams). There is one recently published study (<a href="./references#CD002229-bbs2-0089" title="NCT00154180 . Kronos Early Estrogen Prevention Study (KEEPS). www.clinicaltrials.gov/ct2/show/NCT00154180 (accessed 15 March 2013). [NCT00154180] NaftolinF . The kronos early estrogen prevention study (KEEPS). Climacteric2011;14:35‐6. NaftolinF , HarmanSM , BlackD , BrintonE , BudoffM , et al. Adverse events during four years of daily oral conjugated estrogen or transdermal estradiol plus cyclic oral progesterone treatment in recently menopausal women: The KRONOS early estrogen prevention study (KEEPS). Menopause2012;19(12):1402‐3. ">NCT00154180</a>) and one ongoing study (<a href="./references#CD002229-bbs2-0090" title="HowardH . The early versus late intervention trial with estradiol (ELITE). Climacteric2011;14:35. NCT00114517 . ELITE: early versus late intervention trial with estradiol. www.clinicaltrials.gov/ct2/show/NCT00114517 (accessed 15 March 2013). [NCT00114517] ">NCT00114517</a>) that assess the timing hypothesis through surrogate endpoints. They should lay the foundation for future research in this area, especially as supportive evidence for the timing hypothesis in this review comes from post‐protocol subgroup analyses. Future updates of this review will look to incorporate their findings fully, but it may be that analysis of data at the level of individual participants from the existing trials is needed to evaluate the credibility of the timing hypothesis on mortality and coronary heart disease. Due to low event rates, definitive studies assessing the timing hypothesis through hard endpoints would likely need a very large study population, estimated at 30,000 with 10 to 15 years follow‐up, and hence be very costly (<a href="./references#CD002229-bbs2-0138" title="RossouwJE , MansonJE , KaunitzAM , AndersonGL . Lessons learned from the Women's Health Initiative trials of menopausal hormone therapy. Obstetrics and Gynecology2013;121:172‐6. ">Rossouw 2013</a>). </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD002229-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD002229-sec-0043"></div> <div class="table" id="CD002229-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Hormone therapy compared to placebo for primary prevention of cardiovascular disease in post‐menopausal women</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Hormone therapy compared to placebo for primary prevention of cardiovascular disease in post‐menopausal women</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Post‐menopausal women without prior cardiovascular disease<br/> <b>Intervention:</b> Hormone therapy<br/> <b>Comparison: P</b>lacebo or no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Hormone therapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Death (all‐causes)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1</b> <br/> (0.89 to 1.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>34,422<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>32 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>32 per 1000</b> <br/> (29 to 36) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Death (cardiovascular causes)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.81</b> <br/> (0.47 to 1.40) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>28,353<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 1000</b> <br/> (4 to 11) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Stroke</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.32</b> <br/> (1.12 to 1.56) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>28,719<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>23 per 1000</b> <br/> (20 to 28) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Venous thromboembolism</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.92</b> <br/> (1.24 to 2.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>33,477<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>20 per 1000</b> <br/> (13 to 31) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Pulmonary embolism</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>31,732<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Risks were calculated from pooled risk differences</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>9 per 1000</b> <br/> (5 to 15) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the median control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to inconsistency. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002229-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Hormone therapy compared to placebo for secondary prevention of cardiovascular disease in post‐menopausal women</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Hormone therapy compared to placebo for secondary prevention of cardiovascular disease in post‐menopausal women </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Post‐menopausal women with pre‐exisiting cardiovascular disease </p> <p><b>Intervention:</b> Hormone therapy </p> <p><b>Comparison:</b> Placebo or no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Hormone therapy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Death (all‐causes)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 1.04</b> </p> <p>(0.87 to 1.24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>5445</p> <p>(7 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>84 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>88 per 1000</b> </p> <p>(73 to 105)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Death (cardiovascular causes)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 1.00</b> </p> <p>(0.78 to 1.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>5259</p> <p>(6 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>45 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>45 per 1000</b> </p> <p>(35 to 58)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Stroke</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 1.09</b> </p> <p>(0.89 to 1.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>5172</p> <p>(5 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>65 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>71 per 1000</b> </p> <p>(58 to 86)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Venous thromboembolism</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 2.02</b> </p> <p>(1.13 to 3.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>4399</p> <p>(6 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>11 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>23 per 1000</b> </p> <p>(13 to 40)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Pulmonary embolism</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 2.48</b> </p> <p>(0.92 to 6.70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>3920</p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>4 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>10 per 1000</b> </p> <p>(4 to 27)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the median control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to imprecision: Confidence interval for the absolute effect includes small decrease and large increased risk. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002229-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Hormone therapy commenced less than 10 years after the menopause for preventing cardiovascular disease in post‐menopausal women</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Hormone therapy commenced less than 10 years after the menopause for preventing cardiovascular disease in post‐menopausal women</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Post‐menopausal women<br/> <b>Intervention:</b> Hormone therapy commenced lessthan 10 years after the menopause </p> <p><b>Comparison</b>: Placebo or no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Hormone therapy commenced <br/> less than 10 years after the menopause</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Death (all‐causes)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.70</b> <br/> (0.52 to 0.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>9088<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>22 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>16 per 1000</b> <br/> (12 to 21) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Coronary heart disease (death from cardiovascular causes and non‐fatal myocardial infarction)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.52</b> <br/> (0.29 to 0.96) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8311<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b> <br/> (5 to 18) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Stroke</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.37</b> <br/> (0.80 to 2.34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8143<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>9 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b> <br/> (7 to 21) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Venous thromboembolism</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.74</b> <br/> (1.11 to 2.73) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>9838<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>11 per 1000</b> <br/> (7 to 17) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the median control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to risk of bias. The results are significant due to the DOPS 2012 trial, that has high risk of bias. We downgraded our confidence in the results of that metanalysis because, had the DOPS not been there, the metanalysis would not be significant.<br/> <sup>2</sup> Composite outcome. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002229-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Hormone therapy commenced more than 10 years after the menopause for preventing cardiovascular disease in post‐menopausal women</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Hormone therapy commenced more than 10 years after the menopause for preventing cardiovascular disease in post‐menopausal women</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Post‐menopausal women </p> <p><b>Intervention:</b> Hormone therapy commenced less than 10 years after the menopause </p> <p><b>Comparison:</b> Placebo or no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Hormone therapy commenced <br/> morethan 10 years after the menopause</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Death (all‐causes)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 1.06</b> </p> <p>(0.95 to 1.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>27,750</p> <p>(12 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>45 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>47 per 1000</b> </p> <p>(42 to 53)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Coronary heart disease (death from cardiovascular causes and non‐fatal myocardial infarction)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 1.07</b> </p> <p>(0.96 to 1.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>23,491</p> <p>(12 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>49 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>52 per 1000</b> </p> <p>(47 to 59)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Stroke</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 1.21</b> </p> <p>(1.06 to 1.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>22,722</p> <p>(8 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>32 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>39 per 1000</b> </p> <p>(34 to 44)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Venous thromboembolism</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 1.96</b> </p> <p>(1.37 to 2.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>27,475</p> <p>(9 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/> <b>high</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>12 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>24 per 1000</b> </p> <p>(16 to 34)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the median control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>We did not downgrade for inconsistency. Although the I square indicated that there was a substantial amount of statistical variation (41%), the direction of effect across the results of the studies was consistent. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD002229-sec-0044" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD002229-sec-0044"></div> <p>Despite falling incidence of coronary heart disease and stroke, which makes up the majority of cardiovascular disease, there is increasing prevalence due to lower case‐fatality. It remains the leading cause of death in both high‐ and middle‐income countries (<a href="./references#CD002229-bbs2-0149" title="World Health Organization. Leading causes of death according to income group. http://who.int/mediacentre/factsheets/fs310/en/index.html (accessed 20 May 2013). ">WHO 2008</a>), and is increasingly the cause in low‐income countries. In 2013, cardiovascular disease caused an estimated 30% of all global deaths, and killed 17.3 million people worldwide (<a href="./references#CD002229-bbs2-0150" title="World Health Organization. Global status report on noncommunicable diseases 2010. www.who.int/nmh/publications/ncd_report2010/en/2011. ">WHO 2011</a>). In the United Kingdom (UK), in 2010, cardiovascular disease caused 32% of deaths, and killed just over 179,000 people. Analysing this data according to gender demonstrates no significant overall difference in numbers between men and women; 31% of women died from cardiovascular disease in 2010 in the UK (<a href="./references#CD002229-bbs2-0093" title="British Heart Foundation Statistics Database 2012. Number dying from CVD and CHD. www.bhf.org.uk/publications/view‐publication.aspx?ps=1002097 (accessed 14 May 2013). ">British Heart Foundation Statistics Database 2012</a>). </p> <p>The burden of coronary heart disease is costly, both in terms of reduced patient health‐related quality of life, and healthcare costs in the management of these conditions. Morbidity statistics indicate that cardiovascular disease is the leading single cause of disability in Europe, with a prevalence of 6.0% to 6.5% in men and 4.0% to 4.5% in women within the UK. Cardiovascular disease is therefore costly in terms of both direct and indirect healthcare costs, accounting for 9.8% of total disability‐adjusted years (<a href="./references#CD002229-bbs2-0144" title="TownsendN , WickramasingheK , BhatnagarP , SmolinaK , NicholsM , LealJ , et al. Coronary Heart Disease Statistics. London: British Heart Foundation, 2012. ">Townsend 2012</a>). In 2009, it was estimated that cardiovascular disease cost the UK healthcare system approximately GBP 8.6 billion, equating to approximately just under GBP 141 per capita. Overall, the cost from cardiovascular disease in the UK is estimated to be GBP 19 billion, the balance attributed to lost productivity and caring for those with cardiovascular disease (<a href="./references#CD002229-bbs2-0093" title="British Heart Foundation Statistics Database 2012. Number dying from CVD and CHD. www.bhf.org.uk/publications/view‐publication.aspx?ps=1002097 (accessed 14 May 2013). ">British Heart Foundation Statistics Database 2012</a>). </p> <section id="CD002229-sec-0045"> <h3 class="title" id="CD002229-sec-0045">Description of the condition</h3> <p>Whilst the overall risk of cardiovascular disease is matched in men and women, this risk varies according to age. The risk is higher in men compared to women in younger age groups, with women’s cardiovascular disease incidence rates found to lag approximately ten years behind those of men. Most women experience the menopause (the last menstrual period) in their early fifties, after a phase of changing ovarian function (the peri‐menopause) that may last several years and which is characterised by irregular menstrual cycles (<a href="./references#CD002229-bbs2-0104" title="GreendaleGA , LeeNP , ArriolaER . The menopause. Lancet1999;353:571–80. ">Greendale 1999</a>). Following menopause and loss of endogenous oestradiol (major ovarian oestrogen), these gender‐based differences narrow (<a href="./references#CD002229-bbs2-0091" title="Barrett‐ConnorE . Sex differences in coronary heart disease. Why are women so superior?. Circulation1997;95:252–64. ">Barrett‐Connor 1997</a>; <a href="./references#CD002229-bbs2-0123" title="MaxwellSR . Women and heart disease. Basic Research in Cardiology1998;934(93 (Suppl 2)):79–84. ">Maxwell 1998</a>). Most women who enter menopause are asymptomatic for cardiovascular disease, and 95% of women who develop cardiovascular disease do so after menopause. Evidence suggests that younger age at natural menopause is associated with cardiovascular disease (<a href="./references#CD002229-bbs2-0111" title="HuFB , GrodsteinF , HennekensCH , ColditzGA , JohnsonM , MansonJE , et al. Age at natural menopause and risk of cardiovascular disease. Archives of Internal Medicine1999;159:1061–6. ">Hu 1999</a>) and cardiovascular disease mortality (<a href="./references#CD002229-bbs2-0112" title="JacobsenBK , NilssenS , HeuchI , KvaleG . Does age at natural menopause affect mortality from ischemic heart disease?. Journal of Clinical Epidemiology1997;50:475–9. ">Jacobsen 1997</a>; <a href="./references#CD002229-bbs2-0145" title="van derSchouwYT , van derGraafGY , SteyerbergEW , EijkemansJD , BangaJD . Age at menopause as a risk factor for cardiovascular mortality. Lancet1996;347:714–8. ">van der Schouw 1996</a>). Post‐menopausal women have 2.6 times the rate of cardiovascular events compared to their age‐matched pre‐menopausal peers (<a href="./references#CD002229-bbs2-0113" title="KannelW , HjortlandM , McNamaraP , GordonT . Menopause and risk of cardiovascular disease: the Framingham study. Annals of Internal Medicine1976;85:447‐52. ">Kannel 1976</a>). There are many possible explanations for this associated increase in risk. The menopause has an adverse effect on lipid profile; low‐density lipoprotein and triglyceride levels rise after the menopause, and high‐density lipoprotein falls (<a href="./references#CD002229-bbs2-0114" title="KilimSR , ChandalaSR . A comparative study of lipid profile and oestradiol in pre‐ and post‐menopausal women. Journal of Clinical and Diagnostic Research2013;7(8):1596‐8. ">Kilim 2013</a>). Weight gain and a change in body fat distribution, increases in blood pressure and a host of other metabolic factors are amongst the other changes seen. The management and prognosis of women with cardiovascular disease is not aided by their being under‐represented in trials (<a href="./references#CD002229-bbs2-0125" title="MelloniC , BergerJ , WangT , GunesF , StebbinsA , PieperK , et al. Representation of women in randomized clinical trials of cardiovascular disease prevention. Circulation2010;3(2):135‐42. ">Melloni 2010</a>) and are more likely to present atypically with lower cardiovascular revascularisation rates (<a href="./references#CD002229-bbs2-0134" title="RathoreS , FoodyJ , RadfordM , KrumholzH . Sex differences in use of coronary revascularization in elderly patients after acute myocardial infarction: a tale of two therapies. Chest2003;124(6):2079‐86. ">Rathore 2003</a>). </p> </section> <section id="CD002229-sec-0046"> <h3 class="title" id="CD002229-sec-0046">Description of the intervention</h3> <p>The term 'hormone replacement therapy' has been replaced by 'hormone therapy', as the older term infers that hormone therapy is replacing the function of a defective organ. Hormone therapy includes either oestrogen alone (oestrogen‐only hormone therapy) or oestrogen in combination with a progestogen (combined hormone therapy). It is used in a variety of formulations and doses which can be taken orally, vaginally, intranasally or as an implant, skin patch, cream or gel. The clinical effects vary according to the type of hormone therapy and the duration of its use. Formulations of oral oestrogen may include oestradiol (an oestrogen derived from wild Mexican yam), oestradiol valerate (a pro‐drug for oestradiol), or conjugated equine oestrogen, a blend of equine oestrogens extracted from horse urine. Historically, larger doses were prescribed but doses have fallen in the past two decades as prescribers aim to minimise side effects associated with larger doses. The progestogens used for hormone therapy include synthetic derivatives of progesterone, synthetic derivatives of testosterone, and natural progesterones derived from plants. These differ in their metabolic action and potential for adverse effects, and the risk‐benefit profile of each type of progestogen for use in hormone therapy is currently unclear. In combined hormone therapy, progestogen can be taken either every day (continuous combined therapy), cyclically with oestrogens taken daily and progestogens taken for part of the month (sequentially combined hormone therapy), or less frequently.<br/> <br/> The addition of a progestogen to oestrogen reduces the risk of endometrial hyperplasia associated with the use of oestrogen alone in women with a uterus (<a href="./references#CD002229-bbs2-0101" title="FurnessS , RobertsH , MarjoribanksJ , LethabyA , HickeyM , FarquharC . Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database of Systematic Reviews2009, Issue 2. [DOI: 10.1002/14651858.CD000402.pub4] ">Furness 2009</a>). However, the addition of progestogens can be problematic as they have adverse effects on blood lipid profiles and may cause symptoms such as headaches, bloating and breast tenderness (<a href="./references#CD002229-bbs2-0124" title="McKinneyKA , ThompsonW . A practical guide to prescribing hormone replacement therapy. Drugs2009;56(1):49‐56. ">McKinney 1998</a>). </p> </section> <section id="CD002229-sec-0047"> <h3 class="title" id="CD002229-sec-0047">How the intervention might work</h3> <p>The finding that cardiovascular disease rates in women rise sharply after the menopause has led to the suggestion that endogenous oestradiol may attenuate age‐related vascular remodelling in pre‐menopausal women. Age‐associated vascular remodelling involves endothelial dysfunction, enhanced growth of intimal smooth muscle cells, and increased prevalence of vascular plaques. The same cellular processes participate in atherosclerosis (<a href="./references#CD002229-bbs2-0116" title="LakattaEG . Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part III. Cellular and molecular clues to heart and arterial aging. Circulation2003;107:490–7. ">Lakatta 2003</a>). The decline in oestradiol levels during menopause leads to a higher androgen‐to‐oestradiol ratio. Androgens induce vasoconstriction and smooth muscle cell growth and exacerbate diet‐induced atherosclerosis, plaque formation, and pro‐atherosclerotic arterial remodelling. This suggests that the increase in the androgen‐to‐oestradiol ratio in post‐menopausal women may be another mechanism which contributes to the observed acceleration of atherosclerosis. The exact mechanism by which cardiovascular disease risk may be reduced by oestrogen is not completely understood, but leading hypotheses involve inhibition of vascular remodelling, lowering cholesterol and improving vascular tone (<a href="./references#CD002229-bbs2-0100" title="DubeyRK , JacksonEK . Estrogen‐induced cardiorenal protection:potential cellular, biochemical, and molecular mechanisms. American Journal of Physiology. Renal Physiology2001;280:365–88. ">Dubey 2001</a>; <a href="./references#CD002229-bbs2-0126" title="MendelsohnME , KarasRH . The protective effects of estrogen on the cardiovascular system. New England Journal of Medicine1999;340:1801–11. ">Mendelsohn 1999</a>; <a href="./references#CD002229-bbs2-0070" title="Barrett‐ConnorE , SloneS , GreendaleG , Kritz‐SilversteinD , EspelandM , JohnsonS , et al. The Postmenopausal Estrogen/Progestin Interventions Study: primary outcomes in adherent women. Maturitas1997;27(3):261‐74. EspelandM , HoganP , FinebergS , HowardG , SchrottH , WaclawiwM , et al. Effect of postmenopausal hormone therapy on glucose and insulin concentrations. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions. Diabetes Care1998;21(10):1589‐95. EspelandM , MarcovinaS , MillerV , WoodP , WasilauskasC , SherwinR , et al. Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions. Circulation1998;97(10):979‐86. JohnsonS , Mebane‐SimsI , HoganP , SoyD . Recruitment of postmenopausal women in the PEPI Trial. Postmenopausal Estrogen/Progestin Interventions. Controlled Clinical Trials1995;16(Suppl 4):S20‐35. SmithN , WileyJ , LegaultC , RiceK , HeckbertS , PsatyB , et al. Effect of progestogen and progestogen type on hemostasis measures in postmenopausal women: the Postmenopausal Estrogen/Progestin Intervention (PEPI) Study. Menopause2008;15(6):1145‐50. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA1995;273(3):199‐208. ">PEPI 1995</a>; <a href="./references#CD002229-bbs2-0147" title="WalshB , SchiffI , RosnerB , GreenbergL , RavnikarV , SacksF . Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. New England Journal of Medicine1991;325:1196‐204. ">Walsh 1991</a>). Other factors that may play a role are changes in coagulation factors, blood pressure, insulin, and body fat distribution (<a href="./references#CD002229-bbs2-0115" title="KohKK , ShinMS , SakumaI , AhnJY , JinDK , KimHS , et al. Effects of conventional or lower doses of hormone replacement therapy in postmenopausal women. Arteriosclerosis, Thrombosis and Vascualr Biology2004;24(8):1516‐21. ">Koh 2004</a>; <a href="./references#CD002229-bbs2-0117" title="LiebermanEH , GerhardMD , UehataA , WalshBW , SelwynAP , GanzP , et al. Estrogen improves endothelium‐dependent, flow mediated vasodilation in postmenopausal women. Annals of Internal Medicine1994;121(12):936‐41. ">Lieberman 1994</a>; <a href="./references#CD002229-bbs2-0070" title="Barrett‐ConnorE , SloneS , GreendaleG , Kritz‐SilversteinD , EspelandM , JohnsonS , et al. The Postmenopausal Estrogen/Progestin Interventions Study: primary outcomes in adherent women. Maturitas1997;27(3):261‐74. EspelandM , HoganP , FinebergS , HowardG , SchrottH , WaclawiwM , et al. Effect of postmenopausal hormone therapy on glucose and insulin concentrations. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions. Diabetes Care1998;21(10):1589‐95. EspelandM , MarcovinaS , MillerV , WoodP , WasilauskasC , SherwinR , et al. Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions. Circulation1998;97(10):979‐86. JohnsonS , Mebane‐SimsI , HoganP , SoyD . Recruitment of postmenopausal women in the PEPI Trial. Postmenopausal Estrogen/Progestin Interventions. Controlled Clinical Trials1995;16(Suppl 4):S20‐35. SmithN , WileyJ , LegaultC , RiceK , HeckbertS , PsatyB , et al. Effect of progestogen and progestogen type on hemostasis measures in postmenopausal women: the Postmenopausal Estrogen/Progestin Intervention (PEPI) Study. Menopause2008;15(6):1145‐50. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA1995;273(3):199‐208. ">PEPI 1995</a>). </p> <p>Hormone therapy to treat menopausal oestrogen deficiency has been in widespread use for more than 60 years (<a href="./references#CD002229-bbs2-0146" title="WallachS , HennemanPH . Prolonged estrogen therapy in postmenopausal women. Journal of the American Medical Association1959;171:1637‐42. ">Wallach 1959</a>). Long‐term treatment was assumed to prevent atherosclerosis, and the increased cardiovascular disease and mortality risk observed following the menopausal transition (<a href="./references#CD002229-bbs2-0136" title="RobinsonRW , HiganoN , CohenWD . Increased incidence of coronary heart disease in women castrated prior to the menopause. Archives of Internal Medicine1959;104:908‐13. ">Robinson 1959</a>; <a href="./references#CD002229-bbs2-0146" title="WallachS , HennemanPH . Prolonged estrogen therapy in postmenopausal women. Journal of the American Medical Association1959;171:1637‐42. ">Wallach 1959</a>; <a href="./references#CD002229-bbs2-0151" title="WilsonRA , BrevettiRE , WilsonTA . Specific procedures for the elimination of the menopause. Western Journal of Surgery, Obstetrics, and Gynecology1963;71:110‐21. ">Wilson 1963</a>), either in the form of primary prevention (prevention of disease before it has first presented) or secondary prevention (preventing the progression or recurrence of disease). Since the early 1980s, several observational studies have consistently shown that hormone therapy users, many of whom started treatment shortly after menopause, had a reduction in total mortality and risk of cardiovascular disease events of approximately 30% to 50% relative to women who did not use hormone therapy (<a href="./references#CD002229-bbs2-0102" title="GradyD , RubinSM , PetittiDB , FoxCS , BlackD , EttingerB , et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Annals of Internal Medicine1992;117(12):1016‐37. ">Grady 1992</a>; <a href="./references#CD002229-bbs2-0105" title="GrodsteinF , StampferMJ , FalkebornM , NaessenT , PerssonI . Postmenopausal hormone therapy and risk of cardiovascular disease and hip fracture in a cohort of Swedish women. Epidemiology1999;10:476‐80. ">Grodstein 1999</a>; <a href="./references#CD002229-bbs2-0106" title="GrodsteinF , MansonJE , ColditzGA , WilletWC , SpeizerFE , StampferMJ . A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Annals of Internal Medicine2000;133:933‐41. ">Grodstein 2000</a>; <a href="./references#CD002229-bbs2-0121" title="MannRD , LisY , ChukwujinduJ , ChanterDO . A study of the association between hormone replacement therapy, smoking and the occurrence of myocardial infarction in women. Journal of Clinical Epidemiology1994;47:307‐12. ">Mann 1994</a>; <a href="./references#CD002229-bbs2-0133" title="PsatyBM , HeckbertSR , AtkinsD , LemaitreR , KoepsellTD , WahlPW , et al. The risk of myocardial infarction associated with the combined use of estrogen and progestins in postmenopausal women. Archives of Internal Medicine1994;154(12):1333‐9. ">Psaty 1994</a>; <a href="./references#CD002229-bbs2-0137" title="RosenbergL , PalmerJR , ShapiroS . A case‐control study of myocardial infarction in relation to use of estrogen supplements. American Journal of Epidemiology1993;137:54‐63. ">Rosenberg 1993</a>; <a href="./references#CD002229-bbs2-0141" title="StampferM , ColditzG . Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Preventive Medicine1991;20:47‐63. ">Stampfer 1991</a>). However, most observational data sets suggest that the risk reduction in mortality and coronary heart disease events, is coupled with a higher impact of the risk of venous thromboembolic events and an apparent increased incidence of stroke, but lower stroke mortality (<a href="./references#CD002229-bbs2-0131" title="Paganini‐HillA . Hormone replacement therapy and stroke: risk protection or no effect?. Maturitas2001;38:243‐61. ">Paganini‐Hill 2001</a>). Overall, the accumulated available epidemiological evidence supported the use of hormone therapy to increase longevity in post‐menopausal women (<a href="./references#CD002229-bbs2-0129" title="MishellDRJr . Estrogen replacement therapy: an overview. American Journal of Obstetrics and Gynecology1989;161(6 Pt 2):1825‐7. ">Mishell 1989</a>). Following these observational studies two large RCTs, the Heart and Estrogen/progestin Replacement Study, assessing secondary prevention (<a href="./references#CD002229-bbs2-0011" title="Bibbins‐DomingoK , LinF , VittinghoffE , Barrett‐ConnorE , HulleyS , GradyD , et al. Effect of hormone therapy on mortality rates among women with heart failure and coronary artery disease. American Journal of Cardiology2005;95(2):289‐91. GiddingsL . Oestrogen plus progestin increased venous thromboembolic disease in postmenopausal women with coronary artery disease. Evidence Based Nursing2000;3(4):123. GradyD , ApplegateW , BushT , FurbergC , RiggsB , HulleyS , et al. Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics. Controlled Clinical Trials1998;19(4):314‐35. GradyD , HerringtonD , BittnerV , DavidsonM , HlatkyM , HsiaJ , et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study Follow‐up (HERS II). JAMA2002;288(1):49‐57. GradyD , WengerN , HerringtonD , KhanS , FurbergC , Hunninghake , et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. Annals of Internal Medicine2000;132:689‐96. HlatkyM , BoothroydD , VittinghoffE , SharpP , WhooleyMA . Quality‐of life and depressive symptoms in postmenopausal women after receiving hormone therapy. Results from the Heart and Estrogen/Progestin Replacement Study (HERS) Trial. JAMA2002;287(5):591‐7. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA1998;280(7):605‐13. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Obstetrical and Gynecological Survey1999;54(1):41‐2. KhanM , HlatkyM , LiuM , LinF , RogersW , ShlipakM . Effect of postmenopausal hormone therapy on coronary heart disease events after percutaneous transluminal coronary angioplasty. The American Journal of Cardiology2003;91(8):989‐91, A7. ShlipakM , SimonJ , VittinghoffE , LinF , Barrett‐ConnorE , KnoppR . Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA2000;283(14):1845‐52. SimonJA , HsiaJ , CauleyJA , RichardsC , HarrisF , FongJ , et al. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen‐progestin Replacement Study (HERS). Circulation2001;103(5):638‐42. SimonJA , LinF , VittinghoffE , BittnerV , Heart and Estrogen‐Progestin Replacement Study (HERS) Research Group. The relation of postmenopausal hormone therapy to serum uric acid and the risk of coronary heart disease events: The heart and estrogen‐progestin replacement study (HERS). Annals of Epidemiology2006;16(2):138‐45. SperoffL . The heart and estrogen/progestin replacement study (HERS). Maturitas1998;31(1):9‐14. ">HERS I 1998</a>) and the Women’s Health Initiative, assessing primary prevention (<a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a>) were carried out and both appeared to contradict the evidence from observational studies. </p> <p>In light of these trials not confirming a cardioprotective effect of oestrogen, attention was focused on the age of the women enrolled in both <a href="./references#CD002229-bbs2-0011" title="Bibbins‐DomingoK , LinF , VittinghoffE , Barrett‐ConnorE , HulleyS , GradyD , et al. Effect of hormone therapy on mortality rates among women with heart failure and coronary artery disease. American Journal of Cardiology2005;95(2):289‐91. GiddingsL . Oestrogen plus progestin increased venous thromboembolic disease in postmenopausal women with coronary artery disease. Evidence Based Nursing2000;3(4):123. GradyD , ApplegateW , BushT , FurbergC , RiggsB , HulleyS , et al. Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics. Controlled Clinical Trials1998;19(4):314‐35. GradyD , HerringtonD , BittnerV , DavidsonM , HlatkyM , HsiaJ , et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study Follow‐up (HERS II). JAMA2002;288(1):49‐57. GradyD , WengerN , HerringtonD , KhanS , FurbergC , Hunninghake , et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. Annals of Internal Medicine2000;132:689‐96. HlatkyM , BoothroydD , VittinghoffE , SharpP , WhooleyMA . Quality‐of life and depressive symptoms in postmenopausal women after receiving hormone therapy. Results from the Heart and Estrogen/Progestin Replacement Study (HERS) Trial. JAMA2002;287(5):591‐7. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA1998;280(7):605‐13. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Obstetrical and Gynecological Survey1999;54(1):41‐2. KhanM , HlatkyM , LiuM , LinF , RogersW , ShlipakM . Effect of postmenopausal hormone therapy on coronary heart disease events after percutaneous transluminal coronary angioplasty. The American Journal of Cardiology2003;91(8):989‐91, A7. ShlipakM , SimonJ , VittinghoffE , LinF , Barrett‐ConnorE , KnoppR . Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA2000;283(14):1845‐52. SimonJA , HsiaJ , CauleyJA , RichardsC , HarrisF , FongJ , et al. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen‐progestin Replacement Study (HERS). Circulation2001;103(5):638‐42. SimonJA , LinF , VittinghoffE , BittnerV , Heart and Estrogen‐Progestin Replacement Study (HERS) Research Group. The relation of postmenopausal hormone therapy to serum uric acid and the risk of coronary heart disease events: The heart and estrogen‐progestin replacement study (HERS). Annals of Epidemiology2006;16(2):138‐45. SperoffL . The heart and estrogen/progestin replacement study (HERS). Maturitas1998;31(1):9‐14. ">HERS I 1998</a> and <a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a> (mean age: 67 and 63 years, respectively), as non‐significant data trends suggested hormone therapy did not lead to excess coronary risk when started shortly after the menopause and interest alighted upon the timing of initiation of hormone therapy in relation to the time of menopause. This ‘timing hypothesis’, first proposed in 2002, states that there may be a window of opportunity where hormone therapy is beneficial for prevention of cardiovascular disease in women when started in early menopause, with this benefit lost in older women. This hypothesis is supported by the Clarkson primate model, where conjugated equine oestrogen prevented atherosclerosis only in animals treated early after surgically induced menopause (within the calculated equivalent of six human post‐menopausal years) before the onset of diet‐induced atherosclerosis (<a href="./references#CD002229-bbs2-0127" title="MikkolaTS , ClarksonTB . Estrogen replacement therapy,atherosclerosis, and vascular function. Cardiovascular Research2002;53:605–19. ">Mikkola 2002</a>). The reasoning behind the ‘timing hypothesis’ is that oestrogen effects differ with the presence and severity of atherosclerosis and that this is linked to the timing of the menopause and age. This may be due to fewer oestrogen receptors in the artery wall (<a href="./references#CD002229-bbs2-0118" title="LosordoDW , KearneyM , KimEA , JekanowskiJ , IsnerJM . Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women. Circulation1994;89:1501‐10. ">Losordo 1994</a>) and reduced vasodilatory effects of oestrogen with progressing atherosclerosis (<a href="./references#CD002229-bbs2-0095" title="CampisiR , NathanL , PampaloniMH , SchöderH , SayreJW , ChaudhuriG , et al. Noninvasive assessment of coronary microcirculatory function in postmenopausal women and effects of short‐term and long‐term estrogen administration. Circulation2002;105(4):425‐30. ">Campisi 2002</a>). When there is minimal or no atherosclerosis, oestrogen leads to reduced platelet and inflammatory activation. It also enables nitric oxide mediated vasodilatation, an important component of healthy endothelial function (<a href="./references#CD002229-bbs2-0126" title="MendelsohnME , KarasRH . The protective effects of estrogen on the cardiovascular system. New England Journal of Medicine1999;340:1801–11. ">Mendelsohn 1999</a>). When there is established atherosclerosis, many of these beneficial physiological changes are attenuated or even reversed, with reduced vasodilatation and increased inflammatory activation (<a href="./references#CD002229-bbs2-0130" title="OuyangP , MichosE , KarasR . Hormone replacement therapy and the cardiovascular system: lessons learned and unanswered questions. Journal of the American College of Cardiology2006;47(9):1741‐53. ">Ouyang 2006</a>). It is also hypothesised that although hormone therapy reduces the risk of plaque formation, it increases plaque instability and the risk of plaque erosion or rupture, through production of matrix metalloproteinases (<a href="./references#CD002229-bbs2-0132" title="PhillipsLS , LangerRD . Postmenopausal hormone therapy: critical reappraisal and a unified hypothesis. Fertility and Sterility2005;83:558‐66. ">Phillips 2005</a>). Therefore, as it is known that cardiovascular risk (including atherosclerosis) increases significantly after the menopause (<a href="./references#CD002229-bbs2-0113" title="KannelW , HjortlandM , McNamaraP , GordonT . Menopause and risk of cardiovascular disease: the Framingham study. Annals of Internal Medicine1976;85:447‐52. ">Kannel 1976</a>) the ‘timing hypothesis’ suggests that if hormone therapy is instigated many years after menopause, it is much more likely that there will be established atherosclerosis, and therefore the benefit of reduced plaque formation will be abrogated by the increased risk of plaque erosion or rupture. In support of the ‘timing hypothesis’, reanalysis of the Nurses’ Health Study (<a href="./references#CD002229-bbs2-0107" title="GrodsteinF , MansonJE , StampferMJ . Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. Journal of Womens Health2006;15(1):35‐44. ">Grodstein 2006</a>) demonstrated a benefit to starting treatment less than four years after the menopause compared to more than 10 years after the menopause. A stratified meta‐analysis by <a href="./references#CD002229-bbs2-0139" title="SalpeterSR , WalshJME , GreyberE , OrmistonTM , SalpeterEE . Mortality associated with hormone replacement therapy in younger and older women. Journal of General Internal Medicine2004;19:791‐804. ">Salpeter 2004</a> also indicated differential treatment effects with hormone therapy relative to placebo, according to the participants' baseline age, favouring use in women under 60 years of age. </p> </section> <section id="CD002229-sec-0048"> <h3 class="title" id="CD002229-sec-0048">Why it is important to do this review</h3> <p>The previous Cochrane Review on hormone therapy for the prevention of cardiovascular disease in post‐menopausal women (<a href="./references#CD002229-bbs2-0120" title="MainC , KnightB , MoxhamT , Gabriel SanchezR , Sanchez GomezLM , Roquéi Figuls M , et al. Hormone therapy for preventing cardiovascular disease in post‐menopausal women. Cochrane Database of Systematic Reviews2013, Issue 11. [DOI: 10.1002/14651858.CD002229.pub3] ">Main 2013</a>) identified a total of 13 RCTs which included 38,171 post‐menopausal women (19,302 randomised to hormone therapy and 18,869 to placebo). The review reported no protective cardiovascular effects for hormone therapy observed in either healthy women or women with one or more pre‐existing cardiovascular disease risk factors, but a higher risk of stroke, venous thromboembolic events and pulmonary embolism was observed. </p> <p>Since the literature search for the previous Cochrane review (<a href="./references#CD002229-bbs2-0120" title="MainC , KnightB , MoxhamT , Gabriel SanchezR , Sanchez GomezLM , Roquéi Figuls M , et al. Hormone therapy for preventing cardiovascular disease in post‐menopausal women. Cochrane Database of Systematic Reviews2013, Issue 11. [DOI: 10.1002/14651858.CD002229.pub3] ">Main 2013</a>), the BMJ (October 2012) reported the results of the cardiovascular outcomes of the Danish Osteoporosis Prevention Study (<a href="./references#CD002229-bbs2-0001" title="BladbjergE , MadsenJ , KristensenS , AbrahamsenB , BrixenK , MosekildeL , et al. Effect of long‐term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. Journal of Thrombosis and Haemostasis2003;1(6):1208‐14. KristensenS , AbrahamsenB , MadsenJ , GramJ , RejnmarkL , RudB , et al. Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: results from the Danish Osteoporosis Prevention Study (DOPS). Thrombosis and Haemostasis2006;95:915‐6. MadsenJ , KristensenS , GramJ , BladbjergE , HenriksenF , ChristensenK , et al. Positive impact of hormone replacement therapy on the fibrinolytic system: a long‐term randomized controlled study in healthy postmenopausal women. Journal of Thrombosis and Haemostasis2003;1(9):1984‐91. SchierbeckL , RejnmarkL , ToftengC , StilgrenL , EikenP , MosekildeL , et al. Hormone replacement treatment in early postmenopausal women reduces cardiovascular events ‐ A randomized controlled study. Circulation2011;124:A11380. SchierbeckLL , RejnmarkL , ToftengCL , StilgrenL , EikenP , MosekildeL , et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ2012;345:e6409. ToftengC , JensenJ , AbrahamsenB , OdumL , BrotC . Two polymorphisms in the vitamin D receptor gene‐association with bone mass and 5‐year change in bone mass with or without hormone‐replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study. Journal of Bone and Mineral Research2002;17(8):1535‐44. deMaatM , MadsenJ , LangdalB , BladbjergE , ToftengC , AbrahamsenL , et al. Genetic variation in estrogen receptor, C‐reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. Thrombosis and Haemostasis2007;97(2):234‐9. ">DOPS 2012</a>). This trial was designed to assess the long‐term impact of hormone therapy on bone mineral density and predefined adverse cardiovascular endpoints in healthy women compared to a no treatment control group. The trial had over 10 years of randomised follow‐up and a further 5.7 years of post‐interventional follow‐up, the longest of any comparable trial. The trial had some noticeable differences to the majority of previous studies that used hormone therapy to prevent cardiovascular disease, other than its long follow‐up; the women included were younger and the hormone preparation was different to that used in the majority of previous trials. The results indicated that women receiving hormone therapy early after menopause had a reduced risk of the composite endpoint of mortality, heart failure or myocardial infarction, without any apparent increase in risk of cancer, venous thromboembolism, or stroke. This led to great media interest and a revival of the debate on whether hormone therapy is safe, when it should be prescribed and in whom it should be prescribed. </p> <p>However, the DOPS trial had many criticisms levelled against it; the low event rate, open‐label design and the higher mean age in the control group. To bring clarity to the subject, we felt it was important to update the review to assess whether this new trial altered the balance of evidence on hormone therapy and its effect on cardiovascular disease. </p> <p>There are also further data not available to the previous review, which reported events by year of treatment and also by participants’ age from trials. Additionally, it has become increasingly clear that the risk from hormone therapy is not constant for the time for which it is taken. Whether women are taking it to treat symptoms or reduce the risk of other diseases, it is important that they are informed regarding the risks as accurately as possible for them as individuals, and this varies according to duration of therapy, their age and when their menopause started. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD002229-sec-0049" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD002229-sec-0049"></div> <p>To assess the effects of hormone therapy for the prevention of cardiovascular disease in post‐menopausal women, and whether there are differential effects between use in primary or secondary prevention.<br/> <br/> Secondary aims were to undertake exploratory analyses to (i) assess the impact of time since menopause that treatment was commenced (≥ 10 years versus &lt; 10 years), and where these data were not available, use age of trial participants at baseline as a proxy (≥ 60 years of age versus &lt; 60 years of age); and (ii) assess the effects of length of time on treatment. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD002229-sec-0050" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD002229-sec-0050"></div> <section id="CD002229-sec-0051"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD002229-sec-0052"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs) comparing oral hormone therapy with either placebo or a no treatment control for a follow‐up duration of six months or longer. We included RCTs which compared two or more different types of oral hormone therapy, provided that they were additionally compared with a placebo or a no treatment control arm. </p> </section> <section id="CD002229-sec-0053"> <h4 class="title">Types of participants</h4> <p>Post‐menopausal women (with either spontaneous or induced cessation of menstrual bleeding for a continuous period of six months or more), either with or without evidence of existing cardiovascular disease.  </p> </section> <section id="CD002229-sec-0054"> <h4 class="title">Types of interventions</h4> <p>Oral hormone therapy, consisting of either oestrogen alone or in combination with a progestogen, compared with either a placebo or a no treatment control. Combined hormone therapy (oestrogen plus progestogen) could be delivered continuously daily (continuous combined hormone therapy) or sequentially (oestrogen taken daily with progestogens taken for part of the month).<br/> <br/> In accordance with the inclusion criteria from the previous review (<a href="./references#CD002229-bbs2-0120" title="MainC , KnightB , MoxhamT , Gabriel SanchezR , Sanchez GomezLM , Roquéi Figuls M , et al. Hormone therapy for preventing cardiovascular disease in post‐menopausal women. Cochrane Database of Systematic Reviews2013, Issue 11. [DOI: 10.1002/14651858.CD002229.pub3] ">Main 2013</a>), we excluded RCTs in which hormone therapy was delivered to the body via either patches, tablets, creams, troches, an intrauterine device, vaginal ring, gels or injections compared with placebo or no treatment. Likewise, we excluded RCTs assessing the effects of selective oestrogen receptor modulators (e.g. raloxifene) compared to placebo or a no treatment control.   </p> </section> <section id="CD002229-sec-0055"> <h4 class="title">Types of outcome measures</h4> <section id="CD002229-sec-0056"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD002229-list-0001"> <li> <p>Death from any cause</p> </li> <li> <p>Cardiovascular death</p> </li> <li> <p>Non‐fatal myocardial infarction</p> </li> <li> <p>Stroke</p> </li> <li> <p>Angina</p> </li> </ul> </p> </section> <section id="CD002229-sec-0057"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD002229-list-0002"> <li> <p>Venous thromboemboli (pulmonary emboli plus deep vein thromboses)</p> </li> <li> <p>Pulmonary emboli</p> </li> <li> <p>Revascularisation (coronary artery bypass grafting and angioplasty (with or without a stent)) </p> </li> </ul> </p> <p>We reviewed trials which were above a given size (based on number of participants and length of follow‐up) to see if relevant outcomes were reported as adverse events. We reviewed trials which included 1000 or more participants (where the participants were followed up for six months or more) and all other trials of comparable or larger size. For example, we reviewed trials which included 500 participants (where the participants were followed up for one year or more). We also included trials with 250 participants or more (where the participants were followed up for two years or more). All the trials which were reviewed due to their size to assess whether they reported relevant outcomes as adverse events are listed in <a href="#CD002229-tbl-0005">Table 1</a>. Outcomes with zero events in one or more arms of a trial were not included from the trial in question. This was done to minimise bias. </p> <div class="table" id="CD002229-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Studies reviewed for relevant adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Population size</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Duration of follow‐up (years)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Included in Review</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Adverse events reported</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Death (all‐ causes)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Death (CV causes)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Non‐fatal MI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Stroke</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Angina</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Revascularisation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VTE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PE</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0025" title="RowanJ , SimonJ , SperoffL , EllmanH . Effects of low‐dose norethindrone acetate plus ethinyl estradiol (0.5 mg/2.5 mug) in women with postmenopausal symptoms: Updated analysis of three randomized, controlled trials. Clinical Therapeutics2006;28(6):921‐32. SperoffL , RowanJ , SymonsJ , GenantH , WilbornW . The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study). A randomized controlled trial. JAMA1996;276(17):1397‐403. ">CHART 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1265</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bone mineral density</p> <p>Serum lipids (LDL, HDL, TG)</p> <p>Endometrial hyperplasia and proliferation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0098" title="deMaatM , MadsenJ , LangdahlB , BladbergE , ToftengC , et al. Genetic variation in estrogen receptor, C‐reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after long term hormone replacement therapy. Thrombosis and Haemostasis2007;97(2):234‐9. ">de Maat 2007</a>² </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>436</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CRP</p> <p>Fibrinogen</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0006" title="NachtigallLE , NachtigallRH , NachtigallRD , BeckmanEM . Estrogen replacement therapy II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstetrics Gynecology1979;54(1):74‐9. ">ERT II 1979</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>168</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0037" title="GenantHK , LucasJ , WeissS , AkinM , EmkeyR , McNaney‐FlintH , et al. Low‐dose esterified estrogen therapy. Archives of Internal Medicine1997;157:2609‐15. ">Genant 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>406</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bone mineral density</p> <p>Serum lipids</p> <p>Endometrial tissue structure</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> <p>(no events in placebo arm)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0009" title="GreenspanSL , ResnickNM , ParkerRA . The effect of hormone replacement on physical performance in community‐dwelling elderly women. The American Journal of Medicine2005;118:1232‐9. ">Greenspan 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>373</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to rise from a chair</p> <p>Timed walking</p> <p>Balance</p> <p>Instrumental Activities of Daily Living<br/> Physical Activity Scale of the Elderly<br/> Folstein Mini‐Mental State Examination<br/> Falls </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0039" title="HartD , FarishE , FletcherC , HowieC , KitchenerH . Ten years post‐menopausal hormone replacement therapy‐effect on lipoproteins. Maturitas1984;5(4):271‐6. ">Hart 1984</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bone mineral density</p> <p>Serum lipids</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0041" title="HeikkinenA , TuppurainenM , NiskanenL , KomulainenM , PenttilaI , SaarikoskiS . Long‐term vitamin D3 supplementation may have adverse effects on serum lipids during postmenopausal hormone replacement therapy. European Journal of Endocrinology1997;137(5):495‐502. ">Heikkinen 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>232</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serum lipids</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0045" title="LindsayR , GallagherJ , KleerekoperM , PickarH . Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA2002;287(20):2668‐76. LoboR , BushT , CarrB , PickarJ . Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertility and Sterility2001;76(1):13‐24. UtianW , ShoupeD , BachmannG , PinkertonJ , PickarJ . Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertility and Sterility2001;75(6):1065‐79. ">HOPE 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2673</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number and severity of hot flushes<br/> Papanicolaou smear with vaginal maturation index </p> <p>Bone mineral density</p> <p>Serum lipids</p> <p>Lipoproteins</p> <p>Glucose tolerance</p> <p>Coagulation/fibrinolytic factors</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0052" title="KimC , MinY , RyuW , KwakJ , RyooU . Effect of hormone replacement therapy on lipoprotein(a) and lipid levels in postmenopausal women: Influence of various progestogens and duration of therapy. Archives of Internal Medicine1996;156(15):1693‐1700. ">Kim 1996</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>551</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serum lipids,</p> <p>Lipoproteins</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0056" title="LeggateJ , FarishE , FletcherC , McIntoshW , HartD , SommervilleJM . Calcitonin and postmenopausal osteoporosis. Clinical Endocrinology1984;20(1):85‐92. ">Leggate 1984</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bone mineral density</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0068" title="BotsM , EvansG , RileyW , McBrideK , PaskettE , HelmondFA , et al. OPAL Investigators. The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on progression of carotid intima‐media thickness: The Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study. European Heart Journal2006;27(6):746‐55. MeijerR , StörkS , EvansGW , GrobbeeDE , BotsML . Striking increases in carotid artery wall thickness in healthy subjects. Cerebrovascular Diseases2010;30(5):448‐55. ">OPAL 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>571</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in carotid intima media thickness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> <p>(no events in one group)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓*</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0070" title="Barrett‐ConnorE , SloneS , GreendaleG , Kritz‐SilversteinD , EspelandM , JohnsonS , et al. The Postmenopausal Estrogen/Progestin Interventions Study: primary outcomes in adherent women. Maturitas1997;27(3):261‐74. EspelandM , HoganP , FinebergS , HowardG , SchrottH , WaclawiwM , et al. Effect of postmenopausal hormone therapy on glucose and insulin concentrations. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions. Diabetes Care1998;21(10):1589‐95. EspelandM , MarcovinaS , MillerV , WoodP , WasilauskasC , SherwinR , et al. Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions. Circulation1998;97(10):979‐86. JohnsonS , Mebane‐SimsI , HoganP , SoyD . Recruitment of postmenopausal women in the PEPI Trial. Postmenopausal Estrogen/Progestin Interventions. Controlled Clinical Trials1995;16(Suppl 4):S20‐35. SmithN , WileyJ , LegaultC , RiceK , HeckbertS , PsatyB , et al. Effect of progestogen and progestogen type on hemostasis measures in postmenopausal women: the Postmenopausal Estrogen/Progestin Intervention (PEPI) Study. Menopause2008;15(6):1145‐50. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA1995;273(3):199‐208. ">PEPI 1995</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>875</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HDL</p> <p>Systolic blood pressure</p> <p>Serum insulin</p> <p>Serum glucose</p> <p>Fibrinogen</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> <p>(no events in some groups)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓*</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0076" title="GallagherJC , LindsayR , PanK , RyanKA , MirkinS , ChinesAA . Bazedoxifene/conjugated estrogens: Effects on bone mineral density and bone turnover markers in a double‐blind, randomised, placebo‐ and active‐controlled phase 3 study. Osteoporosis International2012;23(S2):S63‐S64. MirkinS , ArcherD , LoboR , PanK , ChinesA . Safety and tolerability of bazedoxifene/conjugated estrogens in postmenopausal women: Findings from a 1‐year, randomized, placebo‐ and active‐controlled, phase 3 TRIAL. Maturitas2012;71:S43‐S44. MirkinS , HarveyJ , PinkertonJ , PanK , ThompsonJ , ChinesA . The effects of bazedoxifene/conjugated estrogens on breast density in postmenopausal women. Maturitas2012;71:S44. MirkinS , RyanK , ThompsonJ , ChinesA . Effects of bazedoxifene/conjugated estrogens on coagulation parameters in a 1‐year, randomized, placebo‐and active‐controlled, phase 3 trial of postmenopausal women. Endocrine Reviews2012;33:3 Meeting Abstracts. ">SMART‐5 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>503</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endometrial hyperplasia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> <p>(no events in one group)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓✝</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0079" title="StevensonJ , RiouxJ , KomerL , GelfandM . 1 and 2 mg 17beta‐estradiol combined with sequential dydrogesterone have similar effects on the serum lipid profile of postmenopausal women. Climacteric2005;8(4):352‐9. ">Stevenson 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>579</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serum lipids</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0012" title="GallagherJ , RapuriB , HaynatzkiG , DetterR . Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. The Journal of Clinical Endocrinology and Metabolism2002;87(11):4914‐23. GallagherJC , FowlerSE , DetterJR , ShermanSS . Combination treatment with estrogen and calcitriol in the prevention of age‐related bone loss. The Journal of Clinical Endocrinology and Metabolism2001;86(8):3618‐28. RapuriP , GallagherJ , KnezeticJ , HaynatzkaV . Estrogen receptor alpha gene polymorphisms are associated with changes in bone remodeling markers and treatment response to estrogen. Maturitas2006;53(4):371‐9. SaiA , GallagherJ , FangX . Effect of hormone therapy and calcitriol on serum lipid profile in postmenopausal older women: association with estrogen receptor‐alpha genotypes. Menopause2011;18(10):1101‐12. YalamanchiliV , GallagherJ . Treatment with hormone therapy and calcitriol did not affect depression in older postmenopausal women: no interaction with estrogen and vitamin D receptor genotype polymorphisms. Menopause2012;19(6):697‐703. ">STOP IT 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>369</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bone mineral density</p> <p>Serum 25‐hydroxyvitamin D</p> <p>Serum lipids</p> <p>Depression</p> <p>Calcium absorption</p> <p>Serum PTH</p> <p>Osteocalcin</p> <p>Urinary N ‐telopeptides/creatinine ratio</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0143" title="ToftengC , JensenJ , AbrahamsenB , OdumL , BrotC . Two Polymorphisms in the Vitamin D Receptor Gene—Association With Bone Mass and 5‐Year Change in BoneMass With or Without Hormone‐Replacement Therapy inPostmenopausal Women: The Danish OsteoporosisPrevention Study. Journal of Bone and Mineral Research2002;17(8):1535‐44. ">Tofteng 2002</a>² </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>429</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bone mineral density</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0014" title="HodisHN , MackWJ , AzenSP , LoboRA , ShoupeD , MahrerPR , et al. Hormone therapy and the progression of coronary‐artery atherosclerosis in postmenopausal women. New England Journal of Medicine2003;349(6):535‐45. ">WELL‐HART 2003</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>226</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in coronary stenosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓*</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0018" title="CollinsP , FlatherM , LeesB , MisterR , ProudlerA , StevensonJC , WHISP (Women's Hormone Intervention Secondary Prevention Study) Pilot Study Investigators. Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study. European Heart Journal2006;27(17):2046‐53. ">WHISP 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.58</p> <p>(7 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serum lipids</p> <p>Antithrombin</p> <p>Factor VII</p> <p>Fibrinogen</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓¹</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓¹</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="13" rowspan="1" valign=""> <p>*Part of a composite endpoint.</p> <p>✝In a non‐relevant treatment group (bazedoxifene and oestrogen).</p> <p>¹Not included in analysis as no event in one of the groups.</p> <p>²Sub‐study of <a href="./references#CD002229-bbs2-0001" title="BladbjergE , MadsenJ , KristensenS , AbrahamsenB , BrixenK , MosekildeL , et al. Effect of long‐term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. Journal of Thrombosis and Haemostasis2003;1(6):1208‐14. KristensenS , AbrahamsenB , MadsenJ , GramJ , RejnmarkL , RudB , et al. Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: results from the Danish Osteoporosis Prevention Study (DOPS). Thrombosis and Haemostasis2006;95:915‐6. MadsenJ , KristensenS , GramJ , BladbjergE , HenriksenF , ChristensenK , et al. Positive impact of hormone replacement therapy on the fibrinolytic system: a long‐term randomized controlled study in healthy postmenopausal women. Journal of Thrombosis and Haemostasis2003;1(9):1984‐91. SchierbeckL , RejnmarkL , ToftengC , StilgrenL , EikenP , MosekildeL , et al. Hormone replacement treatment in early postmenopausal women reduces cardiovascular events ‐ A randomized controlled study. Circulation2011;124:A11380. SchierbeckLL , RejnmarkL , ToftengCL , StilgrenL , EikenP , MosekildeL , et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ2012;345:e6409. ToftengC , JensenJ , AbrahamsenB , OdumL , BrotC . Two polymorphisms in the vitamin D receptor gene‐association with bone mass and 5‐year change in bone mass with or without hormone‐replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study. Journal of Bone and Mineral Research2002;17(8):1535‐44. deMaatM , MadsenJ , LangdalB , BladbjergE , ToftengC , AbrahamsenL , et al. Genetic variation in estrogen receptor, C‐reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. Thrombosis and Haemostasis2007;97(2):234‐9. ">DOPS 2012</a> </p> </td> </tr> </tbody> </table> </div> </section> </section> </section> <section id="CD002229-sec-0058"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD002229-sec-0059"> <h4 class="title">Electronic searches</h4> <p>We identified randomised controlled trials (RCTs) that assessed the effects of hormone therapy compared to placebo or no treatment with a minimum of six months duration through searching the following electronic databases on 25 February 2014: </p> <p> <ul id="CD002229-list-0003"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; Issue 1, 2014) in <i>The Cochrane Library</i>, </p> </li> <li> <p>MEDLINE (Ovid; 1946 to week 9 2014),</p> </li> <li> <p>EMBASE (Ovid; 1980 to week 9 2014),</p> </li> <li> <p>LILACS (<a href="http://lilacs.bvsalud.org/en/" target="_blank">http://lilacs.bvsalud.org/en/</a>) (1982 to 25 February 2014). </p> </li> </ul> </p> <p>Additionally, we searched the following trials and research registers for any ongoing trials on cardiovascular disease on 25 February 2014: ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>), the World Health Organization (WHO) International Clinical Trials Registry Platform (<a href="http://www.who.int/ictrp/" target="_blank">www.who.int/ictrp/</a>‎), the UK Clinical Research Network Portfolio Database (<a href="http://public.ukcrn.org.uk" target="_blank">http://public.ukcrn.org.uk</a>) and Centerwatch (<a href="http://www.centerwatch.com" target="_blank">www.centerwatch.com</a>).<br/> <br/> We did not apply any language restrictions. The full search strategies, designed and run in each database, are presented in <a href="./appendices#CD002229-sec-0113">Appendix 1</a> (original review), <a href="./appendices#CD002229-sec-0114">Appendix 2</a> (2010) and <a href="./appendices#CD002229-sec-0119">Appendix 3</a> (2014). </p> </section> <section id="CD002229-sec-0060"> <h4 class="title">Searching other resources</h4> <p>We searched reference lists of all eligible RCTs and relevant systematic reviews for additional trials. </p> </section> </section> <section id="CD002229-sec-0061"> <h3 class="title" id="CD002229-sec-0061">Data collection and analysis</h3> <section id="CD002229-sec-0062"> <h4 class="title">Selection of studies</h4> <p>We identified relevant studies in two stages. Two review authors (HB and LH) independently screened the titles and abstracts returned by the database searches for relevance. The full text of any references that were considered as potentially relevant by either author were obtained. They then independently assessed the relevance of each paper, according to the review's prespecified eligibility criteria. This assessment was performed unblinded. Any discrepancies between the authors were resolved by recourse to the papers, and if necessary, a third author was consulted.  </p> </section> <section id="CD002229-sec-0063"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (HB and LH) independently extracted data from the included studies using a standardised data extraction form in Microsoft Word. The data extraction was checked for agreement and any discrepancies were resolved through recourse to the papers. We assessed the following study details. </p> <section id="CD002229-sec-0064"> <h5 class="title">Trial characteristics</h5> <p> <ol id="CD002229-list-0004"> <li> <p>Method of randomisation</p> </li> <li> <p>Method of allocation concealment</p> </li> <li> <p>Use of stratification</p> </li> <li> <p>Adequacy of double‐blinding</p> </li> <li> <p>Means of recruitment</p> </li> <li> <p>Number of participants screened for eligibility, randomised, analysed, excluded, lost to follow‐up or dropped‐out (i.e. withdrew from the trial but were followed‐up) </p> </li> <li> <p>Baseline equality of treatment groups</p> </li> <li> <p>Level of adherence to therapy</p> </li> <li> <p>Whether analyses were conducted on an intention‐to‐treat basis</p> </li> <li> <p>Study design (parallel versus multi‐arm, single centre or multi‐centre)</p> </li> <li> <p>Funding source</p> </li> </ol> </p> </section> <section id="CD002229-sec-0065"> <h5 class="title">Characteristics of the trial participants</h5> <p> <ol id="CD002229-list-0005"> <li> <p>Inclusion and exclusion criteria</p> </li> <li> <p>Age and other recorded prognostic baseline variables</p> </li> <li> <p>Menopausal status (definition of menopause and how this was defined, surgical or natural menopause) of participants </p> </li> </ol> </p> </section> <section id="CD002229-sec-0066"> <h5 class="title">Interventions</h5> <p> <ol id="CD002229-list-0006"> <li> <p>Type of hormone therapy (oestrogen‐only or combination oestrogen and progestogen)</p> </li> <li> <p>Dosage</p> </li> <li> <p>Duration of therapy (minimum six months)</p> </li> </ol> </p> </section> <section id="CD002229-sec-0067"> <h5 class="title">Outcomes</h5> <p> <ol id="CD002229-list-0007"> <li> <p>Which relevant primary and secondary outcomes were measured</p> </li> <li> <p>How relevant outcomes were defined and measured</p> </li> </ol> </p> <p>See <a href="#CD002229-sec-0074">Description of studies</a>; <a href="#CD002229-sec-0086">Risk of bias in included studies</a>  </p> </section> </section> <section id="CD002229-sec-0068"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed risk of bias according to the risk of bias assessment criteria detailed in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD002229-bbs2-0109" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1. [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). These criteria focus upon the quality of random sequence generation and allocation concealment, blinding (participants, trial personnel and outcome assessors), incomplete outcome data, selective outcome reporting, and other sources of bias. Assessment of risk of bias was undertaken by two review authors (HB and LH) independently, with any disagreements resolved by discussion. </p> </section> <section id="CD002229-sec-0069"> <h4 class="title">Assessment of heterogeneity</h4> <p>We explored heterogeneity between studies qualitatively (by comparing the characteristics of included studies) and quantitatively using the Chi<sup>2</sup> test of heterogeneity and the I<sup>2</sup> statistic. We considered trials with a Chi<sup>2</sup> test resulting in a P value &lt; 0.10 indicative of significant statistical heterogeneity. In order to assess and quantify the possible magnitude of heterogeneity between trials, and the potential impact for undertaking meta‐analyses, we interpreted an I<sup>2</sup> statistic of 0% to 40% as potentially not being important; 30% to 60% as representing moderate heterogeneity; 50% to 90% as representing substantial heterogeneity; and 75% to 100% as being considerably heterogeneous and potentially unsuitable for meta‐analyses (<a href="./references#CD002229-bbs2-0099" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Deeks 2011</a>). Published graphs display the results of analysis using the random‐effects model. We assessed reporting bias through the examination of funnel plots. </p> </section> <section id="CD002229-sec-0070"> <h4 class="title">Data synthesis</h4> <p>We undertook statistical analyses following the guidelines in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD002229-bbs2-0109" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1. [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>).  </p> <p>For dichotomous data, we generated two‐by‐two tables for each study and expressed the data as a risk ratio (RR) with 95% confidence intervals (CIs). We grouped the data according to whether the intervention was primary or secondary prevention. We undertook further analyses to assess the effect of both single and combination therapy in the overall patient population (both primary and secondary prevention) and commencement of treatment according to time since the menopause (&lt; 10 years and ≥ 10 years). Where time since menopause data was not available then mean age of the population at baseline was used (&lt; 60 years old and ≥ 60 years old). We combined data for meta‐analysis in Review Manager software (<a href="./references#CD002229-bbs2-0135" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.4. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>), using the Peto‐modified Mantel‐Haenszel method with a random‐effects model to provide an overall estimate of treatment effect. We chose the random‐effects model due to the wide variety in sample sizes between studies and the heterogeneity found for some outcomes. For comparisons showing statistically significant differences between treatment groups, we calculated the absolute risk reduction and number needed to treat, or absolute risk increase and number needed to harm using the pooled RR data. </p> </section> <section id="CD002229-sec-0071"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>To assess the effect of duration of treatment, we compared data in two different ways. Where data were reported by year of follow‐up, we analysed the data both non‐cumulatively (year‐by‐year), as well as cumulatively, incorporating the remainder of the trials where data were not reported by year of follow‐up, according to the total duration of trial follow‐up. We classified these trials <i>a priori</i> as exploratory given the heterogeneity between the different hormone therapy regimens assessed and the patient populations in the different trials. </p> <p>To assess the timing hypothesis and the potential impact of the time since menopause that treatment was commenced, we stratified trials according to when treatment was started. This was characterised as starting treatment either &lt; 10 or ≥ 10 years after the menopause, or if these data were not available, then we used mean age of participants at baseline (&gt; 60 years of age versus &lt; 60 years of age) as a surrogate. </p> <section id="CD002229-sec-0072"> <h5 class="title">Summary of Findings tables</h5> <p>We used methods developed by the <a href="http://www.gradeworkinggroup.org/" target="_blank">GRADE working group</a> to rate the quality of the evidence for the following outcomes: </p> <p> <ol id="CD002229-list-0008"> <li> <p>Death (all causes)</p> </li> <li> <p>Coronary heart disease</p> </li> <li> <p>Stroke</p> </li> <li> <p>Venous thromboembolism</p> </li> <li> <p>Pulmonary embolism</p> </li> </ol> </p> <p>We have presented the quality ratings in Summary of Findings tables for the comparison of HT and placebo in primary and secondary prevention of cardiovascular disease and for the subgroup analysis addressing the timing hypothesis. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD002229-sec-0073" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD002229-sec-0073"></div> <section id="CD002229-sec-0074"> <h3 class="title">Description of studies</h3> <p>See: <a href="#CD002229-sec-0076">Included studies</a>; <a href="#CD002229-sec-0085">Excluded studies</a>. </p> <section id="CD002229-sec-0075"> <h4 class="title">Results of the search</h4> <p>For this update, we retrieved 3930 records from the database searches and found 33 additional records through other sources, bringing the total results to 3963. Of these, we excluded 3866 records after assessment of titles and abstracts. We considered the full text of 97 references for inclusion. </p> <p>We found six new trials (12 papers) for inclusion and additional 25 papers on ten previously included studies. We excluded 58 papers. One study has completed and is awaiting classification (<a href="./references#CD002229-bbs2-0089" title="NCT00154180 . Kronos Early Estrogen Prevention Study (KEEPS). www.clinicaltrials.gov/ct2/show/NCT00154180 (accessed 15 March 2013). [NCT00154180] NaftolinF . The kronos early estrogen prevention study (KEEPS). Climacteric2011;14:35‐6. NaftolinF , HarmanSM , BlackD , BrintonE , BudoffM , et al. Adverse events during four years of daily oral conjugated estrogen or transdermal estradiol plus cyclic oral progesterone treatment in recently menopausal women: The KRONOS early estrogen prevention study (KEEPS). Menopause2012;19(12):1402‐3. ">NCT00154180</a>) and one study is ongoing (<a href="./references#CD002229-bbs2-0090" title="HowardH . The early versus late intervention trial with estradiol (ELITE). Climacteric2011;14:35. NCT00114517 . ELITE: early versus late intervention trial with estradiol. www.clinicaltrials.gov/ct2/show/NCT00114517 (accessed 15 March 2013). [NCT00114517] ">NCT00114517</a>). The process of study selection for the original review in <a href="#CD002229-fig-0001">Figure 1</a> and for this updated review is presented in <a href="#CD002229-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD002229-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt=": Process of study selection for the review" data-id="CD002229-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><a href="#CD002229-fig-0001">Figure 1</a>: Process of study selection for the review </p> </div> </div> </div> <div class="figure" id="CD002229-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Process of study selection for the updated review" data-id="CD002229-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Process of study selection for the updated review</p> </div> </div> </div> </section> <section id="CD002229-sec-0076"> <h4 class="title">Included studies</h4> <p>In total we identified 19 RCTs with at least six‐months follow‐up that compared hormone therapy to placebo or no treatment published between 1979 and 2012 (<a href="./references#CD002229-bbs2-0001" title="BladbjergE , MadsenJ , KristensenS , AbrahamsenB , BrixenK , MosekildeL , et al. Effect of long‐term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. Journal of Thrombosis and Haemostasis2003;1(6):1208‐14. KristensenS , AbrahamsenB , MadsenJ , GramJ , RejnmarkL , RudB , et al. Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: results from the Danish Osteoporosis Prevention Study (DOPS). Thrombosis and Haemostasis2006;95:915‐6. MadsenJ , KristensenS , GramJ , BladbjergE , HenriksenF , ChristensenK , et al. Positive impact of hormone replacement therapy on the fibrinolytic system: a long‐term randomized controlled study in healthy postmenopausal women. Journal of Thrombosis and Haemostasis2003;1(9):1984‐91. SchierbeckL , RejnmarkL , ToftengC , StilgrenL , EikenP , MosekildeL , et al. Hormone replacement treatment in early postmenopausal women reduces cardiovascular events ‐ A randomized controlled study. Circulation2011;124:A11380. SchierbeckLL , RejnmarkL , ToftengCL , StilgrenL , EikenP , MosekildeL , et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ2012;345:e6409. ToftengC , JensenJ , AbrahamsenB , OdumL , BrotC . Two polymorphisms in the vitamin D receptor gene‐association with bone mass and 5‐year change in bone mass with or without hormone‐replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study. Journal of Bone and Mineral Research2002;17(8):1535‐44. deMaatM , MadsenJ , LangdalB , BladbjergE , ToftengC , AbrahamsenL , et al. Genetic variation in estrogen receptor, C‐reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. Thrombosis and Haemostasis2007;97(2):234‐9. ">DOPS 2012</a>; <a href="./references#CD002229-bbs2-0002" title="Ouyang P , TardifJ , HerringtonD , StewartK , ThompsonP , WalshM , et al. Randomized trial of hormone therapy in women after coronary bypass surgery: Evidence of differential effect of hormone therapy on angiographic progression of disease in saphenous vein grafts and native coronary arteries. Atherosclerosis2006;189(2):375‐86. ">EAGAR 2006</a>; <a href="./references#CD002229-bbs2-0003" title="HodisH , MackW , LoboR , MahrerP , LiuC R , LiuC H . Estrogen replacement therapy effects on the progression of subclinical atherosclerosis are mediated by lipids but not by carbohydrate metabolic factors: results from the Estrogen in the Prevention of Athersclerosis Trial (EPAT). Circulation2002;106(19 Suppl II):II‐744. HodisHN , MackWJ , LoboRA , ShoupeD , SevanianA , MahrerPR , et al. Estrogen in the prevention of atherosclerosis. A randomized, double‐blind, placebo‐controlled trial. Annals of Internal Medicine2001;135(11):939‐53. ">EPAT 2001</a>; <a href="./references#CD002229-bbs2-0004" title="HemminkiE , HoviS , VeerusP , SevónT , TuimalaR , RahuM , et al. Blinding decreased recruitment in a prevention trial of postmenopausal women. Journal of Clinical Epidemiology2004;57:1237‐43. VeerusP , FischerK , HoviS‐L , KarroH , RahuM , HemminkiE . Symptom reporting and quality of life in the Estonian Postmenopausal Hormone Therapy Trial. BMC Women’s Health2008;8:5. VeerusP , HoviS , FischerK , RahuM , HakamaM , HemminkiE . Results for the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]. Maturitas2006;55(2):162‐73. ">EPHT 2006</a>; <a href="./references#CD002229-bbs2-0005" title="HerringtonDM , ReboussinDM , Bridget BrosnihanK , SharpPC , ShumakerSA , SnyderTE , et al. Effects of estrogen replacement on the progression of coronary‐artery atherosclerosis. New England Journal of Medicine2000;343(8):522‐9. HerringtonDM , ReboussinDM , KleinKP , SharpPC , ShumakerSA , SnyderTE , et al. The estrogen replacement and atherosclerosis (ERA) study: study design and baseline characteristics of the cohort. Controlled Clinical Trials2000;21(3):257‐85. NairG , HerringtonD . The ERA trial: findings and implications for the future. Climacteric2000;3:227‐32. ">ERA 2000</a>; <a href="./references#CD002229-bbs2-0006" title="NachtigallLE , NachtigallRH , NachtigallRD , BeckmanEM . Estrogen replacement therapy II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstetrics Gynecology1979;54(1):74‐9. ">ERT II 1979</a>; <a href="./references#CD002229-bbs2-0007" title="The ESPRIT Team. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet2002;360:2001‐8. ">ESPRIT 2002</a>; <a href="./references#CD002229-bbs2-0008" title="HoibraatenE , ArnesenH , LarsenS , WickstromE , SandsetPM . Increased risk of recurrent venous thromboembolism during hormone replacement therapy: results of the randomized, double blind, placebo‐controlled estrogen in venous thromboembolism trial (EVTET). Thrombosis and Haemostasis2000;84:961‐7. Qvigtad , HoibraatenH , ArnesenH , LarsenS , WickstromE , SandsetP . Recurrent venous thromboembolism during hormone replacement therapy ‐ results of the estrogen in venous thromboembolism trial. XVI FIGO World Congress of O and G2000;Abstract book 1:58. ">EVTET 2000</a>; <a href="./references#CD002229-bbs2-0009" title="GreenspanSL , ResnickNM , ParkerRA . The effect of hormone replacement on physical performance in community‐dwelling elderly women. The American Journal of Medicine2005;118:1232‐9. ">Greenspan 2005</a>; <a href="./references#CD002229-bbs2-0010" title="HallG , PrippU , Schenk‐GustafssonK , LandgrenBM . Long‐term effects of hormone replacement therapy on symptoms of angina pectoris, quality of life and compliance in women with coronary artery disease. Maturitas1998 ;28 :235‐42 . ">HALL 1998</a>; <a href="./references#CD002229-bbs2-0011" title="Bibbins‐DomingoK , LinF , VittinghoffE , Barrett‐ConnorE , HulleyS , GradyD , et al. Effect of hormone therapy on mortality rates among women with heart failure and coronary artery disease. American Journal of Cardiology2005;95(2):289‐91. GiddingsL . Oestrogen plus progestin increased venous thromboembolic disease in postmenopausal women with coronary artery disease. Evidence Based Nursing2000;3(4):123. GradyD , ApplegateW , BushT , FurbergC , RiggsB , HulleyS , et al. Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics. Controlled Clinical Trials1998;19(4):314‐35. GradyD , HerringtonD , BittnerV , DavidsonM , HlatkyM , HsiaJ , et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study Follow‐up (HERS II). JAMA2002;288(1):49‐57. GradyD , WengerN , HerringtonD , KhanS , FurbergC , Hunninghake , et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. Annals of Internal Medicine2000;132:689‐96. HlatkyM , BoothroydD , VittinghoffE , SharpP , WhooleyMA . Quality‐of life and depressive symptoms in postmenopausal women after receiving hormone therapy. Results from the Heart and Estrogen/Progestin Replacement Study (HERS) Trial. JAMA2002;287(5):591‐7. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA1998;280(7):605‐13. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Obstetrical and Gynecological Survey1999;54(1):41‐2. KhanM , HlatkyM , LiuM , LinF , RogersW , ShlipakM . Effect of postmenopausal hormone therapy on coronary heart disease events after percutaneous transluminal coronary angioplasty. The American Journal of Cardiology2003;91(8):989‐91, A7. ShlipakM , SimonJ , VittinghoffE , LinF , Barrett‐ConnorE , KnoppR . Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA2000;283(14):1845‐52. SimonJA , HsiaJ , CauleyJA , RichardsC , HarrisF , FongJ , et al. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen‐progestin Replacement Study (HERS). Circulation2001;103(5):638‐42. SimonJA , LinF , VittinghoffE , BittnerV , Heart and Estrogen‐Progestin Replacement Study (HERS) Research Group. The relation of postmenopausal hormone therapy to serum uric acid and the risk of coronary heart disease events: The heart and estrogen‐progestin replacement study (HERS). Annals of Epidemiology2006;16(2):138‐45. SperoffL . The heart and estrogen/progestin replacement study (HERS). Maturitas1998;31(1):9‐14. ">HERS I 1998</a>; <a href="./references#CD002229-bbs2-0012" title="GallagherJ , RapuriB , HaynatzkiG , DetterR . Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. The Journal of Clinical Endocrinology and Metabolism2002;87(11):4914‐23. GallagherJC , FowlerSE , DetterJR , ShermanSS . Combination treatment with estrogen and calcitriol in the prevention of age‐related bone loss. The Journal of Clinical Endocrinology and Metabolism2001;86(8):3618‐28. RapuriP , GallagherJ , KnezeticJ , HaynatzkaV . Estrogen receptor alpha gene polymorphisms are associated with changes in bone remodeling markers and treatment response to estrogen. Maturitas2006;53(4):371‐9. SaiA , GallagherJ , FangX . Effect of hormone therapy and calcitriol on serum lipid profile in postmenopausal older women: association with estrogen receptor‐alpha genotypes. Menopause2011;18(10):1101‐12. YalamanchiliV , GallagherJ . Treatment with hormone therapy and calcitriol did not affect depression in older postmenopausal women: no interaction with estrogen and vitamin D receptor genotype polymorphisms. Menopause2012;19(6):697‐703. ">STOP IT 2001</a>; <a href="./references#CD002229-bbs2-0013" title="HsiaJ , AldermanEL , VerterJI , RogersWJ , ThompsonP , HowardBV , et al. Women’s angiographic vitamin and estrogen trial: design and methods. Controlled Clinical Trials2002;23:708‐27. WatersD , AldermanE , HsiaJ , HowardB , CobbF , RogersW , et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women. JAMA2001;288(19):2432‐40. ">WAVE 2002</a>; <a href="./references#CD002229-bbs2-0014" title="HodisHN , MackWJ , AzenSP , LoboRA , ShoupeD , MahrerPR , et al. Hormone therapy and the progression of coronary‐artery atherosclerosis in postmenopausal women. New England Journal of Medicine2003;349(6):535‐45. ">WELL‐HART 2003</a>; <a href="./references#CD002229-bbs2-0015" title="KernanWN , BrassLM , ViscoliCM , SarrellPM , MakuchR , HorwitzRI . Estrogen after ischemic stroke: clinical basis and design of the Womens Estrogen for Stroke Trial. Journal of Stroke and Cerebrovascular Diseases1998;7(1):85‐95. ViscoliC , BrassL , Kernan , SarrelP , SuissaS , HorwitzR . Estrogen therapy and risk of cognitive decline: Results from the Women's Estrogen for Stroke Trial (WEST). American Journal of Obstetrics and Gynecology2005;192(2):387‐93. ViscoliCM , BrassLM , KernanWN , SarrelPM , SuissaS , HorwitzRI . A clinical trial of estrogen‐replacement therapy after ischemic stroke. New England Journal of Medicine2001;345(17):1243‐9. ">WEST 2001</a>; <a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a>; <a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a>; <a href="./references#CD002229-bbs2-0018" title="CollinsP , FlatherM , LeesB , MisterR , ProudlerA , StevensonJC , WHISP (Women's Hormone Intervention Secondary Prevention Study) Pilot Study Investigators. Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study. European Heart Journal2006;27(17):2046‐53. ">WHISP 2006</a>; <a href="./references#CD002229-bbs2-0019" title="VickersMR , MacLacLennanA , LawtonB , FordD , MartinJ , MeredithS , et al. WISDOM group. Main morbidities recorded in the women's international study of long duration estrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ2007;335(7613):239. VickersMR , MartinJ , MeadeTW , WISDOM study team. The Women’s international study of long‐duration of estrogen after menopause (WISDOM): a randomised controlled trial. BMC Women's Health2007;7:2. WeltonAJ , VickersMR , KimJ , FordD , LawtonBA , MacLennanAH , et al. WISDOM team. Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ2008;337:a1190. ">WISDOM 2007</a>). Thirteen of the identified trials had been included in the previous review. Six new trials were therefore identified for this update (<a href="./references#CD002229-bbs2-0001" title="BladbjergE , MadsenJ , KristensenS , AbrahamsenB , BrixenK , MosekildeL , et al. Effect of long‐term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. Journal of Thrombosis and Haemostasis2003;1(6):1208‐14. KristensenS , AbrahamsenB , MadsenJ , GramJ , RejnmarkL , RudB , et al. Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: results from the Danish Osteoporosis Prevention Study (DOPS). Thrombosis and Haemostasis2006;95:915‐6. MadsenJ , KristensenS , GramJ , BladbjergE , HenriksenF , ChristensenK , et al. Positive impact of hormone replacement therapy on the fibrinolytic system: a long‐term randomized controlled study in healthy postmenopausal women. Journal of Thrombosis and Haemostasis2003;1(9):1984‐91. SchierbeckL , RejnmarkL , ToftengC , StilgrenL , EikenP , MosekildeL , et al. Hormone replacement treatment in early postmenopausal women reduces cardiovascular events ‐ A randomized controlled study. Circulation2011;124:A11380. SchierbeckLL , RejnmarkL , ToftengCL , StilgrenL , EikenP , MosekildeL , et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ2012;345:e6409. ToftengC , JensenJ , AbrahamsenB , OdumL , BrotC . Two polymorphisms in the vitamin D receptor gene‐association with bone mass and 5‐year change in bone mass with or without hormone‐replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study. Journal of Bone and Mineral Research2002;17(8):1535‐44. deMaatM , MadsenJ , LangdalB , BladbjergE , ToftengC , AbrahamsenL , et al. Genetic variation in estrogen receptor, C‐reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. Thrombosis and Haemostasis2007;97(2):234‐9. ">DOPS 2012</a>; <a href="./references#CD002229-bbs2-0006" title="NachtigallLE , NachtigallRH , NachtigallRD , BeckmanEM . Estrogen replacement therapy II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstetrics Gynecology1979;54(1):74‐9. ">ERT II 1979</a>; <a href="./references#CD002229-bbs2-0009" title="GreenspanSL , ResnickNM , ParkerRA . The effect of hormone replacement on physical performance in community‐dwelling elderly women. The American Journal of Medicine2005;118:1232‐9. ">Greenspan 2005</a>; <a href="./references#CD002229-bbs2-0012" title="GallagherJ , RapuriB , HaynatzkiG , DetterR . Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. The Journal of Clinical Endocrinology and Metabolism2002;87(11):4914‐23. GallagherJC , FowlerSE , DetterJR , ShermanSS . Combination treatment with estrogen and calcitriol in the prevention of age‐related bone loss. The Journal of Clinical Endocrinology and Metabolism2001;86(8):3618‐28. RapuriP , GallagherJ , KnezeticJ , HaynatzkaV . Estrogen receptor alpha gene polymorphisms are associated with changes in bone remodeling markers and treatment response to estrogen. Maturitas2006;53(4):371‐9. SaiA , GallagherJ , FangX . Effect of hormone therapy and calcitriol on serum lipid profile in postmenopausal older women: association with estrogen receptor‐alpha genotypes. Menopause2011;18(10):1101‐12. YalamanchiliV , GallagherJ . Treatment with hormone therapy and calcitriol did not affect depression in older postmenopausal women: no interaction with estrogen and vitamin D receptor genotype polymorphisms. Menopause2012;19(6):697‐703. ">STOP IT 2001</a>; <a href="./references#CD002229-bbs2-0014" title="HodisHN , MackWJ , AzenSP , LoboRA , ShoupeD , MahrerPR , et al. Hormone therapy and the progression of coronary‐artery atherosclerosis in postmenopausal women. New England Journal of Medicine2003;349(6):535‐45. ">WELL‐HART 2003</a>; <a href="./references#CD002229-bbs2-0018" title="CollinsP , FlatherM , LeesB , MisterR , ProudlerA , StevensonJC , WHISP (Women's Hormone Intervention Secondary Prevention Study) Pilot Study Investigators. Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study. European Heart Journal2006;27(17):2046‐53. ">WHISP 2006</a>).<br/> <br/> The 19 trials included 40,410 post‐menopausal women; 20,517 randomised to receive some form of hormone therapy and 19,893 to receive either placebo or a no treatment control. <a href="./references#CD002229-bbs2-0012" title="GallagherJ , RapuriB , HaynatzkiG , DetterR . Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. The Journal of Clinical Endocrinology and Metabolism2002;87(11):4914‐23. GallagherJC , FowlerSE , DetterJR , ShermanSS . Combination treatment with estrogen and calcitriol in the prevention of age‐related bone loss. The Journal of Clinical Endocrinology and Metabolism2001;86(8):3618‐28. RapuriP , GallagherJ , KnezeticJ , HaynatzkaV . Estrogen receptor alpha gene polymorphisms are associated with changes in bone remodeling markers and treatment response to estrogen. Maturitas2006;53(4):371‐9. SaiA , GallagherJ , FangX . Effect of hormone therapy and calcitriol on serum lipid profile in postmenopausal older women: association with estrogen receptor‐alpha genotypes. Menopause2011;18(10):1101‐12. YalamanchiliV , GallagherJ . Treatment with hormone therapy and calcitriol did not affect depression in older postmenopausal women: no interaction with estrogen and vitamin D receptor genotype polymorphisms. Menopause2012;19(6):697‐703. ">STOP IT 2001</a> also included a group randomised to calcitriol who were not included in this review. Likewise, <a href="./references#CD002229-bbs2-0019" title="VickersMR , MacLacLennanA , LawtonB , FordD , MartinJ , MeredithS , et al. WISDOM group. Main morbidities recorded in the women's international study of long duration estrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ2007;335(7613):239. VickersMR , MartinJ , MeadeTW , WISDOM study team. The Women’s international study of long‐duration of estrogen after menopause (WISDOM): a randomised controlled trial. BMC Women's Health2007;7:2. WeltonAJ , VickersMR , KimJ , FordD , LawtonBA , MacLennanAH , et al. WISDOM team. Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ2008;337:a1190. ">WISDOM 2007</a> also included a further 1307 women randomised to a comparison of two active hormone therapies, and <a href="./references#CD002229-bbs2-0004" title="HemminkiE , HoviS , VeerusP , SevónT , TuimalaR , RahuM , et al. Blinding decreased recruitment in a prevention trial of postmenopausal women. Journal of Clinical Epidemiology2004;57:1237‐43. VeerusP , FischerK , HoviS‐L , KarroH , RahuM , HemminkiE . Symptom reporting and quality of life in the Estonian Postmenopausal Hormone Therapy Trial. BMC Women’s Health2008;8:5. VeerusP , HoviS , FischerK , RahuM , HakamaM , HemminkiE . Results for the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]. Maturitas2006;55(2):162‐73. ">EPHT 2006</a>, also included 1001 women randomised to either open‐label hormone therapy, or a no treatment control. The data from these further 2306 women randomised into either of these trials (<a href="./references#CD002229-bbs2-0004" title="HemminkiE , HoviS , VeerusP , SevónT , TuimalaR , RahuM , et al. Blinding decreased recruitment in a prevention trial of postmenopausal women. Journal of Clinical Epidemiology2004;57:1237‐43. VeerusP , FischerK , HoviS‐L , KarroH , RahuM , HemminkiE . Symptom reporting and quality of life in the Estonian Postmenopausal Hormone Therapy Trial. BMC Women’s Health2008;8:5. VeerusP , HoviS , FischerK , RahuM , HakamaM , HemminkiE . Results for the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]. Maturitas2006;55(2):162‐73. ">EPHT 2006</a>; <a href="./references#CD002229-bbs2-0019" title="VickersMR , MacLacLennanA , LawtonB , FordD , MartinJ , MeredithS , et al. WISDOM group. Main morbidities recorded in the women's international study of long duration estrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ2007;335(7613):239. VickersMR , MartinJ , MeadeTW , WISDOM study team. The Women’s international study of long‐duration of estrogen after menopause (WISDOM): a randomised controlled trial. BMC Women's Health2007;7:2. WeltonAJ , VickersMR , KimJ , FordD , LawtonBA , MacLennanAH , et al. WISDOM team. Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ2008;337:a1190. ">WISDOM 2007</a>) were not included in this review.<br/> <br/> The trials varied considerably in size, ranging from 40 (<a href="./references#CD002229-bbs2-0010" title="HallG , PrippU , Schenk‐GustafssonK , LandgrenBM . Long‐term effects of hormone replacement therapy on symptoms of angina pectoris, quality of life and compliance in women with coronary artery disease. Maturitas1998 ;28 :235‐42 . ">HALL 1998</a>) to 16,608 (<a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a>). Likewise, there was large variation in the length of follow‐up within the trials ranging from seven months (<a href="./references#CD002229-bbs2-0018" title="CollinsP , FlatherM , LeesB , MisterR , ProudlerA , StevensonJC , WHISP (Women's Hormone Intervention Secondary Prevention Study) Pilot Study Investigators. Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study. European Heart Journal2006;27(17):2046‐53. ">WHISP 2006</a>) to 10.1 years (<a href="./references#CD002229-bbs2-0001" title="BladbjergE , MadsenJ , KristensenS , AbrahamsenB , BrixenK , MosekildeL , et al. Effect of long‐term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. Journal of Thrombosis and Haemostasis2003;1(6):1208‐14. KristensenS , AbrahamsenB , MadsenJ , GramJ , RejnmarkL , RudB , et al. Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: results from the Danish Osteoporosis Prevention Study (DOPS). Thrombosis and Haemostasis2006;95:915‐6. MadsenJ , KristensenS , GramJ , BladbjergE , HenriksenF , ChristensenK , et al. Positive impact of hormone replacement therapy on the fibrinolytic system: a long‐term randomized controlled study in healthy postmenopausal women. Journal of Thrombosis and Haemostasis2003;1(9):1984‐91. SchierbeckL , RejnmarkL , ToftengC , StilgrenL , EikenP , MosekildeL , et al. Hormone replacement treatment in early postmenopausal women reduces cardiovascular events ‐ A randomized controlled study. Circulation2011;124:A11380. SchierbeckLL , RejnmarkL , ToftengCL , StilgrenL , EikenP , MosekildeL , et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ2012;345:e6409. ToftengC , JensenJ , AbrahamsenB , OdumL , BrotC . Two polymorphisms in the vitamin D receptor gene‐association with bone mass and 5‐year change in bone mass with or without hormone‐replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study. Journal of Bone and Mineral Research2002;17(8):1535‐44. deMaatM , MadsenJ , LangdalB , BladbjergE , ToftengC , AbrahamsenL , et al. Genetic variation in estrogen receptor, C‐reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. Thrombosis and Haemostasis2007;97(2):234‐9. ">DOPS 2012</a>). Overall, three large trials (<a href="./references#CD002229-bbs2-0011" title="Bibbins‐DomingoK , LinF , VittinghoffE , Barrett‐ConnorE , HulleyS , GradyD , et al. Effect of hormone therapy on mortality rates among women with heart failure and coronary artery disease. American Journal of Cardiology2005;95(2):289‐91. GiddingsL . Oestrogen plus progestin increased venous thromboembolic disease in postmenopausal women with coronary artery disease. Evidence Based Nursing2000;3(4):123. GradyD , ApplegateW , BushT , FurbergC , RiggsB , HulleyS , et al. Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics. Controlled Clinical Trials1998;19(4):314‐35. GradyD , HerringtonD , BittnerV , DavidsonM , HlatkyM , HsiaJ , et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study Follow‐up (HERS II). JAMA2002;288(1):49‐57. GradyD , WengerN , HerringtonD , KhanS , FurbergC , Hunninghake , et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. Annals of Internal Medicine2000;132:689‐96. HlatkyM , BoothroydD , VittinghoffE , SharpP , WhooleyMA . Quality‐of life and depressive symptoms in postmenopausal women after receiving hormone therapy. Results from the Heart and Estrogen/Progestin Replacement Study (HERS) Trial. JAMA2002;287(5):591‐7. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA1998;280(7):605‐13. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Obstetrical and Gynecological Survey1999;54(1):41‐2. KhanM , HlatkyM , LiuM , LinF , RogersW , ShlipakM . Effect of postmenopausal hormone therapy on coronary heart disease events after percutaneous transluminal coronary angioplasty. The American Journal of Cardiology2003;91(8):989‐91, A7. ShlipakM , SimonJ , VittinghoffE , LinF , Barrett‐ConnorE , KnoppR . Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA2000;283(14):1845‐52. SimonJA , HsiaJ , CauleyJA , RichardsC , HarrisF , FongJ , et al. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen‐progestin Replacement Study (HERS). Circulation2001;103(5):638‐42. SimonJA , LinF , VittinghoffE , BittnerV , Heart and Estrogen‐Progestin Replacement Study (HERS) Research Group. The relation of postmenopausal hormone therapy to serum uric acid and the risk of coronary heart disease events: The heart and estrogen‐progestin replacement study (HERS). Annals of Epidemiology2006;16(2):138‐45. SperoffL . The heart and estrogen/progestin replacement study (HERS). Maturitas1998;31(1):9‐14. ">HERS I 1998</a>; <a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a>; <a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a>) with a mean follow‐up duration of 5.6 years (range: 4.1 to 7.1) randomised 30,110 women to either hormone therapy treatment or placebo, and therefore contributed approximately 75% of the included participants from the 19 trials.<br/> <br/> The majority of the trials (n = 11) had been conducted in the US, two were conducted in more than one country (one in the US and Canada, and one in England, New Zealand and Australia), two trials were conducted in the UK, with one trial conducted in each of the following countries: Norway, Denmark, Sweden, and Estonia.<br/> <br/> Seven trials were stopped early (<a href="./references#CD002229-bbs2-0001" title="BladbjergE , MadsenJ , KristensenS , AbrahamsenB , BrixenK , MosekildeL , et al. Effect of long‐term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. Journal of Thrombosis and Haemostasis2003;1(6):1208‐14. KristensenS , AbrahamsenB , MadsenJ , GramJ , RejnmarkL , RudB , et al. Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: results from the Danish Osteoporosis Prevention Study (DOPS). Thrombosis and Haemostasis2006;95:915‐6. MadsenJ , KristensenS , GramJ , BladbjergE , HenriksenF , ChristensenK , et al. Positive impact of hormone replacement therapy on the fibrinolytic system: a long‐term randomized controlled study in healthy postmenopausal women. Journal of Thrombosis and Haemostasis2003;1(9):1984‐91. SchierbeckL , RejnmarkL , ToftengC , StilgrenL , EikenP , MosekildeL , et al. Hormone replacement treatment in early postmenopausal women reduces cardiovascular events ‐ A randomized controlled study. Circulation2011;124:A11380. SchierbeckLL , RejnmarkL , ToftengCL , StilgrenL , EikenP , MosekildeL , et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ2012;345:e6409. ToftengC , JensenJ , AbrahamsenB , OdumL , BrotC . Two polymorphisms in the vitamin D receptor gene‐association with bone mass and 5‐year change in bone mass with or without hormone‐replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study. Journal of Bone and Mineral Research2002;17(8):1535‐44. deMaatM , MadsenJ , LangdalB , BladbjergE , ToftengC , AbrahamsenL , et al. Genetic variation in estrogen receptor, C‐reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. Thrombosis and Haemostasis2007;97(2):234‐9. ">DOPS 2012</a>; <a href="./references#CD002229-bbs2-0002" title="Ouyang P , TardifJ , HerringtonD , StewartK , ThompsonP , WalshM , et al. Randomized trial of hormone therapy in women after coronary bypass surgery: Evidence of differential effect of hormone therapy on angiographic progression of disease in saphenous vein grafts and native coronary arteries. Atherosclerosis2006;189(2):375‐86. ">EAGAR 2006</a>; <a href="./references#CD002229-bbs2-0004" title="HemminkiE , HoviS , VeerusP , SevónT , TuimalaR , RahuM , et al. Blinding decreased recruitment in a prevention trial of postmenopausal women. Journal of Clinical Epidemiology2004;57:1237‐43. VeerusP , FischerK , HoviS‐L , KarroH , RahuM , HemminkiE . Symptom reporting and quality of life in the Estonian Postmenopausal Hormone Therapy Trial. BMC Women’s Health2008;8:5. VeerusP , HoviS , FischerK , RahuM , HakamaM , HemminkiE . Results for the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]. Maturitas2006;55(2):162‐73. ">EPHT 2006</a>; <a href="./references#CD002229-bbs2-0008" title="HoibraatenE , ArnesenH , LarsenS , WickstromE , SandsetPM . Increased risk of recurrent venous thromboembolism during hormone replacement therapy: results of the randomized, double blind, placebo‐controlled estrogen in venous thromboembolism trial (EVTET). Thrombosis and Haemostasis2000;84:961‐7. Qvigtad , HoibraatenH , ArnesenH , LarsenS , WickstromE , SandsetP . Recurrent venous thromboembolism during hormone replacement therapy ‐ results of the estrogen in venous thromboembolism trial. XVI FIGO World Congress of O and G2000;Abstract book 1:58. ">EVTET 2000</a>; <a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a>; <a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a>; <a href="./references#CD002229-bbs2-0019" title="VickersMR , MacLacLennanA , LawtonB , FordD , MartinJ , MeredithS , et al. WISDOM group. Main morbidities recorded in the women's international study of long duration estrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ2007;335(7613):239. VickersMR , MartinJ , MeadeTW , WISDOM study team. The Women’s international study of long‐duration of estrogen after menopause (WISDOM): a randomised controlled trial. BMC Women's Health2007;7:2. WeltonAJ , VickersMR , KimJ , FordD , LawtonBA , MacLennanAH , et al. WISDOM team. Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ2008;337:a1190. ">WISDOM 2007</a>); either as other trial results were published showing no beneficial effect, or a detrimental effect of hormone therapy on cardiovascular disease outcomes (<a href="./references#CD002229-bbs2-0001" title="BladbjergE , MadsenJ , KristensenS , AbrahamsenB , BrixenK , MosekildeL , et al. Effect of long‐term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. Journal of Thrombosis and Haemostasis2003;1(6):1208‐14. KristensenS , AbrahamsenB , MadsenJ , GramJ , RejnmarkL , RudB , et al. Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: results from the Danish Osteoporosis Prevention Study (DOPS). Thrombosis and Haemostasis2006;95:915‐6. MadsenJ , KristensenS , GramJ , BladbjergE , HenriksenF , ChristensenK , et al. Positive impact of hormone replacement therapy on the fibrinolytic system: a long‐term randomized controlled study in healthy postmenopausal women. Journal of Thrombosis and Haemostasis2003;1(9):1984‐91. SchierbeckL , RejnmarkL , ToftengC , StilgrenL , EikenP , MosekildeL , et al. Hormone replacement treatment in early postmenopausal women reduces cardiovascular events ‐ A randomized controlled study. Circulation2011;124:A11380. SchierbeckLL , RejnmarkL , ToftengCL , StilgrenL , EikenP , MosekildeL , et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ2012;345:e6409. ToftengC , JensenJ , AbrahamsenB , OdumL , BrotC . Two polymorphisms in the vitamin D receptor gene‐association with bone mass and 5‐year change in bone mass with or without hormone‐replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study. Journal of Bone and Mineral Research2002;17(8):1535‐44. deMaatM , MadsenJ , LangdalB , BladbjergE , ToftengC , AbrahamsenL , et al. Genetic variation in estrogen receptor, C‐reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. Thrombosis and Haemostasis2007;97(2):234‐9. ">DOPS 2012</a>; <a href="./references#CD002229-bbs2-0002" title="Ouyang P , TardifJ , HerringtonD , StewartK , ThompsonP , WalshM , et al. Randomized trial of hormone therapy in women after coronary bypass surgery: Evidence of differential effect of hormone therapy on angiographic progression of disease in saphenous vein grafts and native coronary arteries. Atherosclerosis2006;189(2):375‐86. ">EAGAR 2006</a>; <a href="./references#CD002229-bbs2-0004" title="HemminkiE , HoviS , VeerusP , SevónT , TuimalaR , RahuM , et al. Blinding decreased recruitment in a prevention trial of postmenopausal women. Journal of Clinical Epidemiology2004;57:1237‐43. VeerusP , FischerK , HoviS‐L , KarroH , RahuM , HemminkiE . Symptom reporting and quality of life in the Estonian Postmenopausal Hormone Therapy Trial. BMC Women’s Health2008;8:5. VeerusP , HoviS , FischerK , RahuM , HakamaM , HemminkiE . Results for the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]. Maturitas2006;55(2):162‐73. ">EPHT 2006</a>; <a href="./references#CD002229-bbs2-0008" title="HoibraatenE , ArnesenH , LarsenS , WickstromE , SandsetPM . Increased risk of recurrent venous thromboembolism during hormone replacement therapy: results of the randomized, double blind, placebo‐controlled estrogen in venous thromboembolism trial (EVTET). Thrombosis and Haemostasis2000;84:961‐7. Qvigtad , HoibraatenH , ArnesenH , LarsenS , WickstromE , SandsetP . Recurrent venous thromboembolism during hormone replacement therapy ‐ results of the estrogen in venous thromboembolism trial. XVI FIGO World Congress of O and G2000;Abstract book 1:58. ">EVTET 2000</a>; <a href="./references#CD002229-bbs2-0019" title="VickersMR , MacLacLennanA , LawtonB , FordD , MartinJ , MeredithS , et al. WISDOM group. Main morbidities recorded in the women's international study of long duration estrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ2007;335(7613):239. VickersMR , MartinJ , MeadeTW , WISDOM study team. The Women’s international study of long‐duration of estrogen after menopause (WISDOM): a randomised controlled trial. BMC Women's Health2007;7:2. WeltonAJ , VickersMR , KimJ , FordD , LawtonBA , MacLennanAH , et al. WISDOM team. Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ2008;337:a1190. ">WISDOM 2007</a>), or due to it being established that the overall risks (adverse events) associated with hormone therapy use were unlikely to be outweighed by any potential benefits of hormone therapy use on cardiovascular disease outcomes within the time frame of the trial (<a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a>; <a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a>).<br/> <br/> A summary of the main characteristics of the included trials is displayed in <a href="#CD002229-tbl-0006">Table 2</a>. </p> <div class="table" id="CD002229-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary of trial characteristics</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Trial (year)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Country</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Length of follow‐up (years)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> No. participants</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Mean age of participants (years)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> % hysterectomy</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Primary or secondary prevention</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> HT type</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Participant previous indication</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0001" title="BladbjergE , MadsenJ , KristensenS , AbrahamsenB , BrixenK , MosekildeL , et al. Effect of long‐term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. Journal of Thrombosis and Haemostasis2003;1(6):1208‐14. KristensenS , AbrahamsenB , MadsenJ , GramJ , RejnmarkL , RudB , et al. Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: results from the Danish Osteoporosis Prevention Study (DOPS). Thrombosis and Haemostasis2006;95:915‐6. MadsenJ , KristensenS , GramJ , BladbjergE , HenriksenF , ChristensenK , et al. Positive impact of hormone replacement therapy on the fibrinolytic system: a long‐term randomized controlled study in healthy postmenopausal women. Journal of Thrombosis and Haemostasis2003;1(9):1984‐91. SchierbeckL , RejnmarkL , ToftengC , StilgrenL , EikenP , MosekildeL , et al. Hormone replacement treatment in early postmenopausal women reduces cardiovascular events ‐ A randomized controlled study. Circulation2011;124:A11380. SchierbeckLL , RejnmarkL , ToftengCL , StilgrenL , EikenP , MosekildeL , et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ2012;345:e6409. ToftengC , JensenJ , AbrahamsenB , OdumL , BrotC . Two polymorphisms in the vitamin D receptor gene‐association with bone mass and 5‐year change in bone mass with or without hormone‐replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study. Journal of Bone and Mineral Research2002;17(8):1535‐44. deMaatM , MadsenJ , LangdalB , BladbjergE , ToftengC , AbrahamsenL , et al. Genetic variation in estrogen receptor, C‐reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. Thrombosis and Haemostasis2007;97(2):234‐9. ">DOPS 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Denmark</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1006</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single and combination</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0002" title="Ouyang P , TardifJ , HerringtonD , StewartK , ThompsonP , WalshM , et al. Randomized trial of hormone therapy in women after coronary bypass surgery: Evidence of differential effect of hormone therapy on angiographic progression of disease in saphenous vein grafts and native coronary arteries. Atherosclerosis2006;189(2):375‐86. ">EAGAR 2006</a><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CAGB</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0003" title="HodisH , MackW , LoboR , MahrerP , LiuC R , LiuC H . Estrogen replacement therapy effects on the progression of subclinical atherosclerosis are mediated by lipids but not by carbohydrate metabolic factors: results from the Estrogen in the Prevention of Athersclerosis Trial (EPAT). Circulation2002;106(19 Suppl II):II‐744. HodisHN , MackWJ , LoboRA , ShoupeD , SevanianA , MahrerPR , et al. Estrogen in the prevention of atherosclerosis. A randomized, double‐blind, placebo‐controlled trial. Annals of Internal Medicine2001;135(11):939‐53. ">EPAT 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>222</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0004" title="HemminkiE , HoviS , VeerusP , SevónT , TuimalaR , RahuM , et al. Blinding decreased recruitment in a prevention trial of postmenopausal women. Journal of Clinical Epidemiology2004;57:1237‐43. VeerusP , FischerK , HoviS‐L , KarroH , RahuM , HemminkiE . Symptom reporting and quality of life in the Estonian Postmenopausal Hormone Therapy Trial. BMC Women’s Health2008;8:5. VeerusP , HoviS , FischerK , RahuM , HakamaM , HemminkiE . Results for the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]. Maturitas2006;55(2):162‐73. ">EPHT 2006</a><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Estonia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>777</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combination</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0005" title="HerringtonDM , ReboussinDM , Bridget BrosnihanK , SharpPC , ShumakerSA , SnyderTE , et al. Effects of estrogen replacement on the progression of coronary‐artery atherosclerosis. New England Journal of Medicine2000;343(8):522‐9. HerringtonDM , ReboussinDM , KleinKP , SharpPC , ShumakerSA , SnyderTE , et al. The estrogen replacement and atherosclerosis (ERA) study: study design and baseline characteristics of the cohort. Controlled Clinical Trials2000;21(3):257‐85. NairG , HerringtonD . The ERA trial: findings and implications for the future. Climacteric2000;3:227‐32. ">ERA 2000</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>310</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single and combination</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CHD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0006" title="NachtigallLE , NachtigallRH , NachtigallRD , BeckmanEM . Estrogen replacement therapy II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstetrics Gynecology1979;54(1):74‐9. ">ERT II 1979</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>168</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combination</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0007" title="The ESPRIT Team. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet2002;360:2001‐8. ">ESPRIT 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 .0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MI or TIA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0008" title="HoibraatenE , ArnesenH , LarsenS , WickstromE , SandsetPM . Increased risk of recurrent venous thromboembolism during hormone replacement therapy: results of the randomized, double blind, placebo‐controlled estrogen in venous thromboembolism trial (EVTET). Thrombosis and Haemostasis2000;84:961‐7. Qvigtad , HoibraatenH , ArnesenH , LarsenS , WickstromE , SandsetP . Recurrent venous thromboembolism during hormone replacement therapy ‐ results of the estrogen in venous thromboembolism trial. XVI FIGO World Congress of O and G2000;Abstract book 1:58. ">EVTET 2000</a><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Norway</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>140</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combination</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DVT or PE</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0012" title="GallagherJ , RapuriB , HaynatzkiG , DetterR . Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. The Journal of Clinical Endocrinology and Metabolism2002;87(11):4914‐23. GallagherJC , FowlerSE , DetterJR , ShermanSS . Combination treatment with estrogen and calcitriol in the prevention of age‐related bone loss. The Journal of Clinical Endocrinology and Metabolism2001;86(8):3618‐28. RapuriP , GallagherJ , KnezeticJ , HaynatzkaV . Estrogen receptor alpha gene polymorphisms are associated with changes in bone remodeling markers and treatment response to estrogen. Maturitas2006;53(4):371‐9. SaiA , GallagherJ , FangX . Effect of hormone therapy and calcitriol on serum lipid profile in postmenopausal older women: association with estrogen receptor‐alpha genotypes. Menopause2011;18(10):1101‐12. YalamanchiliV , GallagherJ . Treatment with hormone therapy and calcitriol did not affect depression in older postmenopausal women: no interaction with estrogen and vitamin D receptor genotype polymorphisms. Menopause2012;19(6):697‐703. ">STOP IT 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>366</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single and combination</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0009" title="GreenspanSL , ResnickNM , ParkerRA . The effect of hormone replacement on physical performance in community‐dwelling elderly women. The American Journal of Medicine2005;118:1232‐9. ">Greenspan 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>373</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single and combination</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0010" title="HallG , PrippU , Schenk‐GustafssonK , LandgrenBM . Long‐term effects of hormone replacement therapy on symptoms of angina pectoris, quality of life and compliance in women with coronary artery disease. Maturitas1998 ;28 :235‐42 . ">HALL 1998</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sweden</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combination</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CHD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0011" title="Bibbins‐DomingoK , LinF , VittinghoffE , Barrett‐ConnorE , HulleyS , GradyD , et al. Effect of hormone therapy on mortality rates among women with heart failure and coronary artery disease. American Journal of Cardiology2005;95(2):289‐91. GiddingsL . Oestrogen plus progestin increased venous thromboembolic disease in postmenopausal women with coronary artery disease. Evidence Based Nursing2000;3(4):123. GradyD , ApplegateW , BushT , FurbergC , RiggsB , HulleyS , et al. Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics. Controlled Clinical Trials1998;19(4):314‐35. GradyD , HerringtonD , BittnerV , DavidsonM , HlatkyM , HsiaJ , et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study Follow‐up (HERS II). JAMA2002;288(1):49‐57. GradyD , WengerN , HerringtonD , KhanS , FurbergC , Hunninghake , et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. Annals of Internal Medicine2000;132:689‐96. HlatkyM , BoothroydD , VittinghoffE , SharpP , WhooleyMA . Quality‐of life and depressive symptoms in postmenopausal women after receiving hormone therapy. Results from the Heart and Estrogen/Progestin Replacement Study (HERS) Trial. JAMA2002;287(5):591‐7. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA1998;280(7):605‐13. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Obstetrical and Gynecological Survey1999;54(1):41‐2. KhanM , HlatkyM , LiuM , LinF , RogersW , ShlipakM . Effect of postmenopausal hormone therapy on coronary heart disease events after percutaneous transluminal coronary angioplasty. The American Journal of Cardiology2003;91(8):989‐91, A7. ShlipakM , SimonJ , VittinghoffE , LinF , Barrett‐ConnorE , KnoppR . Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA2000;283(14):1845‐52. SimonJA , HsiaJ , CauleyJA , RichardsC , HarrisF , FongJ , et al. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen‐progestin Replacement Study (HERS). Circulation2001;103(5):638‐42. SimonJA , LinF , VittinghoffE , BittnerV , Heart and Estrogen‐Progestin Replacement Study (HERS) Research Group. The relation of postmenopausal hormone therapy to serum uric acid and the risk of coronary heart disease events: The heart and estrogen‐progestin replacement study (HERS). Annals of Epidemiology2006;16(2):138‐45. SperoffL . The heart and estrogen/progestin replacement study (HERS). Maturitas1998;31(1):9‐14. ">HERS I 1998</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2763</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combination</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CHD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0013" title="HsiaJ , AldermanEL , VerterJI , RogersWJ , ThompsonP , HowardBV , et al. Women’s angiographic vitamin and estrogen trial: design and methods. Controlled Clinical Trials2002;23:708‐27. WatersD , AldermanE , HsiaJ , HowardB , CobbF , RogersW , et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women. JAMA2001;288(19):2432‐40. ">WAVE 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>International</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>423</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combination</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CHD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0014" title="HodisHN , MackWJ , AzenSP , LoboRA , ShoupeD , MahrerPR , et al. Hormone therapy and the progression of coronary‐artery atherosclerosis in postmenopausal women. New England Journal of Medicine2003;349(6):535‐45. ">WELL‐HART 2003</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>226</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single and combination</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CHD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0015" title="KernanWN , BrassLM , ViscoliCM , SarrellPM , MakuchR , HorwitzRI . Estrogen after ischemic stroke: clinical basis and design of the Womens Estrogen for Stroke Trial. Journal of Stroke and Cerebrovascular Diseases1998;7(1):85‐95. ViscoliC , BrassL , Kernan , SarrelP , SuissaS , HorwitzR . Estrogen therapy and risk of cognitive decline: Results from the Women's Estrogen for Stroke Trial (WEST). American Journal of Obstetrics and Gynecology2005;192(2):387‐93. ViscoliCM , BrassLM , KernanWN , SarrelPM , SuissaS , HorwitzRI . A clinical trial of estrogen‐replacement therapy after ischemic stroke. New England Journal of Medicine2001;345(17):1243‐9. ">WEST 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>664</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MI or TIA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16,608</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combination</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10,739</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0018" title="CollinsP , FlatherM , LeesB , MisterR , ProudlerA , StevensonJC , WHISP (Women's Hormone Intervention Secondary Prevention Study) Pilot Study Investigators. Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study. European Heart Journal2006;27(17):2046‐53. ">WHISP 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.58 (7 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combination</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ACS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0019" title="VickersMR , MacLacLennanA , LawtonB , FordD , MartinJ , MeredithS , et al. WISDOM group. Main morbidities recorded in the women's international study of long duration estrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ2007;335(7613):239. VickersMR , MartinJ , MeadeTW , WISDOM study team. The Women’s international study of long‐duration of estrogen after menopause (WISDOM): a randomised controlled trial. BMC Women's Health2007;7:2. WeltonAJ , VickersMR , KimJ , FordD , LawtonBA , MacLennanAH , et al. WISDOM team. Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ2008;337:a1190. ">WISDOM 2007</a><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>International</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4385</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combination</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup> Trial stopped early due to publication of WHI I 2002 results<br/> <sup>2</sup> Trial stopped early due to publication of HER I 1998 results<br/> <sup>3</sup> Trial stopped early as the weighted log‐rank test statistic for breast cancer crossed designated stopping boundary, and global index supportive of finding of overall harm.<br/> <sup>4</sup> Trial stopped early as National Institutes of Health (NIH) concluded that conjugated equine oestrogen alone did not appear to affect the risk of heart disease, but was associated with a significant increase in the risk of stroke<br/> CABG: coronary artery bypass graft; CHD: Coronary heart disease; DVT: Deep vein thrombosis; MI: myocardial infarction; NR: not reported; PE: Pulmonary embolism; TIA: Transient ischaemic attack </p> </div> </div> <section id="CD002229-sec-0077"> <h5 class="title">Participants</h5> <p>All the trials included post‐menopausal women, irrespective of whether the absence of menses was natural or an artefact of hysterectomy or oophorectomy, with a mean age of 64 years. In 14 of the 19 trials the mean participant age was over 60 years at baseline. The hysterectomy status of the women in four of the trials was related to the inclusion criteria and therefore in <a href="./references#CD002229-bbs2-0006" title="NachtigallLE , NachtigallRH , NachtigallRD , BeckmanEM . Estrogen replacement therapy II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstetrics Gynecology1979;54(1):74‐9. ">ERT II 1979</a>; <a href="./references#CD002229-bbs2-0011" title="Bibbins‐DomingoK , LinF , VittinghoffE , Barrett‐ConnorE , HulleyS , GradyD , et al. Effect of hormone therapy on mortality rates among women with heart failure and coronary artery disease. American Journal of Cardiology2005;95(2):289‐91. GiddingsL . Oestrogen plus progestin increased venous thromboembolic disease in postmenopausal women with coronary artery disease. Evidence Based Nursing2000;3(4):123. GradyD , ApplegateW , BushT , FurbergC , RiggsB , HulleyS , et al. Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics. Controlled Clinical Trials1998;19(4):314‐35. GradyD , HerringtonD , BittnerV , DavidsonM , HlatkyM , HsiaJ , et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study Follow‐up (HERS II). JAMA2002;288(1):49‐57. GradyD , WengerN , HerringtonD , KhanS , FurbergC , Hunninghake , et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. Annals of Internal Medicine2000;132:689‐96. HlatkyM , BoothroydD , VittinghoffE , SharpP , WhooleyMA . Quality‐of life and depressive symptoms in postmenopausal women after receiving hormone therapy. Results from the Heart and Estrogen/Progestin Replacement Study (HERS) Trial. JAMA2002;287(5):591‐7. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA1998;280(7):605‐13. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Obstetrical and Gynecological Survey1999;54(1):41‐2. KhanM , HlatkyM , LiuM , LinF , RogersW , ShlipakM . Effect of postmenopausal hormone therapy on coronary heart disease events after percutaneous transluminal coronary angioplasty. The American Journal of Cardiology2003;91(8):989‐91, A7. ShlipakM , SimonJ , VittinghoffE , LinF , Barrett‐ConnorE , KnoppR . Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA2000;283(14):1845‐52. SimonJA , HsiaJ , CauleyJA , RichardsC , HarrisF , FongJ , et al. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen‐progestin Replacement Study (HERS). Circulation2001;103(5):638‐42. SimonJA , LinF , VittinghoffE , BittnerV , Heart and Estrogen‐Progestin Replacement Study (HERS) Research Group. The relation of postmenopausal hormone therapy to serum uric acid and the risk of coronary heart disease events: The heart and estrogen‐progestin replacement study (HERS). Annals of Epidemiology2006;16(2):138‐45. SperoffL . The heart and estrogen/progestin replacement study (HERS). Maturitas1998;31(1):9‐14. ">HERS I 1998</a> and <a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a> was 0%, and in <a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a> it was 100%. In the nine trials in which baseline hysterectomy status was reported, this ranged from 10% to 61% (<a href="./references#CD002229-bbs2-0001" title="BladbjergE , MadsenJ , KristensenS , AbrahamsenB , BrixenK , MosekildeL , et al. Effect of long‐term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. Journal of Thrombosis and Haemostasis2003;1(6):1208‐14. KristensenS , AbrahamsenB , MadsenJ , GramJ , RejnmarkL , RudB , et al. Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: results from the Danish Osteoporosis Prevention Study (DOPS). Thrombosis and Haemostasis2006;95:915‐6. MadsenJ , KristensenS , GramJ , BladbjergE , HenriksenF , ChristensenK , et al. Positive impact of hormone replacement therapy on the fibrinolytic system: a long‐term randomized controlled study in healthy postmenopausal women. Journal of Thrombosis and Haemostasis2003;1(9):1984‐91. SchierbeckL , RejnmarkL , ToftengC , StilgrenL , EikenP , MosekildeL , et al. Hormone replacement treatment in early postmenopausal women reduces cardiovascular events ‐ A randomized controlled study. Circulation2011;124:A11380. SchierbeckLL , RejnmarkL , ToftengCL , StilgrenL , EikenP , MosekildeL , et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ2012;345:e6409. ToftengC , JensenJ , AbrahamsenB , OdumL , BrotC . Two polymorphisms in the vitamin D receptor gene‐association with bone mass and 5‐year change in bone mass with or without hormone‐replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study. Journal of Bone and Mineral Research2002;17(8):1535‐44. deMaatM , MadsenJ , LangdalB , BladbjergE , ToftengC , AbrahamsenL , et al. Genetic variation in estrogen receptor, C‐reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. Thrombosis and Haemostasis2007;97(2):234‐9. ">DOPS 2012</a>; <a href="./references#CD002229-bbs2-0003" title="HodisH , MackW , LoboR , MahrerP , LiuC R , LiuC H . Estrogen replacement therapy effects on the progression of subclinical atherosclerosis are mediated by lipids but not by carbohydrate metabolic factors: results from the Estrogen in the Prevention of Athersclerosis Trial (EPAT). Circulation2002;106(19 Suppl II):II‐744. HodisHN , MackWJ , LoboRA , ShoupeD , SevanianA , MahrerPR , et al. Estrogen in the prevention of atherosclerosis. A randomized, double‐blind, placebo‐controlled trial. Annals of Internal Medicine2001;135(11):939‐53. ">EPAT 2001</a>; <a href="./references#CD002229-bbs2-0004" title="HemminkiE , HoviS , VeerusP , SevónT , TuimalaR , RahuM , et al. Blinding decreased recruitment in a prevention trial of postmenopausal women. Journal of Clinical Epidemiology2004;57:1237‐43. VeerusP , FischerK , HoviS‐L , KarroH , RahuM , HemminkiE . Symptom reporting and quality of life in the Estonian Postmenopausal Hormone Therapy Trial. BMC Women’s Health2008;8:5. VeerusP , HoviS , FischerK , RahuM , HakamaM , HemminkiE . Results for the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]. Maturitas2006;55(2):162‐73. ">EPHT 2006</a>; <a href="./references#CD002229-bbs2-0005" title="HerringtonDM , ReboussinDM , Bridget BrosnihanK , SharpPC , ShumakerSA , SnyderTE , et al. Effects of estrogen replacement on the progression of coronary‐artery atherosclerosis. New England Journal of Medicine2000;343(8):522‐9. HerringtonDM , ReboussinDM , KleinKP , SharpPC , ShumakerSA , SnyderTE , et al. The estrogen replacement and atherosclerosis (ERA) study: study design and baseline characteristics of the cohort. Controlled Clinical Trials2000;21(3):257‐85. NairG , HerringtonD . The ERA trial: findings and implications for the future. Climacteric2000;3:227‐32. ">ERA 2000</a>; <a href="./references#CD002229-bbs2-0007" title="The ESPRIT Team. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet2002;360:2001‐8. ">ESPRIT 2002</a>; <a href="./references#CD002229-bbs2-0009" title="GreenspanSL , ResnickNM , ParkerRA . The effect of hormone replacement on physical performance in community‐dwelling elderly women. The American Journal of Medicine2005;118:1232‐9. ">Greenspan 2005</a>; <a href="./references#CD002229-bbs2-0012" title="GallagherJ , RapuriB , HaynatzkiG , DetterR . Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. The Journal of Clinical Endocrinology and Metabolism2002;87(11):4914‐23. GallagherJC , FowlerSE , DetterJR , ShermanSS . Combination treatment with estrogen and calcitriol in the prevention of age‐related bone loss. The Journal of Clinical Endocrinology and Metabolism2001;86(8):3618‐28. RapuriP , GallagherJ , KnezeticJ , HaynatzkaV . Estrogen receptor alpha gene polymorphisms are associated with changes in bone remodeling markers and treatment response to estrogen. Maturitas2006;53(4):371‐9. SaiA , GallagherJ , FangX . Effect of hormone therapy and calcitriol on serum lipid profile in postmenopausal older women: association with estrogen receptor‐alpha genotypes. Menopause2011;18(10):1101‐12. YalamanchiliV , GallagherJ . Treatment with hormone therapy and calcitriol did not affect depression in older postmenopausal women: no interaction with estrogen and vitamin D receptor genotype polymorphisms. Menopause2012;19(6):697‐703. ">STOP IT 2001</a>; <a href="./references#CD002229-bbs2-0014" title="HodisHN , MackWJ , AzenSP , LoboRA , ShoupeD , MahrerPR , et al. Hormone therapy and the progression of coronary‐artery atherosclerosis in postmenopausal women. New England Journal of Medicine2003;349(6):535‐45. ">WELL‐HART 2003</a>; <a href="./references#CD002229-bbs2-0015" title="KernanWN , BrassLM , ViscoliCM , SarrellPM , MakuchR , HorwitzRI . Estrogen after ischemic stroke: clinical basis and design of the Womens Estrogen for Stroke Trial. Journal of Stroke and Cerebrovascular Diseases1998;7(1):85‐95. ViscoliC , BrassL , Kernan , SarrelP , SuissaS , HorwitzR . Estrogen therapy and risk of cognitive decline: Results from the Women's Estrogen for Stroke Trial (WEST). American Journal of Obstetrics and Gynecology2005;192(2):387‐93. ViscoliCM , BrassLM , KernanWN , SarrelPM , SuissaS , HorwitzRI . A clinical trial of estrogen‐replacement therapy after ischemic stroke. New England Journal of Medicine2001;345(17):1243‐9. ">WEST 2001</a>). Six studies did not report data on hysterectomy status (<a href="./references#CD002229-bbs2-0002" title="Ouyang P , TardifJ , HerringtonD , StewartK , ThompsonP , WalshM , et al. Randomized trial of hormone therapy in women after coronary bypass surgery: Evidence of differential effect of hormone therapy on angiographic progression of disease in saphenous vein grafts and native coronary arteries. Atherosclerosis2006;189(2):375‐86. ">EAGAR 2006</a>; <a href="./references#CD002229-bbs2-0008" title="HoibraatenE , ArnesenH , LarsenS , WickstromE , SandsetPM . Increased risk of recurrent venous thromboembolism during hormone replacement therapy: results of the randomized, double blind, placebo‐controlled estrogen in venous thromboembolism trial (EVTET). Thrombosis and Haemostasis2000;84:961‐7. Qvigtad , HoibraatenH , ArnesenH , LarsenS , WickstromE , SandsetP . Recurrent venous thromboembolism during hormone replacement therapy ‐ results of the estrogen in venous thromboembolism trial. XVI FIGO World Congress of O and G2000;Abstract book 1:58. ">EVTET 2000</a>; <a href="./references#CD002229-bbs2-0010" title="HallG , PrippU , Schenk‐GustafssonK , LandgrenBM . Long‐term effects of hormone replacement therapy on symptoms of angina pectoris, quality of life and compliance in women with coronary artery disease. Maturitas1998 ;28 :235‐42 . ">HALL 1998</a>; <a href="./references#CD002229-bbs2-0013" title="HsiaJ , AldermanEL , VerterJI , RogersWJ , ThompsonP , HowardBV , et al. Women’s angiographic vitamin and estrogen trial: design and methods. Controlled Clinical Trials2002;23:708‐27. WatersD , AldermanE , HsiaJ , HowardB , CobbF , RogersW , et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women. JAMA2001;288(19):2432‐40. ">WAVE 2002</a>; <a href="./references#CD002229-bbs2-0018" title="CollinsP , FlatherM , LeesB , MisterR , ProudlerA , StevensonJC , WHISP (Women's Hormone Intervention Secondary Prevention Study) Pilot Study Investigators. Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study. European Heart Journal2006;27(17):2046‐53. ">WHISP 2006</a>; <a href="./references#CD002229-bbs2-0019" title="VickersMR , MacLacLennanA , LawtonB , FordD , MartinJ , MeredithS , et al. WISDOM group. Main morbidities recorded in the women's international study of long duration estrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ2007;335(7613):239. VickersMR , MartinJ , MeadeTW , WISDOM study team. The Women’s international study of long‐duration of estrogen after menopause (WISDOM): a randomised controlled trial. BMC Women's Health2007;7:2. WeltonAJ , VickersMR , KimJ , FordD , LawtonBA , MacLennanAH , et al. WISDOM team. Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ2008;337:a1190. ">WISDOM 2007</a>).<br/> <br/> The trial inclusion criteria varied according to the primary study objectives. Six of the trials were designed to assess the effects of hormone therapy in the primary prevention of cardiovascular disease and therefore enrolled predominantly healthy patient populations (<a href="./references#CD002229-bbs2-0001" title="BladbjergE , MadsenJ , KristensenS , AbrahamsenB , BrixenK , MosekildeL , et al. Effect of long‐term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. Journal of Thrombosis and Haemostasis2003;1(6):1208‐14. KristensenS , AbrahamsenB , MadsenJ , GramJ , RejnmarkL , RudB , et al. Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: results from the Danish Osteoporosis Prevention Study (DOPS). Thrombosis and Haemostasis2006;95:915‐6. MadsenJ , KristensenS , GramJ , BladbjergE , HenriksenF , ChristensenK , et al. Positive impact of hormone replacement therapy on the fibrinolytic system: a long‐term randomized controlled study in healthy postmenopausal women. Journal of Thrombosis and Haemostasis2003;1(9):1984‐91. SchierbeckL , RejnmarkL , ToftengC , StilgrenL , EikenP , MosekildeL , et al. Hormone replacement treatment in early postmenopausal women reduces cardiovascular events ‐ A randomized controlled study. Circulation2011;124:A11380. SchierbeckLL , RejnmarkL , ToftengCL , StilgrenL , EikenP , MosekildeL , et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ2012;345:e6409. ToftengC , JensenJ , AbrahamsenB , OdumL , BrotC . Two polymorphisms in the vitamin D receptor gene‐association with bone mass and 5‐year change in bone mass with or without hormone‐replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study. Journal of Bone and Mineral Research2002;17(8):1535‐44. deMaatM , MadsenJ , LangdalB , BladbjergE , ToftengC , AbrahamsenL , et al. Genetic variation in estrogen receptor, C‐reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. Thrombosis and Haemostasis2007;97(2):234‐9. ">DOPS 2012</a>; <a href="./references#CD002229-bbs2-0003" title="HodisH , MackW , LoboR , MahrerP , LiuC R , LiuC H . Estrogen replacement therapy effects on the progression of subclinical atherosclerosis are mediated by lipids but not by carbohydrate metabolic factors: results from the Estrogen in the Prevention of Athersclerosis Trial (EPAT). Circulation2002;106(19 Suppl II):II‐744. HodisHN , MackWJ , LoboRA , ShoupeD , SevanianA , MahrerPR , et al. Estrogen in the prevention of atherosclerosis. A randomized, double‐blind, placebo‐controlled trial. Annals of Internal Medicine2001;135(11):939‐53. ">EPAT 2001</a>; <a href="./references#CD002229-bbs2-0004" title="HemminkiE , HoviS , VeerusP , SevónT , TuimalaR , RahuM , et al. Blinding decreased recruitment in a prevention trial of postmenopausal women. Journal of Clinical Epidemiology2004;57:1237‐43. VeerusP , FischerK , HoviS‐L , KarroH , RahuM , HemminkiE . Symptom reporting and quality of life in the Estonian Postmenopausal Hormone Therapy Trial. BMC Women’s Health2008;8:5. VeerusP , HoviS , FischerK , RahuM , HakamaM , HemminkiE . Results for the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]. Maturitas2006;55(2):162‐73. ">EPHT 2006</a>; <a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a>; <a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a>; <a href="./references#CD002229-bbs2-0019" title="VickersMR , MacLacLennanA , LawtonB , FordD , MartinJ , MeredithS , et al. WISDOM group. Main morbidities recorded in the women's international study of long duration estrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ2007;335(7613):239. VickersMR , MartinJ , MeadeTW , WISDOM study team. The Women’s international study of long‐duration of estrogen after menopause (WISDOM): a randomised controlled trial. BMC Women's Health2007;7:2. WeltonAJ , VickersMR , KimJ , FordD , LawtonBA , MacLennanAH , et al. WISDOM team. Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ2008;337:a1190. ">WISDOM 2007</a>). Ten of the trials aimed to assess the impact of hormone therapy in secondary prevention, and therefore enrolled women with established cardiovascular disease (<a href="./references#CD002229-bbs2-0005" title="HerringtonDM , ReboussinDM , Bridget BrosnihanK , SharpPC , ShumakerSA , SnyderTE , et al. Effects of estrogen replacement on the progression of coronary‐artery atherosclerosis. New England Journal of Medicine2000;343(8):522‐9. HerringtonDM , ReboussinDM , KleinKP , SharpPC , ShumakerSA , SnyderTE , et al. The estrogen replacement and atherosclerosis (ERA) study: study design and baseline characteristics of the cohort. Controlled Clinical Trials2000;21(3):257‐85. NairG , HerringtonD . The ERA trial: findings and implications for the future. Climacteric2000;3:227‐32. ">ERA 2000</a>; <a href="./references#CD002229-bbs2-0011" title="Bibbins‐DomingoK , LinF , VittinghoffE , Barrett‐ConnorE , HulleyS , GradyD , et al. Effect of hormone therapy on mortality rates among women with heart failure and coronary artery disease. American Journal of Cardiology2005;95(2):289‐91. GiddingsL . Oestrogen plus progestin increased venous thromboembolic disease in postmenopausal women with coronary artery disease. Evidence Based Nursing2000;3(4):123. GradyD , ApplegateW , BushT , FurbergC , RiggsB , HulleyS , et al. Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics. Controlled Clinical Trials1998;19(4):314‐35. GradyD , HerringtonD , BittnerV , DavidsonM , HlatkyM , HsiaJ , et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study Follow‐up (HERS II). JAMA2002;288(1):49‐57. GradyD , WengerN , HerringtonD , KhanS , FurbergC , Hunninghake , et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. Annals of Internal Medicine2000;132:689‐96. HlatkyM , BoothroydD , VittinghoffE , SharpP , WhooleyMA . Quality‐of life and depressive symptoms in postmenopausal women after receiving hormone therapy. Results from the Heart and Estrogen/Progestin Replacement Study (HERS) Trial. JAMA2002;287(5):591‐7. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA1998;280(7):605‐13. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Obstetrical and Gynecological Survey1999;54(1):41‐2. KhanM , HlatkyM , LiuM , LinF , RogersW , ShlipakM . Effect of postmenopausal hormone therapy on coronary heart disease events after percutaneous transluminal coronary angioplasty. The American Journal of Cardiology2003;91(8):989‐91, A7. ShlipakM , SimonJ , VittinghoffE , LinF , Barrett‐ConnorE , KnoppR . Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA2000;283(14):1845‐52. SimonJA , HsiaJ , CauleyJA , RichardsC , HarrisF , FongJ , et al. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen‐progestin Replacement Study (HERS). Circulation2001;103(5):638‐42. SimonJA , LinF , VittinghoffE , BittnerV , Heart and Estrogen‐Progestin Replacement Study (HERS) Research Group. The relation of postmenopausal hormone therapy to serum uric acid and the risk of coronary heart disease events: The heart and estrogen‐progestin replacement study (HERS). Annals of Epidemiology2006;16(2):138‐45. SperoffL . The heart and estrogen/progestin replacement study (HERS). Maturitas1998;31(1):9‐14. ">HERS I 1998</a>; <a href="./references#CD002229-bbs2-0013" title="HsiaJ , AldermanEL , VerterJI , RogersWJ , ThompsonP , HowardBV , et al. Women’s angiographic vitamin and estrogen trial: design and methods. Controlled Clinical Trials2002;23:708‐27. WatersD , AldermanE , HsiaJ , HowardB , CobbF , RogersW , et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women. JAMA2001;288(19):2432‐40. ">WAVE 2002</a>; <a href="./references#CD002229-bbs2-0014" title="HodisHN , MackWJ , AzenSP , LoboRA , ShoupeD , MahrerPR , et al. Hormone therapy and the progression of coronary‐artery atherosclerosis in postmenopausal women. New England Journal of Medicine2003;349(6):535‐45. ">WELL‐HART 2003</a>) or after a designated specific cardiovascular disease event of interest, such as coronary artery bypass graft (<a href="./references#CD002229-bbs2-0002" title="Ouyang P , TardifJ , HerringtonD , StewartK , ThompsonP , WalshM , et al. Randomized trial of hormone therapy in women after coronary bypass surgery: Evidence of differential effect of hormone therapy on angiographic progression of disease in saphenous vein grafts and native coronary arteries. Atherosclerosis2006;189(2):375‐86. ">EAGAR 2006</a>), angina (<a href="./references#CD002229-bbs2-0010" title="HallG , PrippU , Schenk‐GustafssonK , LandgrenBM . Long‐term effects of hormone replacement therapy on symptoms of angina pectoris, quality of life and compliance in women with coronary artery disease. Maturitas1998 ;28 :235‐42 . ">HALL 1998</a>), acute coronary syndrome (<a href="./references#CD002229-bbs2-0018" title="CollinsP , FlatherM , LeesB , MisterR , ProudlerA , StevensonJC , WHISP (Women's Hormone Intervention Secondary Prevention Study) Pilot Study Investigators. Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study. European Heart Journal2006;27(17):2046‐53. ">WHISP 2006</a>), myocardial infarction or transient ischaemic attack (<a href="./references#CD002229-bbs2-0007" title="The ESPRIT Team. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet2002;360:2001‐8. ">ESPRIT 2002</a>; <a href="./references#CD002229-bbs2-0015" title="KernanWN , BrassLM , ViscoliCM , SarrellPM , MakuchR , HorwitzRI . Estrogen after ischemic stroke: clinical basis and design of the Womens Estrogen for Stroke Trial. Journal of Stroke and Cerebrovascular Diseases1998;7(1):85‐95. ViscoliC , BrassL , Kernan , SarrelP , SuissaS , HorwitzR . Estrogen therapy and risk of cognitive decline: Results from the Women's Estrogen for Stroke Trial (WEST). American Journal of Obstetrics and Gynecology2005;192(2):387‐93. ViscoliCM , BrassLM , KernanWN , SarrelPM , SuissaS , HorwitzRI . A clinical trial of estrogen‐replacement therapy after ischemic stroke. New England Journal of Medicine2001;345(17):1243‐9. ">WEST 2001</a>), or pulmonary embolism or deep vein thrombosis (<a href="./references#CD002229-bbs2-0008" title="HoibraatenE , ArnesenH , LarsenS , WickstromE , SandsetPM . Increased risk of recurrent venous thromboembolism during hormone replacement therapy: results of the randomized, double blind, placebo‐controlled estrogen in venous thromboembolism trial (EVTET). Thrombosis and Haemostasis2000;84:961‐7. Qvigtad , HoibraatenH , ArnesenH , LarsenS , WickstromE , SandsetP . Recurrent venous thromboembolism during hormone replacement therapy ‐ results of the estrogen in venous thromboembolism trial. XVI FIGO World Congress of O and G2000;Abstract book 1:58. ">EVTET 2000</a>). Three trials were designed to assess non‐cardiovascular endpoints but reported relevant outcomes as adverse events, safety of long‐term hormone therapy (<a href="./references#CD002229-bbs2-0006" title="NachtigallLE , NachtigallRH , NachtigallRD , BeckmanEM . Estrogen replacement therapy II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstetrics Gynecology1979;54(1):74‐9. ">ERT II 1979</a>), bone mineral density (<a href="./references#CD002229-bbs2-0012" title="GallagherJ , RapuriB , HaynatzkiG , DetterR . Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. The Journal of Clinical Endocrinology and Metabolism2002;87(11):4914‐23. GallagherJC , FowlerSE , DetterJR , ShermanSS . Combination treatment with estrogen and calcitriol in the prevention of age‐related bone loss. The Journal of Clinical Endocrinology and Metabolism2001;86(8):3618‐28. RapuriP , GallagherJ , KnezeticJ , HaynatzkaV . Estrogen receptor alpha gene polymorphisms are associated with changes in bone remodeling markers and treatment response to estrogen. Maturitas2006;53(4):371‐9. SaiA , GallagherJ , FangX . Effect of hormone therapy and calcitriol on serum lipid profile in postmenopausal older women: association with estrogen receptor‐alpha genotypes. Menopause2011;18(10):1101‐12. YalamanchiliV , GallagherJ . Treatment with hormone therapy and calcitriol did not affect depression in older postmenopausal women: no interaction with estrogen and vitamin D receptor genotype polymorphisms. Menopause2012;19(6):697‐703. ">STOP IT 2001</a>), physical performance, functional ability, falls and cognitive function (<a href="./references#CD002229-bbs2-0009" title="GreenspanSL , ResnickNM , ParkerRA . The effect of hormone replacement on physical performance in community‐dwelling elderly women. The American Journal of Medicine2005;118:1232‐9. ">Greenspan 2005</a>). </p> </section> <section id="CD002229-sec-0078"> <h5 class="title">Primary prevention trials</h5> <p>Nine studies enrolled relatively healthy women (<a href="./references#CD002229-bbs2-0001" title="BladbjergE , MadsenJ , KristensenS , AbrahamsenB , BrixenK , MosekildeL , et al. Effect of long‐term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. Journal of Thrombosis and Haemostasis2003;1(6):1208‐14. KristensenS , AbrahamsenB , MadsenJ , GramJ , RejnmarkL , RudB , et al. Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: results from the Danish Osteoporosis Prevention Study (DOPS). Thrombosis and Haemostasis2006;95:915‐6. MadsenJ , KristensenS , GramJ , BladbjergE , HenriksenF , ChristensenK , et al. Positive impact of hormone replacement therapy on the fibrinolytic system: a long‐term randomized controlled study in healthy postmenopausal women. Journal of Thrombosis and Haemostasis2003;1(9):1984‐91. SchierbeckL , RejnmarkL , ToftengC , StilgrenL , EikenP , MosekildeL , et al. Hormone replacement treatment in early postmenopausal women reduces cardiovascular events ‐ A randomized controlled study. Circulation2011;124:A11380. SchierbeckLL , RejnmarkL , ToftengCL , StilgrenL , EikenP , MosekildeL , et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ2012;345:e6409. ToftengC , JensenJ , AbrahamsenB , OdumL , BrotC . Two polymorphisms in the vitamin D receptor gene‐association with bone mass and 5‐year change in bone mass with or without hormone‐replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study. Journal of Bone and Mineral Research2002;17(8):1535‐44. deMaatM , MadsenJ , LangdalB , BladbjergE , ToftengC , AbrahamsenL , et al. Genetic variation in estrogen receptor, C‐reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. Thrombosis and Haemostasis2007;97(2):234‐9. ">DOPS 2012</a>; <a href="./references#CD002229-bbs2-0003" title="HodisH , MackW , LoboR , MahrerP , LiuC R , LiuC H . Estrogen replacement therapy effects on the progression of subclinical atherosclerosis are mediated by lipids but not by carbohydrate metabolic factors: results from the Estrogen in the Prevention of Athersclerosis Trial (EPAT). Circulation2002;106(19 Suppl II):II‐744. HodisHN , MackWJ , LoboRA , ShoupeD , SevanianA , MahrerPR , et al. Estrogen in the prevention of atherosclerosis. A randomized, double‐blind, placebo‐controlled trial. Annals of Internal Medicine2001;135(11):939‐53. ">EPAT 2001</a>; <a href="./references#CD002229-bbs2-0004" title="HemminkiE , HoviS , VeerusP , SevónT , TuimalaR , RahuM , et al. Blinding decreased recruitment in a prevention trial of postmenopausal women. Journal of Clinical Epidemiology2004;57:1237‐43. VeerusP , FischerK , HoviS‐L , KarroH , RahuM , HemminkiE . Symptom reporting and quality of life in the Estonian Postmenopausal Hormone Therapy Trial. BMC Women’s Health2008;8:5. VeerusP , HoviS , FischerK , RahuM , HakamaM , HemminkiE . Results for the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]. Maturitas2006;55(2):162‐73. ">EPHT 2006</a>; <a href="./references#CD002229-bbs2-0006" title="NachtigallLE , NachtigallRH , NachtigallRD , BeckmanEM . Estrogen replacement therapy II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstetrics Gynecology1979;54(1):74‐9. ">ERT II 1979</a>; <a href="./references#CD002229-bbs2-0009" title="GreenspanSL , ResnickNM , ParkerRA . The effect of hormone replacement on physical performance in community‐dwelling elderly women. The American Journal of Medicine2005;118:1232‐9. ">Greenspan 2005</a>; <a href="./references#CD002229-bbs2-0012" title="GallagherJ , RapuriB , HaynatzkiG , DetterR . Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. The Journal of Clinical Endocrinology and Metabolism2002;87(11):4914‐23. GallagherJC , FowlerSE , DetterJR , ShermanSS . Combination treatment with estrogen and calcitriol in the prevention of age‐related bone loss. The Journal of Clinical Endocrinology and Metabolism2001;86(8):3618‐28. RapuriP , GallagherJ , KnezeticJ , HaynatzkaV . Estrogen receptor alpha gene polymorphisms are associated with changes in bone remodeling markers and treatment response to estrogen. Maturitas2006;53(4):371‐9. SaiA , GallagherJ , FangX . Effect of hormone therapy and calcitriol on serum lipid profile in postmenopausal older women: association with estrogen receptor‐alpha genotypes. Menopause2011;18(10):1101‐12. YalamanchiliV , GallagherJ . Treatment with hormone therapy and calcitriol did not affect depression in older postmenopausal women: no interaction with estrogen and vitamin D receptor genotype polymorphisms. Menopause2012;19(6):697‐703. ">STOP IT 2001</a>; <a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a>; <a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a>; <a href="./references#CD002229-bbs2-0019" title="VickersMR , MacLacLennanA , LawtonB , FordD , MartinJ , MeredithS , et al. WISDOM group. Main morbidities recorded in the women's international study of long duration estrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ2007;335(7613):239. VickersMR , MartinJ , MeadeTW , WISDOM study team. The Women’s international study of long‐duration of estrogen after menopause (WISDOM): a randomised controlled trial. BMC Women's Health2007;7:2. WeltonAJ , VickersMR , KimJ , FordD , LawtonBA , MacLennanAH , et al. WISDOM team. Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ2008;337:a1190. ">WISDOM 2007</a>). Although one of the studies enrolled women with one cardiovascular disease risk factor, namely hypercholesterolaemia (<a href="./references#CD002229-bbs2-0003" title="HodisH , MackW , LoboR , MahrerP , LiuC R , LiuC H . Estrogen replacement therapy effects on the progression of subclinical atherosclerosis are mediated by lipids but not by carbohydrate metabolic factors: results from the Estrogen in the Prevention of Athersclerosis Trial (EPAT). Circulation2002;106(19 Suppl II):II‐744. HodisHN , MackWJ , LoboRA , ShoupeD , SevanianA , MahrerPR , et al. Estrogen in the prevention of atherosclerosis. A randomized, double‐blind, placebo‐controlled trial. Annals of Internal Medicine2001;135(11):939‐53. ">EPAT 2001</a>) and a small minority (approximately ≤ 5%) of women within all trials had a history of cardiovascular disease, the trial participants were representative of population samples of fit women in this age group without overt disease. Four of these trials (<a href="./references#CD002229-bbs2-0004" title="HemminkiE , HoviS , VeerusP , SevónT , TuimalaR , RahuM , et al. Blinding decreased recruitment in a prevention trial of postmenopausal women. Journal of Clinical Epidemiology2004;57:1237‐43. VeerusP , FischerK , HoviS‐L , KarroH , RahuM , HemminkiE . Symptom reporting and quality of life in the Estonian Postmenopausal Hormone Therapy Trial. BMC Women’s Health2008;8:5. VeerusP , HoviS , FischerK , RahuM , HakamaM , HemminkiE . Results for the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]. Maturitas2006;55(2):162‐73. ">EPHT 2006</a>; <a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a>; <a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a>; <a href="./references#CD002229-bbs2-0019" title="VickersMR , MacLacLennanA , LawtonB , FordD , MartinJ , MeredithS , et al. WISDOM group. Main morbidities recorded in the women's international study of long duration estrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ2007;335(7613):239. VickersMR , MartinJ , MeadeTW , WISDOM study team. The Women’s international study of long‐duration of estrogen after menopause (WISDOM): a randomised controlled trial. BMC Women's Health2007;7:2. WeltonAJ , VickersMR , KimJ , FordD , LawtonBA , MacLennanAH , et al. WISDOM team. Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ2008;337:a1190. ">WISDOM 2007</a>) assessed the impact of hormone therapy on both cardiovascular disease, as well as a wide range of other endpoints, including cancer, osteoporosis and gallbladder disease, and therefore reported detailed lists of participant inclusion and exclusion criteria. One study included only participants who were admitted for the entire duration of the study (ten years) in a hospital for patients with chronic illnesses (<a href="./references#CD002229-bbs2-0006" title="NachtigallLE , NachtigallRH , NachtigallRD , BeckmanEM . Estrogen replacement therapy II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstetrics Gynecology1979;54(1):74‐9. ">ERT II 1979</a>). The illnesses of the participants are not reported. However, it specified that acute heart disease and hypertension were exclusion criteria. Three studies, mentioned above, were designed to assess non‐cardiovascular outcomes but reported relevant outcomes as adverse events (<a href="./references#CD002229-bbs2-0006" title="NachtigallLE , NachtigallRH , NachtigallRD , BeckmanEM . Estrogen replacement therapy II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstetrics Gynecology1979;54(1):74‐9. ">ERT II 1979</a>; <a href="./references#CD002229-bbs2-0009" title="GreenspanSL , ResnickNM , ParkerRA . The effect of hormone replacement on physical performance in community‐dwelling elderly women. The American Journal of Medicine2005;118:1232‐9. ">Greenspan 2005</a>; <a href="./references#CD002229-bbs2-0012" title="GallagherJ , RapuriB , HaynatzkiG , DetterR . Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. The Journal of Clinical Endocrinology and Metabolism2002;87(11):4914‐23. GallagherJC , FowlerSE , DetterJR , ShermanSS . Combination treatment with estrogen and calcitriol in the prevention of age‐related bone loss. The Journal of Clinical Endocrinology and Metabolism2001;86(8):3618‐28. RapuriP , GallagherJ , KnezeticJ , HaynatzkaV . Estrogen receptor alpha gene polymorphisms are associated with changes in bone remodeling markers and treatment response to estrogen. Maturitas2006;53(4):371‐9. SaiA , GallagherJ , FangX . Effect of hormone therapy and calcitriol on serum lipid profile in postmenopausal older women: association with estrogen receptor‐alpha genotypes. Menopause2011;18(10):1101‐12. YalamanchiliV , GallagherJ . Treatment with hormone therapy and calcitriol did not affect depression in older postmenopausal women: no interaction with estrogen and vitamin D receptor genotype polymorphisms. Menopause2012;19(6):697‐703. ">STOP IT 2001</a>).<br/> <br/> The two biggest primary prevention trials (<a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a>; <a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a>) both set enrolment targets to establish set fractions for baseline age categories and to achieve racial and ethnic group representation within participant groups in the proportions recorded in the US census for the 50 to 79 year old age group. This was achieved, with it being noted that baseline cardiovascular risk factors in the trial participants in both <a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a> and <a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a> were low and consistent with those observed in a generally healthy population of post‐menopausal women (<a href="./references#CD002229-bbs2-0122" title="Manson , JE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349:523‐34. ">Manson 2003</a>; <a href="./references#CD002229-bbs2-0142" title="StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. ">Stefanick 2003</a>). <a href="./references#CD002229-bbs2-0019" title="VickersMR , MacLacLennanA , LawtonB , FordD , MartinJ , MeredithS , et al. WISDOM group. Main morbidities recorded in the women's international study of long duration estrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ2007;335(7613):239. VickersMR , MartinJ , MeadeTW , WISDOM study team. The Women’s international study of long‐duration of estrogen after menopause (WISDOM): a randomised controlled trial. BMC Women's Health2007;7:2. WeltonAJ , VickersMR , KimJ , FordD , LawtonBA , MacLennanAH , et al. WISDOM team. Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ2008;337:a1190. ">WISDOM 2007</a> recruited women with no major health problems from general practice registers in England, Australia and New Zealand, whilst <a href="./references#CD002229-bbs2-0004" title="HemminkiE , HoviS , VeerusP , SevónT , TuimalaR , RahuM , et al. Blinding decreased recruitment in a prevention trial of postmenopausal women. Journal of Clinical Epidemiology2004;57:1237‐43. VeerusP , FischerK , HoviS‐L , KarroH , RahuM , HemminkiE . Symptom reporting and quality of life in the Estonian Postmenopausal Hormone Therapy Trial. BMC Women’s Health2008;8:5. VeerusP , HoviS , FischerK , RahuM , HakamaM , HemminkiE . Results for the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]. Maturitas2006;55(2):162‐73. ">EPHT 2006</a> included healthy women with no major health problems drawn from population samples in Estonia. In both trials, participant baseline cardiovascular risk factors were low and consistent with those observed in the general population of post‐menopausal women within this age group. </p> </section> <section id="CD002229-sec-0079"> <h5 class="title">Secondary prevention trials</h5> <p>Ten studies included women with established cardiovascular disease (<a href="./references#CD002229-bbs2-0002" title="Ouyang P , TardifJ , HerringtonD , StewartK , ThompsonP , WalshM , et al. Randomized trial of hormone therapy in women after coronary bypass surgery: Evidence of differential effect of hormone therapy on angiographic progression of disease in saphenous vein grafts and native coronary arteries. Atherosclerosis2006;189(2):375‐86. ">EAGAR 2006</a>; <a href="./references#CD002229-bbs2-0005" title="HerringtonDM , ReboussinDM , Bridget BrosnihanK , SharpPC , ShumakerSA , SnyderTE , et al. Effects of estrogen replacement on the progression of coronary‐artery atherosclerosis. New England Journal of Medicine2000;343(8):522‐9. HerringtonDM , ReboussinDM , KleinKP , SharpPC , ShumakerSA , SnyderTE , et al. The estrogen replacement and atherosclerosis (ERA) study: study design and baseline characteristics of the cohort. Controlled Clinical Trials2000;21(3):257‐85. NairG , HerringtonD . The ERA trial: findings and implications for the future. Climacteric2000;3:227‐32. ">ERA 2000</a>; <a href="./references#CD002229-bbs2-0007" title="The ESPRIT Team. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet2002;360:2001‐8. ">ESPRIT 2002</a>; <a href="./references#CD002229-bbs2-0008" title="HoibraatenE , ArnesenH , LarsenS , WickstromE , SandsetPM . Increased risk of recurrent venous thromboembolism during hormone replacement therapy: results of the randomized, double blind, placebo‐controlled estrogen in venous thromboembolism trial (EVTET). Thrombosis and Haemostasis2000;84:961‐7. Qvigtad , HoibraatenH , ArnesenH , LarsenS , WickstromE , SandsetP . Recurrent venous thromboembolism during hormone replacement therapy ‐ results of the estrogen in venous thromboembolism trial. XVI FIGO World Congress of O and G2000;Abstract book 1:58. ">EVTET 2000</a>; <a href="./references#CD002229-bbs2-0010" title="HallG , PrippU , Schenk‐GustafssonK , LandgrenBM . Long‐term effects of hormone replacement therapy on symptoms of angina pectoris, quality of life and compliance in women with coronary artery disease. Maturitas1998 ;28 :235‐42 . ">HALL 1998</a>; <a href="./references#CD002229-bbs2-0011" title="Bibbins‐DomingoK , LinF , VittinghoffE , Barrett‐ConnorE , HulleyS , GradyD , et al. Effect of hormone therapy on mortality rates among women with heart failure and coronary artery disease. American Journal of Cardiology2005;95(2):289‐91. GiddingsL . Oestrogen plus progestin increased venous thromboembolic disease in postmenopausal women with coronary artery disease. Evidence Based Nursing2000;3(4):123. GradyD , ApplegateW , BushT , FurbergC , RiggsB , HulleyS , et al. Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics. Controlled Clinical Trials1998;19(4):314‐35. GradyD , HerringtonD , BittnerV , DavidsonM , HlatkyM , HsiaJ , et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study Follow‐up (HERS II). JAMA2002;288(1):49‐57. GradyD , WengerN , HerringtonD , KhanS , FurbergC , Hunninghake , et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. Annals of Internal Medicine2000;132:689‐96. HlatkyM , BoothroydD , VittinghoffE , SharpP , WhooleyMA . Quality‐of life and depressive symptoms in postmenopausal women after receiving hormone therapy. Results from the Heart and Estrogen/Progestin Replacement Study (HERS) Trial. JAMA2002;287(5):591‐7. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA1998;280(7):605‐13. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Obstetrical and Gynecological Survey1999;54(1):41‐2. KhanM , HlatkyM , LiuM , LinF , RogersW , ShlipakM . Effect of postmenopausal hormone therapy on coronary heart disease events after percutaneous transluminal coronary angioplasty. The American Journal of Cardiology2003;91(8):989‐91, A7. ShlipakM , SimonJ , VittinghoffE , LinF , Barrett‐ConnorE , KnoppR . Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA2000;283(14):1845‐52. SimonJA , HsiaJ , CauleyJA , RichardsC , HarrisF , FongJ , et al. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen‐progestin Replacement Study (HERS). Circulation2001;103(5):638‐42. SimonJA , LinF , VittinghoffE , BittnerV , Heart and Estrogen‐Progestin Replacement Study (HERS) Research Group. The relation of postmenopausal hormone therapy to serum uric acid and the risk of coronary heart disease events: The heart and estrogen‐progestin replacement study (HERS). Annals of Epidemiology2006;16(2):138‐45. SperoffL . The heart and estrogen/progestin replacement study (HERS). Maturitas1998;31(1):9‐14. ">HERS I 1998</a>; <a href="./references#CD002229-bbs2-0013" title="HsiaJ , AldermanEL , VerterJI , RogersWJ , ThompsonP , HowardBV , et al. Women’s angiographic vitamin and estrogen trial: design and methods. Controlled Clinical Trials2002;23:708‐27. WatersD , AldermanE , HsiaJ , HowardB , CobbF , RogersW , et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women. JAMA2001;288(19):2432‐40. ">WAVE 2002</a>; <a href="./references#CD002229-bbs2-0014" title="HodisHN , MackWJ , AzenSP , LoboRA , ShoupeD , MahrerPR , et al. Hormone therapy and the progression of coronary‐artery atherosclerosis in postmenopausal women. New England Journal of Medicine2003;349(6):535‐45. ">WELL‐HART 2003</a>; <a href="./references#CD002229-bbs2-0015" title="KernanWN , BrassLM , ViscoliCM , SarrellPM , MakuchR , HorwitzRI . Estrogen after ischemic stroke: clinical basis and design of the Womens Estrogen for Stroke Trial. Journal of Stroke and Cerebrovascular Diseases1998;7(1):85‐95. ViscoliC , BrassL , Kernan , SarrelP , SuissaS , HorwitzR . Estrogen therapy and risk of cognitive decline: Results from the Women's Estrogen for Stroke Trial (WEST). American Journal of Obstetrics and Gynecology2005;192(2):387‐93. ViscoliCM , BrassLM , KernanWN , SarrelPM , SuissaS , HorwitzRI . A clinical trial of estrogen‐replacement therapy after ischemic stroke. New England Journal of Medicine2001;345(17):1243‐9. ">WEST 2001</a>; <a href="./references#CD002229-bbs2-0018" title="CollinsP , FlatherM , LeesB , MisterR , ProudlerA , StevensonJC , WHISP (Women's Hormone Intervention Secondary Prevention Study) Pilot Study Investigators. Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study. European Heart Journal2006;27(17):2046‐53. ">WHISP 2006</a>). <a href="./references#CD002229-bbs2-0005" title="HerringtonDM , ReboussinDM , Bridget BrosnihanK , SharpPC , ShumakerSA , SnyderTE , et al. Effects of estrogen replacement on the progression of coronary‐artery atherosclerosis. New England Journal of Medicine2000;343(8):522‐9. HerringtonDM , ReboussinDM , KleinKP , SharpPC , ShumakerSA , SnyderTE , et al. The estrogen replacement and atherosclerosis (ERA) study: study design and baseline characteristics of the cohort. Controlled Clinical Trials2000;21(3):257‐85. NairG , HerringtonD . The ERA trial: findings and implications for the future. Climacteric2000;3:227‐32. ">ERA 2000</a>, <a href="./references#CD002229-bbs2-0013" title="HsiaJ , AldermanEL , VerterJI , RogersWJ , ThompsonP , HowardBV , et al. Women’s angiographic vitamin and estrogen trial: design and methods. Controlled Clinical Trials2002;23:708‐27. WatersD , AldermanE , HsiaJ , HowardB , CobbF , RogersW , et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women. JAMA2001;288(19):2432‐40. ">WAVE 2002</a> and <a href="./references#CD002229-bbs2-0014" title="HodisHN , MackWJ , AzenSP , LoboRA , ShoupeD , MahrerPR , et al. Hormone therapy and the progression of coronary‐artery atherosclerosis in postmenopausal women. New England Journal of Medicine2003;349(6):535‐45. ">WELL‐HART 2003</a> included women who had coronary artery stenosis evidenced by angiogram. <a href="./references#CD002229-bbs2-0011" title="Bibbins‐DomingoK , LinF , VittinghoffE , Barrett‐ConnorE , HulleyS , GradyD , et al. Effect of hormone therapy on mortality rates among women with heart failure and coronary artery disease. American Journal of Cardiology2005;95(2):289‐91. GiddingsL . Oestrogen plus progestin increased venous thromboembolic disease in postmenopausal women with coronary artery disease. Evidence Based Nursing2000;3(4):123. GradyD , ApplegateW , BushT , FurbergC , RiggsB , HulleyS , et al. Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics. Controlled Clinical Trials1998;19(4):314‐35. GradyD , HerringtonD , BittnerV , DavidsonM , HlatkyM , HsiaJ , et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study Follow‐up (HERS II). JAMA2002;288(1):49‐57. GradyD , WengerN , HerringtonD , KhanS , FurbergC , Hunninghake , et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. Annals of Internal Medicine2000;132:689‐96. HlatkyM , BoothroydD , VittinghoffE , SharpP , WhooleyMA . Quality‐of life and depressive symptoms in postmenopausal women after receiving hormone therapy. Results from the Heart and Estrogen/Progestin Replacement Study (HERS) Trial. JAMA2002;287(5):591‐7. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA1998;280(7):605‐13. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Obstetrical and Gynecological Survey1999;54(1):41‐2. KhanM , HlatkyM , LiuM , LinF , RogersW , ShlipakM . Effect of postmenopausal hormone therapy on coronary heart disease events after percutaneous transluminal coronary angioplasty. The American Journal of Cardiology2003;91(8):989‐91, A7. ShlipakM , SimonJ , VittinghoffE , LinF , Barrett‐ConnorE , KnoppR . Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA2000;283(14):1845‐52. SimonJA , HsiaJ , CauleyJA , RichardsC , HarrisF , FongJ , et al. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen‐progestin Replacement Study (HERS). Circulation2001;103(5):638‐42. SimonJA , LinF , VittinghoffE , BittnerV , Heart and Estrogen‐Progestin Replacement Study (HERS) Research Group. The relation of postmenopausal hormone therapy to serum uric acid and the risk of coronary heart disease events: The heart and estrogen‐progestin replacement study (HERS). Annals of Epidemiology2006;16(2):138‐45. SperoffL . The heart and estrogen/progestin replacement study (HERS). Maturitas1998;31(1):9‐14. ">HERS I 1998</a> and <a href="./references#CD002229-bbs2-0002" title="Ouyang P , TardifJ , HerringtonD , StewartK , ThompsonP , WalshM , et al. Randomized trial of hormone therapy in women after coronary bypass surgery: Evidence of differential effect of hormone therapy on angiographic progression of disease in saphenous vein grafts and native coronary arteries. Atherosclerosis2006;189(2):375‐86. ">EAGAR 2006</a> both included women who had undergone a revascularisation procedure (coronary artery bypass graft or percutaneous coronary intervention), whilst <a href="./references#CD002229-bbs2-0007" title="The ESPRIT Team. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet2002;360:2001‐8. ">ESPRIT 2002</a>, <a href="./references#CD002229-bbs2-0015" title="KernanWN , BrassLM , ViscoliCM , SarrellPM , MakuchR , HorwitzRI . Estrogen after ischemic stroke: clinical basis and design of the Womens Estrogen for Stroke Trial. Journal of Stroke and Cerebrovascular Diseases1998;7(1):85‐95. ViscoliC , BrassL , Kernan , SarrelP , SuissaS , HorwitzR . Estrogen therapy and risk of cognitive decline: Results from the Women's Estrogen for Stroke Trial (WEST). American Journal of Obstetrics and Gynecology2005;192(2):387‐93. ViscoliCM , BrassLM , KernanWN , SarrelPM , SuissaS , HorwitzRI . A clinical trial of estrogen‐replacement therapy after ischemic stroke. New England Journal of Medicine2001;345(17):1243‐9. ">WEST 2001</a> and <a href="./references#CD002229-bbs2-0018" title="CollinsP , FlatherM , LeesB , MisterR , ProudlerA , StevensonJC , WHISP (Women's Hormone Intervention Secondary Prevention Study) Pilot Study Investigators. Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study. European Heart Journal2006;27(17):2046‐53. ">WHISP 2006</a> included women who had had a previous acute coronary syndrome or a transient ischaemic attack (TIA). <a href="./references#CD002229-bbs2-0010" title="HallG , PrippU , Schenk‐GustafssonK , LandgrenBM . Long‐term effects of hormone replacement therapy on symptoms of angina pectoris, quality of life and compliance in women with coronary artery disease. Maturitas1998 ;28 :235‐42 . ">HALL 1998</a> included women previously hospitalised with angina, and <a href="./references#CD002229-bbs2-0008" title="HoibraatenE , ArnesenH , LarsenS , WickstromE , SandsetPM . Increased risk of recurrent venous thromboembolism during hormone replacement therapy: results of the randomized, double blind, placebo‐controlled estrogen in venous thromboembolism trial (EVTET). Thrombosis and Haemostasis2000;84:961‐7. Qvigtad , HoibraatenH , ArnesenH , LarsenS , WickstromE , SandsetP . Recurrent venous thromboembolism during hormone replacement therapy ‐ results of the estrogen in venous thromboembolism trial. XVI FIGO World Congress of O and G2000;Abstract book 1:58. ">EVTET 2000</a> included women who had suffered a thromboembolic event, pulmonary embolism or deep vein thrombosis.<br/> <br/> The largest of the ten trials (<a href="./references#CD002229-bbs2-0011" title="Bibbins‐DomingoK , LinF , VittinghoffE , Barrett‐ConnorE , HulleyS , GradyD , et al. Effect of hormone therapy on mortality rates among women with heart failure and coronary artery disease. American Journal of Cardiology2005;95(2):289‐91. GiddingsL . Oestrogen plus progestin increased venous thromboembolic disease in postmenopausal women with coronary artery disease. Evidence Based Nursing2000;3(4):123. GradyD , ApplegateW , BushT , FurbergC , RiggsB , HulleyS , et al. Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics. Controlled Clinical Trials1998;19(4):314‐35. GradyD , HerringtonD , BittnerV , DavidsonM , HlatkyM , HsiaJ , et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study Follow‐up (HERS II). JAMA2002;288(1):49‐57. GradyD , WengerN , HerringtonD , KhanS , FurbergC , Hunninghake , et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. Annals of Internal Medicine2000;132:689‐96. HlatkyM , BoothroydD , VittinghoffE , SharpP , WhooleyMA . Quality‐of life and depressive symptoms in postmenopausal women after receiving hormone therapy. Results from the Heart and Estrogen/Progestin Replacement Study (HERS) Trial. JAMA2002;287(5):591‐7. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA1998;280(7):605‐13. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Obstetrical and Gynecological Survey1999;54(1):41‐2. KhanM , HlatkyM , LiuM , LinF , RogersW , ShlipakM . Effect of postmenopausal hormone therapy on coronary heart disease events after percutaneous transluminal coronary angioplasty. The American Journal of Cardiology2003;91(8):989‐91, A7. ShlipakM , SimonJ , VittinghoffE , LinF , Barrett‐ConnorE , KnoppR . Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA2000;283(14):1845‐52. SimonJA , HsiaJ , CauleyJA , RichardsC , HarrisF , FongJ , et al. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen‐progestin Replacement Study (HERS). Circulation2001;103(5):638‐42. SimonJA , LinF , VittinghoffE , BittnerV , Heart and Estrogen‐Progestin Replacement Study (HERS) Research Group. The relation of postmenopausal hormone therapy to serum uric acid and the risk of coronary heart disease events: The heart and estrogen‐progestin replacement study (HERS). Annals of Epidemiology2006;16(2):138‐45. SperoffL . The heart and estrogen/progestin replacement study (HERS). Maturitas1998;31(1):9‐14. ">HERS I 1998</a>) compared the baseline characteristics of the trial participants with a similar group of women presumed to have coronary heart disease who were participants in a survey designed to produce nationally representative data. The <a href="./references#CD002229-bbs2-0011" title="Bibbins‐DomingoK , LinF , VittinghoffE , Barrett‐ConnorE , HulleyS , GradyD , et al. Effect of hormone therapy on mortality rates among women with heart failure and coronary artery disease. American Journal of Cardiology2005;95(2):289‐91. GiddingsL . Oestrogen plus progestin increased venous thromboembolic disease in postmenopausal women with coronary artery disease. Evidence Based Nursing2000;3(4):123. GradyD , ApplegateW , BushT , FurbergC , RiggsB , HulleyS , et al. Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics. Controlled Clinical Trials1998;19(4):314‐35. GradyD , HerringtonD , BittnerV , DavidsonM , HlatkyM , HsiaJ , et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study Follow‐up (HERS II). JAMA2002;288(1):49‐57. GradyD , WengerN , HerringtonD , KhanS , FurbergC , Hunninghake , et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. Annals of Internal Medicine2000;132:689‐96. HlatkyM , BoothroydD , VittinghoffE , SharpP , WhooleyMA . Quality‐of life and depressive symptoms in postmenopausal women after receiving hormone therapy. Results from the Heart and Estrogen/Progestin Replacement Study (HERS) Trial. JAMA2002;287(5):591‐7. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA1998;280(7):605‐13. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Obstetrical and Gynecological Survey1999;54(1):41‐2. KhanM , HlatkyM , LiuM , LinF , RogersW , ShlipakM . Effect of postmenopausal hormone therapy on coronary heart disease events after percutaneous transluminal coronary angioplasty. The American Journal of Cardiology2003;91(8):989‐91, A7. ShlipakM , SimonJ , VittinghoffE , LinF , Barrett‐ConnorE , KnoppR . Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA2000;283(14):1845‐52. SimonJA , HsiaJ , CauleyJA , RichardsC , HarrisF , FongJ , et al. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen‐progestin Replacement Study (HERS). Circulation2001;103(5):638‐42. SimonJA , LinF , VittinghoffE , BittnerV , Heart and Estrogen‐Progestin Replacement Study (HERS) Research Group. The relation of postmenopausal hormone therapy to serum uric acid and the risk of coronary heart disease events: The heart and estrogen‐progestin replacement study (HERS). Annals of Epidemiology2006;16(2):138‐45. SperoffL . The heart and estrogen/progestin replacement study (HERS). Maturitas1998;31(1):9‐14. ">HERS I 1998</a> participants had significantly fewer smokers, women with hypertension and diabetes than the comparison group but were comparable with respect to blood pressure, body mass index, physical activity and cholesterol levels (<a href="./references#CD002229-bbs2-0103" title="GradyD , ApplegateW , BushT , FurbergC , RiggsB , HulleyS , et al. Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics. Controlled Clinical Trials1998;19(4):314‐35. ">Grady 1998</a>). </p> </section> <section id="CD002229-sec-0080"> <h5 class="title">Interventions</h5> <p>A number of different oestrogen alone or oestrogen and progestogen combinations had been assessed in the different trials. Two trials (<a href="./references#CD002229-bbs2-0005" title="HerringtonDM , ReboussinDM , Bridget BrosnihanK , SharpPC , ShumakerSA , SnyderTE , et al. Effects of estrogen replacement on the progression of coronary‐artery atherosclerosis. New England Journal of Medicine2000;343(8):522‐9. HerringtonDM , ReboussinDM , KleinKP , SharpPC , ShumakerSA , SnyderTE , et al. The estrogen replacement and atherosclerosis (ERA) study: study design and baseline characteristics of the cohort. Controlled Clinical Trials2000;21(3):257‐85. NairG , HerringtonD . The ERA trial: findings and implications for the future. Climacteric2000;3:227‐32. ">ERA 2000</a>; <a href="./references#CD002229-bbs2-0014" title="HodisHN , MackWJ , AzenSP , LoboRA , ShoupeD , MahrerPR , et al. Hormone therapy and the progression of coronary‐artery atherosclerosis in postmenopausal women. New England Journal of Medicine2003;349(6):535‐45. ">WELL‐HART 2003</a>) were three‐armed trials, and therefore assessed both oestrogen alone and in combination with a progestogen versus placebo. Most of the included comparisons used a moderate dose of oestrogen, for example, oestradiol 1 mg or conjugated equine oestrogen 0.625 mg daily. We assessed the following interventions. </p> </section> <section id="CD002229-sec-0081"> <h5 class="title">Oestrogen‐alone hormone therapy</h5> <p> <ul id="CD002229-list-0009"> <li> <p>1 mg 17‐ß oestradiol  (<a href="./references#CD002229-bbs2-0002" title="Ouyang P , TardifJ , HerringtonD , StewartK , ThompsonP , WalshM , et al. Randomized trial of hormone therapy in women after coronary bypass surgery: Evidence of differential effect of hormone therapy on angiographic progression of disease in saphenous vein grafts and native coronary arteries. Atherosclerosis2006;189(2):375‐86. ">EAGAR 2006</a>; <a href="./references#CD002229-bbs2-0003" title="HodisH , MackW , LoboR , MahrerP , LiuC R , LiuC H . Estrogen replacement therapy effects on the progression of subclinical atherosclerosis are mediated by lipids but not by carbohydrate metabolic factors: results from the Estrogen in the Prevention of Athersclerosis Trial (EPAT). Circulation2002;106(19 Suppl II):II‐744. HodisHN , MackWJ , LoboRA , ShoupeD , SevanianA , MahrerPR , et al. Estrogen in the prevention of atherosclerosis. A randomized, double‐blind, placebo‐controlled trial. Annals of Internal Medicine2001;135(11):939‐53. ">EPAT 2001</a>; <a href="./references#CD002229-bbs2-0014" title="HodisHN , MackWJ , AzenSP , LoboRA , ShoupeD , MahrerPR , et al. Hormone therapy and the progression of coronary‐artery atherosclerosis in postmenopausal women. New England Journal of Medicine2003;349(6):535‐45. ">WELL‐HART 2003</a>; <a href="./references#CD002229-bbs2-0015" title="KernanWN , BrassLM , ViscoliCM , SarrellPM , MakuchR , HorwitzRI . Estrogen after ischemic stroke: clinical basis and design of the Womens Estrogen for Stroke Trial. Journal of Stroke and Cerebrovascular Diseases1998;7(1):85‐95. ViscoliC , BrassL , Kernan , SarrelP , SuissaS , HorwitzR . Estrogen therapy and risk of cognitive decline: Results from the Women's Estrogen for Stroke Trial (WEST). American Journal of Obstetrics and Gynecology2005;192(2):387‐93. ViscoliCM , BrassLM , KernanWN , SarrelPM , SuissaS , HorwitzRI . A clinical trial of estrogen‐replacement therapy after ischemic stroke. New England Journal of Medicine2001;345(17):1243‐9. ">WEST 2001</a>). </p> </li> <li> <p>2 mg 17‐ß oestradiol (<a href="./references#CD002229-bbs2-0001" title="BladbjergE , MadsenJ , KristensenS , AbrahamsenB , BrixenK , MosekildeL , et al. Effect of long‐term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. Journal of Thrombosis and Haemostasis2003;1(6):1208‐14. KristensenS , AbrahamsenB , MadsenJ , GramJ , RejnmarkL , RudB , et al. Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: results from the Danish Osteoporosis Prevention Study (DOPS). Thrombosis and Haemostasis2006;95:915‐6. MadsenJ , KristensenS , GramJ , BladbjergE , HenriksenF , ChristensenK , et al. Positive impact of hormone replacement therapy on the fibrinolytic system: a long‐term randomized controlled study in healthy postmenopausal women. Journal of Thrombosis and Haemostasis2003;1(9):1984‐91. SchierbeckL , RejnmarkL , ToftengC , StilgrenL , EikenP , MosekildeL , et al. Hormone replacement treatment in early postmenopausal women reduces cardiovascular events ‐ A randomized controlled study. Circulation2011;124:A11380. SchierbeckLL , RejnmarkL , ToftengCL , StilgrenL , EikenP , MosekildeL , et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ2012;345:e6409. ToftengC , JensenJ , AbrahamsenB , OdumL , BrotC . Two polymorphisms in the vitamin D receptor gene‐association with bone mass and 5‐year change in bone mass with or without hormone‐replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study. Journal of Bone and Mineral Research2002;17(8):1535‐44. deMaatM , MadsenJ , LangdalB , BladbjergE , ToftengC , AbrahamsenL , et al. Genetic variation in estrogen receptor, C‐reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. Thrombosis and Haemostasis2007;97(2):234‐9. ">DOPS 2012</a>). </p> </li> <li> <p>2 mg oestradiol valerate (<a href="./references#CD002229-bbs2-0007" title="The ESPRIT Team. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet2002;360:2001‐8. ">ESPRIT 2002</a>). </p> </li> <li> <p>0.625 mg conjugated equine oestrogen (<a href="./references#CD002229-bbs2-0005" title="HerringtonDM , ReboussinDM , Bridget BrosnihanK , SharpPC , ShumakerSA , SnyderTE , et al. Effects of estrogen replacement on the progression of coronary‐artery atherosclerosis. New England Journal of Medicine2000;343(8):522‐9. HerringtonDM , ReboussinDM , KleinKP , SharpPC , ShumakerSA , SnyderTE , et al. The estrogen replacement and atherosclerosis (ERA) study: study design and baseline characteristics of the cohort. Controlled Clinical Trials2000;21(3):257‐85. NairG , HerringtonD . The ERA trial: findings and implications for the future. Climacteric2000;3:227‐32. ">ERA 2000</a>; <a href="./references#CD002229-bbs2-0009" title="GreenspanSL , ResnickNM , ParkerRA . The effect of hormone replacement on physical performance in community‐dwelling elderly women. The American Journal of Medicine2005;118:1232‐9. ">Greenspan 2005</a>; <a href="./references#CD002229-bbs2-0012" title="GallagherJ , RapuriB , HaynatzkiG , DetterR . Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. The Journal of Clinical Endocrinology and Metabolism2002;87(11):4914‐23. GallagherJC , FowlerSE , DetterJR , ShermanSS . Combination treatment with estrogen and calcitriol in the prevention of age‐related bone loss. The Journal of Clinical Endocrinology and Metabolism2001;86(8):3618‐28. RapuriP , GallagherJ , KnezeticJ , HaynatzkaV . Estrogen receptor alpha gene polymorphisms are associated with changes in bone remodeling markers and treatment response to estrogen. Maturitas2006;53(4):371‐9. SaiA , GallagherJ , FangX . Effect of hormone therapy and calcitriol on serum lipid profile in postmenopausal older women: association with estrogen receptor‐alpha genotypes. Menopause2011;18(10):1101‐12. YalamanchiliV , GallagherJ . Treatment with hormone therapy and calcitriol did not affect depression in older postmenopausal women: no interaction with estrogen and vitamin D receptor genotype polymorphisms. Menopause2012;19(6):697‐703. ">STOP IT 2001</a>; <a href="./references#CD002229-bbs2-0013" title="HsiaJ , AldermanEL , VerterJI , RogersWJ , ThompsonP , HowardBV , et al. Women’s angiographic vitamin and estrogen trial: design and methods. Controlled Clinical Trials2002;23:708‐27. WatersD , AldermanE , HsiaJ , HowardB , CobbF , RogersW , et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women. JAMA2001;288(19):2432‐40. ">WAVE 2002</a>; <a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a>). </p> </li> </ul> </p> </section> <section id="CD002229-sec-0082"> <h5 class="title">Combined hormone therapy regimes</h5> <p>Combined hormone therapy regimens included one of the above types of oestrogen in combination with one of the two progestogens: </p> <p> <ul id="CD002229-list-0010"> <li> <p>medroxyprogesterone acetate (MPA);</p> </li> <li> <p>norethisterone.</p> </li> </ul> </p> <p>The continuous combined regimens were composed of the following.</p> <p> <ul id="CD002229-list-0011"> <li> <p>Conjugated equine oestrogen 0.625 mg with MPA 2.5 mg daily (<a href="./references#CD002229-bbs2-0004" title="HemminkiE , HoviS , VeerusP , SevónT , TuimalaR , RahuM , et al. Blinding decreased recruitment in a prevention trial of postmenopausal women. Journal of Clinical Epidemiology2004;57:1237‐43. VeerusP , FischerK , HoviS‐L , KarroH , RahuM , HemminkiE . Symptom reporting and quality of life in the Estonian Postmenopausal Hormone Therapy Trial. BMC Women’s Health2008;8:5. VeerusP , HoviS , FischerK , RahuM , HakamaM , HemminkiE . Results for the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]. Maturitas2006;55(2):162‐73. ">EPHT 2006</a>; <a href="./references#CD002229-bbs2-0005" title="HerringtonDM , ReboussinDM , Bridget BrosnihanK , SharpPC , ShumakerSA , SnyderTE , et al. Effects of estrogen replacement on the progression of coronary‐artery atherosclerosis. New England Journal of Medicine2000;343(8):522‐9. HerringtonDM , ReboussinDM , KleinKP , SharpPC , ShumakerSA , SnyderTE , et al. The estrogen replacement and atherosclerosis (ERA) study: study design and baseline characteristics of the cohort. Controlled Clinical Trials2000;21(3):257‐85. NairG , HerringtonD . The ERA trial: findings and implications for the future. Climacteric2000;3:227‐32. ">ERA 2000</a>; <a href="./references#CD002229-bbs2-0009" title="GreenspanSL , ResnickNM , ParkerRA . The effect of hormone replacement on physical performance in community‐dwelling elderly women. The American Journal of Medicine2005;118:1232‐9. ">Greenspan 2005</a>; <a href="./references#CD002229-bbs2-0011" title="Bibbins‐DomingoK , LinF , VittinghoffE , Barrett‐ConnorE , HulleyS , GradyD , et al. Effect of hormone therapy on mortality rates among women with heart failure and coronary artery disease. American Journal of Cardiology2005;95(2):289‐91. GiddingsL . Oestrogen plus progestin increased venous thromboembolic disease in postmenopausal women with coronary artery disease. Evidence Based Nursing2000;3(4):123. GradyD , ApplegateW , BushT , FurbergC , RiggsB , HulleyS , et al. Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics. Controlled Clinical Trials1998;19(4):314‐35. GradyD , HerringtonD , BittnerV , DavidsonM , HlatkyM , HsiaJ , et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study Follow‐up (HERS II). JAMA2002;288(1):49‐57. GradyD , WengerN , HerringtonD , KhanS , FurbergC , Hunninghake , et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. Annals of Internal Medicine2000;132:689‐96. HlatkyM , BoothroydD , VittinghoffE , SharpP , WhooleyMA . Quality‐of life and depressive symptoms in postmenopausal women after receiving hormone therapy. Results from the Heart and Estrogen/Progestin Replacement Study (HERS) Trial. JAMA2002;287(5):591‐7. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA1998;280(7):605‐13. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Obstetrical and Gynecological Survey1999;54(1):41‐2. KhanM , HlatkyM , LiuM , LinF , RogersW , ShlipakM . Effect of postmenopausal hormone therapy on coronary heart disease events after percutaneous transluminal coronary angioplasty. The American Journal of Cardiology2003;91(8):989‐91, A7. ShlipakM , SimonJ , VittinghoffE , LinF , Barrett‐ConnorE , KnoppR . Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA2000;283(14):1845‐52. SimonJA , HsiaJ , CauleyJA , RichardsC , HarrisF , FongJ , et al. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen‐progestin Replacement Study (HERS). Circulation2001;103(5):638‐42. SimonJA , LinF , VittinghoffE , BittnerV , Heart and Estrogen‐Progestin Replacement Study (HERS) Research Group. The relation of postmenopausal hormone therapy to serum uric acid and the risk of coronary heart disease events: The heart and estrogen‐progestin replacement study (HERS). Annals of Epidemiology2006;16(2):138‐45. SperoffL . The heart and estrogen/progestin replacement study (HERS). Maturitas1998;31(1):9‐14. ">HERS I 1998</a>; <a href="./references#CD002229-bbs2-0012" title="GallagherJ , RapuriB , HaynatzkiG , DetterR . Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. The Journal of Clinical Endocrinology and Metabolism2002;87(11):4914‐23. GallagherJC , FowlerSE , DetterJR , ShermanSS . Combination treatment with estrogen and calcitriol in the prevention of age‐related bone loss. The Journal of Clinical Endocrinology and Metabolism2001;86(8):3618‐28. RapuriP , GallagherJ , KnezeticJ , HaynatzkaV . Estrogen receptor alpha gene polymorphisms are associated with changes in bone remodeling markers and treatment response to estrogen. Maturitas2006;53(4):371‐9. SaiA , GallagherJ , FangX . Effect of hormone therapy and calcitriol on serum lipid profile in postmenopausal older women: association with estrogen receptor‐alpha genotypes. Menopause2011;18(10):1101‐12. YalamanchiliV , GallagherJ . Treatment with hormone therapy and calcitriol did not affect depression in older postmenopausal women: no interaction with estrogen and vitamin D receptor genotype polymorphisms. Menopause2012;19(6):697‐703. ">STOP IT 2001</a>; <a href="./references#CD002229-bbs2-0013" title="HsiaJ , AldermanEL , VerterJI , RogersWJ , ThompsonP , HowardBV , et al. Women’s angiographic vitamin and estrogen trial: design and methods. Controlled Clinical Trials2002;23:708‐27. WatersD , AldermanE , HsiaJ , HowardB , CobbF , RogersW , et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women. JAMA2001;288(19):2432‐40. ">WAVE 2002</a>; <a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a>; <a href="./references#CD002229-bbs2-0019" title="VickersMR , MacLacLennanA , LawtonB , FordD , MartinJ , MeredithS , et al. WISDOM group. Main morbidities recorded in the women's international study of long duration estrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ2007;335(7613):239. VickersMR , MartinJ , MeadeTW , WISDOM study team. The Women’s international study of long‐duration of estrogen after menopause (WISDOM): a randomised controlled trial. BMC Women's Health2007;7:2. WeltonAJ , VickersMR , KimJ , FordD , LawtonBA , MacLennanAH , et al. WISDOM team. Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ2008;337:a1190. ">WISDOM 2007</a>). </p> </li> <li> <p>Oestradiol 2 mg with 1 mg norethisterone daily (<a href="./references#CD002229-bbs2-0001" title="BladbjergE , MadsenJ , KristensenS , AbrahamsenB , BrixenK , MosekildeL , et al. Effect of long‐term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. Journal of Thrombosis and Haemostasis2003;1(6):1208‐14. KristensenS , AbrahamsenB , MadsenJ , GramJ , RejnmarkL , RudB , et al. Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: results from the Danish Osteoporosis Prevention Study (DOPS). Thrombosis and Haemostasis2006;95:915‐6. MadsenJ , KristensenS , GramJ , BladbjergE , HenriksenF , ChristensenK , et al. Positive impact of hormone replacement therapy on the fibrinolytic system: a long‐term randomized controlled study in healthy postmenopausal women. Journal of Thrombosis and Haemostasis2003;1(9):1984‐91. SchierbeckL , RejnmarkL , ToftengC , StilgrenL , EikenP , MosekildeL , et al. Hormone replacement treatment in early postmenopausal women reduces cardiovascular events ‐ A randomized controlled study. Circulation2011;124:A11380. SchierbeckLL , RejnmarkL , ToftengCL , StilgrenL , EikenP , MosekildeL , et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ2012;345:e6409. ToftengC , JensenJ , AbrahamsenB , OdumL , BrotC . Two polymorphisms in the vitamin D receptor gene‐association with bone mass and 5‐year change in bone mass with or without hormone‐replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study. Journal of Bone and Mineral Research2002;17(8):1535‐44. deMaatM , MadsenJ , LangdalB , BladbjergE , ToftengC , AbrahamsenL , et al. Genetic variation in estrogen receptor, C‐reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. Thrombosis and Haemostasis2007;97(2):234‐9. ">DOPS 2012</a>; <a href="./references#CD002229-bbs2-0008" title="HoibraatenE , ArnesenH , LarsenS , WickstromE , SandsetPM . Increased risk of recurrent venous thromboembolism during hormone replacement therapy: results of the randomized, double blind, placebo‐controlled estrogen in venous thromboembolism trial (EVTET). Thrombosis and Haemostasis2000;84:961‐7. Qvigtad , HoibraatenH , ArnesenH , LarsenS , WickstromE , SandsetP . Recurrent venous thromboembolism during hormone replacement therapy ‐ results of the estrogen in venous thromboembolism trial. XVI FIGO World Congress of O and G2000;Abstract book 1:58. ">EVTET 2000</a>). </p> </li> </ul> </p> <p>Whist the combined sequential regimes included:</p> <p> <ul id="CD002229-list-0012"> <li> <p>oestradiol 1 mg daily with MPA 5 mg for 12 days each month (<a href="./references#CD002229-bbs2-0014" title="HodisHN , MackWJ , AzenSP , LoboRA , ShoupeD , MahrerPR , et al. Hormone therapy and the progression of coronary‐artery atherosclerosis in postmenopausal women. New England Journal of Medicine2003;349(6):535‐45. ">WELL‐HART 2003</a>); </p> </li> <li> <p>conjugated equine oestrogen 0.625 mg for 18 days followed by a combination with oral 5 mg MPA (<a href="./references#CD002229-bbs2-0010" title="HallG , PrippU , Schenk‐GustafssonK , LandgrenBM . Long‐term effects of hormone replacement therapy on symptoms of angina pectoris, quality of life and compliance in women with coronary artery disease. Maturitas1998 ;28 :235‐42 . ">HALL 1998</a>); </p> </li> <li> <p>conjugated equine oestrogen 2.5 mg with MPA 10 mg for seven days each month (<a href="./references#CD002229-bbs2-0006" title="NachtigallLE , NachtigallRH , NachtigallRD , BeckmanEM . Estrogen replacement therapy II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstetrics Gynecology1979;54(1):74‐9. ">ERT II 1979</a>); and </p> </li> <li> <p>oestradiol 1 mg daily with 0.5 mg norethisterone daily (<a href="./references#CD002229-bbs2-0018" title="CollinsP , FlatherM , LeesB , MisterR , ProudlerA , StevensonJC , WHISP (Women's Hormone Intervention Secondary Prevention Study) Pilot Study Investigators. Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study. European Heart Journal2006;27(17):2046‐53. ">WHISP 2006</a>). </p> </li> </ul> </p> <p>The control arm in each of the trials received placebo tablets, except <a href="./references#CD002229-bbs2-0001" title="BladbjergE , MadsenJ , KristensenS , AbrahamsenB , BrixenK , MosekildeL , et al. Effect of long‐term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. Journal of Thrombosis and Haemostasis2003;1(6):1208‐14. KristensenS , AbrahamsenB , MadsenJ , GramJ , RejnmarkL , RudB , et al. Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: results from the Danish Osteoporosis Prevention Study (DOPS). Thrombosis and Haemostasis2006;95:915‐6. MadsenJ , KristensenS , GramJ , BladbjergE , HenriksenF , ChristensenK , et al. Positive impact of hormone replacement therapy on the fibrinolytic system: a long‐term randomized controlled study in healthy postmenopausal women. Journal of Thrombosis and Haemostasis2003;1(9):1984‐91. SchierbeckL , RejnmarkL , ToftengC , StilgrenL , EikenP , MosekildeL , et al. Hormone replacement treatment in early postmenopausal women reduces cardiovascular events ‐ A randomized controlled study. Circulation2011;124:A11380. SchierbeckLL , RejnmarkL , ToftengCL , StilgrenL , EikenP , MosekildeL , et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ2012;345:e6409. ToftengC , JensenJ , AbrahamsenB , OdumL , BrotC . Two polymorphisms in the vitamin D receptor gene‐association with bone mass and 5‐year change in bone mass with or without hormone‐replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study. Journal of Bone and Mineral Research2002;17(8):1535‐44. deMaatM , MadsenJ , LangdalB , BladbjergE , ToftengC , AbrahamsenL , et al. Genetic variation in estrogen receptor, C‐reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. Thrombosis and Haemostasis2007;97(2):234‐9. ">DOPS 2012</a> which used a no treatment control.<br/> <br/> The duration of hormone therapy use varied widely across the trials, with follow‐up duration ranging from seven months (<a href="./references#CD002229-bbs2-0018" title="CollinsP , FlatherM , LeesB , MisterR , ProudlerA , StevensonJC , WHISP (Women's Hormone Intervention Secondary Prevention Study) Pilot Study Investigators. Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study. European Heart Journal2006;27(17):2046‐53. ">WHISP 2006</a>) to 10.1 years (<a href="./references#CD002229-bbs2-0001" title="BladbjergE , MadsenJ , KristensenS , AbrahamsenB , BrixenK , MosekildeL , et al. Effect of long‐term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. Journal of Thrombosis and Haemostasis2003;1(6):1208‐14. KristensenS , AbrahamsenB , MadsenJ , GramJ , RejnmarkL , RudB , et al. Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: results from the Danish Osteoporosis Prevention Study (DOPS). Thrombosis and Haemostasis2006;95:915‐6. MadsenJ , KristensenS , GramJ , BladbjergE , HenriksenF , ChristensenK , et al. Positive impact of hormone replacement therapy on the fibrinolytic system: a long‐term randomized controlled study in healthy postmenopausal women. Journal of Thrombosis and Haemostasis2003;1(9):1984‐91. SchierbeckL , RejnmarkL , ToftengC , StilgrenL , EikenP , MosekildeL , et al. Hormone replacement treatment in early postmenopausal women reduces cardiovascular events ‐ A randomized controlled study. Circulation2011;124:A11380. SchierbeckLL , RejnmarkL , ToftengCL , StilgrenL , EikenP , MosekildeL , et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ2012;345:e6409. ToftengC , JensenJ , AbrahamsenB , OdumL , BrotC . Two polymorphisms in the vitamin D receptor gene‐association with bone mass and 5‐year change in bone mass with or without hormone‐replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study. Journal of Bone and Mineral Research2002;17(8):1535‐44. deMaatM , MadsenJ , LangdalB , BladbjergE , ToftengC , AbrahamsenL , et al. Genetic variation in estrogen receptor, C‐reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. Thrombosis and Haemostasis2007;97(2):234‐9. ">DOPS 2012</a>). Four trials reported outcomes after hormone therapy use for around one year (<a href="./references#CD002229-bbs2-0008" title="HoibraatenE , ArnesenH , LarsenS , WickstromE , SandsetPM . Increased risk of recurrent venous thromboembolism during hormone replacement therapy: results of the randomized, double blind, placebo‐controlled estrogen in venous thromboembolism trial (EVTET). Thrombosis and Haemostasis2000;84:961‐7. Qvigtad , HoibraatenH , ArnesenH , LarsenS , WickstromE , SandsetP . Recurrent venous thromboembolism during hormone replacement therapy ‐ results of the estrogen in venous thromboembolism trial. XVI FIGO World Congress of O and G2000;Abstract book 1:58. ">EVTET 2000</a>; <a href="./references#CD002229-bbs2-0010" title="HallG , PrippU , Schenk‐GustafssonK , LandgrenBM . Long‐term effects of hormone replacement therapy on symptoms of angina pectoris, quality of life and compliance in women with coronary artery disease. Maturitas1998 ;28 :235‐42 . ">HALL 1998</a>; <a href="./references#CD002229-bbs2-0018" title="CollinsP , FlatherM , LeesB , MisterR , ProudlerA , StevensonJC , WHISP (Women's Hormone Intervention Secondary Prevention Study) Pilot Study Investigators. Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study. European Heart Journal2006;27(17):2046‐53. ">WHISP 2006</a>; <a href="./references#CD002229-bbs2-0019" title="VickersMR , MacLacLennanA , LawtonB , FordD , MartinJ , MeredithS , et al. WISDOM group. Main morbidities recorded in the women's international study of long duration estrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ2007;335(7613):239. VickersMR , MartinJ , MeadeTW , WISDOM study team. The Women’s international study of long‐duration of estrogen after menopause (WISDOM): a randomised controlled trial. BMC Women's Health2007;7:2. WeltonAJ , VickersMR , KimJ , FordD , LawtonBA , MacLennanAH , et al. WISDOM team. Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ2008;337:a1190. ">WISDOM 2007</a>); two trials for two years (<a href="./references#CD002229-bbs2-0003" title="HodisH , MackW , LoboR , MahrerP , LiuC R , LiuC H . Estrogen replacement therapy effects on the progression of subclinical atherosclerosis are mediated by lipids but not by carbohydrate metabolic factors: results from the Estrogen in the Prevention of Athersclerosis Trial (EPAT). Circulation2002;106(19 Suppl II):II‐744. HodisHN , MackWJ , LoboRA , ShoupeD , SevanianA , MahrerPR , et al. Estrogen in the prevention of atherosclerosis. A randomized, double‐blind, placebo‐controlled trial. Annals of Internal Medicine2001;135(11):939‐53. ">EPAT 2001</a>; <a href="./references#CD002229-bbs2-0007" title="The ESPRIT Team. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet2002;360:2001‐8. ">ESPRIT 2002</a>), and eight trials for approximately three years (<a href="./references#CD002229-bbs2-0002" title="Ouyang P , TardifJ , HerringtonD , StewartK , ThompsonP , WalshM , et al. Randomized trial of hormone therapy in women after coronary bypass surgery: Evidence of differential effect of hormone therapy on angiographic progression of disease in saphenous vein grafts and native coronary arteries. Atherosclerosis2006;189(2):375‐86. ">EAGAR 2006</a>; <a href="./references#CD002229-bbs2-0004" title="HemminkiE , HoviS , VeerusP , SevónT , TuimalaR , RahuM , et al. Blinding decreased recruitment in a prevention trial of postmenopausal women. Journal of Clinical Epidemiology2004;57:1237‐43. VeerusP , FischerK , HoviS‐L , KarroH , RahuM , HemminkiE . Symptom reporting and quality of life in the Estonian Postmenopausal Hormone Therapy Trial. BMC Women’s Health2008;8:5. VeerusP , HoviS , FischerK , RahuM , HakamaM , HemminkiE . Results for the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]. Maturitas2006;55(2):162‐73. ">EPHT 2006</a>; <a href="./references#CD002229-bbs2-0005" title="HerringtonDM , ReboussinDM , Bridget BrosnihanK , SharpPC , ShumakerSA , SnyderTE , et al. Effects of estrogen replacement on the progression of coronary‐artery atherosclerosis. New England Journal of Medicine2000;343(8):522‐9. HerringtonDM , ReboussinDM , KleinKP , SharpPC , ShumakerSA , SnyderTE , et al. The estrogen replacement and atherosclerosis (ERA) study: study design and baseline characteristics of the cohort. Controlled Clinical Trials2000;21(3):257‐85. NairG , HerringtonD . The ERA trial: findings and implications for the future. Climacteric2000;3:227‐32. ">ERA 2000</a>; <a href="./references#CD002229-bbs2-0009" title="GreenspanSL , ResnickNM , ParkerRA . The effect of hormone replacement on physical performance in community‐dwelling elderly women. The American Journal of Medicine2005;118:1232‐9. ">Greenspan 2005</a>; <a href="./references#CD002229-bbs2-0012" title="GallagherJ , RapuriB , HaynatzkiG , DetterR . Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. The Journal of Clinical Endocrinology and Metabolism2002;87(11):4914‐23. GallagherJC , FowlerSE , DetterJR , ShermanSS . Combination treatment with estrogen and calcitriol in the prevention of age‐related bone loss. The Journal of Clinical Endocrinology and Metabolism2001;86(8):3618‐28. RapuriP , GallagherJ , KnezeticJ , HaynatzkaV . Estrogen receptor alpha gene polymorphisms are associated with changes in bone remodeling markers and treatment response to estrogen. Maturitas2006;53(4):371‐9. SaiA , GallagherJ , FangX . Effect of hormone therapy and calcitriol on serum lipid profile in postmenopausal older women: association with estrogen receptor‐alpha genotypes. Menopause2011;18(10):1101‐12. YalamanchiliV , GallagherJ . Treatment with hormone therapy and calcitriol did not affect depression in older postmenopausal women: no interaction with estrogen and vitamin D receptor genotype polymorphisms. Menopause2012;19(6):697‐703. ">STOP IT 2001</a>; <a href="./references#CD002229-bbs2-0013" title="HsiaJ , AldermanEL , VerterJI , RogersWJ , ThompsonP , HowardBV , et al. Women’s angiographic vitamin and estrogen trial: design and methods. Controlled Clinical Trials2002;23:708‐27. WatersD , AldermanE , HsiaJ , HowardB , CobbF , RogersW , et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women. JAMA2001;288(19):2432‐40. ">WAVE 2002</a>; <a href="./references#CD002229-bbs2-0014" title="HodisHN , MackWJ , AzenSP , LoboRA , ShoupeD , MahrerPR , et al. Hormone therapy and the progression of coronary‐artery atherosclerosis in postmenopausal women. New England Journal of Medicine2003;349(6):535‐45. ">WELL‐HART 2003</a>; <a href="./references#CD002229-bbs2-0015" title="KernanWN , BrassLM , ViscoliCM , SarrellPM , MakuchR , HorwitzRI . Estrogen after ischemic stroke: clinical basis and design of the Womens Estrogen for Stroke Trial. Journal of Stroke and Cerebrovascular Diseases1998;7(1):85‐95. ViscoliC , BrassL , Kernan , SarrelP , SuissaS , HorwitzR . Estrogen therapy and risk of cognitive decline: Results from the Women's Estrogen for Stroke Trial (WEST). American Journal of Obstetrics and Gynecology2005;192(2):387‐93. ViscoliCM , BrassLM , KernanWN , SarrelPM , SuissaS , HorwitzRI . A clinical trial of estrogen‐replacement therapy after ischemic stroke. New England Journal of Medicine2001;345(17):1243‐9. ">WEST 2001</a>). <a href="./references#CD002229-bbs2-0011" title="Bibbins‐DomingoK , LinF , VittinghoffE , Barrett‐ConnorE , HulleyS , GradyD , et al. Effect of hormone therapy on mortality rates among women with heart failure and coronary artery disease. American Journal of Cardiology2005;95(2):289‐91. GiddingsL . Oestrogen plus progestin increased venous thromboembolic disease in postmenopausal women with coronary artery disease. Evidence Based Nursing2000;3(4):123. GradyD , ApplegateW , BushT , FurbergC , RiggsB , HulleyS , et al. Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics. Controlled Clinical Trials1998;19(4):314‐35. GradyD , HerringtonD , BittnerV , DavidsonM , HlatkyM , HsiaJ , et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study Follow‐up (HERS II). JAMA2002;288(1):49‐57. GradyD , WengerN , HerringtonD , KhanS , FurbergC , Hunninghake , et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. Annals of Internal Medicine2000;132:689‐96. HlatkyM , BoothroydD , VittinghoffE , SharpP , WhooleyMA . Quality‐of life and depressive symptoms in postmenopausal women after receiving hormone therapy. Results from the Heart and Estrogen/Progestin Replacement Study (HERS) Trial. JAMA2002;287(5):591‐7. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA1998;280(7):605‐13. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Obstetrical and Gynecological Survey1999;54(1):41‐2. KhanM , HlatkyM , LiuM , LinF , RogersW , ShlipakM . Effect of postmenopausal hormone therapy on coronary heart disease events after percutaneous transluminal coronary angioplasty. The American Journal of Cardiology2003;91(8):989‐91, A7. ShlipakM , SimonJ , VittinghoffE , LinF , Barrett‐ConnorE , KnoppR . Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA2000;283(14):1845‐52. SimonJA , HsiaJ , CauleyJA , RichardsC , HarrisF , FongJ , et al. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen‐progestin Replacement Study (HERS). Circulation2001;103(5):638‐42. SimonJA , LinF , VittinghoffE , BittnerV , Heart and Estrogen‐Progestin Replacement Study (HERS) Research Group. The relation of postmenopausal hormone therapy to serum uric acid and the risk of coronary heart disease events: The heart and estrogen‐progestin replacement study (HERS). Annals of Epidemiology2006;16(2):138‐45. SperoffL . The heart and estrogen/progestin replacement study (HERS). Maturitas1998;31(1):9‐14. ">HERS I 1998</a> measured outcomes after 4.1 years, and continued the study unblinded for a further 2.7 years follow‐up (<a href="./references#CD002229-bbs2-0043" title="GradyD , HerringtonD , BittnerV , BlumenthalR , DavidsonM , HlatkyM , et al. HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow‐up (HERS II). JAMA2002;288(1):49‐57. ">HERS II</a>). Both the <a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a> and <a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a> trials were planned to continue for 8.5 years, but both trials were terminated early. Outcomes in <a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a> were reported at 5.2 years and subsequently for a further four months of follow‐up (total follow‐up 5.6 years) for primary and selected secondary outcome measures. <a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a> reported outcomes at 6.8 years and for a subsequent further three months of follow‐up (7.1 years) for primary and selected secondary outcomes, with a median time of 5.9 and 5.8 years on treatment for the hormone therapy and placebo groups, respectively. <a href="./references#CD002229-bbs2-0006" title="NachtigallLE , NachtigallRH , NachtigallRD , BeckmanEM . Estrogen replacement therapy II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstetrics Gynecology1979;54(1):74‐9. ">ERT II 1979</a> measured outcomes at 10 years. <a href="./references#CD002229-bbs2-0001" title="BladbjergE , MadsenJ , KristensenS , AbrahamsenB , BrixenK , MosekildeL , et al. Effect of long‐term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. Journal of Thrombosis and Haemostasis2003;1(6):1208‐14. KristensenS , AbrahamsenB , MadsenJ , GramJ , RejnmarkL , RudB , et al. Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: results from the Danish Osteoporosis Prevention Study (DOPS). Thrombosis and Haemostasis2006;95:915‐6. MadsenJ , KristensenS , GramJ , BladbjergE , HenriksenF , ChristensenK , et al. Positive impact of hormone replacement therapy on the fibrinolytic system: a long‐term randomized controlled study in healthy postmenopausal women. Journal of Thrombosis and Haemostasis2003;1(9):1984‐91. SchierbeckL , RejnmarkL , ToftengC , StilgrenL , EikenP , MosekildeL , et al. Hormone replacement treatment in early postmenopausal women reduces cardiovascular events ‐ A randomized controlled study. Circulation2011;124:A11380. SchierbeckLL , RejnmarkL , ToftengCL , StilgrenL , EikenP , MosekildeL , et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ2012;345:e6409. ToftengC , JensenJ , AbrahamsenB , OdumL , BrotC . Two polymorphisms in the vitamin D receptor gene‐association with bone mass and 5‐year change in bone mass with or without hormone‐replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study. Journal of Bone and Mineral Research2002;17(8):1535‐44. deMaatM , MadsenJ , LangdalB , BladbjergE , ToftengC , AbrahamsenL , et al. Genetic variation in estrogen receptor, C‐reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. Thrombosis and Haemostasis2007;97(2):234‐9. ">DOPS 2012</a> measured outcomes after 10.1 years, and continued the study unblinded for a further 5.7 years (<a href="./references#CD002229-bbs2-0001" title="BladbjergE , MadsenJ , KristensenS , AbrahamsenB , BrixenK , MosekildeL , et al. Effect of long‐term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. Journal of Thrombosis and Haemostasis2003;1(6):1208‐14. KristensenS , AbrahamsenB , MadsenJ , GramJ , RejnmarkL , RudB , et al. Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: results from the Danish Osteoporosis Prevention Study (DOPS). Thrombosis and Haemostasis2006;95:915‐6. MadsenJ , KristensenS , GramJ , BladbjergE , HenriksenF , ChristensenK , et al. Positive impact of hormone replacement therapy on the fibrinolytic system: a long‐term randomized controlled study in healthy postmenopausal women. Journal of Thrombosis and Haemostasis2003;1(9):1984‐91. SchierbeckL , RejnmarkL , ToftengC , StilgrenL , EikenP , MosekildeL , et al. Hormone replacement treatment in early postmenopausal women reduces cardiovascular events ‐ A randomized controlled study. Circulation2011;124:A11380. SchierbeckLL , RejnmarkL , ToftengCL , StilgrenL , EikenP , MosekildeL , et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ2012;345:e6409. ToftengC , JensenJ , AbrahamsenB , OdumL , BrotC . Two polymorphisms in the vitamin D receptor gene‐association with bone mass and 5‐year change in bone mass with or without hormone‐replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study. Journal of Bone and Mineral Research2002;17(8):1535‐44. deMaatM , MadsenJ , LangdalB , BladbjergE , ToftengC , AbrahamsenL , et al. Genetic variation in estrogen receptor, C‐reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. Thrombosis and Haemostasis2007;97(2):234‐9. ">DOPS 2012</a>). </p> </section> <section id="CD002229-sec-0083"> <h5 class="title">Outcomes</h5> <p>The outcomes assessed in the individual trials varied according to the trial objectives. One primary prevention trial (<a href="./references#CD002229-bbs2-0003" title="HodisH , MackW , LoboR , MahrerP , LiuC R , LiuC H . Estrogen replacement therapy effects on the progression of subclinical atherosclerosis are mediated by lipids but not by carbohydrate metabolic factors: results from the Estrogen in the Prevention of Athersclerosis Trial (EPAT). Circulation2002;106(19 Suppl II):II‐744. HodisHN , MackWJ , LoboRA , ShoupeD , SevanianA , MahrerPR , et al. Estrogen in the prevention of atherosclerosis. A randomized, double‐blind, placebo‐controlled trial. Annals of Internal Medicine2001;135(11):939‐53. ">EPAT 2001</a>) and five secondary prevention trials (<a href="./references#CD002229-bbs2-0005" title="HerringtonDM , ReboussinDM , Bridget BrosnihanK , SharpPC , ShumakerSA , SnyderTE , et al. Effects of estrogen replacement on the progression of coronary‐artery atherosclerosis. New England Journal of Medicine2000;343(8):522‐9. HerringtonDM , ReboussinDM , KleinKP , SharpPC , ShumakerSA , SnyderTE , et al. The estrogen replacement and atherosclerosis (ERA) study: study design and baseline characteristics of the cohort. Controlled Clinical Trials2000;21(3):257‐85. NairG , HerringtonD . The ERA trial: findings and implications for the future. Climacteric2000;3:227‐32. ">ERA 2000</a>; <a href="./references#CD002229-bbs2-0007" title="The ESPRIT Team. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet2002;360:2001‐8. ">ESPRIT 2002</a>; <a href="./references#CD002229-bbs2-0013" title="HsiaJ , AldermanEL , VerterJI , RogersWJ , ThompsonP , HowardBV , et al. Women’s angiographic vitamin and estrogen trial: design and methods. Controlled Clinical Trials2002;23:708‐27. WatersD , AldermanE , HsiaJ , HowardB , CobbF , RogersW , et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women. JAMA2001;288(19):2432‐40. ">WAVE 2002</a>; <a href="./references#CD002229-bbs2-0014" title="HodisHN , MackWJ , AzenSP , LoboRA , ShoupeD , MahrerPR , et al. Hormone therapy and the progression of coronary‐artery atherosclerosis in postmenopausal women. New England Journal of Medicine2003;349(6):535‐45. ">WELL‐HART 2003</a>; <a href="./references#CD002229-bbs2-0018" title="CollinsP , FlatherM , LeesB , MisterR , ProudlerA , StevensonJC , WHISP (Women's Hormone Intervention Secondary Prevention Study) Pilot Study Investigators. Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study. European Heart Journal2006;27(17):2046‐53. ">WHISP 2006</a>) aimed to assess the effects of hormone therapy upon intermediate outcomes: carotid artery intima‐media thickness, lipid and coagulation biomarkers and the impact on coronary atherosclerosis as measured by angiographic coronary stenosis. Two trials, including populations free from cardiovascular disease assessed bone mineral density, physical and cognitive parameters (<a href="./references#CD002229-bbs2-0009" title="GreenspanSL , ResnickNM , ParkerRA . The effect of hormone replacement on physical performance in community‐dwelling elderly women. The American Journal of Medicine2005;118:1232‐9. ">Greenspan 2005</a>; <a href="./references#CD002229-bbs2-0012" title="GallagherJ , RapuriB , HaynatzkiG , DetterR . Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. The Journal of Clinical Endocrinology and Metabolism2002;87(11):4914‐23. GallagherJC , FowlerSE , DetterJR , ShermanSS . Combination treatment with estrogen and calcitriol in the prevention of age‐related bone loss. The Journal of Clinical Endocrinology and Metabolism2001;86(8):3618‐28. RapuriP , GallagherJ , KnezeticJ , HaynatzkaV . Estrogen receptor alpha gene polymorphisms are associated with changes in bone remodeling markers and treatment response to estrogen. Maturitas2006;53(4):371‐9. SaiA , GallagherJ , FangX . Effect of hormone therapy and calcitriol on serum lipid profile in postmenopausal older women: association with estrogen receptor‐alpha genotypes. Menopause2011;18(10):1101‐12. YalamanchiliV , GallagherJ . Treatment with hormone therapy and calcitriol did not affect depression in older postmenopausal women: no interaction with estrogen and vitamin D receptor genotype polymorphisms. Menopause2012;19(6):697‐703. ">STOP IT 2001</a>), and one study did not state any outcomes but reported a range of adverse events seen in the participants over a ten year follow‐up period (<a href="./references#CD002229-bbs2-0006" title="NachtigallLE , NachtigallRH , NachtigallRD , BeckmanEM . Estrogen replacement therapy II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstetrics Gynecology1979;54(1):74‐9. ">ERT II 1979</a>). </p> <p>The primary aim in the largest two trials, <a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a> and <a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a>, was to assess the potential cardioprotective effect of hormone therapy in relatively healthy post‐menopausal women, and therefore both trials reported cardiovascular clinical endpoints as the primary outcome. Invasive breast cancer was the designated primary adverse outcome in both trials, with the incidence of other cancers, fractures, gallbladder disease and death reported as secondary outcomes. A further two primary prevention trials (<a href="./references#CD002229-bbs2-0004" title="HemminkiE , HoviS , VeerusP , SevónT , TuimalaR , RahuM , et al. Blinding decreased recruitment in a prevention trial of postmenopausal women. Journal of Clinical Epidemiology2004;57:1237‐43. VeerusP , FischerK , HoviS‐L , KarroH , RahuM , HemminkiE . Symptom reporting and quality of life in the Estonian Postmenopausal Hormone Therapy Trial. BMC Women’s Health2008;8:5. VeerusP , HoviS , FischerK , RahuM , HakamaM , HemminkiE . Results for the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]. Maturitas2006;55(2):162‐73. ">EPHT 2006</a>; <a href="./references#CD002229-bbs2-0019" title="VickersMR , MacLacLennanA , LawtonB , FordD , MartinJ , MeredithS , et al. WISDOM group. Main morbidities recorded in the women's international study of long duration estrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ2007;335(7613):239. VickersMR , MartinJ , MeadeTW , WISDOM study team. The Women’s international study of long‐duration of estrogen after menopause (WISDOM): a randomised controlled trial. BMC Women's Health2007;7:2. WeltonAJ , VickersMR , KimJ , FordD , LawtonBA , MacLennanAH , et al. WISDOM team. Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ2008;337:a1190. ">WISDOM 2007</a>) also measured similar outcomes, with cardiovascular disease outcomes designated as the primary ones of interest. A further primary prevention study (<a href="./references#CD002229-bbs2-0001" title="BladbjergE , MadsenJ , KristensenS , AbrahamsenB , BrixenK , MosekildeL , et al. Effect of long‐term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. Journal of Thrombosis and Haemostasis2003;1(6):1208‐14. KristensenS , AbrahamsenB , MadsenJ , GramJ , RejnmarkL , RudB , et al. Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: results from the Danish Osteoporosis Prevention Study (DOPS). Thrombosis and Haemostasis2006;95:915‐6. MadsenJ , KristensenS , GramJ , BladbjergE , HenriksenF , ChristensenK , et al. Positive impact of hormone replacement therapy on the fibrinolytic system: a long‐term randomized controlled study in healthy postmenopausal women. Journal of Thrombosis and Haemostasis2003;1(9):1984‐91. SchierbeckL , RejnmarkL , ToftengC , StilgrenL , EikenP , MosekildeL , et al. Hormone replacement treatment in early postmenopausal women reduces cardiovascular events ‐ A randomized controlled study. Circulation2011;124:A11380. SchierbeckLL , RejnmarkL , ToftengCL , StilgrenL , EikenP , MosekildeL , et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ2012;345:e6409. ToftengC , JensenJ , AbrahamsenB , OdumL , BrotC . Two polymorphisms in the vitamin D receptor gene‐association with bone mass and 5‐year change in bone mass with or without hormone‐replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study. Journal of Bone and Mineral Research2002;17(8):1535‐44. deMaatM , MadsenJ , LangdalB , BladbjergE , ToftengC , AbrahamsenL , et al. Genetic variation in estrogen receptor, C‐reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. Thrombosis and Haemostasis2007;97(2):234‐9. ">DOPS 2012</a>) had a primary outcome of osteoporotic fractures but had a predefined safety composite endpoint of death, admission to hospital for myocardial infarction and heart failure; it also reported a number of cardiovascular endpoints individually. The remaining five secondary prevention trials aimed to examine the effects of hormone therapy in women with already established clinical disease, with the primary outcome designated according to the underlying patient pathology. Their primary outcomes were myocardial infarction or death (<a href="./references#CD002229-bbs2-0007" title="The ESPRIT Team. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet2002;360:2001‐8. ">ESPRIT 2002</a>; <a href="./references#CD002229-bbs2-0011" title="Bibbins‐DomingoK , LinF , VittinghoffE , Barrett‐ConnorE , HulleyS , GradyD , et al. Effect of hormone therapy on mortality rates among women with heart failure and coronary artery disease. American Journal of Cardiology2005;95(2):289‐91. GiddingsL . Oestrogen plus progestin increased venous thromboembolic disease in postmenopausal women with coronary artery disease. Evidence Based Nursing2000;3(4):123. GradyD , ApplegateW , BushT , FurbergC , RiggsB , HulleyS , et al. Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics. Controlled Clinical Trials1998;19(4):314‐35. GradyD , HerringtonD , BittnerV , DavidsonM , HlatkyM , HsiaJ , et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study Follow‐up (HERS II). JAMA2002;288(1):49‐57. GradyD , WengerN , HerringtonD , KhanS , FurbergC , Hunninghake , et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. Annals of Internal Medicine2000;132:689‐96. HlatkyM , BoothroydD , VittinghoffE , SharpP , WhooleyMA . Quality‐of life and depressive symptoms in postmenopausal women after receiving hormone therapy. Results from the Heart and Estrogen/Progestin Replacement Study (HERS) Trial. JAMA2002;287(5):591‐7. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA1998;280(7):605‐13. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Obstetrical and Gynecological Survey1999;54(1):41‐2. KhanM , HlatkyM , LiuM , LinF , RogersW , ShlipakM . Effect of postmenopausal hormone therapy on coronary heart disease events after percutaneous transluminal coronary angioplasty. The American Journal of Cardiology2003;91(8):989‐91, A7. ShlipakM , SimonJ , VittinghoffE , LinF , Barrett‐ConnorE , KnoppR . Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA2000;283(14):1845‐52. SimonJA , HsiaJ , CauleyJA , RichardsC , HarrisF , FongJ , et al. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen‐progestin Replacement Study (HERS). Circulation2001;103(5):638‐42. SimonJA , LinF , VittinghoffE , BittnerV , Heart and Estrogen‐Progestin Replacement Study (HERS) Research Group. The relation of postmenopausal hormone therapy to serum uric acid and the risk of coronary heart disease events: The heart and estrogen‐progestin replacement study (HERS). Annals of Epidemiology2006;16(2):138‐45. SperoffL . The heart and estrogen/progestin replacement study (HERS). Maturitas1998;31(1):9‐14. ">HERS I 1998</a>), thromboembolism (<a href="./references#CD002229-bbs2-0008" title="HoibraatenE , ArnesenH , LarsenS , WickstromE , SandsetPM . Increased risk of recurrent venous thromboembolism during hormone replacement therapy: results of the randomized, double blind, placebo‐controlled estrogen in venous thromboembolism trial (EVTET). Thrombosis and Haemostasis2000;84:961‐7. Qvigtad , HoibraatenH , ArnesenH , LarsenS , WickstromE , SandsetP . Recurrent venous thromboembolism during hormone replacement therapy ‐ results of the estrogen in venous thromboembolism trial. XVI FIGO World Congress of O and G2000;Abstract book 1:58. ">EVTET 2000</a>), stroke (<a href="./references#CD002229-bbs2-0015" title="KernanWN , BrassLM , ViscoliCM , SarrellPM , MakuchR , HorwitzRI . Estrogen after ischemic stroke: clinical basis and design of the Womens Estrogen for Stroke Trial. Journal of Stroke and Cerebrovascular Diseases1998;7(1):85‐95. ViscoliC , BrassL , Kernan , SarrelP , SuissaS , HorwitzR . Estrogen therapy and risk of cognitive decline: Results from the Women's Estrogen for Stroke Trial (WEST). American Journal of Obstetrics and Gynecology2005;192(2):387‐93. ViscoliCM , BrassLM , KernanWN , SarrelPM , SuissaS , HorwitzRI . A clinical trial of estrogen‐replacement therapy after ischemic stroke. New England Journal of Medicine2001;345(17):1243‐9. ">WEST 2001</a>), and angina (<a href="./references#CD002229-bbs2-0010" title="HallG , PrippU , Schenk‐GustafssonK , LandgrenBM . Long‐term effects of hormone replacement therapy on symptoms of angina pectoris, quality of life and compliance in women with coronary artery disease. Maturitas1998 ;28 :235‐42 . ">HALL 1998</a>). Adverse events due to hormone therapy were not analysed other than those prespecified as primary or secondary outcomes. </p> </section> <section id="CD002229-sec-0084"> <h5 class="title">Funding Source</h5> <p>Eighteen out of 19 trials reported the funding source. Only one of the trials, <a href="./references#CD002229-bbs2-0011" title="Bibbins‐DomingoK , LinF , VittinghoffE , Barrett‐ConnorE , HulleyS , GradyD , et al. Effect of hormone therapy on mortality rates among women with heart failure and coronary artery disease. American Journal of Cardiology2005;95(2):289‐91. GiddingsL . Oestrogen plus progestin increased venous thromboembolic disease in postmenopausal women with coronary artery disease. Evidence Based Nursing2000;3(4):123. GradyD , ApplegateW , BushT , FurbergC , RiggsB , HulleyS , et al. Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics. Controlled Clinical Trials1998;19(4):314‐35. GradyD , HerringtonD , BittnerV , DavidsonM , HlatkyM , HsiaJ , et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study Follow‐up (HERS II). JAMA2002;288(1):49‐57. GradyD , WengerN , HerringtonD , KhanS , FurbergC , Hunninghake , et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. Annals of Internal Medicine2000;132:689‐96. HlatkyM , BoothroydD , VittinghoffE , SharpP , WhooleyMA . Quality‐of life and depressive symptoms in postmenopausal women after receiving hormone therapy. Results from the Heart and Estrogen/Progestin Replacement Study (HERS) Trial. JAMA2002;287(5):591‐7. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA1998;280(7):605‐13. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Obstetrical and Gynecological Survey1999;54(1):41‐2. KhanM , HlatkyM , LiuM , LinF , RogersW , ShlipakM . Effect of postmenopausal hormone therapy on coronary heart disease events after percutaneous transluminal coronary angioplasty. The American Journal of Cardiology2003;91(8):989‐91, A7. ShlipakM , SimonJ , VittinghoffE , LinF , Barrett‐ConnorE , KnoppR . Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA2000;283(14):1845‐52. SimonJA , HsiaJ , CauleyJA , RichardsC , HarrisF , FongJ , et al. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen‐progestin Replacement Study (HERS). Circulation2001;103(5):638‐42. SimonJA , LinF , VittinghoffE , BittnerV , Heart and Estrogen‐Progestin Replacement Study (HERS) Research Group. The relation of postmenopausal hormone therapy to serum uric acid and the risk of coronary heart disease events: The heart and estrogen‐progestin replacement study (HERS). Annals of Epidemiology2006;16(2):138‐45. SperoffL . The heart and estrogen/progestin replacement study (HERS). Maturitas1998;31(1):9‐14. ">HERS I 1998</a> was exclusively funded by the pharmaceutical industry (Wyeth‐Ayerst), whilst <a href="./references#CD002229-bbs2-0008" title="HoibraatenE , ArnesenH , LarsenS , WickstromE , SandsetPM . Increased risk of recurrent venous thromboembolism during hormone replacement therapy: results of the randomized, double blind, placebo‐controlled estrogen in venous thromboembolism trial (EVTET). Thrombosis and Haemostasis2000;84:961‐7. Qvigtad , HoibraatenH , ArnesenH , LarsenS , WickstromE , SandsetP . Recurrent venous thromboembolism during hormone replacement therapy ‐ results of the estrogen in venous thromboembolism trial. XVI FIGO World Congress of O and G2000;Abstract book 1:58. ">EVTET 2000</a> and <a href="./references#CD002229-bbs2-0018" title="CollinsP , FlatherM , LeesB , MisterR , ProudlerA , StevensonJC , WHISP (Women's Hormone Intervention Secondary Prevention Study) Pilot Study Investigators. Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study. European Heart Journal2006;27(17):2046‐53. ">WHISP 2006</a> were part funded by a grant from Novo‐Nordisk Pharmaceutical. <a href="./references#CD002229-bbs2-0012" title="GallagherJ , RapuriB , HaynatzkiG , DetterR . Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. The Journal of Clinical Endocrinology and Metabolism2002;87(11):4914‐23. GallagherJC , FowlerSE , DetterJR , ShermanSS . Combination treatment with estrogen and calcitriol in the prevention of age‐related bone loss. The Journal of Clinical Endocrinology and Metabolism2001;86(8):3618‐28. RapuriP , GallagherJ , KnezeticJ , HaynatzkaV . Estrogen receptor alpha gene polymorphisms are associated with changes in bone remodeling markers and treatment response to estrogen. Maturitas2006;53(4):371‐9. SaiA , GallagherJ , FangX . Effect of hormone therapy and calcitriol on serum lipid profile in postmenopausal older women: association with estrogen receptor‐alpha genotypes. Menopause2011;18(10):1101‐12. YalamanchiliV , GallagherJ . Treatment with hormone therapy and calcitriol did not affect depression in older postmenopausal women: no interaction with estrogen and vitamin D receptor genotype polymorphisms. Menopause2012;19(6):697‐703. ">STOP IT 2001</a> was mainly funded by the US National Institutes of Health (NIH) but was additionally supported by Wyeth‐Ayerst, Hoffman‐LaRoche, Inc. Pharm. and Pharmacia and Upjohn. The study medication for <a href="./references#CD002229-bbs2-0005" title="HerringtonDM , ReboussinDM , Bridget BrosnihanK , SharpPC , ShumakerSA , SnyderTE , et al. Effects of estrogen replacement on the progression of coronary‐artery atherosclerosis. New England Journal of Medicine2000;343(8):522‐9. HerringtonDM , ReboussinDM , KleinKP , SharpPC , ShumakerSA , SnyderTE , et al. The estrogen replacement and atherosclerosis (ERA) study: study design and baseline characteristics of the cohort. Controlled Clinical Trials2000;21(3):257‐85. NairG , HerringtonD . The ERA trial: findings and implications for the future. Climacteric2000;3:227‐32. ">ERA 2000</a>, <a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a> and <a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a> was provided by Wyeth‐Ayerst Research, for <a href="./references#CD002229-bbs2-0007" title="The ESPRIT Team. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet2002;360:2001‐8. ">ESPRIT 2002</a> by Schering AG and for <a href="./references#CD002229-bbs2-0015" title="KernanWN , BrassLM , ViscoliCM , SarrellPM , MakuchR , HorwitzRI . Estrogen after ischemic stroke: clinical basis and design of the Womens Estrogen for Stroke Trial. Journal of Stroke and Cerebrovascular Diseases1998;7(1):85‐95. ViscoliC , BrassL , Kernan , SarrelP , SuissaS , HorwitzR . Estrogen therapy and risk of cognitive decline: Results from the Women's Estrogen for Stroke Trial (WEST). American Journal of Obstetrics and Gynecology2005;192(2):387‐93. ViscoliCM , BrassLM , KernanWN , SarrelPM , SuissaS , HorwitzRI . A clinical trial of estrogen‐replacement therapy after ischemic stroke. New England Journal of Medicine2001;345(17):1243‐9. ">WEST 2001</a> by Mead Johnson laboratories. <a href="./references#CD002229-bbs2-0001" title="BladbjergE , MadsenJ , KristensenS , AbrahamsenB , BrixenK , MosekildeL , et al. Effect of long‐term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. Journal of Thrombosis and Haemostasis2003;1(6):1208‐14. KristensenS , AbrahamsenB , MadsenJ , GramJ , RejnmarkL , RudB , et al. Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: results from the Danish Osteoporosis Prevention Study (DOPS). Thrombosis and Haemostasis2006;95:915‐6. MadsenJ , KristensenS , GramJ , BladbjergE , HenriksenF , ChristensenK , et al. Positive impact of hormone replacement therapy on the fibrinolytic system: a long‐term randomized controlled study in healthy postmenopausal women. Journal of Thrombosis and Haemostasis2003;1(9):1984‐91. SchierbeckL , RejnmarkL , ToftengC , StilgrenL , EikenP , MosekildeL , et al. Hormone replacement treatment in early postmenopausal women reduces cardiovascular events ‐ A randomized controlled study. Circulation2011;124:A11380. SchierbeckLL , RejnmarkL , ToftengCL , StilgrenL , EikenP , MosekildeL , et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ2012;345:e6409. ToftengC , JensenJ , AbrahamsenB , OdumL , BrotC . Two polymorphisms in the vitamin D receptor gene‐association with bone mass and 5‐year change in bone mass with or without hormone‐replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study. Journal of Bone and Mineral Research2002;17(8):1535‐44. deMaatM , MadsenJ , LangdalB , BladbjergE , ToftengC , AbrahamsenL , et al. Genetic variation in estrogen receptor, C‐reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. Thrombosis and Haemostasis2007;97(2):234‐9. ">DOPS 2012</a> was supported by study medication from Novo Nordisk, Novartis and Leo Pharma Denmark, <a href="./references#CD002229-bbs2-0009" title="GreenspanSL , ResnickNM , ParkerRA . The effect of hormone replacement on physical performance in community‐dwelling elderly women. The American Journal of Medicine2005;118:1232‐9. ">Greenspan 2005</a> by medication from Wyeth‐Ayerst Laboratories and Merck Research Laboratories and <a href="./references#CD002229-bbs2-0014" title="HodisHN , MackWJ , AzenSP , LoboRA , ShoupeD , MahrerPR , et al. Hormone therapy and the progression of coronary‐artery atherosclerosis in postmenopausal women. New England Journal of Medicine2003;349(6):535‐45. ">WELL‐HART 2003</a> by medication from Mead Johnson Laboratries and Pharmacia and Upjohn. </p> </section> </section> <section id="CD002229-sec-0085"> <h4 class="title">Excluded studies</h4> <p>We excluded fifty papers. The primary reasons for the exclusion were:</p> <p> <ul id="CD002229-list-0013"> <li> <p>thirty‐seven studies reported no relevant outcomes of interest to this review;</p> </li> <li> <p>three assessed a different intervention;</p> </li> <li> <p>five were not RCTs;</p> </li> <li> <p>two did not investigate the relevant population;</p> </li> <li> <p>one reported the open‐label follow‐up of an included study; and</p> </li> <li> <p>two had insufficient duration of intervention or follow‐up.</p> </li> </ul> </p> </section> </section> <section id="CD002229-sec-0086"> <h3 class="title">Risk of bias in included studies</h3> <p>The design and methods within the trials were generally well reported. The review authors’ judgements about the risk of bias in the included studies are presented in <a href="#CD002229-fig-0003">Figure 3</a> and <a href="#CD002229-fig-0004">Figure 4</a>. </p> <div class="figure" id="CD002229-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt=": Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD002229-fig-0003" src="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><a href="#CD002229-fig-0003">Figure 3</a>: Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD002229-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt=": Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD002229-fig-0004" src="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><a href="#CD002229-fig-0004">Figure 4</a>: Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD002229-sec-0087"> <h4 class="title">Allocation</h4> <p>The generation of randomised sequence was adequate in 15 out of the 19 trials; in all but three of these 15 trials (<a href="./references#CD002229-bbs2-0009" title="GreenspanSL , ResnickNM , ParkerRA . The effect of hormone replacement on physical performance in community‐dwelling elderly women. The American Journal of Medicine2005;118:1232‐9. ">Greenspan 2005</a>; <a href="./references#CD002229-bbs2-0012" title="GallagherJ , RapuriB , HaynatzkiG , DetterR . Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. The Journal of Clinical Endocrinology and Metabolism2002;87(11):4914‐23. GallagherJC , FowlerSE , DetterJR , ShermanSS . Combination treatment with estrogen and calcitriol in the prevention of age‐related bone loss. The Journal of Clinical Endocrinology and Metabolism2001;86(8):3618‐28. RapuriP , GallagherJ , KnezeticJ , HaynatzkaV . Estrogen receptor alpha gene polymorphisms are associated with changes in bone remodeling markers and treatment response to estrogen. Maturitas2006;53(4):371‐9. SaiA , GallagherJ , FangX . Effect of hormone therapy and calcitriol on serum lipid profile in postmenopausal older women: association with estrogen receptor‐alpha genotypes. Menopause2011;18(10):1101‐12. YalamanchiliV , GallagherJ . Treatment with hormone therapy and calcitriol did not affect depression in older postmenopausal women: no interaction with estrogen and vitamin D receptor genotype polymorphisms. Menopause2012;19(6):697‐703. ">STOP IT 2001</a>; <a href="./references#CD002229-bbs2-0018" title="CollinsP , FlatherM , LeesB , MisterR , ProudlerA , StevensonJC , WHISP (Women's Hormone Intervention Secondary Prevention Study) Pilot Study Investigators. Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study. European Heart Journal2006;27(17):2046‐53. ">WHISP 2006</a>) it was computer‐generated. Three trials (<a href="./references#CD002229-bbs2-0001" title="BladbjergE , MadsenJ , KristensenS , AbrahamsenB , BrixenK , MosekildeL , et al. Effect of long‐term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. Journal of Thrombosis and Haemostasis2003;1(6):1208‐14. KristensenS , AbrahamsenB , MadsenJ , GramJ , RejnmarkL , RudB , et al. Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: results from the Danish Osteoporosis Prevention Study (DOPS). Thrombosis and Haemostasis2006;95:915‐6. MadsenJ , KristensenS , GramJ , BladbjergE , HenriksenF , ChristensenK , et al. Positive impact of hormone replacement therapy on the fibrinolytic system: a long‐term randomized controlled study in healthy postmenopausal women. Journal of Thrombosis and Haemostasis2003;1(9):1984‐91. SchierbeckL , RejnmarkL , ToftengC , StilgrenL , EikenP , MosekildeL , et al. Hormone replacement treatment in early postmenopausal women reduces cardiovascular events ‐ A randomized controlled study. Circulation2011;124:A11380. SchierbeckLL , RejnmarkL , ToftengCL , StilgrenL , EikenP , MosekildeL , et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ2012;345:e6409. ToftengC , JensenJ , AbrahamsenB , OdumL , BrotC . Two polymorphisms in the vitamin D receptor gene‐association with bone mass and 5‐year change in bone mass with or without hormone‐replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study. Journal of Bone and Mineral Research2002;17(8):1535‐44. deMaatM , MadsenJ , LangdalB , BladbjergE , ToftengC , AbrahamsenL , et al. Genetic variation in estrogen receptor, C‐reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. Thrombosis and Haemostasis2007;97(2):234‐9. ">DOPS 2012</a>; <a href="./references#CD002229-bbs2-0002" title="Ouyang P , TardifJ , HerringtonD , StewartK , ThompsonP , WalshM , et al. Randomized trial of hormone therapy in women after coronary bypass surgery: Evidence of differential effect of hormone therapy on angiographic progression of disease in saphenous vein grafts and native coronary arteries. Atherosclerosis2006;189(2):375‐86. ">EAGAR 2006</a>; <a href="./references#CD002229-bbs2-0010" title="HallG , PrippU , Schenk‐GustafssonK , LandgrenBM . Long‐term effects of hormone replacement therapy on symptoms of angina pectoris, quality of life and compliance in women with coronary artery disease. Maturitas1998 ;28 :235‐42 . ">HALL 1998</a>) did not report the methods used to generate random allocation, and therefore it is unclear as to whether the method used was satisfactory. One trial used a research nurse to randomly assign matched pairs of participants to treatment or placebo (<a href="./references#CD002229-bbs2-0006" title="NachtigallLE , NachtigallRH , NachtigallRD , BeckmanEM . Estrogen replacement therapy II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstetrics Gynecology1979;54(1):74‐9. ">ERT II 1979</a>). </p> <p>Thirteen trials described a satisfactory method of allocation concealment. One of these thirteen trials, <a href="./references#CD002229-bbs2-0004" title="HemminkiE , HoviS , VeerusP , SevónT , TuimalaR , RahuM , et al. Blinding decreased recruitment in a prevention trial of postmenopausal women. Journal of Clinical Epidemiology2004;57:1237‐43. VeerusP , FischerK , HoviS‐L , KarroH , RahuM , HemminkiE . Symptom reporting and quality of life in the Estonian Postmenopausal Hormone Therapy Trial. BMC Women’s Health2008;8:5. VeerusP , HoviS , FischerK , RahuM , HakamaM , HemminkiE . Results for the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]. Maturitas2006;55(2):162‐73. ">EPHT 2006</a> randomised women who expressed an interest in participating, but did not open the randomisation envelope until their eligibility had been checked and they had consented. Five of the trials (<a href="./references#CD002229-bbs2-0001" title="BladbjergE , MadsenJ , KristensenS , AbrahamsenB , BrixenK , MosekildeL , et al. Effect of long‐term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. Journal of Thrombosis and Haemostasis2003;1(6):1208‐14. KristensenS , AbrahamsenB , MadsenJ , GramJ , RejnmarkL , RudB , et al. Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: results from the Danish Osteoporosis Prevention Study (DOPS). Thrombosis and Haemostasis2006;95:915‐6. MadsenJ , KristensenS , GramJ , BladbjergE , HenriksenF , ChristensenK , et al. Positive impact of hormone replacement therapy on the fibrinolytic system: a long‐term randomized controlled study in healthy postmenopausal women. Journal of Thrombosis and Haemostasis2003;1(9):1984‐91. SchierbeckL , RejnmarkL , ToftengC , StilgrenL , EikenP , MosekildeL , et al. Hormone replacement treatment in early postmenopausal women reduces cardiovascular events ‐ A randomized controlled study. Circulation2011;124:A11380. SchierbeckLL , RejnmarkL , ToftengCL , StilgrenL , EikenP , MosekildeL , et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ2012;345:e6409. ToftengC , JensenJ , AbrahamsenB , OdumL , BrotC . Two polymorphisms in the vitamin D receptor gene‐association with bone mass and 5‐year change in bone mass with or without hormone‐replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study. Journal of Bone and Mineral Research2002;17(8):1535‐44. deMaatM , MadsenJ , LangdalB , BladbjergE , ToftengC , AbrahamsenL , et al. Genetic variation in estrogen receptor, C‐reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. Thrombosis and Haemostasis2007;97(2):234‐9. ">DOPS 2012</a>; <a href="./references#CD002229-bbs2-0002" title="Ouyang P , TardifJ , HerringtonD , StewartK , ThompsonP , WalshM , et al. Randomized trial of hormone therapy in women after coronary bypass surgery: Evidence of differential effect of hormone therapy on angiographic progression of disease in saphenous vein grafts and native coronary arteries. Atherosclerosis2006;189(2):375‐86. ">EAGAR 2006</a>; <a href="./references#CD002229-bbs2-0008" title="HoibraatenE , ArnesenH , LarsenS , WickstromE , SandsetPM . Increased risk of recurrent venous thromboembolism during hormone replacement therapy: results of the randomized, double blind, placebo‐controlled estrogen in venous thromboembolism trial (EVTET). Thrombosis and Haemostasis2000;84:961‐7. Qvigtad , HoibraatenH , ArnesenH , LarsenS , WickstromE , SandsetP . Recurrent venous thromboembolism during hormone replacement therapy ‐ results of the estrogen in venous thromboembolism trial. XVI FIGO World Congress of O and G2000;Abstract book 1:58. ">EVTET 2000</a>; <a href="./references#CD002229-bbs2-0010" title="HallG , PrippU , Schenk‐GustafssonK , LandgrenBM . Long‐term effects of hormone replacement therapy on symptoms of angina pectoris, quality of life and compliance in women with coronary artery disease. Maturitas1998 ;28 :235‐42 . ">HALL 1998</a>; <a href="./references#CD002229-bbs2-0014" title="HodisHN , MackWJ , AzenSP , LoboRA , ShoupeD , MahrerPR , et al. Hormone therapy and the progression of coronary‐artery atherosclerosis in postmenopausal women. New England Journal of Medicine2003;349(6):535‐45. ">WELL‐HART 2003</a>) did not report methods of allocation concealment. One trial reported inadequate methods for allocation concealment (<a href="./references#CD002229-bbs2-0006" title="NachtigallLE , NachtigallRH , NachtigallRD , BeckmanEM . Estrogen replacement therapy II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstetrics Gynecology1979;54(1):74‐9. ">ERT II 1979</a>). </p> </section> <section id="CD002229-sec-0088"> <h4 class="title">Blinding</h4> <p>All the trials except <a href="./references#CD002229-bbs2-0010" title="HallG , PrippU , Schenk‐GustafssonK , LandgrenBM . Long‐term effects of hormone replacement therapy on symptoms of angina pectoris, quality of life and compliance in women with coronary artery disease. Maturitas1998 ;28 :235‐42 . ">HALL 1998</a> and <a href="./references#CD002229-bbs2-0001" title="BladbjergE , MadsenJ , KristensenS , AbrahamsenB , BrixenK , MosekildeL , et al. Effect of long‐term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. Journal of Thrombosis and Haemostasis2003;1(6):1208‐14. KristensenS , AbrahamsenB , MadsenJ , GramJ , RejnmarkL , RudB , et al. Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: results from the Danish Osteoporosis Prevention Study (DOPS). Thrombosis and Haemostasis2006;95:915‐6. MadsenJ , KristensenS , GramJ , BladbjergE , HenriksenF , ChristensenK , et al. Positive impact of hormone replacement therapy on the fibrinolytic system: a long‐term randomized controlled study in healthy postmenopausal women. Journal of Thrombosis and Haemostasis2003;1(9):1984‐91. SchierbeckL , RejnmarkL , ToftengC , StilgrenL , EikenP , MosekildeL , et al. Hormone replacement treatment in early postmenopausal women reduces cardiovascular events ‐ A randomized controlled study. Circulation2011;124:A11380. SchierbeckLL , RejnmarkL , ToftengCL , StilgrenL , EikenP , MosekildeL , et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ2012;345:e6409. ToftengC , JensenJ , AbrahamsenB , OdumL , BrotC . Two polymorphisms in the vitamin D receptor gene‐association with bone mass and 5‐year change in bone mass with or without hormone‐replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study. Journal of Bone and Mineral Research2002;17(8):1535‐44. deMaatM , MadsenJ , LangdalB , BladbjergE , ToftengC , AbrahamsenL , et al. Genetic variation in estrogen receptor, C‐reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. Thrombosis and Haemostasis2007;97(2):234‐9. ">DOPS 2012</a> were described as double‐blind. Twelve of the trials explicitly stated that all participants, clinical staff and outcome assessors were blinded to treatment allocation, and all 19 trials reported ‘hard’ outcomes; the verification of which is unlikely to be affected by blinding. Unblinding of participants occurred in 331 women initially randomised into the active single hormone therapy treatment arm in <a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a>, who, after a protocol change, were unblinded and changed arms into the <a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a> combined therapy arm. Eight of the trials additionally described an unblinding mechanism to be used in the management of adverse events (<a href="./references#CD002229-bbs2-0005" title="HerringtonDM , ReboussinDM , Bridget BrosnihanK , SharpPC , ShumakerSA , SnyderTE , et al. Effects of estrogen replacement on the progression of coronary‐artery atherosclerosis. New England Journal of Medicine2000;343(8):522‐9. HerringtonDM , ReboussinDM , KleinKP , SharpPC , ShumakerSA , SnyderTE , et al. The estrogen replacement and atherosclerosis (ERA) study: study design and baseline characteristics of the cohort. Controlled Clinical Trials2000;21(3):257‐85. NairG , HerringtonD . The ERA trial: findings and implications for the future. Climacteric2000;3:227‐32. ">ERA 2000</a>; <a href="./references#CD002229-bbs2-0006" title="NachtigallLE , NachtigallRH , NachtigallRD , BeckmanEM . Estrogen replacement therapy II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstetrics Gynecology1979;54(1):74‐9. ">ERT II 1979</a>; <a href="./references#CD002229-bbs2-0007" title="The ESPRIT Team. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet2002;360:2001‐8. ">ESPRIT 2002</a>; <a href="./references#CD002229-bbs2-0013" title="HsiaJ , AldermanEL , VerterJI , RogersWJ , ThompsonP , HowardBV , et al. Women’s angiographic vitamin and estrogen trial: design and methods. Controlled Clinical Trials2002;23:708‐27. WatersD , AldermanE , HsiaJ , HowardB , CobbF , RogersW , et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women. JAMA2001;288(19):2432‐40. ">WAVE 2002</a>; <a href="./references#CD002229-bbs2-0015" title="KernanWN , BrassLM , ViscoliCM , SarrellPM , MakuchR , HorwitzRI . Estrogen after ischemic stroke: clinical basis and design of the Womens Estrogen for Stroke Trial. Journal of Stroke and Cerebrovascular Diseases1998;7(1):85‐95. ViscoliC , BrassL , Kernan , SarrelP , SuissaS , HorwitzR . Estrogen therapy and risk of cognitive decline: Results from the Women's Estrogen for Stroke Trial (WEST). American Journal of Obstetrics and Gynecology2005;192(2):387‐93. ViscoliCM , BrassLM , KernanWN , SarrelPM , SuissaS , HorwitzRI . A clinical trial of estrogen‐replacement therapy after ischemic stroke. New England Journal of Medicine2001;345(17):1243‐9. ">WEST 2001</a>; <a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a>; <a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a>; <a href="./references#CD002229-bbs2-0019" title="VickersMR , MacLacLennanA , LawtonB , FordD , MartinJ , MeredithS , et al. WISDOM group. Main morbidities recorded in the women's international study of long duration estrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ2007;335(7613):239. VickersMR , MartinJ , MeadeTW , WISDOM study team. The Women’s international study of long‐duration of estrogen after menopause (WISDOM): a randomised controlled trial. BMC Women's Health2007;7:2. WeltonAJ , VickersMR , KimJ , FordD , LawtonBA , MacLennanAH , et al. WISDOM team. Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ2008;337:a1190. ">WISDOM 2007</a>). </p> </section> <section id="CD002229-sec-0089"> <h4 class="title">Incomplete outcome data</h4> <p>Thirteen of the trials analysed all participants on an intention‐to‐treat basis at least for the outcomes of interest in the present review, whilst data in <a href="./references#CD002229-bbs2-0013" title="HsiaJ , AldermanEL , VerterJI , RogersWJ , ThompsonP , HowardBV , et al. Women’s angiographic vitamin and estrogen trial: design and methods. Controlled Clinical Trials2002;23:708‐27. WatersD , AldermanE , HsiaJ , HowardB , CobbF , RogersW , et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women. JAMA2001;288(19):2432‐40. ">WAVE 2002</a> were analysed on an ITT basis for over 97% of participants. Drop‐out rates (medication non‐compliance) were generally high, particularly in the active treatment groups, and tended to increase over time. In the 15 trials that reported data on adherence, these ranged from greater than 90% compliance rates in <a href="./references#CD002229-bbs2-0003" title="HodisH , MackW , LoboR , MahrerP , LiuC R , LiuC H . Estrogen replacement therapy effects on the progression of subclinical atherosclerosis are mediated by lipids but not by carbohydrate metabolic factors: results from the Estrogen in the Prevention of Athersclerosis Trial (EPAT). Circulation2002;106(19 Suppl II):II‐744. HodisHN , MackWJ , LoboRA , ShoupeD , SevanianA , MahrerPR , et al. Estrogen in the prevention of atherosclerosis. A randomized, double‐blind, placebo‐controlled trial. Annals of Internal Medicine2001;135(11):939‐53. ">EPAT 2001</a> and <a href="./references#CD002229-bbs2-0014" title="HodisHN , MackWJ , AzenSP , LoboRA , ShoupeD , MahrerPR , et al. Hormone therapy and the progression of coronary‐artery atherosclerosis in postmenopausal women. New England Journal of Medicine2003;349(6):535‐45. ">WELL‐HART 2003</a> at two and three years follow‐up, respectively, to less than 40% compliance in <a href="./references#CD002229-bbs2-0004" title="HemminkiE , HoviS , VeerusP , SevónT , TuimalaR , RahuM , et al. Blinding decreased recruitment in a prevention trial of postmenopausal women. Journal of Clinical Epidemiology2004;57:1237‐43. VeerusP , FischerK , HoviS‐L , KarroH , RahuM , HemminkiE . Symptom reporting and quality of life in the Estonian Postmenopausal Hormone Therapy Trial. BMC Women’s Health2008;8:5. VeerusP , HoviS , FischerK , RahuM , HakamaM , HemminkiE . Results for the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]. Maturitas2006;55(2):162‐73. ">EPHT 2006</a> at four‐years follow‐up. In the two WHI trials with the greatest number of participants, 42% of the active treatment group and 38% of the placebo group were no longer taking their allocated treatment at 5.2 years in <a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a>, and 10.7% of the placebo group had initiated active hormone therapy treatment outside of the trial. Whilst in <a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a>, 53% of participants overall were no longer taking their allocated treatment at 6.8 years, and a further 5.7% had initiated hormone use outside the study. The two studies with longest follow‐up duration did not report adherence, <a href="./references#CD002229-bbs2-0001" title="BladbjergE , MadsenJ , KristensenS , AbrahamsenB , BrixenK , MosekildeL , et al. Effect of long‐term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. Journal of Thrombosis and Haemostasis2003;1(6):1208‐14. KristensenS , AbrahamsenB , MadsenJ , GramJ , RejnmarkL , RudB , et al. Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: results from the Danish Osteoporosis Prevention Study (DOPS). Thrombosis and Haemostasis2006;95:915‐6. MadsenJ , KristensenS , GramJ , BladbjergE , HenriksenF , ChristensenK , et al. Positive impact of hormone replacement therapy on the fibrinolytic system: a long‐term randomized controlled study in healthy postmenopausal women. Journal of Thrombosis and Haemostasis2003;1(9):1984‐91. SchierbeckL , RejnmarkL , ToftengC , StilgrenL , EikenP , MosekildeL , et al. Hormone replacement treatment in early postmenopausal women reduces cardiovascular events ‐ A randomized controlled study. Circulation2011;124:A11380. SchierbeckLL , RejnmarkL , ToftengCL , StilgrenL , EikenP , MosekildeL , et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ2012;345:e6409. ToftengC , JensenJ , AbrahamsenB , OdumL , BrotC . Two polymorphisms in the vitamin D receptor gene‐association with bone mass and 5‐year change in bone mass with or without hormone‐replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study. Journal of Bone and Mineral Research2002;17(8):1535‐44. deMaatM , MadsenJ , LangdalB , BladbjergE , ToftengC , AbrahamsenL , et al. Genetic variation in estrogen receptor, C‐reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. Thrombosis and Haemostasis2007;97(2):234‐9. ">DOPS 2012</a> and <a href="./references#CD002229-bbs2-0006" title="NachtigallLE , NachtigallRH , NachtigallRD , BeckmanEM . Estrogen replacement therapy II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstetrics Gynecology1979;54(1):74‐9. ">ERT II 1979</a>. However the latter is likely to have very high, if not complete adherence, as all patients were inpatients for the duration of the study. A summary of medication compliance within the trials is given in <a href="#CD002229-tbl-0007">Table 3</a>.<br/> <br/> Losses to follow‐up were low in most of the trials, with no women lost to follow‐up in nine trials (<a href="./references#CD002229-bbs2-0001" title="BladbjergE , MadsenJ , KristensenS , AbrahamsenB , BrixenK , MosekildeL , et al. Effect of long‐term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. Journal of Thrombosis and Haemostasis2003;1(6):1208‐14. KristensenS , AbrahamsenB , MadsenJ , GramJ , RejnmarkL , RudB , et al. Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: results from the Danish Osteoporosis Prevention Study (DOPS). Thrombosis and Haemostasis2006;95:915‐6. MadsenJ , KristensenS , GramJ , BladbjergE , HenriksenF , ChristensenK , et al. Positive impact of hormone replacement therapy on the fibrinolytic system: a long‐term randomized controlled study in healthy postmenopausal women. Journal of Thrombosis and Haemostasis2003;1(9):1984‐91. SchierbeckL , RejnmarkL , ToftengC , StilgrenL , EikenP , MosekildeL , et al. Hormone replacement treatment in early postmenopausal women reduces cardiovascular events ‐ A randomized controlled study. Circulation2011;124:A11380. SchierbeckLL , RejnmarkL , ToftengCL , StilgrenL , EikenP , MosekildeL , et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ2012;345:e6409. ToftengC , JensenJ , AbrahamsenB , OdumL , BrotC . Two polymorphisms in the vitamin D receptor gene‐association with bone mass and 5‐year change in bone mass with or without hormone‐replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study. Journal of Bone and Mineral Research2002;17(8):1535‐44. deMaatM , MadsenJ , LangdalB , BladbjergE , ToftengC , AbrahamsenL , et al. Genetic variation in estrogen receptor, C‐reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. Thrombosis and Haemostasis2007;97(2):234‐9. ">DOPS 2012</a>; <a href="./references#CD002229-bbs2-0003" title="HodisH , MackW , LoboR , MahrerP , LiuC R , LiuC H . Estrogen replacement therapy effects on the progression of subclinical atherosclerosis are mediated by lipids but not by carbohydrate metabolic factors: results from the Estrogen in the Prevention of Athersclerosis Trial (EPAT). Circulation2002;106(19 Suppl II):II‐744. HodisHN , MackWJ , LoboRA , ShoupeD , SevanianA , MahrerPR , et al. Estrogen in the prevention of atherosclerosis. A randomized, double‐blind, placebo‐controlled trial. Annals of Internal Medicine2001;135(11):939‐53. ">EPAT 2001</a>; <a href="./references#CD002229-bbs2-0005" title="HerringtonDM , ReboussinDM , Bridget BrosnihanK , SharpPC , ShumakerSA , SnyderTE , et al. Effects of estrogen replacement on the progression of coronary‐artery atherosclerosis. New England Journal of Medicine2000;343(8):522‐9. HerringtonDM , ReboussinDM , KleinKP , SharpPC , ShumakerSA , SnyderTE , et al. The estrogen replacement and atherosclerosis (ERA) study: study design and baseline characteristics of the cohort. Controlled Clinical Trials2000;21(3):257‐85. NairG , HerringtonD . The ERA trial: findings and implications for the future. Climacteric2000;3:227‐32. ">ERA 2000</a>; <a href="./references#CD002229-bbs2-0006" title="NachtigallLE , NachtigallRH , NachtigallRD , BeckmanEM . Estrogen replacement therapy II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstetrics Gynecology1979;54(1):74‐9. ">ERT II 1979</a>; <a href="./references#CD002229-bbs2-0007" title="The ESPRIT Team. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet2002;360:2001‐8. ">ESPRIT 2002</a>; <a href="./references#CD002229-bbs2-0008" title="HoibraatenE , ArnesenH , LarsenS , WickstromE , SandsetPM . Increased risk of recurrent venous thromboembolism during hormone replacement therapy: results of the randomized, double blind, placebo‐controlled estrogen in venous thromboembolism trial (EVTET). Thrombosis and Haemostasis2000;84:961‐7. Qvigtad , HoibraatenH , ArnesenH , LarsenS , WickstromE , SandsetP . Recurrent venous thromboembolism during hormone replacement therapy ‐ results of the estrogen in venous thromboembolism trial. XVI FIGO World Congress of O and G2000;Abstract book 1:58. ">EVTET 2000</a>; <a href="./references#CD002229-bbs2-0009" title="GreenspanSL , ResnickNM , ParkerRA . The effect of hormone replacement on physical performance in community‐dwelling elderly women. The American Journal of Medicine2005;118:1232‐9. ">Greenspan 2005</a>; <a href="./references#CD002229-bbs2-0010" title="HallG , PrippU , Schenk‐GustafssonK , LandgrenBM . Long‐term effects of hormone replacement therapy on symptoms of angina pectoris, quality of life and compliance in women with coronary artery disease. Maturitas1998 ;28 :235‐42 . ">HALL 1998</a>; <a href="./references#CD002229-bbs2-0015" title="KernanWN , BrassLM , ViscoliCM , SarrellPM , MakuchR , HorwitzRI . Estrogen after ischemic stroke: clinical basis and design of the Womens Estrogen for Stroke Trial. Journal of Stroke and Cerebrovascular Diseases1998;7(1):85‐95. ViscoliC , BrassL , Kernan , SarrelP , SuissaS , HorwitzR . Estrogen therapy and risk of cognitive decline: Results from the Women's Estrogen for Stroke Trial (WEST). American Journal of Obstetrics and Gynecology2005;192(2):387‐93. ViscoliCM , BrassLM , KernanWN , SarrelPM , SuissaS , HorwitzRI . A clinical trial of estrogen‐replacement therapy after ischemic stroke. New England Journal of Medicine2001;345(17):1243‐9. ">WEST 2001</a>) and between 0.1% to 5.2% lost in six other trials (<a href="./references#CD002229-bbs2-0004" title="HemminkiE , HoviS , VeerusP , SevónT , TuimalaR , RahuM , et al. Blinding decreased recruitment in a prevention trial of postmenopausal women. Journal of Clinical Epidemiology2004;57:1237‐43. VeerusP , FischerK , HoviS‐L , KarroH , RahuM , HemminkiE . Symptom reporting and quality of life in the Estonian Postmenopausal Hormone Therapy Trial. BMC Women’s Health2008;8:5. VeerusP , HoviS , FischerK , RahuM , HakamaM , HemminkiE . Results for the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]. Maturitas2006;55(2):162‐73. ">EPHT 2006</a>; <a href="./references#CD002229-bbs2-0011" title="Bibbins‐DomingoK , LinF , VittinghoffE , Barrett‐ConnorE , HulleyS , GradyD , et al. Effect of hormone therapy on mortality rates among women with heart failure and coronary artery disease. American Journal of Cardiology2005;95(2):289‐91. GiddingsL . Oestrogen plus progestin increased venous thromboembolic disease in postmenopausal women with coronary artery disease. Evidence Based Nursing2000;3(4):123. GradyD , ApplegateW , BushT , FurbergC , RiggsB , HulleyS , et al. Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics. Controlled Clinical Trials1998;19(4):314‐35. GradyD , HerringtonD , BittnerV , DavidsonM , HlatkyM , HsiaJ , et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study Follow‐up (HERS II). JAMA2002;288(1):49‐57. GradyD , WengerN , HerringtonD , KhanS , FurbergC , Hunninghake , et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. Annals of Internal Medicine2000;132:689‐96. HlatkyM , BoothroydD , VittinghoffE , SharpP , WhooleyMA . Quality‐of life and depressive symptoms in postmenopausal women after receiving hormone therapy. Results from the Heart and Estrogen/Progestin Replacement Study (HERS) Trial. JAMA2002;287(5):591‐7. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA1998;280(7):605‐13. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Obstetrical and Gynecological Survey1999;54(1):41‐2. KhanM , HlatkyM , LiuM , LinF , RogersW , ShlipakM . Effect of postmenopausal hormone therapy on coronary heart disease events after percutaneous transluminal coronary angioplasty. The American Journal of Cardiology2003;91(8):989‐91, A7. ShlipakM , SimonJ , VittinghoffE , LinF , Barrett‐ConnorE , KnoppR . Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA2000;283(14):1845‐52. SimonJA , HsiaJ , CauleyJA , RichardsC , HarrisF , FongJ , et al. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen‐progestin Replacement Study (HERS). Circulation2001;103(5):638‐42. SimonJA , LinF , VittinghoffE , BittnerV , Heart and Estrogen‐Progestin Replacement Study (HERS) Research Group. The relation of postmenopausal hormone therapy to serum uric acid and the risk of coronary heart disease events: The heart and estrogen‐progestin replacement study (HERS). Annals of Epidemiology2006;16(2):138‐45. SperoffL . The heart and estrogen/progestin replacement study (HERS). Maturitas1998;31(1):9‐14. ">HERS I 1998</a>; <a href="./references#CD002229-bbs2-0013" title="HsiaJ , AldermanEL , VerterJI , RogersWJ , ThompsonP , HowardBV , et al. Women’s angiographic vitamin and estrogen trial: design and methods. Controlled Clinical Trials2002;23:708‐27. WatersD , AldermanE , HsiaJ , HowardB , CobbF , RogersW , et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women. JAMA2001;288(19):2432‐40. ">WAVE 2002</a>; <a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a>; <a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a>; <a href="./references#CD002229-bbs2-0019" title="VickersMR , MacLacLennanA , LawtonB , FordD , MartinJ , MeredithS , et al. WISDOM group. Main morbidities recorded in the women's international study of long duration estrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ2007;335(7613):239. VickersMR , MartinJ , MeadeTW , WISDOM study team. The Women’s international study of long‐duration of estrogen after menopause (WISDOM): a randomised controlled trial. BMC Women's Health2007;7:2. WeltonAJ , VickersMR , KimJ , FordD , LawtonBA , MacLennanAH , et al. WISDOM team. Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ2008;337:a1190. ">WISDOM 2007</a>); two trials with significant levels of participants lost to follow‐up were <a href="./references#CD002229-bbs2-0012" title="GallagherJ , RapuriB , HaynatzkiG , DetterR . Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. The Journal of Clinical Endocrinology and Metabolism2002;87(11):4914‐23. GallagherJC , FowlerSE , DetterJR , ShermanSS . Combination treatment with estrogen and calcitriol in the prevention of age‐related bone loss. The Journal of Clinical Endocrinology and Metabolism2001;86(8):3618‐28. RapuriP , GallagherJ , KnezeticJ , HaynatzkaV . Estrogen receptor alpha gene polymorphisms are associated with changes in bone remodeling markers and treatment response to estrogen. Maturitas2006;53(4):371‐9. SaiA , GallagherJ , FangX . Effect of hormone therapy and calcitriol on serum lipid profile in postmenopausal older women: association with estrogen receptor‐alpha genotypes. Menopause2011;18(10):1101‐12. YalamanchiliV , GallagherJ . Treatment with hormone therapy and calcitriol did not affect depression in older postmenopausal women: no interaction with estrogen and vitamin D receptor genotype polymorphisms. Menopause2012;19(6):697‐703. ">STOP IT 2001</a> (14.9%) and <a href="./references#CD002229-bbs2-0018" title="CollinsP , FlatherM , LeesB , MisterR , ProudlerA , StevensonJC , WHISP (Women's Hormone Intervention Secondary Prevention Study) Pilot Study Investigators. Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study. European Heart Journal2006;27(17):2046‐53. ">WHISP 2006</a> (19%). </p> <div class="table" id="CD002229-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Medication adherence in the trials</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Adherence definition</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Assessment method</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> HR arm</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Placebo arm</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002229-bbs2-0001" title="BladbjergE , MadsenJ , KristensenS , AbrahamsenB , BrixenK , MosekildeL , et al. Effect of long‐term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. Journal of Thrombosis and Haemostasis2003;1(6):1208‐14. KristensenS , AbrahamsenB , MadsenJ , GramJ , RejnmarkL , RudB , et al. Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: results from the Danish Osteoporosis Prevention Study (DOPS). Thrombosis and Haemostasis2006;95:915‐6. MadsenJ , KristensenS , GramJ , BladbjergE , HenriksenF , ChristensenK , et al. Positive impact of hormone replacement therapy on the fibrinolytic system: a long‐term randomized controlled study in healthy postmenopausal women. Journal of Thrombosis and Haemostasis2003;1(9):1984‐91. SchierbeckL , RejnmarkL , ToftengC , StilgrenL , EikenP , MosekildeL , et al. Hormone replacement treatment in early postmenopausal women reduces cardiovascular events ‐ A randomized controlled study. Circulation2011;124:A11380. SchierbeckLL , RejnmarkL , ToftengCL , StilgrenL , EikenP , MosekildeL , et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ2012;345:e6409. ToftengC , JensenJ , AbrahamsenB , OdumL , BrotC . Two polymorphisms in the vitamin D receptor gene‐association with bone mass and 5‐year change in bone mass with or without hormone‐replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study. Journal of Bone and Mineral Research2002;17(8):1535‐44. deMaatM , MadsenJ , LangdalB , BladbjergE , ToftengC , AbrahamsenL , et al. Genetic variation in estrogen receptor, C‐reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. Thrombosis and Haemostasis2007;97(2):234‐9. ">DOPS 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0002" title="Ouyang P , TardifJ , HerringtonD , StewartK , ThompsonP , WalshM , et al. Randomized trial of hormone therapy in women after coronary bypass surgery: Evidence of differential effect of hormone therapy on angiographic progression of disease in saphenous vein grafts and native coronary arteries. Atherosclerosis2006;189(2):375‐86. ">EAGAR 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>% study medication</p> <p>taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pill counts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 80% up to 30 months of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 80% up to 30 months of treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0003" title="HodisH , MackW , LoboR , MahrerP , LiuC R , LiuC H . Estrogen replacement therapy effects on the progression of subclinical atherosclerosis are mediated by lipids but not by carbohydrate metabolic factors: results from the Estrogen in the Prevention of Athersclerosis Trial (EPAT). Circulation2002;106(19 Suppl II):II‐744. HodisHN , MackWJ , LoboRA , ShoupeD , SevanianA , MahrerPR , et al. Estrogen in the prevention of atherosclerosis. A randomized, double‐blind, placebo‐controlled trial. Annals of Internal Medicine2001;135(11):939‐53. ">EPAT 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>% study medication</p> <p>taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pill counts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Level of adherence 95% (87% of participants evaluated)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Level of adherence 92% (92% of participants evaluated)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0004" title="HemminkiE , HoviS , VeerusP , SevónT , TuimalaR , RahuM , et al. Blinding decreased recruitment in a prevention trial of postmenopausal women. Journal of Clinical Epidemiology2004;57:1237‐43. VeerusP , FischerK , HoviS‐L , KarroH , RahuM , HemminkiE . Symptom reporting and quality of life in the Estonian Postmenopausal Hormone Therapy Trial. BMC Women’s Health2008;8:5. VeerusP , HoviS , FischerK , RahuM , HakamaM , HemminkiE . Results for the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]. Maturitas2006;55(2):162‐73. ">EPHT 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 80% of prescribed</p> <p>treatment taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of collected/returned</p> <p>drugs and clinic reports</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 40% compliant at three years (estimated from graph)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 30% compliant at three years (estimated</p> <p>from graph)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0005" title="HerringtonDM , ReboussinDM , Bridget BrosnihanK , SharpPC , ShumakerSA , SnyderTE , et al. Effects of estrogen replacement on the progression of coronary‐artery atherosclerosis. New England Journal of Medicine2000;343(8):522‐9. HerringtonDM , ReboussinDM , KleinKP , SharpPC , ShumakerSA , SnyderTE , et al. The estrogen replacement and atherosclerosis (ERA) study: study design and baseline characteristics of the cohort. Controlled Clinical Trials2000;21(3):257‐85. NairG , HerringtonD . The ERA trial: findings and implications for the future. Climacteric2000;3:227‐32. ">ERA 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>% study medication</p> <p>taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pill counts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Level of adherence at 3.2 years:</p> <p>Women on single therapy (measured in 79%</p> <p>of participants): 74%; women on combination therapy (measured in 82% of participants): 84% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Level of adherence at 3.2 years:</p> <p>(measured in 80% of participants): 86%</p> <p> </p> <p>5 women initiated treatment outside study</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002229-bbs2-0006" title="NachtigallLE , NachtigallRH , NachtigallRD , BeckmanEM . Estrogen replacement therapy II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstetrics Gynecology1979;54(1):74‐9. ">ERT II 1979</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0007" title="The ESPRIT Team. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet2002;360:2001‐8. ">ESPRIT 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>“Regular tablet use”</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Self report to family doctor. Self report</p> <p>to study nurse at six weeks and whenever in contact with trial staff</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number non‐adherent:</p> <p>51% at 12 months</p> <p>57% at 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number non‐adherent:</p> <p>31% at 12 months</p> <p>37% at 24 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0008" title="HoibraatenE , ArnesenH , LarsenS , WickstromE , SandsetPM . Increased risk of recurrent venous thromboembolism during hormone replacement therapy: results of the randomized, double blind, placebo‐controlled estrogen in venous thromboembolism trial (EVTET). Thrombosis and Haemostasis2000;84:961‐7. Qvigtad , HoibraatenH , ArnesenH , LarsenS , WickstromE , SandsetP . Recurrent venous thromboembolism during hormone replacement therapy ‐ results of the estrogen in venous thromboembolism trial. XVI FIGO World Congress of O and G2000;Abstract book 1:58. ">EVTET 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002229-bbs2-0012" title="GallagherJ , RapuriB , HaynatzkiG , DetterR . Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. The Journal of Clinical Endocrinology and Metabolism2002;87(11):4914‐23. GallagherJC , FowlerSE , DetterJR , ShermanSS . Combination treatment with estrogen and calcitriol in the prevention of age‐related bone loss. The Journal of Clinical Endocrinology and Metabolism2001;86(8):3618‐28. RapuriP , GallagherJ , KnezeticJ , HaynatzkaV . Estrogen receptor alpha gene polymorphisms are associated with changes in bone remodeling markers and treatment response to estrogen. Maturitas2006;53(4):371‐9. SaiA , GallagherJ , FangX . Effect of hormone therapy and calcitriol on serum lipid profile in postmenopausal older women: association with estrogen receptor‐alpha genotypes. Menopause2011;18(10):1101‐12. YalamanchiliV , GallagherJ . Treatment with hormone therapy and calcitriol did not affect depression in older postmenopausal women: no interaction with estrogen and vitamin D receptor genotype polymorphisms. Menopause2012;19(6):697‐703. ">STOP IT 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not defined</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pill counts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65% at 36 months in those taking HRT</p> <p>62% at 36 months in those taking HRT + calcitriol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78% at 36 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002229-bbs2-0009" title="GreenspanSL , ResnickNM , ParkerRA . The effect of hormone replacement on physical performance in community‐dwelling elderly women. The American Journal of Medicine2005;118:1232‐9. ">Greenspan 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 80% of the medication ≥ 80% of the study period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0010" title="HallG , PrippU , Schenk‐GustafssonK , LandgrenBM . Long‐term effects of hormone replacement therapy on symptoms of angina pectoris, quality of life and compliance in women with coronary artery disease. Maturitas1998 ;28 :235‐42 . ">HALL 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p>Not reported </p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0011" title="Bibbins‐DomingoK , LinF , VittinghoffE , Barrett‐ConnorE , HulleyS , GradyD , et al. Effect of hormone therapy on mortality rates among women with heart failure and coronary artery disease. American Journal of Cardiology2005;95(2):289‐91. GiddingsL . Oestrogen plus progestin increased venous thromboembolic disease in postmenopausal women with coronary artery disease. Evidence Based Nursing2000;3(4):123. GradyD , ApplegateW , BushT , FurbergC , RiggsB , HulleyS , et al. Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics. Controlled Clinical Trials1998;19(4):314‐35. GradyD , HerringtonD , BittnerV , DavidsonM , HlatkyM , HsiaJ , et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study Follow‐up (HERS II). JAMA2002;288(1):49‐57. GradyD , WengerN , HerringtonD , KhanS , FurbergC , Hunninghake , et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. Annals of Internal Medicine2000;132:689‐96. HlatkyM , BoothroydD , VittinghoffE , SharpP , WhooleyMA . Quality‐of life and depressive symptoms in postmenopausal women after receiving hormone therapy. Results from the Heart and Estrogen/Progestin Replacement Study (HERS) Trial. JAMA2002;287(5):591‐7. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA1998;280(7):605‐13. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Obstetrical and Gynecological Survey1999;54(1):41‐2. KhanM , HlatkyM , LiuM , LinF , RogersW , ShlipakM . Effect of postmenopausal hormone therapy on coronary heart disease events after percutaneous transluminal coronary angioplasty. The American Journal of Cardiology2003;91(8):989‐91, A7. ShlipakM , SimonJ , VittinghoffE , LinF , Barrett‐ConnorE , KnoppR . Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA2000;283(14):1845‐52. SimonJA , HsiaJ , CauleyJA , RichardsC , HarrisF , FongJ , et al. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen‐progestin Replacement Study (HERS). Circulation2001;103(5):638‐42. SimonJA , LinF , VittinghoffE , BittnerV , Heart and Estrogen‐Progestin Replacement Study (HERS) Research Group. The relation of postmenopausal hormone therapy to serum uric acid and the risk of coronary heart disease events: The heart and estrogen‐progestin replacement study (HERS). Annals of Epidemiology2006;16(2):138‐45. SperoffL . The heart and estrogen/progestin replacement study (HERS). Maturitas1998;31(1):9‐14. ">HERS I 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Taking at least 80%</p> <p>of study medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pill counts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82% adherent at one year; 75% adherent at three years</p> <p> </p> <p>3% initiated treatment outside study</p> <p> </p> <p>About 50% continued to use open‐label HT during unblinded follow‐up (4.2 to 6.8 years)</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91% adherent at one year;  81% adherent</p> <p>at three years</p> <p> </p> <p>Under 10% used HRT during unblinded follow‐up (4.2 to 6.8 years)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0013" title="HsiaJ , AldermanEL , VerterJI , RogersWJ , ThompsonP , HowardBV , et al. Women’s angiographic vitamin and estrogen trial: design and methods. Controlled Clinical Trials2002;23:708‐27. WatersD , AldermanE , HsiaJ , HowardB , CobbF , RogersW , et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women. JAMA2001;288(19):2432‐40. ">WAVE 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>% study medication</p> <p>taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pill counts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 2.8 years:</p> <p>Adherence 67% in the 78% of women analysed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 2.8 years:</p> <p>Adherence 70% in the 81% of women analysed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002229-bbs2-0014" title="HodisHN , MackWJ , AzenSP , LoboRA , ShoupeD , MahrerPR , et al. Hormone therapy and the progression of coronary‐artery atherosclerosis in postmenopausal women. New England Journal of Medicine2003;349(6):535‐45. ">WELL‐HART 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>% study medication</p> <p>taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pill counts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oestrogen group: 92.6% with oestrogen and 99.9% with progestin matched placebo</p> <p>Oestrogen‐Progestin group: 94.1% with oestrogen and 96.1% with progestin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93.6% with oestrogen matched placebo and 98.4% with progestin matched placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0015" title="KernanWN , BrassLM , ViscoliCM , SarrellPM , MakuchR , HorwitzRI . Estrogen after ischemic stroke: clinical basis and design of the Womens Estrogen for Stroke Trial. Journal of Stroke and Cerebrovascular Diseases1998;7(1):85‐95. ViscoliC , BrassL , Kernan , SarrelP , SuissaS , HorwitzR . Estrogen therapy and risk of cognitive decline: Results from the Women's Estrogen for Stroke Trial (WEST). American Journal of Obstetrics and Gynecology2005;192(2):387‐93. ViscoliCM , BrassLM , KernanWN , SarrelPM , SuissaS , HorwitzRI . A clinical trial of estrogen‐replacement therapy after ischemic stroke. New England Journal of Medicine2001;345(17):1243‐9. ">WEST 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>% study medication</p> <p>taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Self report to study</p> <p>nurse three‐monthly</p> <p> </p> <p>Computer chip in medication</p> <p>bottle records opening date and time</p> <p> </p> <p>Pill counts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 2.8 years:</p> <p>Mean adherence including drop‐outs: 70%</p> <p>Mean adherence excluding dropouts: 90%</p> <p>35% discontinued medication by 2.8 years, of whom 1% initiated treatment outside study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 2.8 years: Mean adherence including dropouts: 74% over 2.8 years</p> <p>Mean adherence excluding dropouts: 90%</p> <p>24% discontinued medication</p> <p> </p> <p>2% initiated treatment outside study</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Taking at least 80% of study medication</p> <p>Temporary</p> <p>discontinuation (e.g. during surgery) permitted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Weighing medication bottles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42% non‐adherent by 5.2 years</p> <p> </p> <p>Of these 6.2% initiated HRT outside study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38% non‐adherent by 5.2 years</p> <p> </p> <p>Of these 10.7% initiated HRT outside study</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Taking at least 80%</p> <p>of study medication</p> <p>Temporary</p> <p>discontinuation (e.g. during surgery) permitted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Weighing medication bottles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 6.8 years, about 53.8% of women were non‐adherent</p> <p> </p> <p>In addition 5.7% of women had initiated hormone use through their own physician</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 6.8 years, about 53.8% of women were non‐adherent</p> <p> </p> <p>In addition 9.1% of women had initiated hormone use through their own physician</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002229-bbs2-0018" title="CollinsP , FlatherM , LeesB , MisterR , ProudlerA , StevensonJC , WHISP (Women's Hormone Intervention Secondary Prevention Study) Pilot Study Investigators. Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study. European Heart Journal2006;27(17):2046‐53. ">WHISP 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not specified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not specified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 out of 49 discontinued study drug (51%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 out of 51 discontinued study drug (27%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0019" title="VickersMR , MacLacLennanA , LawtonB , FordD , MartinJ , MeredithS , et al. WISDOM group. Main morbidities recorded in the women's international study of long duration estrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ2007;335(7613):239. VickersMR , MartinJ , MeadeTW , WISDOM study team. The Women’s international study of long‐duration of estrogen after menopause (WISDOM): a randomised controlled trial. BMC Women's Health2007;7:2. WeltonAJ , VickersMR , KimJ , FordD , LawtonBA , MacLennanAH , et al. WISDOM team. Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ2008;337:a1190. ">WISDOM 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Supply of study</p> <p>medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time at risk minus temporary interruptions and time after withdrawal from treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73% of time</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86% of time</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>HRT: hormone replacement therapy</p> </div> </div> </section> <section id="CD002229-sec-0090"> <h4 class="title">Selective reporting</h4> <p>Two trials (<a href="./references#CD002229-bbs2-0006" title="NachtigallLE , NachtigallRH , NachtigallRD , BeckmanEM . Estrogen replacement therapy II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstetrics Gynecology1979;54(1):74‐9. ">ERT II 1979</a>; <a href="./references#CD002229-bbs2-0010" title="HallG , PrippU , Schenk‐GustafssonK , LandgrenBM . Long‐term effects of hormone replacement therapy on symptoms of angina pectoris, quality of life and compliance in women with coronary artery disease. Maturitas1998 ;28 :235‐42 . ">HALL 1998</a>) may have been subject to selective reporting. The remaining 17 trials reported all expected outcomes. </p> </section> </section> <section id="CD002229-sec-0091"> <h3 class="title" id="CD002229-sec-0091">Effects of interventions</h3> <p>See: <a href="./full#CD002229-tbl-0001"><b>Summary of findings for the main comparison</b> Hormone therapy compared to placebo for primary prevention of cardiovascular disease in post‐menopausal women</a>; <a href="./full#CD002229-tbl-0002"><b>Summary of findings 2</b> Hormone therapy compared to placebo for secondary prevention of cardiovascular disease in post‐menopausal women</a>; <a href="./full#CD002229-tbl-0003"><b>Summary of findings 3</b> Hormone therapy commenced less than 10 years after the menopause for preventing cardiovascular disease in post‐menopausal women</a>; <a href="./full#CD002229-tbl-0004"><b>Summary of findings 4</b> Hormone therapy commenced more than 10 years after the menopause for preventing cardiovascular disease in post‐menopausal women</a> </p> <p>Results are reported below. It was not possible to conduct analyses for all outcomes stratified by time of hormone therapy commenced since menopause (&lt; 10 years or ≥ 10 years), where these data were not available, participants' mean age at baseline was used (&lt; 60 years of age or ≥ 60 years of age), as <a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a> and <a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a>, which contributed the majority of events to this analysis, only reported some of the outcomes of interest in these subgroups. </p> <section id="CD002229-sec-0092"> <h4 class="title">Hormone therapy versus placebo in primary prevention</h4> <p>This comparison was assessed in nine trials (<a href="./references#CD002229-bbs2-0001" title="BladbjergE , MadsenJ , KristensenS , AbrahamsenB , BrixenK , MosekildeL , et al. Effect of long‐term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. Journal of Thrombosis and Haemostasis2003;1(6):1208‐14. KristensenS , AbrahamsenB , MadsenJ , GramJ , RejnmarkL , RudB , et al. Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: results from the Danish Osteoporosis Prevention Study (DOPS). Thrombosis and Haemostasis2006;95:915‐6. MadsenJ , KristensenS , GramJ , BladbjergE , HenriksenF , ChristensenK , et al. Positive impact of hormone replacement therapy on the fibrinolytic system: a long‐term randomized controlled study in healthy postmenopausal women. Journal of Thrombosis and Haemostasis2003;1(9):1984‐91. SchierbeckL , RejnmarkL , ToftengC , StilgrenL , EikenP , MosekildeL , et al. Hormone replacement treatment in early postmenopausal women reduces cardiovascular events ‐ A randomized controlled study. Circulation2011;124:A11380. SchierbeckLL , RejnmarkL , ToftengCL , StilgrenL , EikenP , MosekildeL , et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ2012;345:e6409. ToftengC , JensenJ , AbrahamsenB , OdumL , BrotC . Two polymorphisms in the vitamin D receptor gene‐association with bone mass and 5‐year change in bone mass with or without hormone‐replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study. Journal of Bone and Mineral Research2002;17(8):1535‐44. deMaatM , MadsenJ , LangdalB , BladbjergE , ToftengC , AbrahamsenL , et al. Genetic variation in estrogen receptor, C‐reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. Thrombosis and Haemostasis2007;97(2):234‐9. ">DOPS 2012</a>; <a href="./references#CD002229-bbs2-0003" title="HodisH , MackW , LoboR , MahrerP , LiuC R , LiuC H . Estrogen replacement therapy effects on the progression of subclinical atherosclerosis are mediated by lipids but not by carbohydrate metabolic factors: results from the Estrogen in the Prevention of Athersclerosis Trial (EPAT). Circulation2002;106(19 Suppl II):II‐744. HodisHN , MackWJ , LoboRA , ShoupeD , SevanianA , MahrerPR , et al. Estrogen in the prevention of atherosclerosis. A randomized, double‐blind, placebo‐controlled trial. Annals of Internal Medicine2001;135(11):939‐53. ">EPAT 2001</a>; <a href="./references#CD002229-bbs2-0004" title="HemminkiE , HoviS , VeerusP , SevónT , TuimalaR , RahuM , et al. Blinding decreased recruitment in a prevention trial of postmenopausal women. Journal of Clinical Epidemiology2004;57:1237‐43. VeerusP , FischerK , HoviS‐L , KarroH , RahuM , HemminkiE . Symptom reporting and quality of life in the Estonian Postmenopausal Hormone Therapy Trial. BMC Women’s Health2008;8:5. VeerusP , HoviS , FischerK , RahuM , HakamaM , HemminkiE . Results for the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]. Maturitas2006;55(2):162‐73. ">EPHT 2006</a>; <a href="./references#CD002229-bbs2-0006" title="NachtigallLE , NachtigallRH , NachtigallRD , BeckmanEM . Estrogen replacement therapy II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstetrics Gynecology1979;54(1):74‐9. ">ERT II 1979</a>; <a href="./references#CD002229-bbs2-0009" title="GreenspanSL , ResnickNM , ParkerRA . The effect of hormone replacement on physical performance in community‐dwelling elderly women. The American Journal of Medicine2005;118:1232‐9. ">Greenspan 2005</a>; <a href="./references#CD002229-bbs2-0012" title="GallagherJ , RapuriB , HaynatzkiG , DetterR . Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. The Journal of Clinical Endocrinology and Metabolism2002;87(11):4914‐23. GallagherJC , FowlerSE , DetterJR , ShermanSS . Combination treatment with estrogen and calcitriol in the prevention of age‐related bone loss. The Journal of Clinical Endocrinology and Metabolism2001;86(8):3618‐28. RapuriP , GallagherJ , KnezeticJ , HaynatzkaV . Estrogen receptor alpha gene polymorphisms are associated with changes in bone remodeling markers and treatment response to estrogen. Maturitas2006;53(4):371‐9. SaiA , GallagherJ , FangX . Effect of hormone therapy and calcitriol on serum lipid profile in postmenopausal older women: association with estrogen receptor‐alpha genotypes. Menopause2011;18(10):1101‐12. YalamanchiliV , GallagherJ . Treatment with hormone therapy and calcitriol did not affect depression in older postmenopausal women: no interaction with estrogen and vitamin D receptor genotype polymorphisms. Menopause2012;19(6):697‐703. ">STOP IT 2001</a>; <a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a>; <a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a>; <a href="./references#CD002229-bbs2-0019" title="VickersMR , MacLacLennanA , LawtonB , FordD , MartinJ , MeredithS , et al. WISDOM group. Main morbidities recorded in the women's international study of long duration estrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ2007;335(7613):239. VickersMR , MartinJ , MeadeTW , WISDOM study team. The Women’s international study of long‐duration of estrogen after menopause (WISDOM): a randomised controlled trial. BMC Women's Health2007;7:2. WeltonAJ , VickersMR , KimJ , FordD , LawtonBA , MacLennanAH , et al. WISDOM team. Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ2008;337:a1190. ">WISDOM 2007</a>) with a total of 34,767 participants. A summary of the trials reporting each outcome is presented in <a href="#CD002229-tbl-0008">Table 4</a> and a summary of the outcomes and their relative risks are presented in <a href="./full#CD002229-tbl-0001">summary of findings Table for the main comparison</a>. </p> <div class="table" id="CD002229-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Summary of outcomes by trials ‐ primary prevention</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Outcome </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Death</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Death (CV causes)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Non‐fatal MI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Stroke</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Angina</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Venous thromboembolism</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Pulmonary embolism</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Revascularisation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0001" title="BladbjergE , MadsenJ , KristensenS , AbrahamsenB , BrixenK , MosekildeL , et al. Effect of long‐term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. Journal of Thrombosis and Haemostasis2003;1(6):1208‐14. KristensenS , AbrahamsenB , MadsenJ , GramJ , RejnmarkL , RudB , et al. Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: results from the Danish Osteoporosis Prevention Study (DOPS). Thrombosis and Haemostasis2006;95:915‐6. MadsenJ , KristensenS , GramJ , BladbjergE , HenriksenF , ChristensenK , et al. Positive impact of hormone replacement therapy on the fibrinolytic system: a long‐term randomized controlled study in healthy postmenopausal women. Journal of Thrombosis and Haemostasis2003;1(9):1984‐91. SchierbeckL , RejnmarkL , ToftengC , StilgrenL , EikenP , MosekildeL , et al. Hormone replacement treatment in early postmenopausal women reduces cardiovascular events ‐ A randomized controlled study. Circulation2011;124:A11380. SchierbeckLL , RejnmarkL , ToftengCL , StilgrenL , EikenP , MosekildeL , et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ2012;345:e6409. ToftengC , JensenJ , AbrahamsenB , OdumL , BrotC . Two polymorphisms in the vitamin D receptor gene‐association with bone mass and 5‐year change in bone mass with or without hormone‐replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study. Journal of Bone and Mineral Research2002;17(8):1535‐44. deMaatM , MadsenJ , LangdalB , BladbjergE , ToftengC , AbrahamsenL , et al. Genetic variation in estrogen receptor, C‐reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. Thrombosis and Haemostasis2007;97(2):234‐9. ">DOPS 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0003" title="HodisH , MackW , LoboR , MahrerP , LiuC R , LiuC H . Estrogen replacement therapy effects on the progression of subclinical atherosclerosis are mediated by lipids but not by carbohydrate metabolic factors: results from the Estrogen in the Prevention of Athersclerosis Trial (EPAT). Circulation2002;106(19 Suppl II):II‐744. HodisHN , MackWJ , LoboRA , ShoupeD , SevanianA , MahrerPR , et al. Estrogen in the prevention of atherosclerosis. A randomized, double‐blind, placebo‐controlled trial. Annals of Internal Medicine2001;135(11):939‐53. ">EPAT 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0004" title="HemminkiE , HoviS , VeerusP , SevónT , TuimalaR , RahuM , et al. Blinding decreased recruitment in a prevention trial of postmenopausal women. Journal of Clinical Epidemiology2004;57:1237‐43. VeerusP , FischerK , HoviS‐L , KarroH , RahuM , HemminkiE . Symptom reporting and quality of life in the Estonian Postmenopausal Hormone Therapy Trial. BMC Women’s Health2008;8:5. VeerusP , HoviS , FischerK , RahuM , HakamaM , HemminkiE . Results for the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]. Maturitas2006;55(2):162‐73. ">EPHT 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0006" title="NachtigallLE , NachtigallRH , NachtigallRD , BeckmanEM . Estrogen replacement therapy II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstetrics Gynecology1979;54(1):74‐9. ">ERT II 1979</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0009" title="GreenspanSL , ResnickNM , ParkerRA . The effect of hormone replacement on physical performance in community‐dwelling elderly women. The American Journal of Medicine2005;118:1232‐9. ">Greenspan 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0012" title="GallagherJ , RapuriB , HaynatzkiG , DetterR . Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. The Journal of Clinical Endocrinology and Metabolism2002;87(11):4914‐23. GallagherJC , FowlerSE , DetterJR , ShermanSS . Combination treatment with estrogen and calcitriol in the prevention of age‐related bone loss. The Journal of Clinical Endocrinology and Metabolism2001;86(8):3618‐28. RapuriP , GallagherJ , KnezeticJ , HaynatzkaV . Estrogen receptor alpha gene polymorphisms are associated with changes in bone remodeling markers and treatment response to estrogen. Maturitas2006;53(4):371‐9. SaiA , GallagherJ , FangX . Effect of hormone therapy and calcitriol on serum lipid profile in postmenopausal older women: association with estrogen receptor‐alpha genotypes. Menopause2011;18(10):1101‐12. YalamanchiliV , GallagherJ . Treatment with hormone therapy and calcitriol did not affect depression in older postmenopausal women: no interaction with estrogen and vitamin D receptor genotype polymorphisms. Menopause2012;19(6):697‐703. ">STOP IT 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0019" title="VickersMR , MacLacLennanA , LawtonB , FordD , MartinJ , MeredithS , et al. WISDOM group. Main morbidities recorded in the women's international study of long duration estrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ2007;335(7613):239. VickersMR , MartinJ , MeadeTW , WISDOM study team. The Women’s international study of long‐duration of estrogen after menopause (WISDOM): a randomised controlled trial. BMC Women's Health2007;7:2. WeltonAJ , VickersMR , KimJ , FordD , LawtonBA , MacLennanAH , et al. WISDOM team. Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ2008;337:a1190. ">WISDOM 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of trials</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>8</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>7</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>6</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>34,422</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>28,353</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>29,482</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>28,719</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>27,347</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>33,477</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>31,732</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>27,569</b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup> No events in control group.<br/> CV: cardiovascular; MI: myocardial infarction </p> </div> </div> <p>There was no strong evidence that hormone therapy has an effect on all‐cause mortality (RR 1.00, 95% CI 0.89 to 1.12; 34,422 participants in 8 studies) (<a href="./references#CD002229-fig-0006" title="">Analysis 1.1</a>), or any cardiovascular disease outcomes, including death by cardiovascular causes (RR 0.81, 95% CI 0.47 to 1.40; 28,353 participants in 3 studies) (<a href="./references#CD002229-fig-0007" title="">Analysis 1.2</a>), non‐fatal myocardial infarction (RR 1.02, 95% CI 0.80 to 1.31; 29,482 participants in 7 studies) (<a href="./references#CD002229-fig-0008" title="">Analysis 1.3</a>), angina (RR 0.90, 95% CI 0.74 to 1.08; 27,347 participants in 2 studies) (<a href="./references#CD002229-fig-0010" title="">Analysis 1.5</a>), or revascularisation (RR 0.96, 95% CI 0.85 to 1.09; 27,569 participants in 3 studies) (<a href="./references#CD002229-fig-0013" title="">Analysis 1.8</a>). However there was an increased risk of stroke (RR 1.32, 95% CI 1.12 to 1.56; 28,719 participants in 4 studies) relative to placebo (<a href="./references#CD002229-fig-0009" title="">Analysis 1.4</a>). The <a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a> authors noted that the excess risk of stroke in the intervention arm was due to an increased risk of ischaemic rather than haemorrhagic stroke, which became apparent after four years of follow‐up (<a href="./references#CD002229-bbs2-0108" title="HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. Effects of conjugated equine estrogen on stroke in the women's health initiative. Circulation2006;113:2425‐34. ">Hendrix 2006</a>). There was also an increased risk of venous thromboembolism (RR 1.92, 95% CI 1.24 to 2.99; 33,477 participants in 6 studies) relative to placebo (<a href="./references#CD002229-fig-0011" title="">Analysis 1.6</a>), and also of pulmonary embolism (RR 1.89, 95% CI 1.17 to 3.04; 31,732 participants in 3 studies) relative to placebo (<a href="./references#CD002229-fig-0012" title="">Analysis 1.7</a>). The absolute risk increase for stroke was 0.006 (number needed to treat to harm (NNTH)) = 165; mean length of follow‐up: 4.21 years (range: 2.0 to 7.1), for venous thromboembolism 0.008 (NNTH = 118; mean length of follow‐up: 5.95 years (range: 1.0 to 7.1), and for pulmonary embolism 0.004 (NNTH = 242; mean length of follow‐up: 3.13 years (range: 1.0 to 7.1)). There was substantial heterogeneity in the studies assessing the outcome of death from cardiovascular causes (I<sup>2</sup> = 69%). There was also moderate heterogeneity in the studies assessing the outcome of venous thromboembolism and pulmonary embolism (I<sup>2</sup> = 56% and 54%, respectively). There was no significant heterogeneity between studies for the remaining outcomes. </p> </section> <section id="CD002229-sec-0093"> <h4 class="title">Hormone therapy versus placebo in secondary prevention</h4> <p>This comparison was assessed in ten trials (<a href="./references#CD002229-bbs2-0002" title="Ouyang P , TardifJ , HerringtonD , StewartK , ThompsonP , WalshM , et al. Randomized trial of hormone therapy in women after coronary bypass surgery: Evidence of differential effect of hormone therapy on angiographic progression of disease in saphenous vein grafts and native coronary arteries. Atherosclerosis2006;189(2):375‐86. ">EAGAR 2006</a>; <a href="./references#CD002229-bbs2-0005" title="HerringtonDM , ReboussinDM , Bridget BrosnihanK , SharpPC , ShumakerSA , SnyderTE , et al. Effects of estrogen replacement on the progression of coronary‐artery atherosclerosis. New England Journal of Medicine2000;343(8):522‐9. HerringtonDM , ReboussinDM , KleinKP , SharpPC , ShumakerSA , SnyderTE , et al. The estrogen replacement and atherosclerosis (ERA) study: study design and baseline characteristics of the cohort. Controlled Clinical Trials2000;21(3):257‐85. NairG , HerringtonD . The ERA trial: findings and implications for the future. Climacteric2000;3:227‐32. ">ERA 2000</a>; <a href="./references#CD002229-bbs2-0007" title="The ESPRIT Team. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet2002;360:2001‐8. ">ESPRIT 2002</a>; <a href="./references#CD002229-bbs2-0008" title="HoibraatenE , ArnesenH , LarsenS , WickstromE , SandsetPM . Increased risk of recurrent venous thromboembolism during hormone replacement therapy: results of the randomized, double blind, placebo‐controlled estrogen in venous thromboembolism trial (EVTET). Thrombosis and Haemostasis2000;84:961‐7. Qvigtad , HoibraatenH , ArnesenH , LarsenS , WickstromE , SandsetP . Recurrent venous thromboembolism during hormone replacement therapy ‐ results of the estrogen in venous thromboembolism trial. XVI FIGO World Congress of O and G2000;Abstract book 1:58. ">EVTET 2000</a>; <a href="./references#CD002229-bbs2-0010" title="HallG , PrippU , Schenk‐GustafssonK , LandgrenBM . Long‐term effects of hormone replacement therapy on symptoms of angina pectoris, quality of life and compliance in women with coronary artery disease. Maturitas1998 ;28 :235‐42 . ">HALL 1998</a>; <a href="./references#CD002229-bbs2-0011" title="Bibbins‐DomingoK , LinF , VittinghoffE , Barrett‐ConnorE , HulleyS , GradyD , et al. Effect of hormone therapy on mortality rates among women with heart failure and coronary artery disease. American Journal of Cardiology2005;95(2):289‐91. GiddingsL . Oestrogen plus progestin increased venous thromboembolic disease in postmenopausal women with coronary artery disease. Evidence Based Nursing2000;3(4):123. GradyD , ApplegateW , BushT , FurbergC , RiggsB , HulleyS , et al. Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics. Controlled Clinical Trials1998;19(4):314‐35. GradyD , HerringtonD , BittnerV , DavidsonM , HlatkyM , HsiaJ , et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study Follow‐up (HERS II). JAMA2002;288(1):49‐57. GradyD , WengerN , HerringtonD , KhanS , FurbergC , Hunninghake , et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. Annals of Internal Medicine2000;132:689‐96. HlatkyM , BoothroydD , VittinghoffE , SharpP , WhooleyMA . Quality‐of life and depressive symptoms in postmenopausal women after receiving hormone therapy. Results from the Heart and Estrogen/Progestin Replacement Study (HERS) Trial. JAMA2002;287(5):591‐7. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA1998;280(7):605‐13. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Obstetrical and Gynecological Survey1999;54(1):41‐2. KhanM , HlatkyM , LiuM , LinF , RogersW , ShlipakM . Effect of postmenopausal hormone therapy on coronary heart disease events after percutaneous transluminal coronary angioplasty. The American Journal of Cardiology2003;91(8):989‐91, A7. ShlipakM , SimonJ , VittinghoffE , LinF , Barrett‐ConnorE , KnoppR . Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA2000;283(14):1845‐52. SimonJA , HsiaJ , CauleyJA , RichardsC , HarrisF , FongJ , et al. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen‐progestin Replacement Study (HERS). Circulation2001;103(5):638‐42. SimonJA , LinF , VittinghoffE , BittnerV , Heart and Estrogen‐Progestin Replacement Study (HERS) Research Group. The relation of postmenopausal hormone therapy to serum uric acid and the risk of coronary heart disease events: The heart and estrogen‐progestin replacement study (HERS). Annals of Epidemiology2006;16(2):138‐45. SperoffL . The heart and estrogen/progestin replacement study (HERS). Maturitas1998;31(1):9‐14. ">HERS I 1998</a>; <a href="./references#CD002229-bbs2-0013" title="HsiaJ , AldermanEL , VerterJI , RogersWJ , ThompsonP , HowardBV , et al. Women’s angiographic vitamin and estrogen trial: design and methods. Controlled Clinical Trials2002;23:708‐27. WatersD , AldermanE , HsiaJ , HowardB , CobbF , RogersW , et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women. JAMA2001;288(19):2432‐40. ">WAVE 2002</a>; <a href="./references#CD002229-bbs2-0014" title="HodisHN , MackWJ , AzenSP , LoboRA , ShoupeD , MahrerPR , et al. Hormone therapy and the progression of coronary‐artery atherosclerosis in postmenopausal women. New England Journal of Medicine2003;349(6):535‐45. ">WELL‐HART 2003</a>; <a href="./references#CD002229-bbs2-0015" title="KernanWN , BrassLM , ViscoliCM , SarrellPM , MakuchR , HorwitzRI . Estrogen after ischemic stroke: clinical basis and design of the Womens Estrogen for Stroke Trial. Journal of Stroke and Cerebrovascular Diseases1998;7(1):85‐95. ViscoliC , BrassL , Kernan , SarrelP , SuissaS , HorwitzR . Estrogen therapy and risk of cognitive decline: Results from the Women's Estrogen for Stroke Trial (WEST). American Journal of Obstetrics and Gynecology2005;192(2):387‐93. ViscoliCM , BrassLM , KernanWN , SarrelPM , SuissaS , HorwitzRI . A clinical trial of estrogen‐replacement therapy after ischemic stroke. New England Journal of Medicine2001;345(17):1243‐9. ">WEST 2001</a>; <a href="./references#CD002229-bbs2-0018" title="CollinsP , FlatherM , LeesB , MisterR , ProudlerA , StevensonJC , WHISP (Women's Hormone Intervention Secondary Prevention Study) Pilot Study Investigators. Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study. European Heart Journal2006;27(17):2046‐53. ">WHISP 2006</a>) with a total of 5766 participants. A summary of the outcomes assessed in each of the trials is presented in <a href="#CD002229-tbl-0009">Table 5</a>. </p> <div class="table" id="CD002229-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Summary of outcomes by trials ‐ secondary prevention</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Outcome </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Death</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Death (CV causes)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Non‐fatal MI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Stroke</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Angina</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Venous thromboembolism</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Pulmonary embolism</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Revascularisation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0002" title="Ouyang P , TardifJ , HerringtonD , StewartK , ThompsonP , WalshM , et al. Randomized trial of hormone therapy in women after coronary bypass surgery: Evidence of differential effect of hormone therapy on angiographic progression of disease in saphenous vein grafts and native coronary arteries. Atherosclerosis2006;189(2):375‐86. ">EAGAR 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0005" title="HerringtonDM , ReboussinDM , Bridget BrosnihanK , SharpPC , ShumakerSA , SnyderTE , et al. Effects of estrogen replacement on the progression of coronary‐artery atherosclerosis. New England Journal of Medicine2000;343(8):522‐9. HerringtonDM , ReboussinDM , KleinKP , SharpPC , ShumakerSA , SnyderTE , et al. The estrogen replacement and atherosclerosis (ERA) study: study design and baseline characteristics of the cohort. Controlled Clinical Trials2000;21(3):257‐85. NairG , HerringtonD . The ERA trial: findings and implications for the future. Climacteric2000;3:227‐32. ">ERA 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0007" title="The ESPRIT Team. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet2002;360:2001‐8. ">ESPRIT 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0008" title="HoibraatenE , ArnesenH , LarsenS , WickstromE , SandsetPM . Increased risk of recurrent venous thromboembolism during hormone replacement therapy: results of the randomized, double blind, placebo‐controlled estrogen in venous thromboembolism trial (EVTET). Thrombosis and Haemostasis2000;84:961‐7. Qvigtad , HoibraatenH , ArnesenH , LarsenS , WickstromE , SandsetP . Recurrent venous thromboembolism during hormone replacement therapy ‐ results of the estrogen in venous thromboembolism trial. XVI FIGO World Congress of O and G2000;Abstract book 1:58. ">EVTET 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0010" title="HallG , PrippU , Schenk‐GustafssonK , LandgrenBM . Long‐term effects of hormone replacement therapy on symptoms of angina pectoris, quality of life and compliance in women with coronary artery disease. Maturitas1998 ;28 :235‐42 . ">HALL 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0011" title="Bibbins‐DomingoK , LinF , VittinghoffE , Barrett‐ConnorE , HulleyS , GradyD , et al. Effect of hormone therapy on mortality rates among women with heart failure and coronary artery disease. American Journal of Cardiology2005;95(2):289‐91. GiddingsL . Oestrogen plus progestin increased venous thromboembolic disease in postmenopausal women with coronary artery disease. Evidence Based Nursing2000;3(4):123. GradyD , ApplegateW , BushT , FurbergC , RiggsB , HulleyS , et al. Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics. Controlled Clinical Trials1998;19(4):314‐35. GradyD , HerringtonD , BittnerV , DavidsonM , HlatkyM , HsiaJ , et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study Follow‐up (HERS II). JAMA2002;288(1):49‐57. GradyD , WengerN , HerringtonD , KhanS , FurbergC , Hunninghake , et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. Annals of Internal Medicine2000;132:689‐96. HlatkyM , BoothroydD , VittinghoffE , SharpP , WhooleyMA . Quality‐of life and depressive symptoms in postmenopausal women after receiving hormone therapy. Results from the Heart and Estrogen/Progestin Replacement Study (HERS) Trial. JAMA2002;287(5):591‐7. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA1998;280(7):605‐13. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Obstetrical and Gynecological Survey1999;54(1):41‐2. KhanM , HlatkyM , LiuM , LinF , RogersW , ShlipakM . Effect of postmenopausal hormone therapy on coronary heart disease events after percutaneous transluminal coronary angioplasty. The American Journal of Cardiology2003;91(8):989‐91, A7. ShlipakM , SimonJ , VittinghoffE , LinF , Barrett‐ConnorE , KnoppR . Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA2000;283(14):1845‐52. SimonJA , HsiaJ , CauleyJA , RichardsC , HarrisF , FongJ , et al. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen‐progestin Replacement Study (HERS). Circulation2001;103(5):638‐42. SimonJA , LinF , VittinghoffE , BittnerV , Heart and Estrogen‐Progestin Replacement Study (HERS) Research Group. The relation of postmenopausal hormone therapy to serum uric acid and the risk of coronary heart disease events: The heart and estrogen‐progestin replacement study (HERS). Annals of Epidemiology2006;16(2):138‐45. SperoffL . The heart and estrogen/progestin replacement study (HERS). Maturitas1998;31(1):9‐14. ">HERS I 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0013" title="HsiaJ , AldermanEL , VerterJI , RogersWJ , ThompsonP , HowardBV , et al. Women’s angiographic vitamin and estrogen trial: design and methods. Controlled Clinical Trials2002;23:708‐27. WatersD , AldermanE , HsiaJ , HowardB , CobbF , RogersW , et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women. JAMA2001;288(19):2432‐40. ">WAVE 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0014" title="HodisHN , MackWJ , AzenSP , LoboRA , ShoupeD , MahrerPR , et al. Hormone therapy and the progression of coronary‐artery atherosclerosis in postmenopausal women. New England Journal of Medicine2003;349(6):535‐45. ">WELL‐HART 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0015" title="KernanWN , BrassLM , ViscoliCM , SarrellPM , MakuchR , HorwitzRI . Estrogen after ischemic stroke: clinical basis and design of the Womens Estrogen for Stroke Trial. Journal of Stroke and Cerebrovascular Diseases1998;7(1):85‐95. ViscoliC , BrassL , Kernan , SarrelP , SuissaS , HorwitzR . Estrogen therapy and risk of cognitive decline: Results from the Women's Estrogen for Stroke Trial (WEST). American Journal of Obstetrics and Gynecology2005;192(2):387‐93. ViscoliCM , BrassLM , KernanWN , SarrelPM , SuissaS , HorwitzRI . A clinical trial of estrogen‐replacement therapy after ischemic stroke. New England Journal of Medicine2001;345(17):1243‐9. ">WEST 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0018" title="CollinsP , FlatherM , LeesB , MisterR , ProudlerA , StevensonJC , WHISP (Women's Hormone Intervention Secondary Prevention Study) Pilot Study Investigators. Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study. European Heart Journal2006;27(17):2046‐53. ">WHISP 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of trials</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>7</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>6</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>7</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>6</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5445</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5259</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5359</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5172</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3155</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4399</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3920</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3155</b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup> No outcomes relevant to this review.<br/> CV: cardiovascular; MI: myocardial infarction </p> </div> </div> <p>There was no strong evidence that hormone therapy has an effect on all‐cause mortality (RR 1.04, 95% CI 0.87 to 1.24; 5445 participants in 7 studies) (<a href="./references#CD002229-fig-0014" title="">Analysis 2.1</a>), death by cardiovascular causes (RR 1.00, 95% CI 0.78 to 1.29; 5259 participants in 6 studies) (<a href="./references#CD002229-fig-0015" title="">Analysis 2.2</a>), non‐fatal myocardial infarction (RR 0.98, 95% CI 0.81 to 1.18; 5359 participants in 7 studies) (<a href="./references#CD002229-fig-0016" title="">Analysis 2.3</a>), angina (RR 0.91, 95% CI 0.74 to 1.12; 3155 participants in 3 studies) (<a href="./references#CD002229-fig-0018" title="">Analysis 2.5</a>), revascularisation (RR 0.98, 95% CI 0.63 to 1.53; 3155 participants in 3 studies) (<a href="./references#CD002229-fig-0021" title="">Analysis 2.8</a>), stroke RR 1.09 (95% CI 0.89 to 1.33; 5172 participants in 5 studies) (<a href="./references#CD002229-fig-0017" title="">Analysis 2.4</a>), or pulmonary embolism (RR 2.48, 95% CI 0.92 to 6.70; 3920 participants in 3 studies) (<a href="./references#CD002229-fig-0020" title="">Analysis 2.7</a>). However there was an increased risk of venous thromboembolism (RR 2.02, 95% CI 1.13 to 3.62; 4399 participants in 6 studies) relative to placebo (<a href="./references#CD002229-fig-0019" title="">Analysis 2.6</a>). The absolute risk increase was 0.014 (NNTH = 71; mean length of follow‐up: 2.46 years (range: 1.3 to 4.1)) for venous thromboembolism. There was substantial heterogeneity in studies reporting revascularisation (I² = 60%). There was no significant heterogeneity between studies for the remaining outcomes. </p> </section> <section id="CD002229-sec-0094"> <h4 class="title">Hormone therapy versus placebo in both primary and secondary prevention</h4> <p>Consistent with effects observed in both primary and secondary prevention, there was no strong evidence that hormone therapy overall had an effect on the outcomes of death (RR 1.01, 95% CI 0.92 to 1.11; 35,483 participants in 14 studies) (<a href="./references#CD002229-fig-0022" title="">Analysis 3.1</a>), death from cardiovascular causes (RR 0.96, 95% CI 0.78 to 1.18; 33,613 participants in 9 studies) (<a href="./references#CD002229-fig-0023" title="">Analysis 3.2</a>), non‐fatal myocardial infarction (RR 1.01, 95% CI 0.89 to 1.14; 34,841 participants in 14 studies) (<a href="./references#CD002229-fig-0024" title="">Analysis 3.3</a>), angina (RR 0.90, 95% CI 0.79 to 1.03; 30,502 participants in 5 studies) (<a href="./references#CD002229-fig-0026" title="">Analysis 3.5</a>), or revascularisation procedures (RR 0.95, 95% CI 0.85 to 1.05; 30,724 participants in 6 studies) (<a href="./references#CD002229-fig-0029" title="">Analysis 3.8</a>) compared to placebo. Again, an increased risk of stroke (RR 1.24, 95% CI 1.10 to 1.41; 34,672 participants in 10 studies), venous thromboembolism (RR 1.92, 95% CI 1.36 to 2.69; 37,313 participants in 10 studies) and pulmonary embolism (RR 1.81, 95% CI 1.32 to 2.48; 36,316 participants in 7 studies) relative to placebo was observed (<a href="./references#CD002229-fig-0025" title="">Analysis 3.4</a>; <a href="./references#CD002229-fig-0027" title="">Analysis 3.6</a>; <a href="./references#CD002229-fig-0028" title="">Analysis 3.7</a>). An absolute risk increase of 0.006 (NNTH = 165; mean length of follow‐up: 4.21 years (range: 2.0 to 7.1)) for stroke, an absolute risk increase of 0.008 (NNTH = 118; mean length of follow‐up: 5.95 years (range: 1.0 to 7.1)) for venous thromboembolism, and an absolute risk increase of 0.004 (NNTH = 242; mean length of follow‐up: 3.13 years (range: 1.0 to 7.1)) for pulmonary embolism were observed. There was moderate statistical heterogeneity present between trials for the outcome of venous thromboembolism (I<sup>2</sup> = 40%). There was no significant heterogeneity between studies in the remaining outcomes. There was no evidence of funnel plot asymmetry (<a href="#CD002229-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD002229-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: Hormone therapy versus placebo in primary and secondary prevention, outcome: 5.1 Death (all‐causes)." data-id="CD002229-fig-0005" src="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: Hormone therapy versus placebo in primary and secondary prevention, outcome: 5.1 Death (all‐causes). </p> </div> </div> </div> <section id="CD002229-sec-0095"> <h5 class="title">Sensitivity Analysis</h5> <p>Five trials assessing hormone therapy in primary prevention were stopped early (<a href="./references#CD002229-bbs2-0001" title="BladbjergE , MadsenJ , KristensenS , AbrahamsenB , BrixenK , MosekildeL , et al. Effect of long‐term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. Journal of Thrombosis and Haemostasis2003;1(6):1208‐14. KristensenS , AbrahamsenB , MadsenJ , GramJ , RejnmarkL , RudB , et al. Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: results from the Danish Osteoporosis Prevention Study (DOPS). Thrombosis and Haemostasis2006;95:915‐6. MadsenJ , KristensenS , GramJ , BladbjergE , HenriksenF , ChristensenK , et al. Positive impact of hormone replacement therapy on the fibrinolytic system: a long‐term randomized controlled study in healthy postmenopausal women. Journal of Thrombosis and Haemostasis2003;1(9):1984‐91. SchierbeckL , RejnmarkL , ToftengC , StilgrenL , EikenP , MosekildeL , et al. Hormone replacement treatment in early postmenopausal women reduces cardiovascular events ‐ A randomized controlled study. Circulation2011;124:A11380. SchierbeckLL , RejnmarkL , ToftengCL , StilgrenL , EikenP , MosekildeL , et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ2012;345:e6409. ToftengC , JensenJ , AbrahamsenB , OdumL , BrotC . Two polymorphisms in the vitamin D receptor gene‐association with bone mass and 5‐year change in bone mass with or without hormone‐replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study. Journal of Bone and Mineral Research2002;17(8):1535‐44. deMaatM , MadsenJ , LangdalB , BladbjergE , ToftengC , AbrahamsenL , et al. Genetic variation in estrogen receptor, C‐reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. Thrombosis and Haemostasis2007;97(2):234‐9. ">DOPS 2012</a>; <a href="./references#CD002229-bbs2-0004" title="HemminkiE , HoviS , VeerusP , SevónT , TuimalaR , RahuM , et al. Blinding decreased recruitment in a prevention trial of postmenopausal women. Journal of Clinical Epidemiology2004;57:1237‐43. VeerusP , FischerK , HoviS‐L , KarroH , RahuM , HemminkiE . Symptom reporting and quality of life in the Estonian Postmenopausal Hormone Therapy Trial. BMC Women’s Health2008;8:5. VeerusP , HoviS , FischerK , RahuM , HakamaM , HemminkiE . Results for the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]. Maturitas2006;55(2):162‐73. ">EPHT 2006</a>; <a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a>; <a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a>; <a href="./references#CD002229-bbs2-0019" title="VickersMR , MacLacLennanA , LawtonB , FordD , MartinJ , MeredithS , et al. WISDOM group. Main morbidities recorded in the women's international study of long duration estrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ2007;335(7613):239. VickersMR , MartinJ , MeadeTW , WISDOM study team. The Women’s international study of long‐duration of estrogen after menopause (WISDOM): a randomised controlled trial. BMC Women's Health2007;7:2. WeltonAJ , VickersMR , KimJ , FordD , LawtonBA , MacLennanAH , et al. WISDOM team. Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ2008;337:a1190. ">WISDOM 2007</a>). To assess what effect this may have had, we performed a subgroup analysis on trials which did not stop early to see if the effect was significantly changed. There was no strong evidence of change in the balance of effect for the outcomes of death from any cause, non‐fatal myocardial infarction or revascularisation. It was not possible to perform this analysis for death from cardiovascular causes, angina or pulmonary embolism as there were no studies which reported these outcomes which did not stop early. However, there were changes in the remaining outcomes. For the outcome of stroke, once the studies which stopped early were removed (<a href="./references#CD002229-bbs2-0001" title="BladbjergE , MadsenJ , KristensenS , AbrahamsenB , BrixenK , MosekildeL , et al. Effect of long‐term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. Journal of Thrombosis and Haemostasis2003;1(6):1208‐14. KristensenS , AbrahamsenB , MadsenJ , GramJ , RejnmarkL , RudB , et al. Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: results from the Danish Osteoporosis Prevention Study (DOPS). Thrombosis and Haemostasis2006;95:915‐6. MadsenJ , KristensenS , GramJ , BladbjergE , HenriksenF , ChristensenK , et al. Positive impact of hormone replacement therapy on the fibrinolytic system: a long‐term randomized controlled study in healthy postmenopausal women. Journal of Thrombosis and Haemostasis2003;1(9):1984‐91. SchierbeckL , RejnmarkL , ToftengC , StilgrenL , EikenP , MosekildeL , et al. Hormone replacement treatment in early postmenopausal women reduces cardiovascular events ‐ A randomized controlled study. Circulation2011;124:A11380. SchierbeckLL , RejnmarkL , ToftengCL , StilgrenL , EikenP , MosekildeL , et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ2012;345:e6409. ToftengC , JensenJ , AbrahamsenB , OdumL , BrotC . Two polymorphisms in the vitamin D receptor gene‐association with bone mass and 5‐year change in bone mass with or without hormone‐replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study. Journal of Bone and Mineral Research2002;17(8):1535‐44. deMaatM , MadsenJ , LangdalB , BladbjergE , ToftengC , AbrahamsenL , et al. Genetic variation in estrogen receptor, C‐reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. Thrombosis and Haemostasis2007;97(2):234‐9. ">DOPS 2012</a>; <a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a>; <a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a>) the outcome changed (from: RR 1.32, 95% CI 1.12 to 1.56 to: RR 1.69, 95% CI 0.47 to 6.02) due to only one study remaining in the analysis (<a href="./references#CD002229-bbs2-0012" title="GallagherJ , RapuriB , HaynatzkiG , DetterR . Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. The Journal of Clinical Endocrinology and Metabolism2002;87(11):4914‐23. GallagherJC , FowlerSE , DetterJR , ShermanSS . Combination treatment with estrogen and calcitriol in the prevention of age‐related bone loss. The Journal of Clinical Endocrinology and Metabolism2001;86(8):3618‐28. RapuriP , GallagherJ , KnezeticJ , HaynatzkaV . Estrogen receptor alpha gene polymorphisms are associated with changes in bone remodeling markers and treatment response to estrogen. Maturitas2006;53(4):371‐9. SaiA , GallagherJ , FangX . Effect of hormone therapy and calcitriol on serum lipid profile in postmenopausal older women: association with estrogen receptor‐alpha genotypes. Menopause2011;18(10):1101‐12. YalamanchiliV , GallagherJ . Treatment with hormone therapy and calcitriol did not affect depression in older postmenopausal women: no interaction with estrogen and vitamin D receptor genotype polymorphisms. Menopause2012;19(6):697‐703. ">STOP IT 2001</a>). The outcome of venous thromboembolism also changed (from: RR 1.92, 95% CI 1.24 to 2.99 to: RR 2.01, 95% CI 0.40 to 10.06) with only two trials remaining in the analysis (<a href="./references#CD002229-bbs2-0009" title="GreenspanSL , ResnickNM , ParkerRA . The effect of hormone replacement on physical performance in community‐dwelling elderly women. The American Journal of Medicine2005;118:1232‐9. ">Greenspan 2005</a>; <a href="./references#CD002229-bbs2-0012" title="GallagherJ , RapuriB , HaynatzkiG , DetterR . Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. The Journal of Clinical Endocrinology and Metabolism2002;87(11):4914‐23. GallagherJC , FowlerSE , DetterJR , ShermanSS . Combination treatment with estrogen and calcitriol in the prevention of age‐related bone loss. The Journal of Clinical Endocrinology and Metabolism2001;86(8):3618‐28. RapuriP , GallagherJ , KnezeticJ , HaynatzkaV . Estrogen receptor alpha gene polymorphisms are associated with changes in bone remodeling markers and treatment response to estrogen. Maturitas2006;53(4):371‐9. SaiA , GallagherJ , FangX . Effect of hormone therapy and calcitriol on serum lipid profile in postmenopausal older women: association with estrogen receptor‐alpha genotypes. Menopause2011;18(10):1101‐12. YalamanchiliV , GallagherJ . Treatment with hormone therapy and calcitriol did not affect depression in older postmenopausal women: no interaction with estrogen and vitamin D receptor genotype polymorphisms. Menopause2012;19(6):697‐703. ">STOP IT 2001</a>). </p> <p>Two trials assessing hormone therapy in secondary prevention were stopped early (<a href="./references#CD002229-bbs2-0002" title="Ouyang P , TardifJ , HerringtonD , StewartK , ThompsonP , WalshM , et al. Randomized trial of hormone therapy in women after coronary bypass surgery: Evidence of differential effect of hormone therapy on angiographic progression of disease in saphenous vein grafts and native coronary arteries. Atherosclerosis2006;189(2):375‐86. ">EAGAR 2006</a>; <a href="./references#CD002229-bbs2-0008" title="HoibraatenE , ArnesenH , LarsenS , WickstromE , SandsetPM . Increased risk of recurrent venous thromboembolism during hormone replacement therapy: results of the randomized, double blind, placebo‐controlled estrogen in venous thromboembolism trial (EVTET). Thrombosis and Haemostasis2000;84:961‐7. Qvigtad , HoibraatenH , ArnesenH , LarsenS , WickstromE , SandsetP . Recurrent venous thromboembolism during hormone replacement therapy ‐ results of the estrogen in venous thromboembolism trial. XVI FIGO World Congress of O and G2000;Abstract book 1:58. ">EVTET 2000</a>). To assess what effect this may have had, we performed a subgroup analysis on trials which did not stop early to see if the effect was significantly changed. There was no strong evidence of change in the balance of effect for the outcomes of death from cardiovascular causes, non‐fatal myocardial infarction, angina, venous thromboembolism, pulmonary embolism or revascularisation. It was not possible to perform this analysis for death from any cause or stroke as there were no studies which reported these outcomes which stopped early. </p> <p>Seven trials assessing hormone therapy in primary and secondary prevention were stopped early (<a href="./references#CD002229-bbs2-0001" title="BladbjergE , MadsenJ , KristensenS , AbrahamsenB , BrixenK , MosekildeL , et al. Effect of long‐term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. Journal of Thrombosis and Haemostasis2003;1(6):1208‐14. KristensenS , AbrahamsenB , MadsenJ , GramJ , RejnmarkL , RudB , et al. Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: results from the Danish Osteoporosis Prevention Study (DOPS). Thrombosis and Haemostasis2006;95:915‐6. MadsenJ , KristensenS , GramJ , BladbjergE , HenriksenF , ChristensenK , et al. Positive impact of hormone replacement therapy on the fibrinolytic system: a long‐term randomized controlled study in healthy postmenopausal women. Journal of Thrombosis and Haemostasis2003;1(9):1984‐91. SchierbeckL , RejnmarkL , ToftengC , StilgrenL , EikenP , MosekildeL , et al. Hormone replacement treatment in early postmenopausal women reduces cardiovascular events ‐ A randomized controlled study. Circulation2011;124:A11380. SchierbeckLL , RejnmarkL , ToftengCL , StilgrenL , EikenP , MosekildeL , et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ2012;345:e6409. ToftengC , JensenJ , AbrahamsenB , OdumL , BrotC . Two polymorphisms in the vitamin D receptor gene‐association with bone mass and 5‐year change in bone mass with or without hormone‐replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study. Journal of Bone and Mineral Research2002;17(8):1535‐44. deMaatM , MadsenJ , LangdalB , BladbjergE , ToftengC , AbrahamsenL , et al. Genetic variation in estrogen receptor, C‐reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. Thrombosis and Haemostasis2007;97(2):234‐9. ">DOPS 2012</a>; <a href="./references#CD002229-bbs2-0002" title="Ouyang P , TardifJ , HerringtonD , StewartK , ThompsonP , WalshM , et al. Randomized trial of hormone therapy in women after coronary bypass surgery: Evidence of differential effect of hormone therapy on angiographic progression of disease in saphenous vein grafts and native coronary arteries. Atherosclerosis2006;189(2):375‐86. ">EAGAR 2006</a>; <a href="./references#CD002229-bbs2-0004" title="HemminkiE , HoviS , VeerusP , SevónT , TuimalaR , RahuM , et al. Blinding decreased recruitment in a prevention trial of postmenopausal women. Journal of Clinical Epidemiology2004;57:1237‐43. VeerusP , FischerK , HoviS‐L , KarroH , RahuM , HemminkiE . Symptom reporting and quality of life in the Estonian Postmenopausal Hormone Therapy Trial. BMC Women’s Health2008;8:5. VeerusP , HoviS , FischerK , RahuM , HakamaM , HemminkiE . Results for the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]. Maturitas2006;55(2):162‐73. ">EPHT 2006</a>; <a href="./references#CD002229-bbs2-0008" title="HoibraatenE , ArnesenH , LarsenS , WickstromE , SandsetPM . Increased risk of recurrent venous thromboembolism during hormone replacement therapy: results of the randomized, double blind, placebo‐controlled estrogen in venous thromboembolism trial (EVTET). Thrombosis and Haemostasis2000;84:961‐7. Qvigtad , HoibraatenH , ArnesenH , LarsenS , WickstromE , SandsetP . Recurrent venous thromboembolism during hormone replacement therapy ‐ results of the estrogen in venous thromboembolism trial. XVI FIGO World Congress of O and G2000;Abstract book 1:58. ">EVTET 2000</a>; <a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a>; <a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a>; <a href="./references#CD002229-bbs2-0019" title="VickersMR , MacLacLennanA , LawtonB , FordD , MartinJ , MeredithS , et al. WISDOM group. Main morbidities recorded in the women's international study of long duration estrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ2007;335(7613):239. VickersMR , MartinJ , MeadeTW , WISDOM study team. The Women’s international study of long‐duration of estrogen after menopause (WISDOM): a randomised controlled trial. BMC Women's Health2007;7:2. WeltonAJ , VickersMR , KimJ , FordD , LawtonBA , MacLennanAH , et al. WISDOM team. Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ2008;337:a1190. ">WISDOM 2007</a>). To assess what effect this may have had, we performed a subgroup analysis on trials which did not stop early to see if the effect was significantly changed. There was no strong evidence of change in the balance of effect for the outcomes of death from any cause, death from cardiovascular causes, non‐fatal myocardial infarction, angina, venous thromboembolism or revascularisation. For the outcome of stroke, once the studies which stopped early were removed (<a href="./references#CD002229-bbs2-0001" title="BladbjergE , MadsenJ , KristensenS , AbrahamsenB , BrixenK , MosekildeL , et al. Effect of long‐term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. Journal of Thrombosis and Haemostasis2003;1(6):1208‐14. KristensenS , AbrahamsenB , MadsenJ , GramJ , RejnmarkL , RudB , et al. Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: results from the Danish Osteoporosis Prevention Study (DOPS). Thrombosis and Haemostasis2006;95:915‐6. MadsenJ , KristensenS , GramJ , BladbjergE , HenriksenF , ChristensenK , et al. Positive impact of hormone replacement therapy on the fibrinolytic system: a long‐term randomized controlled study in healthy postmenopausal women. Journal of Thrombosis and Haemostasis2003;1(9):1984‐91. SchierbeckL , RejnmarkL , ToftengC , StilgrenL , EikenP , MosekildeL , et al. Hormone replacement treatment in early postmenopausal women reduces cardiovascular events ‐ A randomized controlled study. Circulation2011;124:A11380. SchierbeckLL , RejnmarkL , ToftengCL , StilgrenL , EikenP , MosekildeL , et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ2012;345:e6409. ToftengC , JensenJ , AbrahamsenB , OdumL , BrotC . Two polymorphisms in the vitamin D receptor gene‐association with bone mass and 5‐year change in bone mass with or without hormone‐replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study. Journal of Bone and Mineral Research2002;17(8):1535‐44. deMaatM , MadsenJ , LangdalB , BladbjergE , ToftengC , AbrahamsenL , et al. Genetic variation in estrogen receptor, C‐reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. Thrombosis and Haemostasis2007;97(2):234‐9. ">DOPS 2012</a>; <a href="./references#CD002229-bbs2-0004" title="HemminkiE , HoviS , VeerusP , SevónT , TuimalaR , RahuM , et al. Blinding decreased recruitment in a prevention trial of postmenopausal women. Journal of Clinical Epidemiology2004;57:1237‐43. VeerusP , FischerK , HoviS‐L , KarroH , RahuM , HemminkiE . Symptom reporting and quality of life in the Estonian Postmenopausal Hormone Therapy Trial. BMC Women’s Health2008;8:5. VeerusP , HoviS , FischerK , RahuM , HakamaM , HemminkiE . Results for the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]. Maturitas2006;55(2):162‐73. ">EPHT 2006</a>; <a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a>; <a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a>) the outcome changed (from: RR 1.24, 95% CI 1.10 to 1.41 to: RR 1.14, 95% CI 0.94 to 1.39). The outcome of pulmonary embolism, once the studies which stopped early were removed (<a href="./references#CD002229-bbs2-0008" title="HoibraatenE , ArnesenH , LarsenS , WickstromE , SandsetPM . Increased risk of recurrent venous thromboembolism during hormone replacement therapy: results of the randomized, double blind, placebo‐controlled estrogen in venous thromboembolism trial (EVTET). Thrombosis and Haemostasis2000;84:961‐7. Qvigtad , HoibraatenH , ArnesenH , LarsenS , WickstromE , SandsetP . Recurrent venous thromboembolism during hormone replacement therapy ‐ results of the estrogen in venous thromboembolism trial. XVI FIGO World Congress of O and G2000;Abstract book 1:58. ">EVTET 2000</a>; <a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a>; <a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a>; <a href="./references#CD002229-bbs2-0019" title="VickersMR , MacLacLennanA , LawtonB , FordD , MartinJ , MeredithS , et al. WISDOM group. Main morbidities recorded in the women's international study of long duration estrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ2007;335(7613):239. VickersMR , MartinJ , MeadeTW , WISDOM study team. The Women’s international study of long‐duration of estrogen after menopause (WISDOM): a randomised controlled trial. BMC Women's Health2007;7:2. WeltonAJ , VickersMR , KimJ , FordD , LawtonBA , MacLennanAH , et al. WISDOM team. Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ2008;337:a1190. ">WISDOM 2007</a>) changed (from: RR 1.81, 95% CI 1.32 to 2.48 to: RR 1.57, 95% CI 0.62 to 3.95). </p> </section> <section id="CD002229-sec-0096"> <h5 class="title">Subgroup analyses</h5> <section id="CD002229-sec-0097"> <h6 class="title">Duration of treatment</h6> <p>To assess the effect of duration of treatment, we compared data in two different ways. Where data were reported by year of follow‐up (<a href="./references#CD002229-bbs2-0011" title="Bibbins‐DomingoK , LinF , VittinghoffE , Barrett‐ConnorE , HulleyS , GradyD , et al. Effect of hormone therapy on mortality rates among women with heart failure and coronary artery disease. American Journal of Cardiology2005;95(2):289‐91. GiddingsL . Oestrogen plus progestin increased venous thromboembolic disease in postmenopausal women with coronary artery disease. Evidence Based Nursing2000;3(4):123. GradyD , ApplegateW , BushT , FurbergC , RiggsB , HulleyS , et al. Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics. Controlled Clinical Trials1998;19(4):314‐35. GradyD , HerringtonD , BittnerV , DavidsonM , HlatkyM , HsiaJ , et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study Follow‐up (HERS II). JAMA2002;288(1):49‐57. GradyD , WengerN , HerringtonD , KhanS , FurbergC , Hunninghake , et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. Annals of Internal Medicine2000;132:689‐96. HlatkyM , BoothroydD , VittinghoffE , SharpP , WhooleyMA . Quality‐of life and depressive symptoms in postmenopausal women after receiving hormone therapy. Results from the Heart and Estrogen/Progestin Replacement Study (HERS) Trial. JAMA2002;287(5):591‐7. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA1998;280(7):605‐13. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Obstetrical and Gynecological Survey1999;54(1):41‐2. KhanM , HlatkyM , LiuM , LinF , RogersW , ShlipakM . Effect of postmenopausal hormone therapy on coronary heart disease events after percutaneous transluminal coronary angioplasty. The American Journal of Cardiology2003;91(8):989‐91, A7. ShlipakM , SimonJ , VittinghoffE , LinF , Barrett‐ConnorE , KnoppR . Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA2000;283(14):1845‐52. SimonJA , HsiaJ , CauleyJA , RichardsC , HarrisF , FongJ , et al. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen‐progestin Replacement Study (HERS). Circulation2001;103(5):638‐42. SimonJA , LinF , VittinghoffE , BittnerV , Heart and Estrogen‐Progestin Replacement Study (HERS) Research Group. The relation of postmenopausal hormone therapy to serum uric acid and the risk of coronary heart disease events: The heart and estrogen‐progestin replacement study (HERS). Annals of Epidemiology2006;16(2):138‐45. SperoffL . The heart and estrogen/progestin replacement study (HERS). Maturitas1998;31(1):9‐14. ">HERS I 1998</a>; <a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a>; <a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a>), we analysed them both non‐cumulatively (year‐by‐year), as well as cumulatively, incorporating the remainder of the trials where data were not reported by year of follow‐up, according to the total duration of trial follow‐up. We classified these analyses <i>a priori</i> as exploratory, given the heterogeneity between the different hormone therapy regimens assessed and the patient populations in the different trials. To conduct the analyses, we had to round up or down the time points for the reporting of outcomes in the trials. We rounded data as follows: <a href="./references#CD002229-bbs2-0018" title="CollinsP , FlatherM , LeesB , MisterR , ProudlerA , StevensonJC , WHISP (Women's Hormone Intervention Secondary Prevention Study) Pilot Study Investigators. Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study. European Heart Journal2006;27(17):2046‐53. ">WHISP 2006</a> and <a href="./references#CD002229-bbs2-0019" title="VickersMR , MacLacLennanA , LawtonB , FordD , MartinJ , MeredithS , et al. WISDOM group. Main morbidities recorded in the women's international study of long duration estrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ2007;335(7613):239. VickersMR , MartinJ , MeadeTW , WISDOM study team. The Women’s international study of long‐duration of estrogen after menopause (WISDOM): a randomised controlled trial. BMC Women's Health2007;7:2. WeltonAJ , VickersMR , KimJ , FordD , LawtonBA , MacLennanAH , et al. WISDOM team. Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ2008;337:a1190. ">WISDOM 2007</a> reported results after a median follow‐up of 7 months and 11.9 months (range 7.1 to 19.6), respectively; results were therefore reported at one‐year follow‐up. <a href="./references#CD002229-bbs2-0008" title="HoibraatenE , ArnesenH , LarsenS , WickstromE , SandsetPM . Increased risk of recurrent venous thromboembolism during hormone replacement therapy: results of the randomized, double blind, placebo‐controlled estrogen in venous thromboembolism trial (EVTET). Thrombosis and Haemostasis2000;84:961‐7. Qvigtad , HoibraatenH , ArnesenH , LarsenS , WickstromE , SandsetP . Recurrent venous thromboembolism during hormone replacement therapy ‐ results of the estrogen in venous thromboembolism trial. XVI FIGO World Congress of O and G2000;Abstract book 1:58. ">EVTET 2000</a> was conducted for a 1.3 year period; results from this trial were therefore also reported for one‐year follow‐up. <a href="./references#CD002229-bbs2-0003" title="HodisH , MackW , LoboR , MahrerP , LiuC R , LiuC H . Estrogen replacement therapy effects on the progression of subclinical atherosclerosis are mediated by lipids but not by carbohydrate metabolic factors: results from the Estrogen in the Prevention of Athersclerosis Trial (EPAT). Circulation2002;106(19 Suppl II):II‐744. HodisHN , MackWJ , LoboRA , ShoupeD , SevanianA , MahrerPR , et al. Estrogen in the prevention of atherosclerosis. A randomized, double‐blind, placebo‐controlled trial. Annals of Internal Medicine2001;135(11):939‐53. ">EPAT 2001</a>, <a href="./references#CD002229-bbs2-0007" title="The ESPRIT Team. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet2002;360:2001‐8. ">ESPRIT 2002</a> and <a href="./references#CD002229-bbs2-0010" title="HallG , PrippU , Schenk‐GustafssonK , LandgrenBM . Long‐term effects of hormone replacement therapy on symptoms of angina pectoris, quality of life and compliance in women with coronary artery disease. Maturitas1998 ;28 :235‐42 . ">HALL 1998</a> were all reported for two years of follow‐up. <a href="./references#CD002229-bbs2-0009" title="GreenspanSL , ResnickNM , ParkerRA . The effect of hormone replacement on physical performance in community‐dwelling elderly women. The American Journal of Medicine2005;118:1232‐9. ">Greenspan 2005</a> and <a href="./references#CD002229-bbs2-0012" title="GallagherJ , RapuriB , HaynatzkiG , DetterR . Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. The Journal of Clinical Endocrinology and Metabolism2002;87(11):4914‐23. GallagherJC , FowlerSE , DetterJR , ShermanSS . Combination treatment with estrogen and calcitriol in the prevention of age‐related bone loss. The Journal of Clinical Endocrinology and Metabolism2001;86(8):3618‐28. RapuriP , GallagherJ , KnezeticJ , HaynatzkaV . Estrogen receptor alpha gene polymorphisms are associated with changes in bone remodeling markers and treatment response to estrogen. Maturitas2006;53(4):371‐9. SaiA , GallagherJ , FangX . Effect of hormone therapy and calcitriol on serum lipid profile in postmenopausal older women: association with estrogen receptor‐alpha genotypes. Menopause2011;18(10):1101‐12. YalamanchiliV , GallagherJ . Treatment with hormone therapy and calcitriol did not affect depression in older postmenopausal women: no interaction with estrogen and vitamin D receptor genotype polymorphisms. Menopause2012;19(6):697‐703. ">STOP IT 2001</a> both reported three years of follow‐up, <a href="./references#CD002229-bbs2-0014" title="HodisHN , MackWJ , AzenSP , LoboRA , ShoupeD , MahrerPR , et al. Hormone therapy and the progression of coronary‐artery atherosclerosis in postmenopausal women. New England Journal of Medicine2003;349(6):535‐45. ">WELL‐HART 2003</a> had a median follow‐up of 3.3 years, <a href="./references#CD002229-bbs2-0004" title="HemminkiE , HoviS , VeerusP , SevónT , TuimalaR , RahuM , et al. Blinding decreased recruitment in a prevention trial of postmenopausal women. Journal of Clinical Epidemiology2004;57:1237‐43. VeerusP , FischerK , HoviS‐L , KarroH , RahuM , HemminkiE . Symptom reporting and quality of life in the Estonian Postmenopausal Hormone Therapy Trial. BMC Women’s Health2008;8:5. VeerusP , HoviS , FischerK , RahuM , HakamaM , HemminkiE . Results for the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]. Maturitas2006;55(2):162‐73. ">EPHT 2006</a> (median length of follow‐up: 3.4 years (range: 2 to 4.9)), <a href="./references#CD002229-bbs2-0002" title="Ouyang P , TardifJ , HerringtonD , StewartK , ThompsonP , WalshM , et al. Randomized trial of hormone therapy in women after coronary bypass surgery: Evidence of differential effect of hormone therapy on angiographic progression of disease in saphenous vein grafts and native coronary arteries. Atherosclerosis2006;189(2):375‐86. ">EAGAR 2006</a> (mean follow‐up: 3.5 years (range: 25 to 41)), <a href="./references#CD002229-bbs2-0005" title="HerringtonDM , ReboussinDM , Bridget BrosnihanK , SharpPC , ShumakerSA , SnyderTE , et al. Effects of estrogen replacement on the progression of coronary‐artery atherosclerosis. New England Journal of Medicine2000;343(8):522‐9. HerringtonDM , ReboussinDM , KleinKP , SharpPC , ShumakerSA , SnyderTE , et al. The estrogen replacement and atherosclerosis (ERA) study: study design and baseline characteristics of the cohort. Controlled Clinical Trials2000;21(3):257‐85. NairG , HerringtonD . The ERA trial: findings and implications for the future. Climacteric2000;3:227‐32. ">ERA 2000</a> (mean follow‐up: 3.2 years (range: 2.8 to 3.8)), <a href="./references#CD002229-bbs2-0013" title="HsiaJ , AldermanEL , VerterJI , RogersWJ , ThompsonP , HowardBV , et al. Women’s angiographic vitamin and estrogen trial: design and methods. Controlled Clinical Trials2002;23:708‐27. WatersD , AldermanE , HsiaJ , HowardB , CobbF , RogersW , et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women. JAMA2001;288(19):2432‐40. ">WAVE 2002</a> (mean follow‐up: 2.8 years (range: 2.1 to 3.9)) and <a href="./references#CD002229-bbs2-0015" title="KernanWN , BrassLM , ViscoliCM , SarrellPM , MakuchR , HorwitzRI . Estrogen after ischemic stroke: clinical basis and design of the Womens Estrogen for Stroke Trial. Journal of Stroke and Cerebrovascular Diseases1998;7(1):85‐95. ViscoliC , BrassL , Kernan , SarrelP , SuissaS , HorwitzR . Estrogen therapy and risk of cognitive decline: Results from the Women's Estrogen for Stroke Trial (WEST). American Journal of Obstetrics and Gynecology2005;192(2):387‐93. ViscoliCM , BrassLM , KernanWN , SarrelPM , SuissaS , HorwitzRI . A clinical trial of estrogen‐replacement therapy after ischemic stroke. New England Journal of Medicine2001;345(17):1243‐9. ">WEST 2001</a> (mean follow‐up: 2.8 years (range: 1.6 to 4.1)) were all classified as having a three‐year follow‐up period. Final outcome results within the blinded part of the <a href="./references#CD002229-bbs2-0011" title="Bibbins‐DomingoK , LinF , VittinghoffE , Barrett‐ConnorE , HulleyS , GradyD , et al. Effect of hormone therapy on mortality rates among women with heart failure and coronary artery disease. American Journal of Cardiology2005;95(2):289‐91. GiddingsL . Oestrogen plus progestin increased venous thromboembolic disease in postmenopausal women with coronary artery disease. Evidence Based Nursing2000;3(4):123. GradyD , ApplegateW , BushT , FurbergC , RiggsB , HulleyS , et al. Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics. Controlled Clinical Trials1998;19(4):314‐35. GradyD , HerringtonD , BittnerV , DavidsonM , HlatkyM , HsiaJ , et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study Follow‐up (HERS II). JAMA2002;288(1):49‐57. GradyD , WengerN , HerringtonD , KhanS , FurbergC , Hunninghake , et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. Annals of Internal Medicine2000;132:689‐96. HlatkyM , BoothroydD , VittinghoffE , SharpP , WhooleyMA . Quality‐of life and depressive symptoms in postmenopausal women after receiving hormone therapy. Results from the Heart and Estrogen/Progestin Replacement Study (HERS) Trial. JAMA2002;287(5):591‐7. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA1998;280(7):605‐13. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Obstetrical and Gynecological Survey1999;54(1):41‐2. KhanM , HlatkyM , LiuM , LinF , RogersW , ShlipakM . Effect of postmenopausal hormone therapy on coronary heart disease events after percutaneous transluminal coronary angioplasty. The American Journal of Cardiology2003;91(8):989‐91, A7. ShlipakM , SimonJ , VittinghoffE , LinF , Barrett‐ConnorE , KnoppR . Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA2000;283(14):1845‐52. SimonJA , HsiaJ , CauleyJA , RichardsC , HarrisF , FongJ , et al. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen‐progestin Replacement Study (HERS). Circulation2001;103(5):638‐42. SimonJA , LinF , VittinghoffE , BittnerV , Heart and Estrogen‐Progestin Replacement Study (HERS) Research Group. The relation of postmenopausal hormone therapy to serum uric acid and the risk of coronary heart disease events: The heart and estrogen‐progestin replacement study (HERS). Annals of Epidemiology2006;16(2):138‐45. SperoffL . The heart and estrogen/progestin replacement study (HERS). Maturitas1998;31(1):9‐14. ">HERS I 1998</a> trial were reported at a mean of 4.1 years and this was classified as having a four‐year follow‐up period. However there were selected clinical outcomes reported for each year of follow‐up which were included in the analysis. Outcome data for the 4 to 6.8 years (unblinded, open‐label) follow‐up period were not included in the standard pair‐wise meta‐analyses. Final outcome results for <a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a> reported results after a mean follow‐up of 5.6 years (range: 3.5 to 8.5), analysed as five years, however selected clinical outcomes were also reported for each year of follow‐up to five years and this was included in the analysis. <a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a> reported results by year of follow‐up for eight years for selected outcomes. <a href="./references#CD002229-bbs2-0006" title="NachtigallLE , NachtigallRH , NachtigallRD , BeckmanEM . Estrogen replacement therapy II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstetrics Gynecology1979;54(1):74‐9. ">ERT II 1979</a> reported a follow‐up of 10 years. <a href="./references#CD002229-bbs2-0001" title="BladbjergE , MadsenJ , KristensenS , AbrahamsenB , BrixenK , MosekildeL , et al. Effect of long‐term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. Journal of Thrombosis and Haemostasis2003;1(6):1208‐14. KristensenS , AbrahamsenB , MadsenJ , GramJ , RejnmarkL , RudB , et al. Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: results from the Danish Osteoporosis Prevention Study (DOPS). Thrombosis and Haemostasis2006;95:915‐6. MadsenJ , KristensenS , GramJ , BladbjergE , HenriksenF , ChristensenK , et al. Positive impact of hormone replacement therapy on the fibrinolytic system: a long‐term randomized controlled study in healthy postmenopausal women. Journal of Thrombosis and Haemostasis2003;1(9):1984‐91. SchierbeckL , RejnmarkL , ToftengC , StilgrenL , EikenP , MosekildeL , et al. Hormone replacement treatment in early postmenopausal women reduces cardiovascular events ‐ A randomized controlled study. Circulation2011;124:A11380. SchierbeckLL , RejnmarkL , ToftengCL , StilgrenL , EikenP , MosekildeL , et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ2012;345:e6409. ToftengC , JensenJ , AbrahamsenB , OdumL , BrotC . Two polymorphisms in the vitamin D receptor gene‐association with bone mass and 5‐year change in bone mass with or without hormone‐replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study. Journal of Bone and Mineral Research2002;17(8):1535‐44. deMaatM , MadsenJ , LangdalB , BladbjergE , ToftengC , AbrahamsenL , et al. Genetic variation in estrogen receptor, C‐reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. Thrombosis and Haemostasis2007;97(2):234‐9. ">DOPS 2012</a> reported a mean follow‐up of 10.1 years which was rounded down to 10 years. </p> <p>We only assessed the outcome of death in this way as with other outcomes there was a risk of counting participants multiple times. By individual year of treatment from year one to eight, there was no strong evidence of difference between hormone therapy and placebo for any year analysed (<a href="./references#CD002229-fig-0030" title="">Analysis 3.9</a>). For the cumulative effect of treatment on the outcome of death, there was no strong evidence of difference between hormone therapy and control for years one up until eight. There were no data for nine years of treatment. Ten years of treatment showed a survival benefit in the hormone therapy group (RR 0.55, 95% CI 0.31 to 0.96) based on the results of two studies (<a href="./references#CD002229-bbs2-0001" title="BladbjergE , MadsenJ , KristensenS , AbrahamsenB , BrixenK , MosekildeL , et al. Effect of long‐term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. Journal of Thrombosis and Haemostasis2003;1(6):1208‐14. KristensenS , AbrahamsenB , MadsenJ , GramJ , RejnmarkL , RudB , et al. Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: results from the Danish Osteoporosis Prevention Study (DOPS). Thrombosis and Haemostasis2006;95:915‐6. MadsenJ , KristensenS , GramJ , BladbjergE , HenriksenF , ChristensenK , et al. Positive impact of hormone replacement therapy on the fibrinolytic system: a long‐term randomized controlled study in healthy postmenopausal women. Journal of Thrombosis and Haemostasis2003;1(9):1984‐91. SchierbeckL , RejnmarkL , ToftengC , StilgrenL , EikenP , MosekildeL , et al. Hormone replacement treatment in early postmenopausal women reduces cardiovascular events ‐ A randomized controlled study. Circulation2011;124:A11380. SchierbeckLL , RejnmarkL , ToftengCL , StilgrenL , EikenP , MosekildeL , et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ2012;345:e6409. ToftengC , JensenJ , AbrahamsenB , OdumL , BrotC . Two polymorphisms in the vitamin D receptor gene‐association with bone mass and 5‐year change in bone mass with or without hormone‐replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study. Journal of Bone and Mineral Research2002;17(8):1535‐44. deMaatM , MadsenJ , LangdalB , BladbjergE , ToftengC , AbrahamsenL , et al. Genetic variation in estrogen receptor, C‐reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. Thrombosis and Haemostasis2007;97(2):234‐9. ">DOPS 2012</a>; <a href="./references#CD002229-bbs2-0006" title="NachtigallLE , NachtigallRH , NachtigallRD , BeckmanEM . Estrogen replacement therapy II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstetrics Gynecology1979;54(1):74‐9. ">ERT II 1979</a>) (<a href="./references#CD002229-fig-0031" title="">Analysis 3.10</a>). The absolute risk reduction for death was 0.003 (NNTH = 333). There was no statistically significant heterogeneity between the trials for any of the outcomes. </p> </section> <section id="CD002229-sec-0098"> <h6 class="title">The timing hypothesis</h6> <p>To assess the timing hypothesis and the potential impact of the time since menopause that treatment was commenced, we stratified trials according to when treatment was started. This was characterised as starting treatment either &lt; 10 or ≥10 years after the menopause, or if these data were not available, then we used mean age of participants at baseline (&lt; 60 versus ≥ 60 years of age) as a surrogate. In some cases, studies reported the results in subgroups, according to the time since the menopause that treatment was started, or age that treatment was started (<a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a> and <a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a>). For the remaining studies, we used mean time since menopause that treatment commenced or mean age that treatment commenced. It is not possible to say with absolute certainty that all individuals in these studies are correctly attributed to the correct treatment timing subgroup, however, with the reported standard deviations of the mean time since menopause or mean age that treatment was commenced, we can be confident that the vast majority are correctly assigned and this allows us to make an important subgroup analysis, though the limitations of this analysis must be borne in mind. </p> <p>The reason we used a composite endpoint of coronary heart disease and did not report the remaining prespecified outcomes was due to the largest trials (<a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a>; <a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a>) reporting this composite endpoint according to number of decades after menopause at which treatment was started, and venous thromboembolism according to age in decades at which treatment was started. We did not include the remaining outcomes in this analysis as there were insufficient data reported according to time that treatment was started in relation to the menopause or age to allow for accurate analysis. </p> <p>The results of the subgroup analysis provide some supportive evidence for the timing hypothesis for the outcomes of death from all causes and coronary heart disease. All cause death was lower in the subgroup of studies where treatment was started within 10 years of the menopause compared with studies where more than 10 had elapsed since the menopause had started (P = 0.01; <a href="./references#CD002229-fig-0032" title="">Analysis 4.1</a>). The risk of coronary heart disease was also lower in women who had commenced therapy less than 10 since the start of the menopause (P = 0.02; <a href="./references#CD002229-fig-0033" title="">Analysis 4.2</a>). We did not find evidence of a difference between the subgroups for the outcomes of stroke and venous thromboembolism (P = 0.66; <a href="./references#CD002229-fig-0034" title="">Analysis 4.3</a>, and P = 0.7; <a href="./references#CD002229-fig-0035" title="">Analysis 4.4</a> respectively). </p> </section> </section> </section> <section id="CD002229-sec-0099"> <h4 class="title">Hormone therapy commenced less than 10 years after the menopause</h4> <p>Six trials and 9629 participants were included in this analysis (<a href="./references#CD002229-bbs2-0001" title="BladbjergE , MadsenJ , KristensenS , AbrahamsenB , BrixenK , MosekildeL , et al. Effect of long‐term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. Journal of Thrombosis and Haemostasis2003;1(6):1208‐14. KristensenS , AbrahamsenB , MadsenJ , GramJ , RejnmarkL , RudB , et al. Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: results from the Danish Osteoporosis Prevention Study (DOPS). Thrombosis and Haemostasis2006;95:915‐6. MadsenJ , KristensenS , GramJ , BladbjergE , HenriksenF , ChristensenK , et al. Positive impact of hormone replacement therapy on the fibrinolytic system: a long‐term randomized controlled study in healthy postmenopausal women. Journal of Thrombosis and Haemostasis2003;1(9):1984‐91. SchierbeckL , RejnmarkL , ToftengC , StilgrenL , EikenP , MosekildeL , et al. Hormone replacement treatment in early postmenopausal women reduces cardiovascular events ‐ A randomized controlled study. Circulation2011;124:A11380. SchierbeckLL , RejnmarkL , ToftengCL , StilgrenL , EikenP , MosekildeL , et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ2012;345:e6409. ToftengC , JensenJ , AbrahamsenB , OdumL , BrotC . Two polymorphisms in the vitamin D receptor gene‐association with bone mass and 5‐year change in bone mass with or without hormone‐replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study. Journal of Bone and Mineral Research2002;17(8):1535‐44. deMaatM , MadsenJ , LangdalB , BladbjergE , ToftengC , AbrahamsenL , et al. Genetic variation in estrogen receptor, C‐reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. Thrombosis and Haemostasis2007;97(2):234‐9. ">DOPS 2012</a>; <a href="./references#CD002229-bbs2-0006" title="NachtigallLE , NachtigallRH , NachtigallRD , BeckmanEM . Estrogen replacement therapy II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstetrics Gynecology1979;54(1):74‐9. ">ERT II 1979</a>; <a href="./references#CD002229-bbs2-0004" title="HemminkiE , HoviS , VeerusP , SevónT , TuimalaR , RahuM , et al. Blinding decreased recruitment in a prevention trial of postmenopausal women. Journal of Clinical Epidemiology2004;57:1237‐43. VeerusP , FischerK , HoviS‐L , KarroH , RahuM , HemminkiE . Symptom reporting and quality of life in the Estonian Postmenopausal Hormone Therapy Trial. BMC Women’s Health2008;8:5. VeerusP , HoviS , FischerK , RahuM , HakamaM , HemminkiE . Results for the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]. Maturitas2006;55(2):162‐73. ">EPHT 2006</a>; <a href="./references#CD002229-bbs2-0008" title="HoibraatenE , ArnesenH , LarsenS , WickstromE , SandsetPM . Increased risk of recurrent venous thromboembolism during hormone replacement therapy: results of the randomized, double blind, placebo‐controlled estrogen in venous thromboembolism trial (EVTET). Thrombosis and Haemostasis2000;84:961‐7. Qvigtad , HoibraatenH , ArnesenH , LarsenS , WickstromE , SandsetP . Recurrent venous thromboembolism during hormone replacement therapy ‐ results of the estrogen in venous thromboembolism trial. XVI FIGO World Congress of O and G2000;Abstract book 1:58. ">EVTET 2000</a>; <a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a>; <a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a>) (<a href="#CD002229-tbl-0010">Table 6</a>). Three trials reported a mean time since menopause for the study population at the start of the study of less than 10 years: <a href="./references#CD002229-bbs2-0001" title="BladbjergE , MadsenJ , KristensenS , AbrahamsenB , BrixenK , MosekildeL , et al. Effect of long‐term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. Journal of Thrombosis and Haemostasis2003;1(6):1208‐14. KristensenS , AbrahamsenB , MadsenJ , GramJ , RejnmarkL , RudB , et al. Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: results from the Danish Osteoporosis Prevention Study (DOPS). Thrombosis and Haemostasis2006;95:915‐6. MadsenJ , KristensenS , GramJ , BladbjergE , HenriksenF , ChristensenK , et al. Positive impact of hormone replacement therapy on the fibrinolytic system: a long‐term randomized controlled study in healthy postmenopausal women. Journal of Thrombosis and Haemostasis2003;1(9):1984‐91. SchierbeckL , RejnmarkL , ToftengC , StilgrenL , EikenP , MosekildeL , et al. Hormone replacement treatment in early postmenopausal women reduces cardiovascular events ‐ A randomized controlled study. Circulation2011;124:A11380. SchierbeckLL , RejnmarkL , ToftengCL , StilgrenL , EikenP , MosekildeL , et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ2012;345:e6409. ToftengC , JensenJ , AbrahamsenB , OdumL , BrotC . Two polymorphisms in the vitamin D receptor gene‐association with bone mass and 5‐year change in bone mass with or without hormone‐replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study. Journal of Bone and Mineral Research2002;17(8):1535‐44. deMaatM , MadsenJ , LangdalB , BladbjergE , ToftengC , AbrahamsenL , et al. Genetic variation in estrogen receptor, C‐reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. Thrombosis and Haemostasis2007;97(2):234‐9. ">DOPS 2012</a> (0.58 years), <a href="./references#CD002229-bbs2-0006" title="NachtigallLE , NachtigallRH , NachtigallRD , BeckmanEM . Estrogen replacement therapy II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstetrics Gynecology1979;54(1):74‐9. ">ERT II 1979</a> (4.6 years) and <a href="./references#CD002229-bbs2-0004" title="HemminkiE , HoviS , VeerusP , SevónT , TuimalaR , RahuM , et al. Blinding decreased recruitment in a prevention trial of postmenopausal women. Journal of Clinical Epidemiology2004;57:1237‐43. VeerusP , FischerK , HoviS‐L , KarroH , RahuM , HemminkiE . Symptom reporting and quality of life in the Estonian Postmenopausal Hormone Therapy Trial. BMC Women’s Health2008;8:5. VeerusP , HoviS , FischerK , RahuM , HakamaM , HemminkiE . Results for the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]. Maturitas2006;55(2):162‐73. ">EPHT 2006</a> (8.8 years). One study which did not report number of years since menopause did report a mean age of the study population under 60 years (<a href="./references#CD002229-bbs2-0008" title="HoibraatenE , ArnesenH , LarsenS , WickstromE , SandsetPM . Increased risk of recurrent venous thromboembolism during hormone replacement therapy: results of the randomized, double blind, placebo‐controlled estrogen in venous thromboembolism trial (EVTET). Thrombosis and Haemostasis2000;84:961‐7. Qvigtad , HoibraatenH , ArnesenH , LarsenS , WickstromE , SandsetP . Recurrent venous thromboembolism during hormone replacement therapy ‐ results of the estrogen in venous thromboembolism trial. XVI FIGO World Congress of O and G2000;Abstract book 1:58. ">EVTET 2000</a> (55 years old)). Two studies reported events stratified by those participants who were less than 10 years since their menopause at the start of the study (<a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a>; <a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a>). </p> <div class="table" id="CD002229-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Trials according to number of years since menopause when treatment commenced</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time since menopause (years)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean age (years)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>&lt; 10 years since menopause (or mean age &lt; 60)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002229-bbs2-0001" title="BladbjergE , MadsenJ , KristensenS , AbrahamsenB , BrixenK , MosekildeL , et al. Effect of long‐term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. Journal of Thrombosis and Haemostasis2003;1(6):1208‐14. KristensenS , AbrahamsenB , MadsenJ , GramJ , RejnmarkL , RudB , et al. Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: results from the Danish Osteoporosis Prevention Study (DOPS). Thrombosis and Haemostasis2006;95:915‐6. MadsenJ , KristensenS , GramJ , BladbjergE , HenriksenF , ChristensenK , et al. Positive impact of hormone replacement therapy on the fibrinolytic system: a long‐term randomized controlled study in healthy postmenopausal women. Journal of Thrombosis and Haemostasis2003;1(9):1984‐91. SchierbeckL , RejnmarkL , ToftengC , StilgrenL , EikenP , MosekildeL , et al. Hormone replacement treatment in early postmenopausal women reduces cardiovascular events ‐ A randomized controlled study. Circulation2011;124:A11380. SchierbeckLL , RejnmarkL , ToftengCL , StilgrenL , EikenP , MosekildeL , et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ2012;345:e6409. ToftengC , JensenJ , AbrahamsenB , OdumL , BrotC . Two polymorphisms in the vitamin D receptor gene‐association with bone mass and 5‐year change in bone mass with or without hormone‐replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study. Journal of Bone and Mineral Research2002;17(8):1535‐44. deMaatM , MadsenJ , LangdalB , BladbjergE , ToftengC , AbrahamsenL , et al. Genetic variation in estrogen receptor, C‐reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. Thrombosis and Haemostasis2007;97(2):234‐9. ">DOPS 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1006</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.59</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002229-bbs2-0006" title="NachtigallLE , NachtigallRH , NachtigallRD , BeckmanEM . Estrogen replacement therapy II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstetrics Gynecology1979;54(1):74‐9. ">ERT II 1979</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>168</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002229-bbs2-0004" title="HemminkiE , HoviS , VeerusP , SevónT , TuimalaR , RahuM , et al. Blinding decreased recruitment in a prevention trial of postmenopausal women. Journal of Clinical Epidemiology2004;57:1237‐43. VeerusP , FischerK , HoviS‐L , KarroH , RahuM , HemminkiE . Symptom reporting and quality of life in the Estonian Postmenopausal Hormone Therapy Trial. BMC Women’s Health2008;8:5. VeerusP , HoviS , FischerK , RahuM , HakamaM , HemminkiE . Results for the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]. Maturitas2006;55(2):162‐73. ">EPHT 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1178</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002229-bbs2-0008" title="HoibraatenE , ArnesenH , LarsenS , WickstromE , SandsetPM . Increased risk of recurrent venous thromboembolism during hormone replacement therapy: results of the randomized, double blind, placebo‐controlled estrogen in venous thromboembolism trial (EVTET). Thrombosis and Haemostasis2000;84:961‐7. Qvigtad , HoibraatenH , ArnesenH , LarsenS , WickstromE , SandsetP . Recurrent venous thromboembolism during hormone replacement therapy ‐ results of the estrogen in venous thromboembolism trial. XVI FIGO World Congress of O and G2000;Abstract book 1:58. ">EVTET 2000</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>140</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NK<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55.7</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5494</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 10 yrs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1643</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 10 yrs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TOTAL</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9629</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>≥ 10 years since menopause (or mean age ≥ 60)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9694</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7468</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002229-bbs2-0010" title="HallG , PrippU , Schenk‐GustafssonK , LandgrenBM . Long‐term effects of hormone replacement therapy on symptoms of angina pectoris, quality of life and compliance in women with coronary artery disease. Maturitas1998 ;28 :235‐42 . ">HALL 1998</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>373</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002229-bbs2-0019" title="VickersMR , MacLacLennanA , LawtonB , FordD , MartinJ , MeredithS , et al. WISDOM group. Main morbidities recorded in the women's international study of long duration estrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ2007;335(7613):239. VickersMR , MartinJ , MeadeTW , WISDOM study team. The Women’s international study of long‐duration of estrogen after menopause (WISDOM): a randomised controlled trial. BMC Women's Health2007;7:2. WeltonAJ , VickersMR , KimJ , FordD , LawtonBA , MacLennanAH , et al. WISDOM team. Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ2008;337:a1190. ">WISDOM 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4385</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002229-bbs2-0007" title="The ESPRIT Team. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet2002;360:2001‐8. ">ESPRIT 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002229-bbs2-0011" title="Bibbins‐DomingoK , LinF , VittinghoffE , Barrett‐ConnorE , HulleyS , GradyD , et al. Effect of hormone therapy on mortality rates among women with heart failure and coronary artery disease. American Journal of Cardiology2005;95(2):289‐91. GiddingsL . Oestrogen plus progestin increased venous thromboembolic disease in postmenopausal women with coronary artery disease. Evidence Based Nursing2000;3(4):123. GradyD , ApplegateW , BushT , FurbergC , RiggsB , HulleyS , et al. Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics. Controlled Clinical Trials1998;19(4):314‐35. GradyD , HerringtonD , BittnerV , DavidsonM , HlatkyM , HsiaJ , et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study Follow‐up (HERS II). JAMA2002;288(1):49‐57. GradyD , WengerN , HerringtonD , KhanS , FurbergC , Hunninghake , et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. Annals of Internal Medicine2000;132:689‐96. HlatkyM , BoothroydD , VittinghoffE , SharpP , WhooleyMA . Quality‐of life and depressive symptoms in postmenopausal women after receiving hormone therapy. Results from the Heart and Estrogen/Progestin Replacement Study (HERS) Trial. JAMA2002;287(5):591‐7. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA1998;280(7):605‐13. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Obstetrical and Gynecological Survey1999;54(1):41‐2. KhanM , HlatkyM , LiuM , LinF , RogersW , ShlipakM . Effect of postmenopausal hormone therapy on coronary heart disease events after percutaneous transluminal coronary angioplasty. The American Journal of Cardiology2003;91(8):989‐91, A7. ShlipakM , SimonJ , VittinghoffE , LinF , Barrett‐ConnorE , KnoppR . Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA2000;283(14):1845‐52. SimonJA , HsiaJ , CauleyJA , RichardsC , HarrisF , FongJ , et al. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen‐progestin Replacement Study (HERS). Circulation2001;103(5):638‐42. SimonJA , LinF , VittinghoffE , BittnerV , Heart and Estrogen‐Progestin Replacement Study (HERS) Research Group. The relation of postmenopausal hormone therapy to serum uric acid and the risk of coronary heart disease events: The heart and estrogen‐progestin replacement study (HERS). Annals of Epidemiology2006;16(2):138‐45. SperoffL . The heart and estrogen/progestin replacement study (HERS). Maturitas1998;31(1):9‐14. ">HERS I 1998</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2763</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002229-bbs2-0014" title="HodisHN , MackWJ , AzenSP , LoboRA , ShoupeD , MahrerPR , et al. Hormone therapy and the progression of coronary‐artery atherosclerosis in postmenopausal women. New England Journal of Medicine2003;349(6):535‐45. ">WELL‐HART 2003</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>226</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002229-bbs2-0018" title="CollinsP , FlatherM , LeesB , MisterR , ProudlerA , StevensonJC , WHISP (Women's Hormone Intervention Secondary Prevention Study) Pilot Study Investigators. Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study. European Heart Journal2006;27(17):2046‐53. ">WHISP 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002229-bbs2-0005" title="HerringtonDM , ReboussinDM , Bridget BrosnihanK , SharpPC , ShumakerSA , SnyderTE , et al. Effects of estrogen replacement on the progression of coronary‐artery atherosclerosis. New England Journal of Medicine2000;343(8):522‐9. HerringtonDM , ReboussinDM , KleinKP , SharpPC , ShumakerSA , SnyderTE , et al. The estrogen replacement and atherosclerosis (ERA) study: study design and baseline characteristics of the cohort. Controlled Clinical Trials2000;21(3):257‐85. NairG , HerringtonD . The ERA trial: findings and implications for the future. Climacteric2000;3:227‐32. ">ERA 2000</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>309</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002229-bbs2-0015" title="KernanWN , BrassLM , ViscoliCM , SarrellPM , MakuchR , HorwitzRI . Estrogen after ischemic stroke: clinical basis and design of the Womens Estrogen for Stroke Trial. Journal of Stroke and Cerebrovascular Diseases1998;7(1):85‐95. ViscoliC , BrassL , Kernan , SarrelP , SuissaS , HorwitzR . Estrogen therapy and risk of cognitive decline: Results from the Women's Estrogen for Stroke Trial (WEST). American Journal of Obstetrics and Gynecology2005;192(2):387‐93. ViscoliCM , BrassLM , KernanWN , SarrelPM , SuissaS , HorwitzRI . A clinical trial of estrogen‐replacement therapy after ischemic stroke. New England Journal of Medicine2001;345(17):1243‐9. ">WEST 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>664</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002229-bbs2-0003" title="HodisH , MackW , LoboR , MahrerP , LiuC R , LiuC H . Estrogen replacement therapy effects on the progression of subclinical atherosclerosis are mediated by lipids but not by carbohydrate metabolic factors: results from the Estrogen in the Prevention of Athersclerosis Trial (EPAT). Circulation2002;106(19 Suppl II):II‐744. HodisHN , MackWJ , LoboRA , ShoupeD , SevanianA , MahrerPR , et al. Estrogen in the prevention of atherosclerosis. A randomized, double‐blind, placebo‐controlled trial. Annals of Internal Medicine2001;135(11):939‐53. ">EPAT 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>222</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NK<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62.2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002229-bbs2-0002" title="Ouyang P , TardifJ , HerringtonD , StewartK , ThompsonP , WalshM , et al. Randomized trial of hormone therapy in women after coronary bypass surgery: Evidence of differential effect of hormone therapy on angiographic progression of disease in saphenous vein grafts and native coronary arteries. Atherosclerosis2006;189(2):375‐86. ">EAGAR 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NK<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002229-bbs2-0013" title="HsiaJ , AldermanEL , VerterJI , RogersWJ , ThompsonP , HowardBV , et al. Women’s angiographic vitamin and estrogen trial: design and methods. Controlled Clinical Trials2002;23:708‐27. WatersD , AldermanE , HsiaJ , HowardB , CobbF , RogersW , et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women. JAMA2001;288(19):2432‐40. ">WAVE 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>423</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NK<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002229-bbs2-0012" title="GallagherJ , RapuriB , HaynatzkiG , DetterR . Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. The Journal of Clinical Endocrinology and Metabolism2002;87(11):4914‐23. GallagherJC , FowlerSE , DetterJR , ShermanSS . Combination treatment with estrogen and calcitriol in the prevention of age‐related bone loss. The Journal of Clinical Endocrinology and Metabolism2001;86(8):3618‐28. RapuriP , GallagherJ , KnezeticJ , HaynatzkaV . Estrogen receptor alpha gene polymorphisms are associated with changes in bone remodeling markers and treatment response to estrogen. Maturitas2006;53(4):371‐9. SaiA , GallagherJ , FangX . Effect of hormone therapy and calcitriol on serum lipid profile in postmenopausal older women: association with estrogen receptor‐alpha genotypes. Menopause2011;18(10):1101‐12. YalamanchiliV , GallagherJ . Treatment with hormone therapy and calcitriol did not affect depression in older postmenopausal women: no interaction with estrogen and vitamin D receptor genotype polymorphisms. Menopause2012;19(6):697‐703. ">STOP IT 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>489</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NK<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002229-bbs2-0009" title="GreenspanSL , ResnickNM , ParkerRA . The effect of hormone replacement on physical performance in community‐dwelling elderly women. The American Journal of Medicine2005;118:1232‐9. ">Greenspan 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>489</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NK<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71.2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TOTAL</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28705</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><sup>1</sup>Author contacted but data was not collected.<br/> <sup>2</sup>Author contacted; reported data available from National Institutes of Health (NIH) (who funded trial) but data currently pending.<br/> <sup>3</sup>Author emailed, but no reply. </p> <p>NK: not known</p> </td> </tr> </tbody> </table> </div> <p>Hormone therapy in a population who, as a mean, started treatment less than 10 years after their menopause or were less than 60 years old, demonstrated an all‐cause mortality benefit (RR 0.70, 95% CI 0.52 to 0.95; 9088 participants in 5 studies) and coronary heart disease benefit (composite of death from cardiovascular causes and non‐fatal myocardial infarction) (RR 0.52, 95% CI 0.29 to 0.96; 8311 participants in 4 studies) compared to placebo (<a href="./references#CD002229-fig-0032" title="">Analysis 4.1</a>; <a href="./references#CD002229-fig-0033" title="">Analysis 4.2</a>). There was a statistically non‐significant trend to increased risk of stroke (RR 1.37, 95% CI 0.80 to 2.34; 8143 participants in 3 studies) (<a href="./references#CD002229-fig-0034" title="">Analysis 4.3</a>). There was, however, strong evidence of increased risk of venous thromboembolism (RR 1.74, 95% CI 1.11 to 2.73; 9838 participants in 3 studies) in the hormone therapy group compared to placebo (<a href="./references#CD002229-fig-0035" title="">Analysis 4.4</a>). The absolute risk reduction for death (all‐causes) was 0.007 (NNTH = 146) and coronary heart disease (death from cardiovascular causes and non‐fatal myocardial infarction) was 0.007 (NNTH = 133). The absolute risk increase for venous thromboembolism was 0.005 (NNTH = 214). A summary of the outcomes and their relative risks are presented in <a href="./full#CD002229-tbl-0003">summary of findings Table 3</a>. There was moderate statistical heterogeneity present between trials for the outcome of coronary heart disease (I<sup>2</sup> = 48%). There was no strong evidence of statistically significant heterogeneity for the remaining analyses. </p> </section> <section id="CD002229-sec-0100"> <h4 class="title">Hormone therapy commenced more than 10 years after the menopause</h4> <p>Fifteen trials and 28,705 participants were included in this analysis (<a href="./references#CD002229-bbs2-0002" title="Ouyang P , TardifJ , HerringtonD , StewartK , ThompsonP , WalshM , et al. Randomized trial of hormone therapy in women after coronary bypass surgery: Evidence of differential effect of hormone therapy on angiographic progression of disease in saphenous vein grafts and native coronary arteries. Atherosclerosis2006;189(2):375‐86. ">EAGAR 2006</a>; <a href="./references#CD002229-bbs2-0003" title="HodisH , MackW , LoboR , MahrerP , LiuC R , LiuC H . Estrogen replacement therapy effects on the progression of subclinical atherosclerosis are mediated by lipids but not by carbohydrate metabolic factors: results from the Estrogen in the Prevention of Athersclerosis Trial (EPAT). Circulation2002;106(19 Suppl II):II‐744. HodisHN , MackWJ , LoboRA , ShoupeD , SevanianA , MahrerPR , et al. Estrogen in the prevention of atherosclerosis. A randomized, double‐blind, placebo‐controlled trial. Annals of Internal Medicine2001;135(11):939‐53. ">EPAT 2001</a>; <a href="./references#CD002229-bbs2-0005" title="HerringtonDM , ReboussinDM , Bridget BrosnihanK , SharpPC , ShumakerSA , SnyderTE , et al. Effects of estrogen replacement on the progression of coronary‐artery atherosclerosis. New England Journal of Medicine2000;343(8):522‐9. HerringtonDM , ReboussinDM , KleinKP , SharpPC , ShumakerSA , SnyderTE , et al. The estrogen replacement and atherosclerosis (ERA) study: study design and baseline characteristics of the cohort. Controlled Clinical Trials2000;21(3):257‐85. NairG , HerringtonD . The ERA trial: findings and implications for the future. Climacteric2000;3:227‐32. ">ERA 2000</a>; <a href="./references#CD002229-bbs2-0007" title="The ESPRIT Team. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet2002;360:2001‐8. ">ESPRIT 2002</a>; <a href="./references#CD002229-bbs2-0009" title="GreenspanSL , ResnickNM , ParkerRA . The effect of hormone replacement on physical performance in community‐dwelling elderly women. The American Journal of Medicine2005;118:1232‐9. ">Greenspan 2005</a>; <a href="./references#CD002229-bbs2-0010" title="HallG , PrippU , Schenk‐GustafssonK , LandgrenBM . Long‐term effects of hormone replacement therapy on symptoms of angina pectoris, quality of life and compliance in women with coronary artery disease. Maturitas1998 ;28 :235‐42 . ">HALL 1998</a>; <a href="./references#CD002229-bbs2-0011" title="Bibbins‐DomingoK , LinF , VittinghoffE , Barrett‐ConnorE , HulleyS , GradyD , et al. Effect of hormone therapy on mortality rates among women with heart failure and coronary artery disease. American Journal of Cardiology2005;95(2):289‐91. GiddingsL . Oestrogen plus progestin increased venous thromboembolic disease in postmenopausal women with coronary artery disease. Evidence Based Nursing2000;3(4):123. GradyD , ApplegateW , BushT , FurbergC , RiggsB , HulleyS , et al. Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics. Controlled Clinical Trials1998;19(4):314‐35. GradyD , HerringtonD , BittnerV , DavidsonM , HlatkyM , HsiaJ , et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study Follow‐up (HERS II). JAMA2002;288(1):49‐57. GradyD , WengerN , HerringtonD , KhanS , FurbergC , Hunninghake , et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. Annals of Internal Medicine2000;132:689‐96. HlatkyM , BoothroydD , VittinghoffE , SharpP , WhooleyMA . Quality‐of life and depressive symptoms in postmenopausal women after receiving hormone therapy. Results from the Heart and Estrogen/Progestin Replacement Study (HERS) Trial. JAMA2002;287(5):591‐7. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA1998;280(7):605‐13. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Obstetrical and Gynecological Survey1999;54(1):41‐2. KhanM , HlatkyM , LiuM , LinF , RogersW , ShlipakM . Effect of postmenopausal hormone therapy on coronary heart disease events after percutaneous transluminal coronary angioplasty. The American Journal of Cardiology2003;91(8):989‐91, A7. ShlipakM , SimonJ , VittinghoffE , LinF , Barrett‐ConnorE , KnoppR . Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA2000;283(14):1845‐52. SimonJA , HsiaJ , CauleyJA , RichardsC , HarrisF , FongJ , et al. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen‐progestin Replacement Study (HERS). Circulation2001;103(5):638‐42. SimonJA , LinF , VittinghoffE , BittnerV , Heart and Estrogen‐Progestin Replacement Study (HERS) Research Group. The relation of postmenopausal hormone therapy to serum uric acid and the risk of coronary heart disease events: The heart and estrogen‐progestin replacement study (HERS). Annals of Epidemiology2006;16(2):138‐45. SperoffL . The heart and estrogen/progestin replacement study (HERS). Maturitas1998;31(1):9‐14. ">HERS I 1998</a>; <a href="./references#CD002229-bbs2-0012" title="GallagherJ , RapuriB , HaynatzkiG , DetterR . Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. The Journal of Clinical Endocrinology and Metabolism2002;87(11):4914‐23. GallagherJC , FowlerSE , DetterJR , ShermanSS . Combination treatment with estrogen and calcitriol in the prevention of age‐related bone loss. The Journal of Clinical Endocrinology and Metabolism2001;86(8):3618‐28. RapuriP , GallagherJ , KnezeticJ , HaynatzkaV . Estrogen receptor alpha gene polymorphisms are associated with changes in bone remodeling markers and treatment response to estrogen. Maturitas2006;53(4):371‐9. SaiA , GallagherJ , FangX . Effect of hormone therapy and calcitriol on serum lipid profile in postmenopausal older women: association with estrogen receptor‐alpha genotypes. Menopause2011;18(10):1101‐12. YalamanchiliV , GallagherJ . Treatment with hormone therapy and calcitriol did not affect depression in older postmenopausal women: no interaction with estrogen and vitamin D receptor genotype polymorphisms. Menopause2012;19(6):697‐703. ">STOP IT 2001</a>; <a href="./references#CD002229-bbs2-0013" title="HsiaJ , AldermanEL , VerterJI , RogersWJ , ThompsonP , HowardBV , et al. Women’s angiographic vitamin and estrogen trial: design and methods. Controlled Clinical Trials2002;23:708‐27. WatersD , AldermanE , HsiaJ , HowardB , CobbF , RogersW , et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women. JAMA2001;288(19):2432‐40. ">WAVE 2002</a>; <a href="./references#CD002229-bbs2-0014" title="HodisHN , MackWJ , AzenSP , LoboRA , ShoupeD , MahrerPR , et al. Hormone therapy and the progression of coronary‐artery atherosclerosis in postmenopausal women. New England Journal of Medicine2003;349(6):535‐45. ">WELL‐HART 2003</a>; <a href="./references#CD002229-bbs2-0015" title="KernanWN , BrassLM , ViscoliCM , SarrellPM , MakuchR , HorwitzRI . Estrogen after ischemic stroke: clinical basis and design of the Womens Estrogen for Stroke Trial. Journal of Stroke and Cerebrovascular Diseases1998;7(1):85‐95. ViscoliC , BrassL , Kernan , SarrelP , SuissaS , HorwitzR . Estrogen therapy and risk of cognitive decline: Results from the Women's Estrogen for Stroke Trial (WEST). American Journal of Obstetrics and Gynecology2005;192(2):387‐93. ViscoliCM , BrassLM , KernanWN , SarrelPM , SuissaS , HorwitzRI . A clinical trial of estrogen‐replacement therapy after ischemic stroke. New England Journal of Medicine2001;345(17):1243‐9. ">WEST 2001</a>; <a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a>; <a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a>; <a href="./references#CD002229-bbs2-0018" title="CollinsP , FlatherM , LeesB , MisterR , ProudlerA , StevensonJC , WHISP (Women's Hormone Intervention Secondary Prevention Study) Pilot Study Investigators. Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study. European Heart Journal2006;27(17):2046‐53. ">WHISP 2006</a>; <a href="./references#CD002229-bbs2-0019" title="VickersMR , MacLacLennanA , LawtonB , FordD , MartinJ , MeredithS , et al. WISDOM group. Main morbidities recorded in the women's international study of long duration estrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ2007;335(7613):239. VickersMR , MartinJ , MeadeTW , WISDOM study team. The Women’s international study of long‐duration of estrogen after menopause (WISDOM): a randomised controlled trial. BMC Women's Health2007;7:2. WeltonAJ , VickersMR , KimJ , FordD , LawtonBA , MacLennanAH , et al. WISDOM team. Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ2008;337:a1190. ">WISDOM 2007</a>) (<a href="#CD002229-tbl-0010">Table 6</a>). Eight studies reported a mean time since menopause for the study population at the start of the study of more than 10 years: <a href="./references#CD002229-bbs2-0010" title="HallG , PrippU , Schenk‐GustafssonK , LandgrenBM . Long‐term effects of hormone replacement therapy on symptoms of angina pectoris, quality of life and compliance in women with coronary artery disease. Maturitas1998 ;28 :235‐42 . ">HALL 1998</a> (12.5 years), <a href="./references#CD002229-bbs2-0019" title="VickersMR , MacLacLennanA , LawtonB , FordD , MartinJ , MeredithS , et al. WISDOM group. Main morbidities recorded in the women's international study of long duration estrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ2007;335(7613):239. VickersMR , MartinJ , MeadeTW , WISDOM study team. The Women’s international study of long‐duration of estrogen after menopause (WISDOM): a randomised controlled trial. BMC Women's Health2007;7:2. WeltonAJ , VickersMR , KimJ , FordD , LawtonBA , MacLennanAH , et al. WISDOM team. Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ2008;337:a1190. ">WISDOM 2007</a> (14.7 years), <a href="./references#CD002229-bbs2-0007" title="The ESPRIT Team. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet2002;360:2001‐8. ">ESPRIT 2002</a> (16.1 years), <a href="./references#CD002229-bbs2-0011" title="Bibbins‐DomingoK , LinF , VittinghoffE , Barrett‐ConnorE , HulleyS , GradyD , et al. Effect of hormone therapy on mortality rates among women with heart failure and coronary artery disease. American Journal of Cardiology2005;95(2):289‐91. GiddingsL . Oestrogen plus progestin increased venous thromboembolic disease in postmenopausal women with coronary artery disease. Evidence Based Nursing2000;3(4):123. GradyD , ApplegateW , BushT , FurbergC , RiggsB , HulleyS , et al. Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics. Controlled Clinical Trials1998;19(4):314‐35. GradyD , HerringtonD , BittnerV , DavidsonM , HlatkyM , HsiaJ , et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study Follow‐up (HERS II). JAMA2002;288(1):49‐57. GradyD , WengerN , HerringtonD , KhanS , FurbergC , Hunninghake , et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. Annals of Internal Medicine2000;132:689‐96. HlatkyM , BoothroydD , VittinghoffE , SharpP , WhooleyMA . Quality‐of life and depressive symptoms in postmenopausal women after receiving hormone therapy. Results from the Heart and Estrogen/Progestin Replacement Study (HERS) Trial. JAMA2002;287(5):591‐7. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA1998;280(7):605‐13. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Obstetrical and Gynecological Survey1999;54(1):41‐2. KhanM , HlatkyM , LiuM , LinF , RogersW , ShlipakM . Effect of postmenopausal hormone therapy on coronary heart disease events after percutaneous transluminal coronary angioplasty. The American Journal of Cardiology2003;91(8):989‐91, A7. ShlipakM , SimonJ , VittinghoffE , LinF , Barrett‐ConnorE , KnoppR . Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA2000;283(14):1845‐52. SimonJA , HsiaJ , CauleyJA , RichardsC , HarrisF , FongJ , et al. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen‐progestin Replacement Study (HERS). Circulation2001;103(5):638‐42. SimonJA , LinF , VittinghoffE , BittnerV , Heart and Estrogen‐Progestin Replacement Study (HERS) Research Group. The relation of postmenopausal hormone therapy to serum uric acid and the risk of coronary heart disease events: The heart and estrogen‐progestin replacement study (HERS). Annals of Epidemiology2006;16(2):138‐45. SperoffL . The heart and estrogen/progestin replacement study (HERS). Maturitas1998;31(1):9‐14. ">HERS I 1998</a> (18 years), <a href="./references#CD002229-bbs2-0014" title="HodisHN , MackWJ , AzenSP , LoboRA , ShoupeD , MahrerPR , et al. Hormone therapy and the progression of coronary‐artery atherosclerosis in postmenopausal women. New England Journal of Medicine2003;349(6):535‐45. ">WELL‐HART 2003</a> (18.2 years), <a href="./references#CD002229-bbs2-0018" title="CollinsP , FlatherM , LeesB , MisterR , ProudlerA , StevensonJC , WHISP (Women's Hormone Intervention Secondary Prevention Study) Pilot Study Investigators. Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study. European Heart Journal2006;27(17):2046‐53. ">WHISP 2006</a> (22.8 years), <a href="./references#CD002229-bbs2-0005" title="HerringtonDM , ReboussinDM , Bridget BrosnihanK , SharpPC , ShumakerSA , SnyderTE , et al. Effects of estrogen replacement on the progression of coronary‐artery atherosclerosis. New England Journal of Medicine2000;343(8):522‐9. HerringtonDM , ReboussinDM , KleinKP , SharpPC , ShumakerSA , SnyderTE , et al. The estrogen replacement and atherosclerosis (ERA) study: study design and baseline characteristics of the cohort. Controlled Clinical Trials2000;21(3):257‐85. NairG , HerringtonD . The ERA trial: findings and implications for the future. Climacteric2000;3:227‐32. ">ERA 2000</a> (23.0 years) and <a href="./references#CD002229-bbs2-0015" title="KernanWN , BrassLM , ViscoliCM , SarrellPM , MakuchR , HorwitzRI . Estrogen after ischemic stroke: clinical basis and design of the Womens Estrogen for Stroke Trial. Journal of Stroke and Cerebrovascular Diseases1998;7(1):85‐95. ViscoliC , BrassL , Kernan , SarrelP , SuissaS , HorwitzR . Estrogen therapy and risk of cognitive decline: Results from the Women's Estrogen for Stroke Trial (WEST). American Journal of Obstetrics and Gynecology2005;192(2):387‐93. ViscoliCM , BrassLM , KernanWN , SarrelPM , SuissaS , HorwitzRI . A clinical trial of estrogen‐replacement therapy after ischemic stroke. New England Journal of Medicine2001;345(17):1243‐9. ">WEST 2001</a> (25 years). Five studies did not report number of years since menopause, but did report a mean age of the study population &gt; 60 years (<a href="./references#CD002229-bbs2-0003" title="HodisH , MackW , LoboR , MahrerP , LiuC R , LiuC H . Estrogen replacement therapy effects on the progression of subclinical atherosclerosis are mediated by lipids but not by carbohydrate metabolic factors: results from the Estrogen in the Prevention of Athersclerosis Trial (EPAT). Circulation2002;106(19 Suppl II):II‐744. HodisHN , MackWJ , LoboRA , ShoupeD , SevanianA , MahrerPR , et al. Estrogen in the prevention of atherosclerosis. A randomized, double‐blind, placebo‐controlled trial. Annals of Internal Medicine2001;135(11):939‐53. ">EPAT 2001</a> (62.2 years old), <a href="./references#CD002229-bbs2-0002" title="Ouyang P , TardifJ , HerringtonD , StewartK , ThompsonP , WalshM , et al. Randomized trial of hormone therapy in women after coronary bypass surgery: Evidence of differential effect of hormone therapy on angiographic progression of disease in saphenous vein grafts and native coronary arteries. Atherosclerosis2006;189(2):375‐86. ">EAGAR 2006</a> (64 years old), <a href="./references#CD002229-bbs2-0013" title="HsiaJ , AldermanEL , VerterJI , RogersWJ , ThompsonP , HowardBV , et al. Women’s angiographic vitamin and estrogen trial: design and methods. Controlled Clinical Trials2002;23:708‐27. WatersD , AldermanE , HsiaJ , HowardB , CobbF , RogersW , et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women. JAMA2001;288(19):2432‐40. ">WAVE 2002</a> (65 years old), <a href="./references#CD002229-bbs2-0012" title="GallagherJ , RapuriB , HaynatzkiG , DetterR . Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. The Journal of Clinical Endocrinology and Metabolism2002;87(11):4914‐23. GallagherJC , FowlerSE , DetterJR , ShermanSS . Combination treatment with estrogen and calcitriol in the prevention of age‐related bone loss. The Journal of Clinical Endocrinology and Metabolism2001;86(8):3618‐28. RapuriP , GallagherJ , KnezeticJ , HaynatzkaV . Estrogen receptor alpha gene polymorphisms are associated with changes in bone remodeling markers and treatment response to estrogen. Maturitas2006;53(4):371‐9. SaiA , GallagherJ , FangX . Effect of hormone therapy and calcitriol on serum lipid profile in postmenopausal older women: association with estrogen receptor‐alpha genotypes. Menopause2011;18(10):1101‐12. YalamanchiliV , GallagherJ . Treatment with hormone therapy and calcitriol did not affect depression in older postmenopausal women: no interaction with estrogen and vitamin D receptor genotype polymorphisms. Menopause2012;19(6):697‐703. ">STOP IT 2001</a> (71 years old) and <a href="./references#CD002229-bbs2-0009" title="GreenspanSL , ResnickNM , ParkerRA . The effect of hormone replacement on physical performance in community‐dwelling elderly women. The American Journal of Medicine2005;118:1232‐9. ">Greenspan 2005</a> (71.2 years old). Two studies reported events stratified by participants who were ≥ 10 years since their menopause at the start of the study <a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a>; <a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a>). </p> <p>Hormone therapy in a population who as a mean started treatment 10 years or more after menopause or were more than 60 years old demonstrated no strong evidence that hormone therapy has an effect on death (RR 1.06, 95% CI 0.95 to 1.18; 27,750 participants in 12 studies) (<a href="./references#CD002229-fig-0032" title="">Analysis 4.1</a>) or coronary heart disease (RR 1.07, 95% CI 0.96 to 1.20; 23,491 participants in 12 studies) (<a href="./references#CD002229-fig-0033" title="">Analysis 4.2</a>). However, there was strong evidence that hormone therapy is associated with an increased risk of stroke (RR 1.21, 95% CI 1.06 to 1.38; 22,722 participants in 8 studies) (<a href="./references#CD002229-fig-0034" title="">Analysis 4.3</a>) and of venous thromboembolism (RR 1.96, 95% CI 1.37 to 2.80; 27,475 participants in 9 studies) (<a href="./references#CD002229-fig-0035" title="">Analysis 4.4</a>). The absolute risk increase for stroke and venous thromboembolism was 0.01 (NNTH = 102) and 0.01 (NNTH = 101), respectively. A summary of the outcomes and their relative risks are presented in <a href="./full#CD002229-tbl-0004">summary of findings Table 4</a>. There was moderate statistical heterogeneity present between trials for the outcome of venous thromboembolism (I<sup>2</sup> = 41%) but not for any other outcomes. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD002229-sec-0101" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD002229-sec-0101"></div> <section id="CD002229-sec-0102"> <h3 class="title" id="CD002229-sec-0102">Summary of main results</h3> <p>The stimulus for updating this review was the publication of <a href="./references#CD002229-bbs2-0001" title="BladbjergE , MadsenJ , KristensenS , AbrahamsenB , BrixenK , MosekildeL , et al. Effect of long‐term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. Journal of Thrombosis and Haemostasis2003;1(6):1208‐14. KristensenS , AbrahamsenB , MadsenJ , GramJ , RejnmarkL , RudB , et al. Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: results from the Danish Osteoporosis Prevention Study (DOPS). Thrombosis and Haemostasis2006;95:915‐6. MadsenJ , KristensenS , GramJ , BladbjergE , HenriksenF , ChristensenK , et al. Positive impact of hormone replacement therapy on the fibrinolytic system: a long‐term randomized controlled study in healthy postmenopausal women. Journal of Thrombosis and Haemostasis2003;1(9):1984‐91. SchierbeckL , RejnmarkL , ToftengC , StilgrenL , EikenP , MosekildeL , et al. Hormone replacement treatment in early postmenopausal women reduces cardiovascular events ‐ A randomized controlled study. Circulation2011;124:A11380. SchierbeckLL , RejnmarkL , ToftengCL , StilgrenL , EikenP , MosekildeL , et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ2012;345:e6409. ToftengC , JensenJ , AbrahamsenB , OdumL , BrotC . Two polymorphisms in the vitamin D receptor gene‐association with bone mass and 5‐year change in bone mass with or without hormone‐replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study. Journal of Bone and Mineral Research2002;17(8):1535‐44. deMaatM , MadsenJ , LangdalB , BladbjergE , ToftengC , AbrahamsenL , et al. Genetic variation in estrogen receptor, C‐reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. Thrombosis and Haemostasis2007;97(2):234‐9. ">DOPS 2012</a>, however this trial only contributed 3.5% and 19.5% weight to the all‐cause mortality and cardiovascular mortality, respectively, in the treatment of a primary prevention population. In the trial population as a whole, there is no evidence that hormone therapy has a role in either the prevention or treatment of cardiovascular disease. There was no strong evidence that treatment with hormone therapy had an effect on overall death rates, cardiovascular disease‐related death, non‐fatal myocardial infarction, angina, or the number of patients undergoing revascularisation procedures. On the contrary, it is associated with an increased risk of stroke, venous thromboembolism and pulmonary embolism. </p> <p>The excess risk of stroke in our analyses was observed in the primary prevention analysis (which includes those randomised to either oestrogen alone or oestrogen in combination with progestogen compared to placebo). These findings are based on the two largest trials, <a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a> and <a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a>, with follow‐up of 5.6 and 7.1 years, respectively. Whilst, no strong evidence of increased risk was observed in any of the secondary prevention trials, including the largest trial <a href="./references#CD002229-bbs2-0011" title="Bibbins‐DomingoK , LinF , VittinghoffE , Barrett‐ConnorE , HulleyS , GradyD , et al. Effect of hormone therapy on mortality rates among women with heart failure and coronary artery disease. American Journal of Cardiology2005;95(2):289‐91. GiddingsL . Oestrogen plus progestin increased venous thromboembolic disease in postmenopausal women with coronary artery disease. Evidence Based Nursing2000;3(4):123. GradyD , ApplegateW , BushT , FurbergC , RiggsB , HulleyS , et al. Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics. Controlled Clinical Trials1998;19(4):314‐35. GradyD , HerringtonD , BittnerV , DavidsonM , HlatkyM , HsiaJ , et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study Follow‐up (HERS II). JAMA2002;288(1):49‐57. GradyD , WengerN , HerringtonD , KhanS , FurbergC , Hunninghake , et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. Annals of Internal Medicine2000;132:689‐96. HlatkyM , BoothroydD , VittinghoffE , SharpP , WhooleyMA . Quality‐of life and depressive symptoms in postmenopausal women after receiving hormone therapy. Results from the Heart and Estrogen/Progestin Replacement Study (HERS) Trial. JAMA2002;287(5):591‐7. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA1998;280(7):605‐13. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Obstetrical and Gynecological Survey1999;54(1):41‐2. KhanM , HlatkyM , LiuM , LinF , RogersW , ShlipakM . Effect of postmenopausal hormone therapy on coronary heart disease events after percutaneous transluminal coronary angioplasty. The American Journal of Cardiology2003;91(8):989‐91, A7. ShlipakM , SimonJ , VittinghoffE , LinF , Barrett‐ConnorE , KnoppR . Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA2000;283(14):1845‐52. SimonJA , HsiaJ , CauleyJA , RichardsC , HarrisF , FongJ , et al. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen‐progestin Replacement Study (HERS). Circulation2001;103(5):638‐42. SimonJA , LinF , VittinghoffE , BittnerV , Heart and Estrogen‐Progestin Replacement Study (HERS) Research Group. The relation of postmenopausal hormone therapy to serum uric acid and the risk of coronary heart disease events: The heart and estrogen‐progestin replacement study (HERS). Annals of Epidemiology2006;16(2):138‐45. SperoffL . The heart and estrogen/progestin replacement study (HERS). Maturitas1998;31(1):9‐14. ">HERS I 1998</a>, it is probable that the results from the primary prevention trials are applicable to secondary prevention populations, and that subgroup analyses of these trials were underpowered (due to small trial sizes, low event rates and shorter length of follow‐up) to detect any statistically significant differences in stroke rates between hormone therapy and placebo treatment arms. In both <a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a> and <a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a>, the excess risk of stroke observed with hormone therapy use was driven by an excess of ischaemic rather than haemorrhagic stroke, with 79.8% and 80.3% of strokes, respectively, observed within the trials being ischaemic (<a href="./references#CD002229-bbs2-0108" title="HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. Effects of conjugated equine estrogen on stroke in the women's health initiative. Circulation2006;113:2425‐34. ">Hendrix 2006</a>; <a href="./references#CD002229-bbs2-0148" title="Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. ">Wassertheil‐Smoller 2003</a>). In the same two trials, an increased risk of stroke was apparent after two years of treatment in women taking combination hormone therapy, and after four years for women randomised to oestrogen alone (<a href="./references#CD002229-bbs2-0108" title="HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. Effects of conjugated equine estrogen on stroke in the women's health initiative. Circulation2006;113:2425‐34. ">Hendrix 2006</a>). In both trials, the hazard ratios for ischaemic stroke did not differ significantly in subgroups based on age, years since menopause, prior cardiovascular disease, hypertension or diabetes mellitus status, body mass index, or statin or aspirin use at baseline (<a href="./references#CD002229-bbs2-0108" title="HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. Effects of conjugated equine estrogen on stroke in the women's health initiative. Circulation2006;113:2425‐34. ">Hendrix 2006</a>; <a href="./references#CD002229-bbs2-0148" title="Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. ">Wassertheil‐Smoller 2003</a>). </p> <p>The finding of increased risk for both venous thromboembolism and pulmonary embolism within the overall trial populations appears in our analyses to be driven largely by the excess risk observed in combination hormone therapy (oestrogen combined with progestogen) trials. The greatest risk in primary prevention populations was shown in <a href="./references#CD002229-bbs2-0019" title="VickersMR , MacLacLennanA , LawtonB , FordD , MartinJ , MeredithS , et al. WISDOM group. Main morbidities recorded in the women's international study of long duration estrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ2007;335(7613):239. VickersMR , MartinJ , MeadeTW , WISDOM study team. The Women’s international study of long‐duration of estrogen after menopause (WISDOM): a randomised controlled trial. BMC Women's Health2007;7:2. WeltonAJ , VickersMR , KimJ , FordD , LawtonBA , MacLennanAH , et al. WISDOM team. Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ2008;337:a1190. ">WISDOM 2007</a> and <a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a>, both testing combination hormone therapy. In secondary prevention populations, the greatest risk was demonstrated in <a href="./references#CD002229-bbs2-0011" title="Bibbins‐DomingoK , LinF , VittinghoffE , Barrett‐ConnorE , HulleyS , GradyD , et al. Effect of hormone therapy on mortality rates among women with heart failure and coronary artery disease. American Journal of Cardiology2005;95(2):289‐91. GiddingsL . Oestrogen plus progestin increased venous thromboembolic disease in postmenopausal women with coronary artery disease. Evidence Based Nursing2000;3(4):123. GradyD , ApplegateW , BushT , FurbergC , RiggsB , HulleyS , et al. Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics. Controlled Clinical Trials1998;19(4):314‐35. GradyD , HerringtonD , BittnerV , DavidsonM , HlatkyM , HsiaJ , et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study Follow‐up (HERS II). JAMA2002;288(1):49‐57. GradyD , WengerN , HerringtonD , KhanS , FurbergC , Hunninghake , et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. Annals of Internal Medicine2000;132:689‐96. HlatkyM , BoothroydD , VittinghoffE , SharpP , WhooleyMA . Quality‐of life and depressive symptoms in postmenopausal women after receiving hormone therapy. Results from the Heart and Estrogen/Progestin Replacement Study (HERS) Trial. JAMA2002;287(5):591‐7. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA1998;280(7):605‐13. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Obstetrical and Gynecological Survey1999;54(1):41‐2. KhanM , HlatkyM , LiuM , LinF , RogersW , ShlipakM . Effect of postmenopausal hormone therapy on coronary heart disease events after percutaneous transluminal coronary angioplasty. The American Journal of Cardiology2003;91(8):989‐91, A7. ShlipakM , SimonJ , VittinghoffE , LinF , Barrett‐ConnorE , KnoppR . Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA2000;283(14):1845‐52. SimonJA , HsiaJ , CauleyJA , RichardsC , HarrisF , FongJ , et al. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen‐progestin Replacement Study (HERS). Circulation2001;103(5):638‐42. SimonJA , LinF , VittinghoffE , BittnerV , Heart and Estrogen‐Progestin Replacement Study (HERS) Research Group. The relation of postmenopausal hormone therapy to serum uric acid and the risk of coronary heart disease events: The heart and estrogen‐progestin replacement study (HERS). Annals of Epidemiology2006;16(2):138‐45. SperoffL . The heart and estrogen/progestin replacement study (HERS). Maturitas1998;31(1):9‐14. ">HERS I 1998</a>, also assessing combination hormone therapy. Subgroup analysis of <a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a> for the outcome of venous thromboembolism demonstrated the greatest risk with combination hormone therapy in the first year of treatment (HR 4.01), with lower risk in subsequent years (<a href="./references#CD002229-bbs2-0097" title="CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. ">Cushman 2004</a>). <a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a> also demonstrated a tendency to higher risk early on with only modest increased risk after two years of treatment with oestrogen alone (<a href="./references#CD002229-bbs2-0096" title="CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166:772‐80. ">Curb 2006</a>). When comparing the two studies (combination hormone therapy compared to oestrogen alone), the difference in risk was most apparent after year two when the higher risk in combination hormone therapy was most noticeable (<a href="./references#CD002229-bbs2-0096" title="CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166:772‐80. ">Curb 2006</a>). </p> <p>Both <a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a> and <a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a> undertook further prespecified subgroup analyses to evaluate the association between participant baseline characteristics and venous thromboembolism and pulmonary embolism risk. Not surprisingly, given the fact that no excess risk was observed within the trial, <a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a> investigators found no strong evidence of interactions between oestrogen alone use and age, body mass index, or most other venous thromboembolism risk factors. The authors did however note, that hazard ratios for combination therapy in <a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a> were significantly higher than those for oestrogen alone, even after adjusting for venous thromboembolism risk factors (<a href="./references#CD002229-bbs2-0096" title="CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166:772‐80. ">Curb 2006</a>). In <a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a>, increasing age, being overweight and obese, and having a factor V Leiden mutation (a blood coagulation disorder) were associated with a higher risk of venous thromboembolism compared to placebo (<a href="./references#CD002229-bbs2-0097" title="CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. ">Cushman 2004</a>). Both <a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a> and <a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a> undertook prespecified subgroup analyses to evaluate whether any clinical characteristics of the trial populations may potentially moderate the effects of hormone therapy. The potential predictor variables examined included: age, time since menopause, presence or absence of vasomotor symptoms, prior hormone use, coronary heart disease risk factor status and presence or absence of preexisting cardiovascular disease (<a href="./references#CD002229-bbs2-0110" title="HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Conjugated equine estrogens and coronary heart disease: The Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. ">Hsia 2006</a>; <a href="./references#CD002229-bbs2-0122" title="Manson , JE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349:523‐34. ">Manson 2003</a>). None of these variables significantly affected results, although we observed a non‐significant trend for a reduction in coronary heart disease risk for women who initiated hormone therapy use within ten years of menopause. </p> <p>Subgroup analysis of time of treatment commencement in relation to the menopause, found a benefit in overall survival and coronary heart disease (composite of death from cardiovascular causes and non‐fatal myocardial infarction) in the hormone therapy group in those who started less than 10 years after their menopause (or before the age of 60). This is similar to the trend in coronary heart disease events in <a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a> shown in <a href="./references#CD002229-bbs2-0110" title="HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Conjugated equine estrogens and coronary heart disease: The Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. ">Hsia 2006</a>. There was no strong evidence of effect on stroke. There was, however, strong evidence of increased risk of venous thromboembolism, whether started before or after the age of 60. </p> <p>There was no strong evidence of effect on death or coronary heart disease for the group who started treatment at 10 years or more after the menopause, however there was an increased risk of stroke and venous thromboembolism. We did not analyse any other outcomes, as these analyses relied significantly on subgroup reporting from <a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a> and <a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a>, which only reported these outcomes according to time since the menopause, or age that treatment was started. There were insufficient data from other trials to make reliable analyses of other outcomes. </p> <p>It is worth noting that the benefit seen in survival and coronary heart disease for the group starting treatment less than 10 years after the menopause is from combining five trials all performed in primary prevention populations and all with quite long follow‐up, ranging from 3.4 years to 10.1 years. Looking at the event rates in these individual trials it can be seen that the greatest benefit is in those trials with the longest follow‐up. It is possible that this could be due to an interaction with time on treatment, whereby coronary heart disease events occur in predisposed individuals early as opposed to later on with hormone therapy treatment, and therefore any risk reduction is observed in the later stages of treatment. This is consistent with the hazard ratio for coronary heart disease for the one‐year intervals of follow‐up observed in <a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a> (<a href="./references#CD002229-bbs2-0122" title="Manson , JE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349:523‐34. ">Manson 2003</a>). Therefore, it is not possible to say if short duration hormone therapy is beneficial in this population, only that hormone therapy taken for between 3.4 to 10 years is beneficial in this population. </p> <p>In analysis of death according to year of treatment, there was no strong evidence of difference between treatment groups by individual year of treatment. There was also no strong evidence of difference in survival comparing cumulative years of treatment, until ten years of treatment, where there was a small survival benefit in the hormone therapy group. However, this was based on two relatively small primary prevention trials, where treatment was started shortly after the menopause (<a href="./references#CD002229-bbs2-0001" title="BladbjergE , MadsenJ , KristensenS , AbrahamsenB , BrixenK , MosekildeL , et al. Effect of long‐term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. Journal of Thrombosis and Haemostasis2003;1(6):1208‐14. KristensenS , AbrahamsenB , MadsenJ , GramJ , RejnmarkL , RudB , et al. Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: results from the Danish Osteoporosis Prevention Study (DOPS). Thrombosis and Haemostasis2006;95:915‐6. MadsenJ , KristensenS , GramJ , BladbjergE , HenriksenF , ChristensenK , et al. Positive impact of hormone replacement therapy on the fibrinolytic system: a long‐term randomized controlled study in healthy postmenopausal women. Journal of Thrombosis and Haemostasis2003;1(9):1984‐91. SchierbeckL , RejnmarkL , ToftengC , StilgrenL , EikenP , MosekildeL , et al. Hormone replacement treatment in early postmenopausal women reduces cardiovascular events ‐ A randomized controlled study. Circulation2011;124:A11380. SchierbeckLL , RejnmarkL , ToftengCL , StilgrenL , EikenP , MosekildeL , et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ2012;345:e6409. ToftengC , JensenJ , AbrahamsenB , OdumL , BrotC . Two polymorphisms in the vitamin D receptor gene‐association with bone mass and 5‐year change in bone mass with or without hormone‐replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study. Journal of Bone and Mineral Research2002;17(8):1535‐44. deMaatM , MadsenJ , LangdalB , BladbjergE , ToftengC , AbrahamsenL , et al. Genetic variation in estrogen receptor, C‐reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. Thrombosis and Haemostasis2007;97(2):234‐9. ">DOPS 2012</a>; <a href="./references#CD002229-bbs2-0006" title="NachtigallLE , NachtigallRH , NachtigallRD , BeckmanEM . Estrogen replacement therapy II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstetrics Gynecology1979;54(1):74‐9. ">ERT II 1979</a>). One of the trials had poor methodology (<a href="./references#CD002229-bbs2-0006" title="NachtigallLE , NachtigallRH , NachtigallRD , BeckmanEM . Estrogen replacement therapy II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstetrics Gynecology1979;54(1):74‐9. ">ERT II 1979</a>). It is possible that there are other explanations for the benefit seen in this analysis, other than the duration of treatment, such as the timing of commencing treatment. </p> </section> <section id="CD002229-sec-0103"> <h3 class="title" id="CD002229-sec-0103">Overall completeness and applicability of evidence</h3> <p>There are a number of limitations to the evidence base reviewed. Firstly, it should be highlighted that the results are based on those obtained in 19 RCTs, with the majority of statistically significant findings derived from the results of the three largest trials, <a href="./references#CD002229-bbs2-0011" title="Bibbins‐DomingoK , LinF , VittinghoffE , Barrett‐ConnorE , HulleyS , GradyD , et al. Effect of hormone therapy on mortality rates among women with heart failure and coronary artery disease. American Journal of Cardiology2005;95(2):289‐91. GiddingsL . Oestrogen plus progestin increased venous thromboembolic disease in postmenopausal women with coronary artery disease. Evidence Based Nursing2000;3(4):123. GradyD , ApplegateW , BushT , FurbergC , RiggsB , HulleyS , et al. Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics. Controlled Clinical Trials1998;19(4):314‐35. GradyD , HerringtonD , BittnerV , DavidsonM , HlatkyM , HsiaJ , et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study Follow‐up (HERS II). JAMA2002;288(1):49‐57. GradyD , WengerN , HerringtonD , KhanS , FurbergC , Hunninghake , et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. Annals of Internal Medicine2000;132:689‐96. HlatkyM , BoothroydD , VittinghoffE , SharpP , WhooleyMA . Quality‐of life and depressive symptoms in postmenopausal women after receiving hormone therapy. Results from the Heart and Estrogen/Progestin Replacement Study (HERS) Trial. JAMA2002;287(5):591‐7. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA1998;280(7):605‐13. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Obstetrical and Gynecological Survey1999;54(1):41‐2. KhanM , HlatkyM , LiuM , LinF , RogersW , ShlipakM . Effect of postmenopausal hormone therapy on coronary heart disease events after percutaneous transluminal coronary angioplasty. The American Journal of Cardiology2003;91(8):989‐91, A7. ShlipakM , SimonJ , VittinghoffE , LinF , Barrett‐ConnorE , KnoppR . Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA2000;283(14):1845‐52. SimonJA , HsiaJ , CauleyJA , RichardsC , HarrisF , FongJ , et al. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen‐progestin Replacement Study (HERS). Circulation2001;103(5):638‐42. SimonJA , LinF , VittinghoffE , BittnerV , Heart and Estrogen‐Progestin Replacement Study (HERS) Research Group. The relation of postmenopausal hormone therapy to serum uric acid and the risk of coronary heart disease events: The heart and estrogen‐progestin replacement study (HERS). Annals of Epidemiology2006;16(2):138‐45. SperoffL . The heart and estrogen/progestin replacement study (HERS). Maturitas1998;31(1):9‐14. ">HERS I 1998</a>, <a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a> and <a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a>, which dominate the results. These three trials all evaluated oral conjugated equine oestrogen 0.625 mg, with or without continuous medroxyprogesterone (MPA) 2.5 mg. Other trials evaluating different types of hormone therapy tended to be much smaller with a shorter duration of follow‐up, and reported few if any major clinical events. There is some debate regarding the external validity of the findings of <a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a> and <a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a>, and the degree to which they apply to any type of hormone therapy, other than continuous combined oral conjugated equine oestrogen 0.625 mg with or without MPA 2.5 mg. The effects of hormone therapy may vary with different oestrogens and progestogens, different doses and routes of administration. However, in order to pool the results of different studies statistically, we had to make assumptions regarding a ‘class effect’ of hormone therapy, which may not be warranted. </p> <p>The clinical outcomes of interest in the review were secondary outcomes in five of the trials (<a href="./references#CD002229-bbs2-0001" title="BladbjergE , MadsenJ , KristensenS , AbrahamsenB , BrixenK , MosekildeL , et al. Effect of long‐term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. Journal of Thrombosis and Haemostasis2003;1(6):1208‐14. KristensenS , AbrahamsenB , MadsenJ , GramJ , RejnmarkL , RudB , et al. Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: results from the Danish Osteoporosis Prevention Study (DOPS). Thrombosis and Haemostasis2006;95:915‐6. MadsenJ , KristensenS , GramJ , BladbjergE , HenriksenF , ChristensenK , et al. Positive impact of hormone replacement therapy on the fibrinolytic system: a long‐term randomized controlled study in healthy postmenopausal women. Journal of Thrombosis and Haemostasis2003;1(9):1984‐91. SchierbeckL , RejnmarkL , ToftengC , StilgrenL , EikenP , MosekildeL , et al. Hormone replacement treatment in early postmenopausal women reduces cardiovascular events ‐ A randomized controlled study. Circulation2011;124:A11380. SchierbeckLL , RejnmarkL , ToftengCL , StilgrenL , EikenP , MosekildeL , et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ2012;345:e6409. ToftengC , JensenJ , AbrahamsenB , OdumL , BrotC . Two polymorphisms in the vitamin D receptor gene‐association with bone mass and 5‐year change in bone mass with or without hormone‐replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study. Journal of Bone and Mineral Research2002;17(8):1535‐44. deMaatM , MadsenJ , LangdalB , BladbjergE , ToftengC , AbrahamsenL , et al. Genetic variation in estrogen receptor, C‐reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. Thrombosis and Haemostasis2007;97(2):234‐9. ">DOPS 2012</a>; <a href="./references#CD002229-bbs2-0003" title="HodisH , MackW , LoboR , MahrerP , LiuC R , LiuC H . Estrogen replacement therapy effects on the progression of subclinical atherosclerosis are mediated by lipids but not by carbohydrate metabolic factors: results from the Estrogen in the Prevention of Athersclerosis Trial (EPAT). Circulation2002;106(19 Suppl II):II‐744. HodisHN , MackWJ , LoboRA , ShoupeD , SevanianA , MahrerPR , et al. Estrogen in the prevention of atherosclerosis. A randomized, double‐blind, placebo‐controlled trial. Annals of Internal Medicine2001;135(11):939‐53. ">EPAT 2001</a>; <a href="./references#CD002229-bbs2-0005" title="HerringtonDM , ReboussinDM , Bridget BrosnihanK , SharpPC , ShumakerSA , SnyderTE , et al. Effects of estrogen replacement on the progression of coronary‐artery atherosclerosis. New England Journal of Medicine2000;343(8):522‐9. HerringtonDM , ReboussinDM , KleinKP , SharpPC , ShumakerSA , SnyderTE , et al. The estrogen replacement and atherosclerosis (ERA) study: study design and baseline characteristics of the cohort. Controlled Clinical Trials2000;21(3):257‐85. NairG , HerringtonD . The ERA trial: findings and implications for the future. Climacteric2000;3:227‐32. ">ERA 2000</a>; <a href="./references#CD002229-bbs2-0007" title="The ESPRIT Team. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet2002;360:2001‐8. ">ESPRIT 2002</a>; <a href="./references#CD002229-bbs2-0013" title="HsiaJ , AldermanEL , VerterJI , RogersWJ , ThompsonP , HowardBV , et al. Women’s angiographic vitamin and estrogen trial: design and methods. Controlled Clinical Trials2002;23:708‐27. WatersD , AldermanE , HsiaJ , HowardB , CobbF , RogersW , et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women. JAMA2001;288(19):2432‐40. ">WAVE 2002</a>) and reported as adverse events in five more (<a href="./references#CD002229-bbs2-0006" title="NachtigallLE , NachtigallRH , NachtigallRD , BeckmanEM . Estrogen replacement therapy II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstetrics Gynecology1979;54(1):74‐9. ">ERT II 1979</a>; <a href="./references#CD002229-bbs2-0009" title="GreenspanSL , ResnickNM , ParkerRA . The effect of hormone replacement on physical performance in community‐dwelling elderly women. The American Journal of Medicine2005;118:1232‐9. ">Greenspan 2005</a>; <a href="./references#CD002229-bbs2-0012" title="GallagherJ , RapuriB , HaynatzkiG , DetterR . Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. The Journal of Clinical Endocrinology and Metabolism2002;87(11):4914‐23. GallagherJC , FowlerSE , DetterJR , ShermanSS . Combination treatment with estrogen and calcitriol in the prevention of age‐related bone loss. The Journal of Clinical Endocrinology and Metabolism2001;86(8):3618‐28. RapuriP , GallagherJ , KnezeticJ , HaynatzkaV . Estrogen receptor alpha gene polymorphisms are associated with changes in bone remodeling markers and treatment response to estrogen. Maturitas2006;53(4):371‐9. SaiA , GallagherJ , FangX . Effect of hormone therapy and calcitriol on serum lipid profile in postmenopausal older women: association with estrogen receptor‐alpha genotypes. Menopause2011;18(10):1101‐12. YalamanchiliV , GallagherJ . Treatment with hormone therapy and calcitriol did not affect depression in older postmenopausal women: no interaction with estrogen and vitamin D receptor genotype polymorphisms. Menopause2012;19(6):697‐703. ">STOP IT 2001</a>; <a href="./references#CD002229-bbs2-0014" title="HodisHN , MackWJ , AzenSP , LoboRA , ShoupeD , MahrerPR , et al. Hormone therapy and the progression of coronary‐artery atherosclerosis in postmenopausal women. New England Journal of Medicine2003;349(6):535‐45. ">WELL‐HART 2003</a>; <a href="./references#CD002229-bbs2-0018" title="CollinsP , FlatherM , LeesB , MisterR , ProudlerA , StevensonJC , WHISP (Women's Hormone Intervention Secondary Prevention Study) Pilot Study Investigators. Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study. European Heart Journal2006;27(17):2046‐53. ">WHISP 2006</a>). It can therefore be postulated that these trials may not have been sufficiently powered in order to detect differences in clinical treatment effects between the hormone therapy and placebo arms, as this was not the primary aim of these trials. Furthermore, as previously highlighted, seven of the trials were stopped early (<a href="./references#CD002229-bbs2-0001" title="BladbjergE , MadsenJ , KristensenS , AbrahamsenB , BrixenK , MosekildeL , et al. Effect of long‐term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. Journal of Thrombosis and Haemostasis2003;1(6):1208‐14. KristensenS , AbrahamsenB , MadsenJ , GramJ , RejnmarkL , RudB , et al. Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: results from the Danish Osteoporosis Prevention Study (DOPS). Thrombosis and Haemostasis2006;95:915‐6. MadsenJ , KristensenS , GramJ , BladbjergE , HenriksenF , ChristensenK , et al. Positive impact of hormone replacement therapy on the fibrinolytic system: a long‐term randomized controlled study in healthy postmenopausal women. Journal of Thrombosis and Haemostasis2003;1(9):1984‐91. SchierbeckL , RejnmarkL , ToftengC , StilgrenL , EikenP , MosekildeL , et al. Hormone replacement treatment in early postmenopausal women reduces cardiovascular events ‐ A randomized controlled study. Circulation2011;124:A11380. SchierbeckLL , RejnmarkL , ToftengCL , StilgrenL , EikenP , MosekildeL , et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ2012;345:e6409. ToftengC , JensenJ , AbrahamsenB , OdumL , BrotC . Two polymorphisms in the vitamin D receptor gene‐association with bone mass and 5‐year change in bone mass with or without hormone‐replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study. Journal of Bone and Mineral Research2002;17(8):1535‐44. deMaatM , MadsenJ , LangdalB , BladbjergE , ToftengC , AbrahamsenL , et al. Genetic variation in estrogen receptor, C‐reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. Thrombosis and Haemostasis2007;97(2):234‐9. ">DOPS 2012</a>; <a href="./references#CD002229-bbs2-0002" title="Ouyang P , TardifJ , HerringtonD , StewartK , ThompsonP , WalshM , et al. Randomized trial of hormone therapy in women after coronary bypass surgery: Evidence of differential effect of hormone therapy on angiographic progression of disease in saphenous vein grafts and native coronary arteries. Atherosclerosis2006;189(2):375‐86. ">EAGAR 2006</a>; <a href="./references#CD002229-bbs2-0004" title="HemminkiE , HoviS , VeerusP , SevónT , TuimalaR , RahuM , et al. Blinding decreased recruitment in a prevention trial of postmenopausal women. Journal of Clinical Epidemiology2004;57:1237‐43. VeerusP , FischerK , HoviS‐L , KarroH , RahuM , HemminkiE . Symptom reporting and quality of life in the Estonian Postmenopausal Hormone Therapy Trial. BMC Women’s Health2008;8:5. VeerusP , HoviS , FischerK , RahuM , HakamaM , HemminkiE . Results for the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]. Maturitas2006;55(2):162‐73. ">EPHT 2006</a>; <a href="./references#CD002229-bbs2-0008" title="HoibraatenE , ArnesenH , LarsenS , WickstromE , SandsetPM . Increased risk of recurrent venous thromboembolism during hormone replacement therapy: results of the randomized, double blind, placebo‐controlled estrogen in venous thromboembolism trial (EVTET). Thrombosis and Haemostasis2000;84:961‐7. Qvigtad , HoibraatenH , ArnesenH , LarsenS , WickstromE , SandsetP . Recurrent venous thromboembolism during hormone replacement therapy ‐ results of the estrogen in venous thromboembolism trial. XVI FIGO World Congress of O and G2000;Abstract book 1:58. ">EVTET 2000</a>; <a href="./references#CD002229-bbs2-0019" title="VickersMR , MacLacLennanA , LawtonB , FordD , MartinJ , MeredithS , et al. WISDOM group. Main morbidities recorded in the women's international study of long duration estrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ2007;335(7613):239. VickersMR , MartinJ , MeadeTW , WISDOM study team. The Women’s international study of long‐duration of estrogen after menopause (WISDOM): a randomised controlled trial. BMC Women's Health2007;7:2. WeltonAJ , VickersMR , KimJ , FordD , LawtonBA , MacLennanAH , et al. WISDOM team. Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ2008;337:a1190. ">WISDOM 2007</a>; <a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a>; <a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a>), either as other trial results were published showing no beneficial effects on cardiovascular disease outcomes for hormone therapy relative to placebo, or observation of a detrimental effect either on cardiovascular disease outcomes or adverse events was shown. The mean length of trial follow‐up therefore ranged considerably from seven months to 10.1 years, with a mean duration of follow‐up of 3.6 (median of three) years across the trials. The early stopping of the trials has implications both for the power to detect differences in treatment effects between the hormone therapy and placebo arms (as the sample size will have been predicated based on the original proposed length of follow‐up, and assumptions regarding the number of events observed), and also for limiting the availability of evidence on the longer‐term treatment effects of hormone therapy compared to placebo. A further limitation of the evidence base reviewed relates to the impact of patient medication compliance, which ranged considerably between the trials. A high proportion of women in the trials did not receive the treatment to which they were randomised. Overall, the number of women who discontinued their medication or took less than 80% was disproportionately high in the hormone therapy trial arms, presumably due to medication side effects. The authors of <a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a> noted that if discontinuation of treatment and initiation of non‐study treatment occurred independently of risk factors for clinical outcomes, their intention‐to‐treat analysis underestimates both the harms and benefits of hormone therapy among women who adhere to treatment. </p> </section> <section id="CD002229-sec-0104"> <h3 class="title" id="CD002229-sec-0104">Quality of the evidence</h3> <p>A summary of the findings and strength of evidence can be found in <a href="./full#CD002229-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD002229-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD002229-tbl-0003">summary of findings Table 3</a> and <a href="./full#CD002229-tbl-0004">summary of findings Table 4</a>. In the primary prevention population, the quality of evidence for death and cardiovascular disease was high. We downgraded the quality of the evidence by one level for venous thromboembolism and pulmonary embolism due to inconsistency of effect across the study results. When HT considered as a secondary prevention strategy, the quality of the evidence was also high for death and venous thromboembolism. The confidence intervals for the estimated effect on stroke and pulmonary embolism could not exclude small decreases or large increases in risk. For the subgroup of studies addressing the effects of HT started less than 10 years since the menopause the quality of evidence was downgraded one level for the outcomes of mortality and coronary heart disease as the results of the analysis were dominated by the results of a few large trials. Overall study quality was high (<a href="#CD002229-fig-0004">Figure 4</a>). The vast majority of trials had adequate generation of randomised sequences (15 out of 19), 17 out of 19 were double‐blinded and 13 out of 19 were analysed on an intention‐to‐treat basis. Participants lost to follow‐up were generally low, except in two trials: 14.9% in <a href="./references#CD002229-bbs2-0012" title="GallagherJ , RapuriB , HaynatzkiG , DetterR . Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. The Journal of Clinical Endocrinology and Metabolism2002;87(11):4914‐23. GallagherJC , FowlerSE , DetterJR , ShermanSS . Combination treatment with estrogen and calcitriol in the prevention of age‐related bone loss. The Journal of Clinical Endocrinology and Metabolism2001;86(8):3618‐28. RapuriP , GallagherJ , KnezeticJ , HaynatzkaV . Estrogen receptor alpha gene polymorphisms are associated with changes in bone remodeling markers and treatment response to estrogen. Maturitas2006;53(4):371‐9. SaiA , GallagherJ , FangX . Effect of hormone therapy and calcitriol on serum lipid profile in postmenopausal older women: association with estrogen receptor‐alpha genotypes. Menopause2011;18(10):1101‐12. YalamanchiliV , GallagherJ . Treatment with hormone therapy and calcitriol did not affect depression in older postmenopausal women: no interaction with estrogen and vitamin D receptor genotype polymorphisms. Menopause2012;19(6):697‐703. ">STOP IT 2001</a> and 19% in <a href="./references#CD002229-bbs2-0018" title="CollinsP , FlatherM , LeesB , MisterR , ProudlerA , StevensonJC , WHISP (Women's Hormone Intervention Secondary Prevention Study) Pilot Study Investigators. Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study. European Heart Journal2006;27(17):2046‐53. ">WHISP 2006</a>, though these provided relatively low weight to the analysis. Only two out of 19 trials were at risk of selective outcome reporting. </p> </section> <section id="CD002229-sec-0105"> <h3 class="title" id="CD002229-sec-0105">Potential biases in the review process</h3> <p>There are a number of potential biases in the review process, although we made attempts to limit these. The bias of most concern is that of patient selection bias which limits external validity. Nearly all of the included trials had a mean participant age of over 60 years at baseline, and only one trial (<a href="./references#CD002229-bbs2-0001" title="BladbjergE , MadsenJ , KristensenS , AbrahamsenB , BrixenK , MosekildeL , et al. Effect of long‐term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. Journal of Thrombosis and Haemostasis2003;1(6):1208‐14. KristensenS , AbrahamsenB , MadsenJ , GramJ , RejnmarkL , RudB , et al. Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: results from the Danish Osteoporosis Prevention Study (DOPS). Thrombosis and Haemostasis2006;95:915‐6. MadsenJ , KristensenS , GramJ , BladbjergE , HenriksenF , ChristensenK , et al. Positive impact of hormone replacement therapy on the fibrinolytic system: a long‐term randomized controlled study in healthy postmenopausal women. Journal of Thrombosis and Haemostasis2003;1(9):1984‐91. SchierbeckL , RejnmarkL , ToftengC , StilgrenL , EikenP , MosekildeL , et al. Hormone replacement treatment in early postmenopausal women reduces cardiovascular events ‐ A randomized controlled study. Circulation2011;124:A11380. SchierbeckLL , RejnmarkL , ToftengCL , StilgrenL , EikenP , MosekildeL , et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ2012;345:e6409. ToftengC , JensenJ , AbrahamsenB , OdumL , BrotC . Two polymorphisms in the vitamin D receptor gene‐association with bone mass and 5‐year change in bone mass with or without hormone‐replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study. Journal of Bone and Mineral Research2002;17(8):1535‐44. deMaatM , MadsenJ , LangdalB , BladbjergE , ToftengC , AbrahamsenL , et al. Genetic variation in estrogen receptor, C‐reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. Thrombosis and Haemostasis2007;97(2):234‐9. ">DOPS 2012</a>) focused on women who were either peri‐menopausal or around the time of the menopause. Whilst these inclusion criteria reflected the aims of the trials, it does not reflect usual clinical practice, in which hormone therapy is prescribed for the relief of vasomotor symptoms at the time of menopause. </p> <p>Despite extensive searches it is possible that we failed to identify all relevant studies. However, given the dominance of <a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a> and <a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a> on the results of the review, it is unlikely that we missed any trials large enough to impact substantially on the results. Additionally, as already indicated, assumptions had to be made in the analyses regarding the effects of different HT preparations in order to undertake meta‐analyses. These assumptions may not be warranted, as it is as yet unclear how different preparations and doses may differ. </p> <p>Our assessment of the timing hypothesis could be considered a post‐hoc change to the original protocol for this review. The data for events since menopause (stratified in decades) were only available for two studies (<a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a>; <a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a>) and for the remaining studies baseline characteristics for eleven studies (<a href="./references#CD002229-bbs2-0001" title="BladbjergE , MadsenJ , KristensenS , AbrahamsenB , BrixenK , MosekildeL , et al. Effect of long‐term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. Journal of Thrombosis and Haemostasis2003;1(6):1208‐14. KristensenS , AbrahamsenB , MadsenJ , GramJ , RejnmarkL , RudB , et al. Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: results from the Danish Osteoporosis Prevention Study (DOPS). Thrombosis and Haemostasis2006;95:915‐6. MadsenJ , KristensenS , GramJ , BladbjergE , HenriksenF , ChristensenK , et al. Positive impact of hormone replacement therapy on the fibrinolytic system: a long‐term randomized controlled study in healthy postmenopausal women. Journal of Thrombosis and Haemostasis2003;1(9):1984‐91. SchierbeckL , RejnmarkL , ToftengC , StilgrenL , EikenP , MosekildeL , et al. Hormone replacement treatment in early postmenopausal women reduces cardiovascular events ‐ A randomized controlled study. Circulation2011;124:A11380. SchierbeckLL , RejnmarkL , ToftengCL , StilgrenL , EikenP , MosekildeL , et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ2012;345:e6409. ToftengC , JensenJ , AbrahamsenB , OdumL , BrotC . Two polymorphisms in the vitamin D receptor gene‐association with bone mass and 5‐year change in bone mass with or without hormone‐replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study. Journal of Bone and Mineral Research2002;17(8):1535‐44. deMaatM , MadsenJ , LangdalB , BladbjergE , ToftengC , AbrahamsenL , et al. Genetic variation in estrogen receptor, C‐reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. Thrombosis and Haemostasis2007;97(2):234‐9. ">DOPS 2012</a>; <a href="./references#CD002229-bbs2-0004" title="HemminkiE , HoviS , VeerusP , SevónT , TuimalaR , RahuM , et al. Blinding decreased recruitment in a prevention trial of postmenopausal women. Journal of Clinical Epidemiology2004;57:1237‐43. VeerusP , FischerK , HoviS‐L , KarroH , RahuM , HemminkiE . Symptom reporting and quality of life in the Estonian Postmenopausal Hormone Therapy Trial. BMC Women’s Health2008;8:5. VeerusP , HoviS , FischerK , RahuM , HakamaM , HemminkiE . Results for the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]. Maturitas2006;55(2):162‐73. ">EPHT 2006</a>; <a href="./references#CD002229-bbs2-0005" title="HerringtonDM , ReboussinDM , Bridget BrosnihanK , SharpPC , ShumakerSA , SnyderTE , et al. Effects of estrogen replacement on the progression of coronary‐artery atherosclerosis. New England Journal of Medicine2000;343(8):522‐9. HerringtonDM , ReboussinDM , KleinKP , SharpPC , ShumakerSA , SnyderTE , et al. The estrogen replacement and atherosclerosis (ERA) study: study design and baseline characteristics of the cohort. Controlled Clinical Trials2000;21(3):257‐85. NairG , HerringtonD . The ERA trial: findings and implications for the future. Climacteric2000;3:227‐32. ">ERA 2000</a>; <a href="./references#CD002229-bbs2-0006" title="NachtigallLE , NachtigallRH , NachtigallRD , BeckmanEM . Estrogen replacement therapy II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstetrics Gynecology1979;54(1):74‐9. ">ERT II 1979</a>; <a href="./references#CD002229-bbs2-0007" title="The ESPRIT Team. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet2002;360:2001‐8. ">ESPRIT 2002</a>; <a href="./references#CD002229-bbs2-0010" title="HallG , PrippU , Schenk‐GustafssonK , LandgrenBM . Long‐term effects of hormone replacement therapy on symptoms of angina pectoris, quality of life and compliance in women with coronary artery disease. Maturitas1998 ;28 :235‐42 . ">HALL 1998</a>; <a href="./references#CD002229-bbs2-0011" title="Bibbins‐DomingoK , LinF , VittinghoffE , Barrett‐ConnorE , HulleyS , GradyD , et al. Effect of hormone therapy on mortality rates among women with heart failure and coronary artery disease. American Journal of Cardiology2005;95(2):289‐91. GiddingsL . Oestrogen plus progestin increased venous thromboembolic disease in postmenopausal women with coronary artery disease. Evidence Based Nursing2000;3(4):123. GradyD , ApplegateW , BushT , FurbergC , RiggsB , HulleyS , et al. Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics. Controlled Clinical Trials1998;19(4):314‐35. GradyD , HerringtonD , BittnerV , DavidsonM , HlatkyM , HsiaJ , et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study Follow‐up (HERS II). JAMA2002;288(1):49‐57. GradyD , WengerN , HerringtonD , KhanS , FurbergC , Hunninghake , et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. Annals of Internal Medicine2000;132:689‐96. HlatkyM , BoothroydD , VittinghoffE , SharpP , WhooleyMA . Quality‐of life and depressive symptoms in postmenopausal women after receiving hormone therapy. Results from the Heart and Estrogen/Progestin Replacement Study (HERS) Trial. JAMA2002;287(5):591‐7. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA1998;280(7):605‐13. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Obstetrical and Gynecological Survey1999;54(1):41‐2. KhanM , HlatkyM , LiuM , LinF , RogersW , ShlipakM . Effect of postmenopausal hormone therapy on coronary heart disease events after percutaneous transluminal coronary angioplasty. The American Journal of Cardiology2003;91(8):989‐91, A7. ShlipakM , SimonJ , VittinghoffE , LinF , Barrett‐ConnorE , KnoppR . Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA2000;283(14):1845‐52. SimonJA , HsiaJ , CauleyJA , RichardsC , HarrisF , FongJ , et al. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen‐progestin Replacement Study (HERS). Circulation2001;103(5):638‐42. SimonJA , LinF , VittinghoffE , BittnerV , Heart and Estrogen‐Progestin Replacement Study (HERS) Research Group. The relation of postmenopausal hormone therapy to serum uric acid and the risk of coronary heart disease events: The heart and estrogen‐progestin replacement study (HERS). Annals of Epidemiology2006;16(2):138‐45. SperoffL . The heart and estrogen/progestin replacement study (HERS). Maturitas1998;31(1):9‐14. ">HERS I 1998</a>; <a href="./references#CD002229-bbs2-0014" title="HodisHN , MackWJ , AzenSP , LoboRA , ShoupeD , MahrerPR , et al. Hormone therapy and the progression of coronary‐artery atherosclerosis in postmenopausal women. New England Journal of Medicine2003;349(6):535‐45. ">WELL‐HART 2003</a>; <a href="./references#CD002229-bbs2-0015" title="KernanWN , BrassLM , ViscoliCM , SarrellPM , MakuchR , HorwitzRI . Estrogen after ischemic stroke: clinical basis and design of the Womens Estrogen for Stroke Trial. Journal of Stroke and Cerebrovascular Diseases1998;7(1):85‐95. ViscoliC , BrassL , Kernan , SarrelP , SuissaS , HorwitzR . Estrogen therapy and risk of cognitive decline: Results from the Women's Estrogen for Stroke Trial (WEST). American Journal of Obstetrics and Gynecology2005;192(2):387‐93. ViscoliCM , BrassLM , KernanWN , SarrelPM , SuissaS , HorwitzRI . A clinical trial of estrogen‐replacement therapy after ischemic stroke. New England Journal of Medicine2001;345(17):1243‐9. ">WEST 2001</a>; <a href="./references#CD002229-bbs2-0018" title="CollinsP , FlatherM , LeesB , MisterR , ProudlerA , StevensonJC , WHISP (Women's Hormone Intervention Secondary Prevention Study) Pilot Study Investigators. Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study. European Heart Journal2006;27(17):2046‐53. ">WHISP 2006</a>; <a href="./references#CD002229-bbs2-0019" title="VickersMR , MacLacLennanA , LawtonB , FordD , MartinJ , MeredithS , et al. WISDOM group. Main morbidities recorded in the women's international study of long duration estrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ2007;335(7613):239. VickersMR , MartinJ , MeadeTW , WISDOM study team. The Women’s international study of long‐duration of estrogen after menopause (WISDOM): a randomised controlled trial. BMC Women's Health2007;7:2. WeltonAJ , VickersMR , KimJ , FordD , LawtonBA , MacLennanAH , et al. WISDOM team. Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ2008;337:a1190. ">WISDOM 2007</a>) were available for us to allocate the study population as a whole to either commencing treatment less than 10 years since the menopause or 10 years or more since the menopause. For six studies (<a href="./references#CD002229-bbs2-0002" title="Ouyang P , TardifJ , HerringtonD , StewartK , ThompsonP , WalshM , et al. Randomized trial of hormone therapy in women after coronary bypass surgery: Evidence of differential effect of hormone therapy on angiographic progression of disease in saphenous vein grafts and native coronary arteries. Atherosclerosis2006;189(2):375‐86. ">EAGAR 2006</a>; <a href="./references#CD002229-bbs2-0003" title="HodisH , MackW , LoboR , MahrerP , LiuC R , LiuC H . Estrogen replacement therapy effects on the progression of subclinical atherosclerosis are mediated by lipids but not by carbohydrate metabolic factors: results from the Estrogen in the Prevention of Athersclerosis Trial (EPAT). Circulation2002;106(19 Suppl II):II‐744. HodisHN , MackWJ , LoboRA , ShoupeD , SevanianA , MahrerPR , et al. Estrogen in the prevention of atherosclerosis. A randomized, double‐blind, placebo‐controlled trial. Annals of Internal Medicine2001;135(11):939‐53. ">EPAT 2001</a>; <a href="./references#CD002229-bbs2-0008" title="HoibraatenE , ArnesenH , LarsenS , WickstromE , SandsetPM . Increased risk of recurrent venous thromboembolism during hormone replacement therapy: results of the randomized, double blind, placebo‐controlled estrogen in venous thromboembolism trial (EVTET). Thrombosis and Haemostasis2000;84:961‐7. Qvigtad , HoibraatenH , ArnesenH , LarsenS , WickstromE , SandsetP . Recurrent venous thromboembolism during hormone replacement therapy ‐ results of the estrogen in venous thromboembolism trial. XVI FIGO World Congress of O and G2000;Abstract book 1:58. ">EVTET 2000</a>; <a href="./references#CD002229-bbs2-0009" title="GreenspanSL , ResnickNM , ParkerRA . The effect of hormone replacement on physical performance in community‐dwelling elderly women. The American Journal of Medicine2005;118:1232‐9. ">Greenspan 2005</a>; <a href="./references#CD002229-bbs2-0012" title="GallagherJ , RapuriB , HaynatzkiG , DetterR . Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. The Journal of Clinical Endocrinology and Metabolism2002;87(11):4914‐23. GallagherJC , FowlerSE , DetterJR , ShermanSS . Combination treatment with estrogen and calcitriol in the prevention of age‐related bone loss. The Journal of Clinical Endocrinology and Metabolism2001;86(8):3618‐28. RapuriP , GallagherJ , KnezeticJ , HaynatzkaV . Estrogen receptor alpha gene polymorphisms are associated with changes in bone remodeling markers and treatment response to estrogen. Maturitas2006;53(4):371‐9. SaiA , GallagherJ , FangX . Effect of hormone therapy and calcitriol on serum lipid profile in postmenopausal older women: association with estrogen receptor‐alpha genotypes. Menopause2011;18(10):1101‐12. YalamanchiliV , GallagherJ . Treatment with hormone therapy and calcitriol did not affect depression in older postmenopausal women: no interaction with estrogen and vitamin D receptor genotype polymorphisms. Menopause2012;19(6):697‐703. ">STOP IT 2001</a>; <a href="./references#CD002229-bbs2-0013" title="HsiaJ , AldermanEL , VerterJI , RogersWJ , ThompsonP , HowardBV , et al. Women’s angiographic vitamin and estrogen trial: design and methods. Controlled Clinical Trials2002;23:708‐27. WatersD , AldermanE , HsiaJ , HowardB , CobbF , RogersW , et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women. JAMA2001;288(19):2432‐40. ">WAVE 2002</a>) these data were not available. However, age was reported and therefore whole study populations were allocated accordingly to those less than 60 years of age or those 60 years of age or older when they commenced treatment. It is highly likely that trial populations were distributed across a range of ages and time since menopause, and it is therefore likely that a proportion of study populations were incorrectly allocated. This will be more of a problem in study samples with large standard deviations for time since menopause, or age, and also in those who have a mean or median age or time since menopause close to the cut‐off (10 years since the menopause and 60 years of age). Although we remain confident that the subgroups are broadly representative of the study populations of interest, subgroup level data for each study or individual participant data would represent more robust approaches to testing the timing hypothesis. </p> </section> <section id="CD002229-sec-0106"> <h3 class="title" id="CD002229-sec-0106">Agreements and disagreements with other studies or reviews</h3> <p><a href="./references#CD002229-bbs2-0119" title="MaglianoDJ , RogersSL , AbramsonMJ , TonkinAM . Hormone therapy and cardiovascular disease: a systematic review and meta‐analysis. BJOG2006;113:5‐15. ">Magliano 2006</a> pooled results from seven of the trials included in the current review (<a href="./references#CD002229-bbs2-0005" title="HerringtonDM , ReboussinDM , Bridget BrosnihanK , SharpPC , ShumakerSA , SnyderTE , et al. Effects of estrogen replacement on the progression of coronary‐artery atherosclerosis. New England Journal of Medicine2000;343(8):522‐9. HerringtonDM , ReboussinDM , KleinKP , SharpPC , ShumakerSA , SnyderTE , et al. The estrogen replacement and atherosclerosis (ERA) study: study design and baseline characteristics of the cohort. Controlled Clinical Trials2000;21(3):257‐85. NairG , HerringtonD . The ERA trial: findings and implications for the future. Climacteric2000;3:227‐32. ">ERA 2000</a>; <a href="./references#CD002229-bbs2-0007" title="The ESPRIT Team. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet2002;360:2001‐8. ">ESPRIT 2002</a>; <a href="./references#CD002229-bbs2-0011" title="Bibbins‐DomingoK , LinF , VittinghoffE , Barrett‐ConnorE , HulleyS , GradyD , et al. Effect of hormone therapy on mortality rates among women with heart failure and coronary artery disease. American Journal of Cardiology2005;95(2):289‐91. GiddingsL . Oestrogen plus progestin increased venous thromboembolic disease in postmenopausal women with coronary artery disease. Evidence Based Nursing2000;3(4):123. GradyD , ApplegateW , BushT , FurbergC , RiggsB , HulleyS , et al. Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics. Controlled Clinical Trials1998;19(4):314‐35. GradyD , HerringtonD , BittnerV , DavidsonM , HlatkyM , HsiaJ , et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study Follow‐up (HERS II). JAMA2002;288(1):49‐57. GradyD , WengerN , HerringtonD , KhanS , FurbergC , Hunninghake , et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. Annals of Internal Medicine2000;132:689‐96. HlatkyM , BoothroydD , VittinghoffE , SharpP , WhooleyMA . Quality‐of life and depressive symptoms in postmenopausal women after receiving hormone therapy. Results from the Heart and Estrogen/Progestin Replacement Study (HERS) Trial. JAMA2002;287(5):591‐7. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA1998;280(7):605‐13. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Obstetrical and Gynecological Survey1999;54(1):41‐2. KhanM , HlatkyM , LiuM , LinF , RogersW , ShlipakM . Effect of postmenopausal hormone therapy on coronary heart disease events after percutaneous transluminal coronary angioplasty. The American Journal of Cardiology2003;91(8):989‐91, A7. ShlipakM , SimonJ , VittinghoffE , LinF , Barrett‐ConnorE , KnoppR . Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA2000;283(14):1845‐52. SimonJA , HsiaJ , CauleyJA , RichardsC , HarrisF , FongJ , et al. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen‐progestin Replacement Study (HERS). Circulation2001;103(5):638‐42. SimonJA , LinF , VittinghoffE , BittnerV , Heart and Estrogen‐Progestin Replacement Study (HERS) Research Group. The relation of postmenopausal hormone therapy to serum uric acid and the risk of coronary heart disease events: The heart and estrogen‐progestin replacement study (HERS). Annals of Epidemiology2006;16(2):138‐45. SperoffL . The heart and estrogen/progestin replacement study (HERS). Maturitas1998;31(1):9‐14. ">HERS I 1998</a>; <a href="./references#CD002229-bbs2-0013" title="HsiaJ , AldermanEL , VerterJI , RogersWJ , ThompsonP , HowardBV , et al. Women’s angiographic vitamin and estrogen trial: design and methods. Controlled Clinical Trials2002;23:708‐27. WatersD , AldermanE , HsiaJ , HowardB , CobbF , RogersW , et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women. JAMA2001;288(19):2432‐40. ">WAVE 2002</a>; <a href="./references#CD002229-bbs2-0015" title="KernanWN , BrassLM , ViscoliCM , SarrellPM , MakuchR , HorwitzRI . Estrogen after ischemic stroke: clinical basis and design of the Womens Estrogen for Stroke Trial. Journal of Stroke and Cerebrovascular Diseases1998;7(1):85‐95. ViscoliC , BrassL , Kernan , SarrelP , SuissaS , HorwitzR . Estrogen therapy and risk of cognitive decline: Results from the Women's Estrogen for Stroke Trial (WEST). American Journal of Obstetrics and Gynecology2005;192(2):387‐93. ViscoliCM , BrassLM , KernanWN , SarrelPM , SuissaS , HorwitzRI . A clinical trial of estrogen‐replacement therapy after ischemic stroke. New England Journal of Medicine2001;345(17):1243‐9. ">WEST 2001</a>; <a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a>; <a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a>), and concluded that there was no impact of hormone therapy compared to placebo on total mortality or non‐fatal myocardial infarction, but strong evidence of an increased risk in the number of strokes (RR 1.29, 95% CI 1.13 to 1.48) observed with hormone therapy use. Likewise, a meta‐analysis by <a href="./references#CD002229-bbs2-0092" title="BathPMW , GrayLJ . Association between hormone replacement therapy and subsequent stroke: a meta‐analysis. BMJ2005;330:342. ">Bath 2005</a>, pooling 28 RCTs, reported  hormone therapy was associated with an increase in the risk of stroke, particularly ischaemic stroke. Furthermore, those participants who had a stroke in the hormone therapy groups appeared to have a worse outcome.  However, it is unclear to what degree the results of this review are applicable to post‐menopausal women, as the review had very broad inclusion criteria, and pooled a wide range of trials which used different types of hormone therapy for a range of indications, some of which included male participants.   <br/> <br/> <a href="./references#CD002229-bbs2-0140" title="SalpeterSR , WalshJME , GreyberE , SalpeterEE . Coronary heart disease events associated with hormone therapy in younger and older women. Journal of General Internal Medicine2006;21:363‐6. ">Salpeter 2006</a>, in a meta‐analysis aimed to examine the effect of hormone therapy on coronary heart disease events in younger and older post‐menopausal women (defined as participants with a mean time from menopause of less than or greater than ten years, or mean age less than or greater than 60 years). The analyses of 23 trials (ten trials with younger women and 11 trials with older women), included the relevant Women's Health Initiative age‐specific subgroup data in one or the other group as though they had originated from separate RCTs. The results showed that hormone therapy reduced coronary heart disease events in younger women, but not in older women. This is comparable with our findings in this review. </p> <p><a href="./references#CD002229-bbs2-0128" title="MillerJ , ChanB , NelsonH . Postmenopausal Estrogen Replacement and Risk for VenousThromboembolism: A Systematic Review and Meta‐Analysis for the U.S. Preventive Services Task Force. Annals of Internal Medicine2002;136:680‐90. ">Miller 2002</a> performed a meta‐analysis of venous thromboembolic outcomes in post‐menopausal women using oestrogen replacement. The review included both oestrogen alone and combination therapy and RCTs, case‐control studies and a cohort study. They found an increased risk with hormone therapy (RR 2.14, 95% CI 1.64 to 2.81). The analysis was published in 2002 and did not include either Women's Health Initiative studies, which contributed the largest portion of our included population, but the risk is comparable with our findings. They also found that the risk was highest in the first year, but in the majority of studies remained elevated for the duration of follow‐up. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD002229-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/urn:x-wiley:14651858:media:CD002229:CD002229-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_t/tCD002229-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt=": Process of study selection for the review" data-id="CD002229-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p><a href="#CD002229-fig-0001">Figure 1</a>: Process of study selection for the review </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/full#CD002229-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002229-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/urn:x-wiley:14651858:media:CD002229:CD002229-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_t/tCD002229-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Process of study selection for the updated review" data-id="CD002229-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Process of study selection for the updated review</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/full#CD002229-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002229-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/urn:x-wiley:14651858:media:CD002229:CD002229-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_t/tCD002229-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt=": Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD002229-fig-0003" src="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p><a href="#CD002229-fig-0003">Figure 3</a>: Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/full#CD002229-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002229-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/urn:x-wiley:14651858:media:CD002229:CD002229-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_t/tCD002229-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt=": Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD002229-fig-0004" src="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p><a href="#CD002229-fig-0004">Figure 4</a>: Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/full#CD002229-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002229-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/urn:x-wiley:14651858:media:CD002229:CD002229-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_t/tCD002229-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: Hormone therapy versus placebo in primary and secondary prevention, outcome: 5.1 Death (all‐causes)." data-id="CD002229-fig-0005" src="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of comparison: Hormone therapy versus placebo in primary and secondary prevention, outcome: 5.1 Death (all‐causes). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/full#CD002229-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002229-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/urn:x-wiley:14651858:media:CD002229:CD002229-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_t/tCD002229-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hormone therapy versus placebo in primary prevention, Outcome 1 Death (all‐causes)." data-id="CD002229-fig-0006" src="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Hormone therapy versus placebo in primary prevention, Outcome 1 Death (all‐causes). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/references#CD002229-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002229-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/urn:x-wiley:14651858:media:CD002229:CD002229-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_t/tCD002229-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hormone therapy versus placebo in primary prevention, Outcome 2 Death (cardiovascular causes)." data-id="CD002229-fig-0007" src="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Hormone therapy versus placebo in primary prevention, Outcome 2 Death (cardiovascular causes). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/references#CD002229-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002229-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/urn:x-wiley:14651858:media:CD002229:CD002229-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_t/tCD002229-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hormone therapy versus placebo in primary prevention, Outcome 3 Non‐fatal myocardial infarction." data-id="CD002229-fig-0008" src="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Hormone therapy versus placebo in primary prevention, Outcome 3 Non‐fatal myocardial infarction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/references#CD002229-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002229-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/urn:x-wiley:14651858:media:CD002229:CD002229-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_t/tCD002229-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hormone therapy versus placebo in primary prevention, Outcome 4 Stroke." data-id="CD002229-fig-0009" src="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Hormone therapy versus placebo in primary prevention, Outcome 4 Stroke.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/references#CD002229-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002229-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/urn:x-wiley:14651858:media:CD002229:CD002229-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_t/tCD002229-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hormone therapy versus placebo in primary prevention, Outcome 5 Angina." data-id="CD002229-fig-0010" src="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Hormone therapy versus placebo in primary prevention, Outcome 5 Angina.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/references#CD002229-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002229-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/urn:x-wiley:14651858:media:CD002229:CD002229-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_t/tCD002229-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hormone therapy versus placebo in primary prevention, Outcome 6 Venous thromboembolism." data-id="CD002229-fig-0011" src="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Hormone therapy versus placebo in primary prevention, Outcome 6 Venous thromboembolism. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/references#CD002229-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002229-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/urn:x-wiley:14651858:media:CD002229:CD002229-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_t/tCD002229-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hormone therapy versus placebo in primary prevention, Outcome 7 Pulmonary embolism." data-id="CD002229-fig-0012" src="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Hormone therapy versus placebo in primary prevention, Outcome 7 Pulmonary embolism. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/references#CD002229-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002229-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/urn:x-wiley:14651858:media:CD002229:CD002229-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_t/tCD002229-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hormone therapy versus placebo in primary prevention, Outcome 8 Revascularisation." data-id="CD002229-fig-0013" src="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Hormone therapy versus placebo in primary prevention, Outcome 8 Revascularisation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/references#CD002229-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002229-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/urn:x-wiley:14651858:media:CD002229:CD002229-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_t/tCD002229-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Hormone therapy versus placebo in secondary prevention, Outcome 1 Death (all‐causes)." data-id="CD002229-fig-0014" src="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Hormone therapy versus placebo in secondary prevention, Outcome 1 Death (all‐causes). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/references#CD002229-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002229-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/urn:x-wiley:14651858:media:CD002229:CD002229-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_t/tCD002229-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Hormone therapy versus placebo in secondary prevention, Outcome 2 Death (cardiovascular causes)." data-id="CD002229-fig-0015" src="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Hormone therapy versus placebo in secondary prevention, Outcome 2 Death (cardiovascular causes). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/references#CD002229-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002229-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/urn:x-wiley:14651858:media:CD002229:CD002229-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_t/tCD002229-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Hormone therapy versus placebo in secondary prevention, Outcome 3 Non‐fatal myocardial infarction." data-id="CD002229-fig-0016" src="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Hormone therapy versus placebo in secondary prevention, Outcome 3 Non‐fatal myocardial infarction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/references#CD002229-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002229-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/urn:x-wiley:14651858:media:CD002229:CD002229-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_t/tCD002229-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Hormone therapy versus placebo in secondary prevention, Outcome 4 Stroke." data-id="CD002229-fig-0017" src="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Hormone therapy versus placebo in secondary prevention, Outcome 4 Stroke.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/references#CD002229-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002229-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/urn:x-wiley:14651858:media:CD002229:CD002229-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_t/tCD002229-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Hormone therapy versus placebo in secondary prevention, Outcome 5 Angina." data-id="CD002229-fig-0018" src="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Hormone therapy versus placebo in secondary prevention, Outcome 5 Angina.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/references#CD002229-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002229-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/urn:x-wiley:14651858:media:CD002229:CD002229-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_t/tCD002229-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Hormone therapy versus placebo in secondary prevention, Outcome 6 Venous thromboembolism." data-id="CD002229-fig-0019" src="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Hormone therapy versus placebo in secondary prevention, Outcome 6 Venous thromboembolism. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/references#CD002229-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002229-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/urn:x-wiley:14651858:media:CD002229:CD002229-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_t/tCD002229-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Hormone therapy versus placebo in secondary prevention, Outcome 7 Pulmonary embolism." data-id="CD002229-fig-0020" src="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Hormone therapy versus placebo in secondary prevention, Outcome 7 Pulmonary embolism. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/references#CD002229-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002229-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/urn:x-wiley:14651858:media:CD002229:CD002229-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_t/tCD002229-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Hormone therapy versus placebo in secondary prevention, Outcome 8 Revascularisation." data-id="CD002229-fig-0021" src="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Hormone therapy versus placebo in secondary prevention, Outcome 8 Revascularisation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/references#CD002229-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002229-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/urn:x-wiley:14651858:media:CD002229:CD002229-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_t/tCD002229-CMP-003-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Hormone therapy versus placebo in both primary and secondary prevention, Outcome 1 Death (all‐causes)." data-id="CD002229-fig-0022" src="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Hormone therapy versus placebo in both primary and secondary prevention, Outcome 1 Death (all‐causes). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/references#CD002229-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002229-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/urn:x-wiley:14651858:media:CD002229:CD002229-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_t/tCD002229-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Hormone therapy versus placebo in both primary and secondary prevention, Outcome 2 Death (cardiovascular causes)." data-id="CD002229-fig-0023" src="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Hormone therapy versus placebo in both primary and secondary prevention, Outcome 2 Death (cardiovascular causes). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/references#CD002229-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002229-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/urn:x-wiley:14651858:media:CD002229:CD002229-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_t/tCD002229-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Hormone therapy versus placebo in both primary and secondary prevention, Outcome 3 Non‐fatal myocardial infarction." data-id="CD002229-fig-0024" src="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Hormone therapy versus placebo in both primary and secondary prevention, Outcome 3 Non‐fatal myocardial infarction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/references#CD002229-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002229-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/urn:x-wiley:14651858:media:CD002229:CD002229-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_t/tCD002229-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Hormone therapy versus placebo in both primary and secondary prevention, Outcome 4 Stroke." data-id="CD002229-fig-0025" src="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Hormone therapy versus placebo in both primary and secondary prevention, Outcome 4 Stroke. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/references#CD002229-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002229-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/urn:x-wiley:14651858:media:CD002229:CD002229-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_t/tCD002229-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Hormone therapy versus placebo in both primary and secondary prevention, Outcome 5 Angina." data-id="CD002229-fig-0026" src="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Hormone therapy versus placebo in both primary and secondary prevention, Outcome 5 Angina. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/references#CD002229-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002229-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/urn:x-wiley:14651858:media:CD002229:CD002229-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_t/tCD002229-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Hormone therapy versus placebo in both primary and secondary prevention, Outcome 6 Venous thromboembolism." data-id="CD002229-fig-0027" src="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Hormone therapy versus placebo in both primary and secondary prevention, Outcome 6 Venous thromboembolism. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/references#CD002229-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002229-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/urn:x-wiley:14651858:media:CD002229:CD002229-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_t/tCD002229-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Hormone therapy versus placebo in both primary and secondary prevention, Outcome 7 Pulmonary embolism." data-id="CD002229-fig-0028" src="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Hormone therapy versus placebo in both primary and secondary prevention, Outcome 7 Pulmonary embolism. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/references#CD002229-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002229-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/urn:x-wiley:14651858:media:CD002229:CD002229-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_t/tCD002229-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Hormone therapy versus placebo in both primary and secondary prevention, Outcome 8 Revascularisation." data-id="CD002229-fig-0029" src="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Hormone therapy versus placebo in both primary and secondary prevention, Outcome 8 Revascularisation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/references#CD002229-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002229-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/urn:x-wiley:14651858:media:CD002229:CD002229-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_t/tCD002229-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Hormone therapy versus placebo in both primary and secondary prevention, Outcome 9 Death (all‐causes): by year on treatment." data-id="CD002229-fig-0030" src="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 Hormone therapy versus placebo in both primary and secondary prevention, Outcome 9 Death (all‐causes): by year on treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/references#CD002229-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002229-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/urn:x-wiley:14651858:media:CD002229:CD002229-CMP-003-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_t/tCD002229-CMP-003-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Hormone therapy versus placebo in both primary and secondary prevention, Outcome 10 Death (all‐causes): cumulatively by year on treatment." data-id="CD002229-fig-0031" src="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-003-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3 Hormone therapy versus placebo in both primary and secondary prevention, Outcome 10 Death (all‐causes): cumulatively by year on treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/references#CD002229-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-003-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002229-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/urn:x-wiley:14651858:media:CD002229:CD002229-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_t/tCD002229-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Subgroup analysis of timing hypothesis (&lt;10 years versus &gt;10 years since menopause), Outcome 1 Death (all‐causes)." data-id="CD002229-fig-0032" src="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Subgroup analysis of timing hypothesis (&lt;10 years versus &gt;10 years since menopause), Outcome 1 Death (all‐causes). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/references#CD002229-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002229-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/urn:x-wiley:14651858:media:CD002229:CD002229-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_t/tCD002229-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Subgroup analysis of timing hypothesis (&lt;10 years versus &gt;10 years since menopause), Outcome 2 Coronary heart disease (death from cardiovascular causes and non‐fatal myocardial infarction)." data-id="CD002229-fig-0033" src="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Subgroup analysis of timing hypothesis (&lt;10 years versus &gt;10 years since menopause), Outcome 2 Coronary heart disease (death from cardiovascular causes and non‐fatal myocardial infarction). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/references#CD002229-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002229-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/urn:x-wiley:14651858:media:CD002229:CD002229-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_t/tCD002229-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Subgroup analysis of timing hypothesis (&lt;10 years versus &gt;10 years since menopause), Outcome 3 Stroke." data-id="CD002229-fig-0034" src="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Subgroup analysis of timing hypothesis (&lt;10 years versus &gt;10 years since menopause), Outcome 3 Stroke. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/references#CD002229-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002229-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/urn:x-wiley:14651858:media:CD002229:CD002229-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_t/tCD002229-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Subgroup analysis of timing hypothesis (&lt;10 years versus &gt;10 years since menopause), Outcome 4 Venous thromboembolism." data-id="CD002229-fig-0035" src="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Subgroup analysis of timing hypothesis (&lt;10 years versus &gt;10 years since menopause), Outcome 4 Venous thromboembolism. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/references#CD002229-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/media/CDSR/CD002229/image_n/nCD002229-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD002229-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Hormone therapy compared to placebo for primary prevention of cardiovascular disease in post‐menopausal women</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Hormone therapy compared to placebo for primary prevention of cardiovascular disease in post‐menopausal women</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Post‐menopausal women without prior cardiovascular disease<br/> <b>Intervention:</b> Hormone therapy<br/> <b>Comparison: P</b>lacebo or no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Hormone therapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Death (all‐causes)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1</b> <br/> (0.89 to 1.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>34,422<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>32 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>32 per 1000</b> <br/> (29 to 36) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Death (cardiovascular causes)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.81</b> <br/> (0.47 to 1.40) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>28,353<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 1000</b> <br/> (4 to 11) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Stroke</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.32</b> <br/> (1.12 to 1.56) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>28,719<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>23 per 1000</b> <br/> (20 to 28) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Venous thromboembolism</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.92</b> <br/> (1.24 to 2.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>33,477<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>20 per 1000</b> <br/> (13 to 31) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Pulmonary embolism</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>31,732<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Risks were calculated from pooled risk differences</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>9 per 1000</b> <br/> (5 to 15) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the median control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to inconsistency. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Hormone therapy compared to placebo for primary prevention of cardiovascular disease in post‐menopausal women</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/full#CD002229-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002229-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Hormone therapy compared to placebo for secondary prevention of cardiovascular disease in post‐menopausal women</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Hormone therapy compared to placebo for secondary prevention of cardiovascular disease in post‐menopausal women </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Post‐menopausal women with pre‐exisiting cardiovascular disease </p> <p><b>Intervention:</b> Hormone therapy </p> <p><b>Comparison:</b> Placebo or no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Hormone therapy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Death (all‐causes)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 1.04</b> </p> <p>(0.87 to 1.24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>5445</p> <p>(7 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>84 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>88 per 1000</b> </p> <p>(73 to 105)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Death (cardiovascular causes)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 1.00</b> </p> <p>(0.78 to 1.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>5259</p> <p>(6 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>45 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>45 per 1000</b> </p> <p>(35 to 58)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Stroke</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 1.09</b> </p> <p>(0.89 to 1.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>5172</p> <p>(5 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>65 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>71 per 1000</b> </p> <p>(58 to 86)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Venous thromboembolism</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 2.02</b> </p> <p>(1.13 to 3.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>4399</p> <p>(6 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>11 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>23 per 1000</b> </p> <p>(13 to 40)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Pulmonary embolism</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 2.48</b> </p> <p>(0.92 to 6.70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>3920</p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>4 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>10 per 1000</b> </p> <p>(4 to 27)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the median control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to imprecision: Confidence interval for the absolute effect includes small decrease and large increased risk. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Hormone therapy compared to placebo for secondary prevention of cardiovascular disease in post‐menopausal women</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/full#CD002229-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002229-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Hormone therapy commenced less than 10 years after the menopause for preventing cardiovascular disease in post‐menopausal women</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Hormone therapy commenced less than 10 years after the menopause for preventing cardiovascular disease in post‐menopausal women</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Post‐menopausal women<br/> <b>Intervention:</b> Hormone therapy commenced lessthan 10 years after the menopause </p> <p><b>Comparison</b>: Placebo or no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Hormone therapy commenced <br/> less than 10 years after the menopause</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Death (all‐causes)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.70</b> <br/> (0.52 to 0.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>9088<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>22 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>16 per 1000</b> <br/> (12 to 21) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Coronary heart disease (death from cardiovascular causes and non‐fatal myocardial infarction)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.52</b> <br/> (0.29 to 0.96) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8311<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b> <br/> (5 to 18) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Stroke</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.37</b> <br/> (0.80 to 2.34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8143<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>9 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b> <br/> (7 to 21) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Venous thromboembolism</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.74</b> <br/> (1.11 to 2.73) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>9838<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>11 per 1000</b> <br/> (7 to 17) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the median control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to risk of bias. The results are significant due to the DOPS 2012 trial, that has high risk of bias. We downgraded our confidence in the results of that metanalysis because, had the DOPS not been there, the metanalysis would not be significant.<br/> <sup>2</sup> Composite outcome. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Hormone therapy commenced less than 10 years after the menopause for preventing cardiovascular disease in post‐menopausal women</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/full#CD002229-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002229-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Hormone therapy commenced more than 10 years after the menopause for preventing cardiovascular disease in post‐menopausal women</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Hormone therapy commenced more than 10 years after the menopause for preventing cardiovascular disease in post‐menopausal women</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Post‐menopausal women </p> <p><b>Intervention:</b> Hormone therapy commenced less than 10 years after the menopause </p> <p><b>Comparison:</b> Placebo or no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Hormone therapy commenced <br/> morethan 10 years after the menopause</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Death (all‐causes)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 1.06</b> </p> <p>(0.95 to 1.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>27,750</p> <p>(12 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>45 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>47 per 1000</b> </p> <p>(42 to 53)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Coronary heart disease (death from cardiovascular causes and non‐fatal myocardial infarction)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 1.07</b> </p> <p>(0.96 to 1.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>23,491</p> <p>(12 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>49 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>52 per 1000</b> </p> <p>(47 to 59)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Stroke</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 1.21</b> </p> <p>(1.06 to 1.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>22,722</p> <p>(8 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>32 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>39 per 1000</b> </p> <p>(34 to 44)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Venous thromboembolism</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 1.96</b> </p> <p>(1.37 to 2.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>27,475</p> <p>(9 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/> <b>high</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>12 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>24 per 1000</b> </p> <p>(16 to 34)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the median control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>We did not downgrade for inconsistency. Although the I square indicated that there was a substantial amount of statistical variation (41%), the direction of effect across the results of the studies was consistent. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Hormone therapy commenced more than 10 years after the menopause for preventing cardiovascular disease in post‐menopausal women</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/full#CD002229-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD002229-tbl-0005"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Studies reviewed for relevant adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Population size</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Duration of follow‐up (years)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Included in Review</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Adverse events reported</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Death (all‐ causes)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Death (CV causes)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Non‐fatal MI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Stroke</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Angina</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Revascularisation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>VTE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PE</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0025" title="RowanJ , SimonJ , SperoffL , EllmanH . Effects of low‐dose norethindrone acetate plus ethinyl estradiol (0.5 mg/2.5 mug) in women with postmenopausal symptoms: Updated analysis of three randomized, controlled trials. Clinical Therapeutics2006;28(6):921‐32. SperoffL , RowanJ , SymonsJ , GenantH , WilbornW . The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study). A randomized controlled trial. JAMA1996;276(17):1397‐403. ">CHART 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1265</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bone mineral density</p> <p>Serum lipids (LDL, HDL, TG)</p> <p>Endometrial hyperplasia and proliferation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0098" title="deMaatM , MadsenJ , LangdahlB , BladbergE , ToftengC , et al. Genetic variation in estrogen receptor, C‐reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after long term hormone replacement therapy. Thrombosis and Haemostasis2007;97(2):234‐9. ">de Maat 2007</a>² </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>436</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CRP</p> <p>Fibrinogen</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0006" title="NachtigallLE , NachtigallRH , NachtigallRD , BeckmanEM . Estrogen replacement therapy II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstetrics Gynecology1979;54(1):74‐9. ">ERT II 1979</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>168</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0037" title="GenantHK , LucasJ , WeissS , AkinM , EmkeyR , McNaney‐FlintH , et al. Low‐dose esterified estrogen therapy. Archives of Internal Medicine1997;157:2609‐15. ">Genant 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>406</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bone mineral density</p> <p>Serum lipids</p> <p>Endometrial tissue structure</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> <p>(no events in placebo arm)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0009" title="GreenspanSL , ResnickNM , ParkerRA . The effect of hormone replacement on physical performance in community‐dwelling elderly women. The American Journal of Medicine2005;118:1232‐9. ">Greenspan 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>373</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to rise from a chair</p> <p>Timed walking</p> <p>Balance</p> <p>Instrumental Activities of Daily Living<br/> Physical Activity Scale of the Elderly<br/> Folstein Mini‐Mental State Examination<br/> Falls </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0039" title="HartD , FarishE , FletcherC , HowieC , KitchenerH . Ten years post‐menopausal hormone replacement therapy‐effect on lipoproteins. Maturitas1984;5(4):271‐6. ">Hart 1984</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bone mineral density</p> <p>Serum lipids</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0041" title="HeikkinenA , TuppurainenM , NiskanenL , KomulainenM , PenttilaI , SaarikoskiS . Long‐term vitamin D3 supplementation may have adverse effects on serum lipids during postmenopausal hormone replacement therapy. European Journal of Endocrinology1997;137(5):495‐502. ">Heikkinen 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>232</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serum lipids</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0045" title="LindsayR , GallagherJ , KleerekoperM , PickarH . Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA2002;287(20):2668‐76. LoboR , BushT , CarrB , PickarJ . Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertility and Sterility2001;76(1):13‐24. UtianW , ShoupeD , BachmannG , PinkertonJ , PickarJ . Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertility and Sterility2001;75(6):1065‐79. ">HOPE 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2673</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number and severity of hot flushes<br/> Papanicolaou smear with vaginal maturation index </p> <p>Bone mineral density</p> <p>Serum lipids</p> <p>Lipoproteins</p> <p>Glucose tolerance</p> <p>Coagulation/fibrinolytic factors</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0052" title="KimC , MinY , RyuW , KwakJ , RyooU . Effect of hormone replacement therapy on lipoprotein(a) and lipid levels in postmenopausal women: Influence of various progestogens and duration of therapy. Archives of Internal Medicine1996;156(15):1693‐1700. ">Kim 1996</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>551</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serum lipids,</p> <p>Lipoproteins</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0056" title="LeggateJ , FarishE , FletcherC , McIntoshW , HartD , SommervilleJM . Calcitonin and postmenopausal osteoporosis. Clinical Endocrinology1984;20(1):85‐92. ">Leggate 1984</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bone mineral density</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0068" title="BotsM , EvansG , RileyW , McBrideK , PaskettE , HelmondFA , et al. OPAL Investigators. The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on progression of carotid intima‐media thickness: The Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study. European Heart Journal2006;27(6):746‐55. MeijerR , StörkS , EvansGW , GrobbeeDE , BotsML . Striking increases in carotid artery wall thickness in healthy subjects. Cerebrovascular Diseases2010;30(5):448‐55. ">OPAL 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>571</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in carotid intima media thickness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> <p>(no events in one group)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓*</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0070" title="Barrett‐ConnorE , SloneS , GreendaleG , Kritz‐SilversteinD , EspelandM , JohnsonS , et al. The Postmenopausal Estrogen/Progestin Interventions Study: primary outcomes in adherent women. Maturitas1997;27(3):261‐74. EspelandM , HoganP , FinebergS , HowardG , SchrottH , WaclawiwM , et al. Effect of postmenopausal hormone therapy on glucose and insulin concentrations. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions. Diabetes Care1998;21(10):1589‐95. EspelandM , MarcovinaS , MillerV , WoodP , WasilauskasC , SherwinR , et al. Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions. Circulation1998;97(10):979‐86. JohnsonS , Mebane‐SimsI , HoganP , SoyD . Recruitment of postmenopausal women in the PEPI Trial. Postmenopausal Estrogen/Progestin Interventions. Controlled Clinical Trials1995;16(Suppl 4):S20‐35. SmithN , WileyJ , LegaultC , RiceK , HeckbertS , PsatyB , et al. Effect of progestogen and progestogen type on hemostasis measures in postmenopausal women: the Postmenopausal Estrogen/Progestin Intervention (PEPI) Study. Menopause2008;15(6):1145‐50. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA1995;273(3):199‐208. ">PEPI 1995</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>875</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HDL</p> <p>Systolic blood pressure</p> <p>Serum insulin</p> <p>Serum glucose</p> <p>Fibrinogen</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> <p>(no events in some groups)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓*</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0076" title="GallagherJC , LindsayR , PanK , RyanKA , MirkinS , ChinesAA . Bazedoxifene/conjugated estrogens: Effects on bone mineral density and bone turnover markers in a double‐blind, randomised, placebo‐ and active‐controlled phase 3 study. Osteoporosis International2012;23(S2):S63‐S64. MirkinS , ArcherD , LoboR , PanK , ChinesA . Safety and tolerability of bazedoxifene/conjugated estrogens in postmenopausal women: Findings from a 1‐year, randomized, placebo‐ and active‐controlled, phase 3 TRIAL. Maturitas2012;71:S43‐S44. MirkinS , HarveyJ , PinkertonJ , PanK , ThompsonJ , ChinesA . The effects of bazedoxifene/conjugated estrogens on breast density in postmenopausal women. Maturitas2012;71:S44. MirkinS , RyanK , ThompsonJ , ChinesA . Effects of bazedoxifene/conjugated estrogens on coagulation parameters in a 1‐year, randomized, placebo‐and active‐controlled, phase 3 trial of postmenopausal women. Endocrine Reviews2012;33:3 Meeting Abstracts. ">SMART‐5 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>503</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endometrial hyperplasia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> <p>(no events in one group)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓✝</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0079" title="StevensonJ , RiouxJ , KomerL , GelfandM . 1 and 2 mg 17beta‐estradiol combined with sequential dydrogesterone have similar effects on the serum lipid profile of postmenopausal women. Climacteric2005;8(4):352‐9. ">Stevenson 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>579</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serum lipids</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0012" title="GallagherJ , RapuriB , HaynatzkiG , DetterR . Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. The Journal of Clinical Endocrinology and Metabolism2002;87(11):4914‐23. GallagherJC , FowlerSE , DetterJR , ShermanSS . Combination treatment with estrogen and calcitriol in the prevention of age‐related bone loss. The Journal of Clinical Endocrinology and Metabolism2001;86(8):3618‐28. RapuriP , GallagherJ , KnezeticJ , HaynatzkaV . Estrogen receptor alpha gene polymorphisms are associated with changes in bone remodeling markers and treatment response to estrogen. Maturitas2006;53(4):371‐9. SaiA , GallagherJ , FangX . Effect of hormone therapy and calcitriol on serum lipid profile in postmenopausal older women: association with estrogen receptor‐alpha genotypes. Menopause2011;18(10):1101‐12. YalamanchiliV , GallagherJ . Treatment with hormone therapy and calcitriol did not affect depression in older postmenopausal women: no interaction with estrogen and vitamin D receptor genotype polymorphisms. Menopause2012;19(6):697‐703. ">STOP IT 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>369</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bone mineral density</p> <p>Serum 25‐hydroxyvitamin D</p> <p>Serum lipids</p> <p>Depression</p> <p>Calcium absorption</p> <p>Serum PTH</p> <p>Osteocalcin</p> <p>Urinary N ‐telopeptides/creatinine ratio</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0143" title="ToftengC , JensenJ , AbrahamsenB , OdumL , BrotC . Two Polymorphisms in the Vitamin D Receptor Gene—Association With Bone Mass and 5‐Year Change in BoneMass With or Without Hormone‐Replacement Therapy inPostmenopausal Women: The Danish OsteoporosisPrevention Study. Journal of Bone and Mineral Research2002;17(8):1535‐44. ">Tofteng 2002</a>² </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>429</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bone mineral density</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0014" title="HodisHN , MackWJ , AzenSP , LoboRA , ShoupeD , MahrerPR , et al. Hormone therapy and the progression of coronary‐artery atherosclerosis in postmenopausal women. New England Journal of Medicine2003;349(6):535‐45. ">WELL‐HART 2003</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>226</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in coronary stenosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓*</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0018" title="CollinsP , FlatherM , LeesB , MisterR , ProudlerA , StevensonJC , WHISP (Women's Hormone Intervention Secondary Prevention Study) Pilot Study Investigators. Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study. European Heart Journal2006;27(17):2046‐53. ">WHISP 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.58</p> <p>(7 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serum lipids</p> <p>Antithrombin</p> <p>Factor VII</p> <p>Fibrinogen</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓¹</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓¹</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="13" rowspan="1" valign=""> <p>*Part of a composite endpoint.</p> <p>✝In a non‐relevant treatment group (bazedoxifene and oestrogen).</p> <p>¹Not included in analysis as no event in one of the groups.</p> <p>²Sub‐study of <a href="./references#CD002229-bbs2-0001" title="BladbjergE , MadsenJ , KristensenS , AbrahamsenB , BrixenK , MosekildeL , et al. Effect of long‐term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. Journal of Thrombosis and Haemostasis2003;1(6):1208‐14. KristensenS , AbrahamsenB , MadsenJ , GramJ , RejnmarkL , RudB , et al. Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: results from the Danish Osteoporosis Prevention Study (DOPS). Thrombosis and Haemostasis2006;95:915‐6. MadsenJ , KristensenS , GramJ , BladbjergE , HenriksenF , ChristensenK , et al. Positive impact of hormone replacement therapy on the fibrinolytic system: a long‐term randomized controlled study in healthy postmenopausal women. Journal of Thrombosis and Haemostasis2003;1(9):1984‐91. SchierbeckL , RejnmarkL , ToftengC , StilgrenL , EikenP , MosekildeL , et al. Hormone replacement treatment in early postmenopausal women reduces cardiovascular events ‐ A randomized controlled study. Circulation2011;124:A11380. SchierbeckLL , RejnmarkL , ToftengCL , StilgrenL , EikenP , MosekildeL , et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ2012;345:e6409. ToftengC , JensenJ , AbrahamsenB , OdumL , BrotC . Two polymorphisms in the vitamin D receptor gene‐association with bone mass and 5‐year change in bone mass with or without hormone‐replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study. Journal of Bone and Mineral Research2002;17(8):1535‐44. deMaatM , MadsenJ , LangdalB , BladbjergE , ToftengC , AbrahamsenL , et al. Genetic variation in estrogen receptor, C‐reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. Thrombosis and Haemostasis2007;97(2):234‐9. ">DOPS 2012</a> </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Studies reviewed for relevant adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/full#CD002229-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD002229-tbl-0006"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary of trial characteristics</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Trial (year)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Country</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Length of follow‐up (years)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> No. participants</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Mean age of participants (years)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> % hysterectomy</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Primary or secondary prevention</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> HT type</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Participant previous indication</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0001" title="BladbjergE , MadsenJ , KristensenS , AbrahamsenB , BrixenK , MosekildeL , et al. Effect of long‐term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. Journal of Thrombosis and Haemostasis2003;1(6):1208‐14. KristensenS , AbrahamsenB , MadsenJ , GramJ , RejnmarkL , RudB , et al. Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: results from the Danish Osteoporosis Prevention Study (DOPS). Thrombosis and Haemostasis2006;95:915‐6. MadsenJ , KristensenS , GramJ , BladbjergE , HenriksenF , ChristensenK , et al. Positive impact of hormone replacement therapy on the fibrinolytic system: a long‐term randomized controlled study in healthy postmenopausal women. Journal of Thrombosis and Haemostasis2003;1(9):1984‐91. SchierbeckL , RejnmarkL , ToftengC , StilgrenL , EikenP , MosekildeL , et al. Hormone replacement treatment in early postmenopausal women reduces cardiovascular events ‐ A randomized controlled study. Circulation2011;124:A11380. SchierbeckLL , RejnmarkL , ToftengCL , StilgrenL , EikenP , MosekildeL , et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ2012;345:e6409. ToftengC , JensenJ , AbrahamsenB , OdumL , BrotC . Two polymorphisms in the vitamin D receptor gene‐association with bone mass and 5‐year change in bone mass with or without hormone‐replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study. Journal of Bone and Mineral Research2002;17(8):1535‐44. deMaatM , MadsenJ , LangdalB , BladbjergE , ToftengC , AbrahamsenL , et al. Genetic variation in estrogen receptor, C‐reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. Thrombosis and Haemostasis2007;97(2):234‐9. ">DOPS 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Denmark</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1006</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single and combination</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0002" title="Ouyang P , TardifJ , HerringtonD , StewartK , ThompsonP , WalshM , et al. Randomized trial of hormone therapy in women after coronary bypass surgery: Evidence of differential effect of hormone therapy on angiographic progression of disease in saphenous vein grafts and native coronary arteries. Atherosclerosis2006;189(2):375‐86. ">EAGAR 2006</a><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CAGB</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0003" title="HodisH , MackW , LoboR , MahrerP , LiuC R , LiuC H . Estrogen replacement therapy effects on the progression of subclinical atherosclerosis are mediated by lipids but not by carbohydrate metabolic factors: results from the Estrogen in the Prevention of Athersclerosis Trial (EPAT). Circulation2002;106(19 Suppl II):II‐744. HodisHN , MackWJ , LoboRA , ShoupeD , SevanianA , MahrerPR , et al. Estrogen in the prevention of atherosclerosis. A randomized, double‐blind, placebo‐controlled trial. Annals of Internal Medicine2001;135(11):939‐53. ">EPAT 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>222</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0004" title="HemminkiE , HoviS , VeerusP , SevónT , TuimalaR , RahuM , et al. Blinding decreased recruitment in a prevention trial of postmenopausal women. Journal of Clinical Epidemiology2004;57:1237‐43. VeerusP , FischerK , HoviS‐L , KarroH , RahuM , HemminkiE . Symptom reporting and quality of life in the Estonian Postmenopausal Hormone Therapy Trial. BMC Women’s Health2008;8:5. VeerusP , HoviS , FischerK , RahuM , HakamaM , HemminkiE . Results for the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]. Maturitas2006;55(2):162‐73. ">EPHT 2006</a><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Estonia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>777</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combination</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0005" title="HerringtonDM , ReboussinDM , Bridget BrosnihanK , SharpPC , ShumakerSA , SnyderTE , et al. Effects of estrogen replacement on the progression of coronary‐artery atherosclerosis. New England Journal of Medicine2000;343(8):522‐9. HerringtonDM , ReboussinDM , KleinKP , SharpPC , ShumakerSA , SnyderTE , et al. The estrogen replacement and atherosclerosis (ERA) study: study design and baseline characteristics of the cohort. Controlled Clinical Trials2000;21(3):257‐85. NairG , HerringtonD . The ERA trial: findings and implications for the future. Climacteric2000;3:227‐32. ">ERA 2000</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>310</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single and combination</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CHD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0006" title="NachtigallLE , NachtigallRH , NachtigallRD , BeckmanEM . Estrogen replacement therapy II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstetrics Gynecology1979;54(1):74‐9. ">ERT II 1979</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>168</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combination</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0007" title="The ESPRIT Team. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet2002;360:2001‐8. ">ESPRIT 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 .0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MI or TIA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0008" title="HoibraatenE , ArnesenH , LarsenS , WickstromE , SandsetPM . Increased risk of recurrent venous thromboembolism during hormone replacement therapy: results of the randomized, double blind, placebo‐controlled estrogen in venous thromboembolism trial (EVTET). Thrombosis and Haemostasis2000;84:961‐7. Qvigtad , HoibraatenH , ArnesenH , LarsenS , WickstromE , SandsetP . Recurrent venous thromboembolism during hormone replacement therapy ‐ results of the estrogen in venous thromboembolism trial. XVI FIGO World Congress of O and G2000;Abstract book 1:58. ">EVTET 2000</a><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Norway</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>140</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combination</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DVT or PE</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0012" title="GallagherJ , RapuriB , HaynatzkiG , DetterR . Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. The Journal of Clinical Endocrinology and Metabolism2002;87(11):4914‐23. GallagherJC , FowlerSE , DetterJR , ShermanSS . Combination treatment with estrogen and calcitriol in the prevention of age‐related bone loss. The Journal of Clinical Endocrinology and Metabolism2001;86(8):3618‐28. RapuriP , GallagherJ , KnezeticJ , HaynatzkaV . Estrogen receptor alpha gene polymorphisms are associated with changes in bone remodeling markers and treatment response to estrogen. Maturitas2006;53(4):371‐9. SaiA , GallagherJ , FangX . Effect of hormone therapy and calcitriol on serum lipid profile in postmenopausal older women: association with estrogen receptor‐alpha genotypes. Menopause2011;18(10):1101‐12. YalamanchiliV , GallagherJ . Treatment with hormone therapy and calcitriol did not affect depression in older postmenopausal women: no interaction with estrogen and vitamin D receptor genotype polymorphisms. Menopause2012;19(6):697‐703. ">STOP IT 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>366</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single and combination</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0009" title="GreenspanSL , ResnickNM , ParkerRA . The effect of hormone replacement on physical performance in community‐dwelling elderly women. The American Journal of Medicine2005;118:1232‐9. ">Greenspan 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>373</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single and combination</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0010" title="HallG , PrippU , Schenk‐GustafssonK , LandgrenBM . Long‐term effects of hormone replacement therapy on symptoms of angina pectoris, quality of life and compliance in women with coronary artery disease. Maturitas1998 ;28 :235‐42 . ">HALL 1998</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sweden</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combination</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CHD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0011" title="Bibbins‐DomingoK , LinF , VittinghoffE , Barrett‐ConnorE , HulleyS , GradyD , et al. Effect of hormone therapy on mortality rates among women with heart failure and coronary artery disease. American Journal of Cardiology2005;95(2):289‐91. GiddingsL . Oestrogen plus progestin increased venous thromboembolic disease in postmenopausal women with coronary artery disease. Evidence Based Nursing2000;3(4):123. GradyD , ApplegateW , BushT , FurbergC , RiggsB , HulleyS , et al. Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics. Controlled Clinical Trials1998;19(4):314‐35. GradyD , HerringtonD , BittnerV , DavidsonM , HlatkyM , HsiaJ , et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study Follow‐up (HERS II). JAMA2002;288(1):49‐57. GradyD , WengerN , HerringtonD , KhanS , FurbergC , Hunninghake , et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. Annals of Internal Medicine2000;132:689‐96. HlatkyM , BoothroydD , VittinghoffE , SharpP , WhooleyMA . Quality‐of life and depressive symptoms in postmenopausal women after receiving hormone therapy. Results from the Heart and Estrogen/Progestin Replacement Study (HERS) Trial. JAMA2002;287(5):591‐7. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA1998;280(7):605‐13. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Obstetrical and Gynecological Survey1999;54(1):41‐2. KhanM , HlatkyM , LiuM , LinF , RogersW , ShlipakM . Effect of postmenopausal hormone therapy on coronary heart disease events after percutaneous transluminal coronary angioplasty. The American Journal of Cardiology2003;91(8):989‐91, A7. ShlipakM , SimonJ , VittinghoffE , LinF , Barrett‐ConnorE , KnoppR . Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA2000;283(14):1845‐52. SimonJA , HsiaJ , CauleyJA , RichardsC , HarrisF , FongJ , et al. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen‐progestin Replacement Study (HERS). Circulation2001;103(5):638‐42. SimonJA , LinF , VittinghoffE , BittnerV , Heart and Estrogen‐Progestin Replacement Study (HERS) Research Group. The relation of postmenopausal hormone therapy to serum uric acid and the risk of coronary heart disease events: The heart and estrogen‐progestin replacement study (HERS). Annals of Epidemiology2006;16(2):138‐45. SperoffL . The heart and estrogen/progestin replacement study (HERS). Maturitas1998;31(1):9‐14. ">HERS I 1998</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2763</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combination</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CHD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0013" title="HsiaJ , AldermanEL , VerterJI , RogersWJ , ThompsonP , HowardBV , et al. Women’s angiographic vitamin and estrogen trial: design and methods. Controlled Clinical Trials2002;23:708‐27. WatersD , AldermanE , HsiaJ , HowardB , CobbF , RogersW , et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women. JAMA2001;288(19):2432‐40. ">WAVE 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>International</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>423</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combination</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CHD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0014" title="HodisHN , MackWJ , AzenSP , LoboRA , ShoupeD , MahrerPR , et al. Hormone therapy and the progression of coronary‐artery atherosclerosis in postmenopausal women. New England Journal of Medicine2003;349(6):535‐45. ">WELL‐HART 2003</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>226</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single and combination</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CHD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0015" title="KernanWN , BrassLM , ViscoliCM , SarrellPM , MakuchR , HorwitzRI . Estrogen after ischemic stroke: clinical basis and design of the Womens Estrogen for Stroke Trial. Journal of Stroke and Cerebrovascular Diseases1998;7(1):85‐95. ViscoliC , BrassL , Kernan , SarrelP , SuissaS , HorwitzR . Estrogen therapy and risk of cognitive decline: Results from the Women's Estrogen for Stroke Trial (WEST). American Journal of Obstetrics and Gynecology2005;192(2):387‐93. ViscoliCM , BrassLM , KernanWN , SarrelPM , SuissaS , HorwitzRI . A clinical trial of estrogen‐replacement therapy after ischemic stroke. New England Journal of Medicine2001;345(17):1243‐9. ">WEST 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>664</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MI or TIA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16,608</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combination</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10,739</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0018" title="CollinsP , FlatherM , LeesB , MisterR , ProudlerA , StevensonJC , WHISP (Women's Hormone Intervention Secondary Prevention Study) Pilot Study Investigators. Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study. European Heart Journal2006;27(17):2046‐53. ">WHISP 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.58 (7 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combination</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ACS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0019" title="VickersMR , MacLacLennanA , LawtonB , FordD , MartinJ , MeredithS , et al. WISDOM group. Main morbidities recorded in the women's international study of long duration estrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ2007;335(7613):239. VickersMR , MartinJ , MeadeTW , WISDOM study team. The Women’s international study of long‐duration of estrogen after menopause (WISDOM): a randomised controlled trial. BMC Women's Health2007;7:2. WeltonAJ , VickersMR , KimJ , FordD , LawtonBA , MacLennanAH , et al. WISDOM team. Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ2008;337:a1190. ">WISDOM 2007</a><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>International</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4385</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combination</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p><sup>1</sup> Trial stopped early due to publication of WHI I 2002 results<br/> <sup>2</sup> Trial stopped early due to publication of HER I 1998 results<br/> <sup>3</sup> Trial stopped early as the weighted log‐rank test statistic for breast cancer crossed designated stopping boundary, and global index supportive of finding of overall harm.<br/> <sup>4</sup> Trial stopped early as National Institutes of Health (NIH) concluded that conjugated equine oestrogen alone did not appear to affect the risk of heart disease, but was associated with a significant increase in the risk of stroke<br/> CABG: coronary artery bypass graft; CHD: Coronary heart disease; DVT: Deep vein thrombosis; MI: myocardial infarction; NR: not reported; PE: Pulmonary embolism; TIA: Transient ischaemic attack </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary of trial characteristics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/full#CD002229-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD002229-tbl-0007"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Medication adherence in the trials</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Adherence definition</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Assessment method</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> HR arm</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Placebo arm</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002229-bbs2-0001" title="BladbjergE , MadsenJ , KristensenS , AbrahamsenB , BrixenK , MosekildeL , et al. Effect of long‐term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. Journal of Thrombosis and Haemostasis2003;1(6):1208‐14. KristensenS , AbrahamsenB , MadsenJ , GramJ , RejnmarkL , RudB , et al. Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: results from the Danish Osteoporosis Prevention Study (DOPS). Thrombosis and Haemostasis2006;95:915‐6. MadsenJ , KristensenS , GramJ , BladbjergE , HenriksenF , ChristensenK , et al. Positive impact of hormone replacement therapy on the fibrinolytic system: a long‐term randomized controlled study in healthy postmenopausal women. Journal of Thrombosis and Haemostasis2003;1(9):1984‐91. SchierbeckL , RejnmarkL , ToftengC , StilgrenL , EikenP , MosekildeL , et al. Hormone replacement treatment in early postmenopausal women reduces cardiovascular events ‐ A randomized controlled study. Circulation2011;124:A11380. SchierbeckLL , RejnmarkL , ToftengCL , StilgrenL , EikenP , MosekildeL , et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ2012;345:e6409. ToftengC , JensenJ , AbrahamsenB , OdumL , BrotC . Two polymorphisms in the vitamin D receptor gene‐association with bone mass and 5‐year change in bone mass with or without hormone‐replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study. Journal of Bone and Mineral Research2002;17(8):1535‐44. deMaatM , MadsenJ , LangdalB , BladbjergE , ToftengC , AbrahamsenL , et al. Genetic variation in estrogen receptor, C‐reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. Thrombosis and Haemostasis2007;97(2):234‐9. ">DOPS 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0002" title="Ouyang P , TardifJ , HerringtonD , StewartK , ThompsonP , WalshM , et al. Randomized trial of hormone therapy in women after coronary bypass surgery: Evidence of differential effect of hormone therapy on angiographic progression of disease in saphenous vein grafts and native coronary arteries. Atherosclerosis2006;189(2):375‐86. ">EAGAR 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>% study medication</p> <p>taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pill counts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 80% up to 30 months of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 80% up to 30 months of treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0003" title="HodisH , MackW , LoboR , MahrerP , LiuC R , LiuC H . Estrogen replacement therapy effects on the progression of subclinical atherosclerosis are mediated by lipids but not by carbohydrate metabolic factors: results from the Estrogen in the Prevention of Athersclerosis Trial (EPAT). Circulation2002;106(19 Suppl II):II‐744. HodisHN , MackWJ , LoboRA , ShoupeD , SevanianA , MahrerPR , et al. Estrogen in the prevention of atherosclerosis. A randomized, double‐blind, placebo‐controlled trial. Annals of Internal Medicine2001;135(11):939‐53. ">EPAT 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>% study medication</p> <p>taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pill counts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Level of adherence 95% (87% of participants evaluated)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Level of adherence 92% (92% of participants evaluated)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0004" title="HemminkiE , HoviS , VeerusP , SevónT , TuimalaR , RahuM , et al. Blinding decreased recruitment in a prevention trial of postmenopausal women. Journal of Clinical Epidemiology2004;57:1237‐43. VeerusP , FischerK , HoviS‐L , KarroH , RahuM , HemminkiE . Symptom reporting and quality of life in the Estonian Postmenopausal Hormone Therapy Trial. BMC Women’s Health2008;8:5. VeerusP , HoviS , FischerK , RahuM , HakamaM , HemminkiE . Results for the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]. Maturitas2006;55(2):162‐73. ">EPHT 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 80% of prescribed</p> <p>treatment taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of collected/returned</p> <p>drugs and clinic reports</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 40% compliant at three years (estimated from graph)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 30% compliant at three years (estimated</p> <p>from graph)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0005" title="HerringtonDM , ReboussinDM , Bridget BrosnihanK , SharpPC , ShumakerSA , SnyderTE , et al. Effects of estrogen replacement on the progression of coronary‐artery atherosclerosis. New England Journal of Medicine2000;343(8):522‐9. HerringtonDM , ReboussinDM , KleinKP , SharpPC , ShumakerSA , SnyderTE , et al. The estrogen replacement and atherosclerosis (ERA) study: study design and baseline characteristics of the cohort. Controlled Clinical Trials2000;21(3):257‐85. NairG , HerringtonD . The ERA trial: findings and implications for the future. Climacteric2000;3:227‐32. ">ERA 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>% study medication</p> <p>taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pill counts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Level of adherence at 3.2 years:</p> <p>Women on single therapy (measured in 79%</p> <p>of participants): 74%; women on combination therapy (measured in 82% of participants): 84% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Level of adherence at 3.2 years:</p> <p>(measured in 80% of participants): 86%</p> <p> </p> <p>5 women initiated treatment outside study</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002229-bbs2-0006" title="NachtigallLE , NachtigallRH , NachtigallRD , BeckmanEM . Estrogen replacement therapy II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstetrics Gynecology1979;54(1):74‐9. ">ERT II 1979</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0007" title="The ESPRIT Team. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet2002;360:2001‐8. ">ESPRIT 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>“Regular tablet use”</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Self report to family doctor. Self report</p> <p>to study nurse at six weeks and whenever in contact with trial staff</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number non‐adherent:</p> <p>51% at 12 months</p> <p>57% at 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number non‐adherent:</p> <p>31% at 12 months</p> <p>37% at 24 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0008" title="HoibraatenE , ArnesenH , LarsenS , WickstromE , SandsetPM . Increased risk of recurrent venous thromboembolism during hormone replacement therapy: results of the randomized, double blind, placebo‐controlled estrogen in venous thromboembolism trial (EVTET). Thrombosis and Haemostasis2000;84:961‐7. Qvigtad , HoibraatenH , ArnesenH , LarsenS , WickstromE , SandsetP . Recurrent venous thromboembolism during hormone replacement therapy ‐ results of the estrogen in venous thromboembolism trial. XVI FIGO World Congress of O and G2000;Abstract book 1:58. ">EVTET 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002229-bbs2-0012" title="GallagherJ , RapuriB , HaynatzkiG , DetterR . Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. The Journal of Clinical Endocrinology and Metabolism2002;87(11):4914‐23. GallagherJC , FowlerSE , DetterJR , ShermanSS . Combination treatment with estrogen and calcitriol in the prevention of age‐related bone loss. The Journal of Clinical Endocrinology and Metabolism2001;86(8):3618‐28. RapuriP , GallagherJ , KnezeticJ , HaynatzkaV . Estrogen receptor alpha gene polymorphisms are associated with changes in bone remodeling markers and treatment response to estrogen. Maturitas2006;53(4):371‐9. SaiA , GallagherJ , FangX . Effect of hormone therapy and calcitriol on serum lipid profile in postmenopausal older women: association with estrogen receptor‐alpha genotypes. Menopause2011;18(10):1101‐12. YalamanchiliV , GallagherJ . Treatment with hormone therapy and calcitriol did not affect depression in older postmenopausal women: no interaction with estrogen and vitamin D receptor genotype polymorphisms. Menopause2012;19(6):697‐703. ">STOP IT 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not defined</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pill counts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65% at 36 months in those taking HRT</p> <p>62% at 36 months in those taking HRT + calcitriol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78% at 36 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002229-bbs2-0009" title="GreenspanSL , ResnickNM , ParkerRA . The effect of hormone replacement on physical performance in community‐dwelling elderly women. The American Journal of Medicine2005;118:1232‐9. ">Greenspan 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 80% of the medication ≥ 80% of the study period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0010" title="HallG , PrippU , Schenk‐GustafssonK , LandgrenBM . Long‐term effects of hormone replacement therapy on symptoms of angina pectoris, quality of life and compliance in women with coronary artery disease. Maturitas1998 ;28 :235‐42 . ">HALL 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p>Not reported </p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0011" title="Bibbins‐DomingoK , LinF , VittinghoffE , Barrett‐ConnorE , HulleyS , GradyD , et al. Effect of hormone therapy on mortality rates among women with heart failure and coronary artery disease. American Journal of Cardiology2005;95(2):289‐91. GiddingsL . Oestrogen plus progestin increased venous thromboembolic disease in postmenopausal women with coronary artery disease. Evidence Based Nursing2000;3(4):123. GradyD , ApplegateW , BushT , FurbergC , RiggsB , HulleyS , et al. Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics. Controlled Clinical Trials1998;19(4):314‐35. GradyD , HerringtonD , BittnerV , DavidsonM , HlatkyM , HsiaJ , et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study Follow‐up (HERS II). JAMA2002;288(1):49‐57. GradyD , WengerN , HerringtonD , KhanS , FurbergC , Hunninghake , et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. Annals of Internal Medicine2000;132:689‐96. HlatkyM , BoothroydD , VittinghoffE , SharpP , WhooleyMA . Quality‐of life and depressive symptoms in postmenopausal women after receiving hormone therapy. Results from the Heart and Estrogen/Progestin Replacement Study (HERS) Trial. JAMA2002;287(5):591‐7. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA1998;280(7):605‐13. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Obstetrical and Gynecological Survey1999;54(1):41‐2. KhanM , HlatkyM , LiuM , LinF , RogersW , ShlipakM . Effect of postmenopausal hormone therapy on coronary heart disease events after percutaneous transluminal coronary angioplasty. The American Journal of Cardiology2003;91(8):989‐91, A7. ShlipakM , SimonJ , VittinghoffE , LinF , Barrett‐ConnorE , KnoppR . Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA2000;283(14):1845‐52. SimonJA , HsiaJ , CauleyJA , RichardsC , HarrisF , FongJ , et al. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen‐progestin Replacement Study (HERS). Circulation2001;103(5):638‐42. SimonJA , LinF , VittinghoffE , BittnerV , Heart and Estrogen‐Progestin Replacement Study (HERS) Research Group. The relation of postmenopausal hormone therapy to serum uric acid and the risk of coronary heart disease events: The heart and estrogen‐progestin replacement study (HERS). Annals of Epidemiology2006;16(2):138‐45. SperoffL . The heart and estrogen/progestin replacement study (HERS). Maturitas1998;31(1):9‐14. ">HERS I 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Taking at least 80%</p> <p>of study medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pill counts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82% adherent at one year; 75% adherent at three years</p> <p> </p> <p>3% initiated treatment outside study</p> <p> </p> <p>About 50% continued to use open‐label HT during unblinded follow‐up (4.2 to 6.8 years)</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91% adherent at one year;  81% adherent</p> <p>at three years</p> <p> </p> <p>Under 10% used HRT during unblinded follow‐up (4.2 to 6.8 years)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0013" title="HsiaJ , AldermanEL , VerterJI , RogersWJ , ThompsonP , HowardBV , et al. Women’s angiographic vitamin and estrogen trial: design and methods. Controlled Clinical Trials2002;23:708‐27. WatersD , AldermanE , HsiaJ , HowardB , CobbF , RogersW , et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women. JAMA2001;288(19):2432‐40. ">WAVE 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>% study medication</p> <p>taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pill counts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 2.8 years:</p> <p>Adherence 67% in the 78% of women analysed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 2.8 years:</p> <p>Adherence 70% in the 81% of women analysed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002229-bbs2-0014" title="HodisHN , MackWJ , AzenSP , LoboRA , ShoupeD , MahrerPR , et al. Hormone therapy and the progression of coronary‐artery atherosclerosis in postmenopausal women. New England Journal of Medicine2003;349(6):535‐45. ">WELL‐HART 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>% study medication</p> <p>taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pill counts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oestrogen group: 92.6% with oestrogen and 99.9% with progestin matched placebo</p> <p>Oestrogen‐Progestin group: 94.1% with oestrogen and 96.1% with progestin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93.6% with oestrogen matched placebo and 98.4% with progestin matched placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0015" title="KernanWN , BrassLM , ViscoliCM , SarrellPM , MakuchR , HorwitzRI . Estrogen after ischemic stroke: clinical basis and design of the Womens Estrogen for Stroke Trial. Journal of Stroke and Cerebrovascular Diseases1998;7(1):85‐95. ViscoliC , BrassL , Kernan , SarrelP , SuissaS , HorwitzR . Estrogen therapy and risk of cognitive decline: Results from the Women's Estrogen for Stroke Trial (WEST). American Journal of Obstetrics and Gynecology2005;192(2):387‐93. ViscoliCM , BrassLM , KernanWN , SarrelPM , SuissaS , HorwitzRI . A clinical trial of estrogen‐replacement therapy after ischemic stroke. New England Journal of Medicine2001;345(17):1243‐9. ">WEST 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>% study medication</p> <p>taken</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Self report to study</p> <p>nurse three‐monthly</p> <p> </p> <p>Computer chip in medication</p> <p>bottle records opening date and time</p> <p> </p> <p>Pill counts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 2.8 years:</p> <p>Mean adherence including drop‐outs: 70%</p> <p>Mean adherence excluding dropouts: 90%</p> <p>35% discontinued medication by 2.8 years, of whom 1% initiated treatment outside study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 2.8 years: Mean adherence including dropouts: 74% over 2.8 years</p> <p>Mean adherence excluding dropouts: 90%</p> <p>24% discontinued medication</p> <p> </p> <p>2% initiated treatment outside study</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Taking at least 80% of study medication</p> <p>Temporary</p> <p>discontinuation (e.g. during surgery) permitted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Weighing medication bottles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42% non‐adherent by 5.2 years</p> <p> </p> <p>Of these 6.2% initiated HRT outside study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38% non‐adherent by 5.2 years</p> <p> </p> <p>Of these 10.7% initiated HRT outside study</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Taking at least 80%</p> <p>of study medication</p> <p>Temporary</p> <p>discontinuation (e.g. during surgery) permitted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Weighing medication bottles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 6.8 years, about 53.8% of women were non‐adherent</p> <p> </p> <p>In addition 5.7% of women had initiated hormone use through their own physician</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 6.8 years, about 53.8% of women were non‐adherent</p> <p> </p> <p>In addition 9.1% of women had initiated hormone use through their own physician</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002229-bbs2-0018" title="CollinsP , FlatherM , LeesB , MisterR , ProudlerA , StevensonJC , WHISP (Women's Hormone Intervention Secondary Prevention Study) Pilot Study Investigators. Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study. European Heart Journal2006;27(17):2046‐53. ">WHISP 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not specified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not specified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 out of 49 discontinued study drug (51%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 out of 51 discontinued study drug (27%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0019" title="VickersMR , MacLacLennanA , LawtonB , FordD , MartinJ , MeredithS , et al. WISDOM group. Main morbidities recorded in the women's international study of long duration estrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ2007;335(7613):239. VickersMR , MartinJ , MeadeTW , WISDOM study team. The Women’s international study of long‐duration of estrogen after menopause (WISDOM): a randomised controlled trial. BMC Women's Health2007;7:2. WeltonAJ , VickersMR , KimJ , FordD , LawtonBA , MacLennanAH , et al. WISDOM team. Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ2008;337:a1190. ">WISDOM 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Supply of study</p> <p>medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time at risk minus temporary interruptions and time after withdrawal from treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73% of time</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86% of time</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>HRT: hormone replacement therapy</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Medication adherence in the trials</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/full#CD002229-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD002229-tbl-0008"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Summary of outcomes by trials ‐ primary prevention</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Outcome </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Death</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Death (CV causes)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Non‐fatal MI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Stroke</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Angina</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Venous thromboembolism</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Pulmonary embolism</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Revascularisation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0001" title="BladbjergE , MadsenJ , KristensenS , AbrahamsenB , BrixenK , MosekildeL , et al. Effect of long‐term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. Journal of Thrombosis and Haemostasis2003;1(6):1208‐14. KristensenS , AbrahamsenB , MadsenJ , GramJ , RejnmarkL , RudB , et al. Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: results from the Danish Osteoporosis Prevention Study (DOPS). Thrombosis and Haemostasis2006;95:915‐6. MadsenJ , KristensenS , GramJ , BladbjergE , HenriksenF , ChristensenK , et al. Positive impact of hormone replacement therapy on the fibrinolytic system: a long‐term randomized controlled study in healthy postmenopausal women. Journal of Thrombosis and Haemostasis2003;1(9):1984‐91. SchierbeckL , RejnmarkL , ToftengC , StilgrenL , EikenP , MosekildeL , et al. Hormone replacement treatment in early postmenopausal women reduces cardiovascular events ‐ A randomized controlled study. Circulation2011;124:A11380. SchierbeckLL , RejnmarkL , ToftengCL , StilgrenL , EikenP , MosekildeL , et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ2012;345:e6409. ToftengC , JensenJ , AbrahamsenB , OdumL , BrotC . Two polymorphisms in the vitamin D receptor gene‐association with bone mass and 5‐year change in bone mass with or without hormone‐replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study. Journal of Bone and Mineral Research2002;17(8):1535‐44. deMaatM , MadsenJ , LangdalB , BladbjergE , ToftengC , AbrahamsenL , et al. Genetic variation in estrogen receptor, C‐reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. Thrombosis and Haemostasis2007;97(2):234‐9. ">DOPS 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0003" title="HodisH , MackW , LoboR , MahrerP , LiuC R , LiuC H . Estrogen replacement therapy effects on the progression of subclinical atherosclerosis are mediated by lipids but not by carbohydrate metabolic factors: results from the Estrogen in the Prevention of Athersclerosis Trial (EPAT). Circulation2002;106(19 Suppl II):II‐744. HodisHN , MackWJ , LoboRA , ShoupeD , SevanianA , MahrerPR , et al. Estrogen in the prevention of atherosclerosis. A randomized, double‐blind, placebo‐controlled trial. Annals of Internal Medicine2001;135(11):939‐53. ">EPAT 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0004" title="HemminkiE , HoviS , VeerusP , SevónT , TuimalaR , RahuM , et al. Blinding decreased recruitment in a prevention trial of postmenopausal women. Journal of Clinical Epidemiology2004;57:1237‐43. VeerusP , FischerK , HoviS‐L , KarroH , RahuM , HemminkiE . Symptom reporting and quality of life in the Estonian Postmenopausal Hormone Therapy Trial. BMC Women’s Health2008;8:5. VeerusP , HoviS , FischerK , RahuM , HakamaM , HemminkiE . Results for the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]. Maturitas2006;55(2):162‐73. ">EPHT 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0006" title="NachtigallLE , NachtigallRH , NachtigallRD , BeckmanEM . Estrogen replacement therapy II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstetrics Gynecology1979;54(1):74‐9. ">ERT II 1979</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0009" title="GreenspanSL , ResnickNM , ParkerRA . The effect of hormone replacement on physical performance in community‐dwelling elderly women. The American Journal of Medicine2005;118:1232‐9. ">Greenspan 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0012" title="GallagherJ , RapuriB , HaynatzkiG , DetterR . Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. The Journal of Clinical Endocrinology and Metabolism2002;87(11):4914‐23. GallagherJC , FowlerSE , DetterJR , ShermanSS . Combination treatment with estrogen and calcitriol in the prevention of age‐related bone loss. The Journal of Clinical Endocrinology and Metabolism2001;86(8):3618‐28. RapuriP , GallagherJ , KnezeticJ , HaynatzkaV . Estrogen receptor alpha gene polymorphisms are associated with changes in bone remodeling markers and treatment response to estrogen. Maturitas2006;53(4):371‐9. SaiA , GallagherJ , FangX . Effect of hormone therapy and calcitriol on serum lipid profile in postmenopausal older women: association with estrogen receptor‐alpha genotypes. Menopause2011;18(10):1101‐12. YalamanchiliV , GallagherJ . Treatment with hormone therapy and calcitriol did not affect depression in older postmenopausal women: no interaction with estrogen and vitamin D receptor genotype polymorphisms. Menopause2012;19(6):697‐703. ">STOP IT 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0019" title="VickersMR , MacLacLennanA , LawtonB , FordD , MartinJ , MeredithS , et al. WISDOM group. Main morbidities recorded in the women's international study of long duration estrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ2007;335(7613):239. VickersMR , MartinJ , MeadeTW , WISDOM study team. The Women’s international study of long‐duration of estrogen after menopause (WISDOM): a randomised controlled trial. BMC Women's Health2007;7:2. WeltonAJ , VickersMR , KimJ , FordD , LawtonBA , MacLennanAH , et al. WISDOM team. Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ2008;337:a1190. ">WISDOM 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of trials</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>8</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>7</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>6</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>34,422</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>28,353</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>29,482</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>28,719</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>27,347</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>33,477</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>31,732</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>27,569</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p><sup>1</sup> No events in control group.<br/> CV: cardiovascular; MI: myocardial infarction </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Summary of outcomes by trials ‐ primary prevention</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/full#CD002229-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD002229-tbl-0009"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Summary of outcomes by trials ‐ secondary prevention</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Outcome </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Death</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Death (CV causes)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Non‐fatal MI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Stroke</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Angina</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Venous thromboembolism</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Pulmonary embolism</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Revascularisation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0002" title="Ouyang P , TardifJ , HerringtonD , StewartK , ThompsonP , WalshM , et al. Randomized trial of hormone therapy in women after coronary bypass surgery: Evidence of differential effect of hormone therapy on angiographic progression of disease in saphenous vein grafts and native coronary arteries. Atherosclerosis2006;189(2):375‐86. ">EAGAR 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0005" title="HerringtonDM , ReboussinDM , Bridget BrosnihanK , SharpPC , ShumakerSA , SnyderTE , et al. Effects of estrogen replacement on the progression of coronary‐artery atherosclerosis. New England Journal of Medicine2000;343(8):522‐9. HerringtonDM , ReboussinDM , KleinKP , SharpPC , ShumakerSA , SnyderTE , et al. The estrogen replacement and atherosclerosis (ERA) study: study design and baseline characteristics of the cohort. Controlled Clinical Trials2000;21(3):257‐85. NairG , HerringtonD . The ERA trial: findings and implications for the future. Climacteric2000;3:227‐32. ">ERA 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0007" title="The ESPRIT Team. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet2002;360:2001‐8. ">ESPRIT 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0008" title="HoibraatenE , ArnesenH , LarsenS , WickstromE , SandsetPM . Increased risk of recurrent venous thromboembolism during hormone replacement therapy: results of the randomized, double blind, placebo‐controlled estrogen in venous thromboembolism trial (EVTET). Thrombosis and Haemostasis2000;84:961‐7. Qvigtad , HoibraatenH , ArnesenH , LarsenS , WickstromE , SandsetP . Recurrent venous thromboembolism during hormone replacement therapy ‐ results of the estrogen in venous thromboembolism trial. XVI FIGO World Congress of O and G2000;Abstract book 1:58. ">EVTET 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0010" title="HallG , PrippU , Schenk‐GustafssonK , LandgrenBM . Long‐term effects of hormone replacement therapy on symptoms of angina pectoris, quality of life and compliance in women with coronary artery disease. Maturitas1998 ;28 :235‐42 . ">HALL 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0011" title="Bibbins‐DomingoK , LinF , VittinghoffE , Barrett‐ConnorE , HulleyS , GradyD , et al. Effect of hormone therapy on mortality rates among women with heart failure and coronary artery disease. American Journal of Cardiology2005;95(2):289‐91. GiddingsL . Oestrogen plus progestin increased venous thromboembolic disease in postmenopausal women with coronary artery disease. Evidence Based Nursing2000;3(4):123. GradyD , ApplegateW , BushT , FurbergC , RiggsB , HulleyS , et al. Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics. Controlled Clinical Trials1998;19(4):314‐35. GradyD , HerringtonD , BittnerV , DavidsonM , HlatkyM , HsiaJ , et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study Follow‐up (HERS II). JAMA2002;288(1):49‐57. GradyD , WengerN , HerringtonD , KhanS , FurbergC , Hunninghake , et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. Annals of Internal Medicine2000;132:689‐96. HlatkyM , BoothroydD , VittinghoffE , SharpP , WhooleyMA . Quality‐of life and depressive symptoms in postmenopausal women after receiving hormone therapy. Results from the Heart and Estrogen/Progestin Replacement Study (HERS) Trial. JAMA2002;287(5):591‐7. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA1998;280(7):605‐13. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Obstetrical and Gynecological Survey1999;54(1):41‐2. KhanM , HlatkyM , LiuM , LinF , RogersW , ShlipakM . Effect of postmenopausal hormone therapy on coronary heart disease events after percutaneous transluminal coronary angioplasty. The American Journal of Cardiology2003;91(8):989‐91, A7. ShlipakM , SimonJ , VittinghoffE , LinF , Barrett‐ConnorE , KnoppR . Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA2000;283(14):1845‐52. SimonJA , HsiaJ , CauleyJA , RichardsC , HarrisF , FongJ , et al. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen‐progestin Replacement Study (HERS). Circulation2001;103(5):638‐42. SimonJA , LinF , VittinghoffE , BittnerV , Heart and Estrogen‐Progestin Replacement Study (HERS) Research Group. The relation of postmenopausal hormone therapy to serum uric acid and the risk of coronary heart disease events: The heart and estrogen‐progestin replacement study (HERS). Annals of Epidemiology2006;16(2):138‐45. SperoffL . The heart and estrogen/progestin replacement study (HERS). Maturitas1998;31(1):9‐14. ">HERS I 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0013" title="HsiaJ , AldermanEL , VerterJI , RogersWJ , ThompsonP , HowardBV , et al. Women’s angiographic vitamin and estrogen trial: design and methods. Controlled Clinical Trials2002;23:708‐27. WatersD , AldermanE , HsiaJ , HowardB , CobbF , RogersW , et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women. JAMA2001;288(19):2432‐40. ">WAVE 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0014" title="HodisHN , MackWJ , AzenSP , LoboRA , ShoupeD , MahrerPR , et al. Hormone therapy and the progression of coronary‐artery atherosclerosis in postmenopausal women. New England Journal of Medicine2003;349(6):535‐45. ">WELL‐HART 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0015" title="KernanWN , BrassLM , ViscoliCM , SarrellPM , MakuchR , HorwitzRI . Estrogen after ischemic stroke: clinical basis and design of the Womens Estrogen for Stroke Trial. Journal of Stroke and Cerebrovascular Diseases1998;7(1):85‐95. ViscoliC , BrassL , Kernan , SarrelP , SuissaS , HorwitzR . Estrogen therapy and risk of cognitive decline: Results from the Women's Estrogen for Stroke Trial (WEST). American Journal of Obstetrics and Gynecology2005;192(2):387‐93. ViscoliCM , BrassLM , KernanWN , SarrelPM , SuissaS , HorwitzRI . A clinical trial of estrogen‐replacement therapy after ischemic stroke. New England Journal of Medicine2001;345(17):1243‐9. ">WEST 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002229-bbs2-0018" title="CollinsP , FlatherM , LeesB , MisterR , ProudlerA , StevensonJC , WHISP (Women's Hormone Intervention Secondary Prevention Study) Pilot Study Investigators. Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study. European Heart Journal2006;27(17):2046‐53. ">WHISP 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>✓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>X</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of trials</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>7</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>6</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>7</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>6</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5445</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5259</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5359</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5172</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3155</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4399</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3920</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3155</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p><sup>1</sup> No outcomes relevant to this review.<br/> CV: cardiovascular; MI: myocardial infarction </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Summary of outcomes by trials ‐ secondary prevention</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/full#CD002229-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD002229-tbl-0010"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Trials according to number of years since menopause when treatment commenced</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time since menopause (years)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean age (years)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>&lt; 10 years since menopause (or mean age &lt; 60)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002229-bbs2-0001" title="BladbjergE , MadsenJ , KristensenS , AbrahamsenB , BrixenK , MosekildeL , et al. Effect of long‐term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. Journal of Thrombosis and Haemostasis2003;1(6):1208‐14. KristensenS , AbrahamsenB , MadsenJ , GramJ , RejnmarkL , RudB , et al. Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: results from the Danish Osteoporosis Prevention Study (DOPS). Thrombosis and Haemostasis2006;95:915‐6. MadsenJ , KristensenS , GramJ , BladbjergE , HenriksenF , ChristensenK , et al. Positive impact of hormone replacement therapy on the fibrinolytic system: a long‐term randomized controlled study in healthy postmenopausal women. Journal of Thrombosis and Haemostasis2003;1(9):1984‐91. SchierbeckL , RejnmarkL , ToftengC , StilgrenL , EikenP , MosekildeL , et al. Hormone replacement treatment in early postmenopausal women reduces cardiovascular events ‐ A randomized controlled study. Circulation2011;124:A11380. SchierbeckLL , RejnmarkL , ToftengCL , StilgrenL , EikenP , MosekildeL , et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ2012;345:e6409. ToftengC , JensenJ , AbrahamsenB , OdumL , BrotC . Two polymorphisms in the vitamin D receptor gene‐association with bone mass and 5‐year change in bone mass with or without hormone‐replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study. Journal of Bone and Mineral Research2002;17(8):1535‐44. deMaatM , MadsenJ , LangdalB , BladbjergE , ToftengC , AbrahamsenL , et al. Genetic variation in estrogen receptor, C‐reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. Thrombosis and Haemostasis2007;97(2):234‐9. ">DOPS 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1006</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.59</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002229-bbs2-0006" title="NachtigallLE , NachtigallRH , NachtigallRD , BeckmanEM . Estrogen replacement therapy II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstetrics Gynecology1979;54(1):74‐9. ">ERT II 1979</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>168</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002229-bbs2-0004" title="HemminkiE , HoviS , VeerusP , SevónT , TuimalaR , RahuM , et al. Blinding decreased recruitment in a prevention trial of postmenopausal women. Journal of Clinical Epidemiology2004;57:1237‐43. VeerusP , FischerK , HoviS‐L , KarroH , RahuM , HemminkiE . Symptom reporting and quality of life in the Estonian Postmenopausal Hormone Therapy Trial. BMC Women’s Health2008;8:5. VeerusP , HoviS , FischerK , RahuM , HakamaM , HemminkiE . Results for the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]. Maturitas2006;55(2):162‐73. ">EPHT 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1178</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002229-bbs2-0008" title="HoibraatenE , ArnesenH , LarsenS , WickstromE , SandsetPM . Increased risk of recurrent venous thromboembolism during hormone replacement therapy: results of the randomized, double blind, placebo‐controlled estrogen in venous thromboembolism trial (EVTET). Thrombosis and Haemostasis2000;84:961‐7. Qvigtad , HoibraatenH , ArnesenH , LarsenS , WickstromE , SandsetP . Recurrent venous thromboembolism during hormone replacement therapy ‐ results of the estrogen in venous thromboembolism trial. XVI FIGO World Congress of O and G2000;Abstract book 1:58. ">EVTET 2000</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>140</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NK<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55.7</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5494</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 10 yrs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1643</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 10 yrs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TOTAL</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9629</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>≥ 10 years since menopause (or mean age ≥ 60)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002229-bbs2-0016" title="AndersonGI , MansonJ , WallaceR , LundB , HallD , DavisS , et al. Implementation of the womens health initiative study design. Annals of Epidemiology2003;13:S5‐17. CushmanM , KullerLH , PrenticeR , RodaboughRJ , PsatyBM , StaffordRS , et al. Estrogen plus progestin and risk of venous thrombosis. JAMA2004;292(13):1573‐80. HaysJ , HuntJR , Hubbell , FA , AndersonGL , LimacherM , AllenC , et al. The Women's Health Initiative recruitment methods and results. Annals of Epidemiology2003;13(Suppl 9):S18‐77. HaysJ , OckeneJK , BrunnerRL , KotchenJM , MansonJE , PattersonRE , et al. Effects of estrogen plus progestin on health‐related quality of life. New England Journal of Medicine2003;348(104):1839‐54. HeissG , WallaceR , AndersonGL , AragakiA , BeresfordSAA , BrzyskiR , et al. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA2008;299(9):1036–45. MansonJE , HsiaJ , JohnsonKC , RossouwJE , AssafA , LasserN , et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine2003;349(6):523‐34. RossouwJ , AndersonG , PrenticeR , LaCroixA , KooperbergC , StefanickM . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. RossouwJE , PrenticeRL , MansonJE , WuL , BaradD , BarnabeiVM , et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297(13):1465–77. StefanickML , CochraneBB , HsiaJ , BaradDH , LiuJH , JohnsonSR , et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Annals of Epidemiology2003;13(Suppl 9):S78‐86. The Womens Health Initiative Study Group. Design of the Womens Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Controlled Clinical Trials1998;19(1):61‐109. Wassertheil‐SmollerS , HendrixS , LimacherM , HeissG , KooperbergC , BairdA , et al. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA2003;289(20):2673‐84. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women's health initiative randomized controlled trial. JAMA2002;288(3):321‐33. ">WHI I 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9694</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002229-bbs2-0017" title="AndersonGL , LimacherM , AssafAR , BassfordT , BeresfordSA , BlackH , et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291(14):1701‐12. BrunnerRL , GassM , AragakiA , HaysJ , GranekI , WoodsN , et al. Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health‐related quality of life in postmenopausal women with hysterectomy. Archives of Internal Medicine2005;165(17):1976‐86. CurbJD , PrenticeRL , BrayPF , LangerRD , VanHornK , BarnabeiVM , et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of Internal Medicine2006;166(7):772‐80. HendrixSL , Wassertheil‐SmollerS , JohnsonKC , HowardBV , KooperbergC , RossouwJE , et al. WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation2006;113(20):2425‐34. HsiaJ , LangerR , MansonJ , KullerL , JohnsonK , HendrixS , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Archives of Internal Medicine2006;166(3):357‐65. HsiaJ , LangerRD , MansonJE , KullerL , JohnsonKC , HendrixSL , et al. Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease. Archives of Internal Medicine2006;291:1701‐12. ">WHI II 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7468</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002229-bbs2-0010" title="HallG , PrippU , Schenk‐GustafssonK , LandgrenBM . Long‐term effects of hormone replacement therapy on symptoms of angina pectoris, quality of life and compliance in women with coronary artery disease. Maturitas1998 ;28 :235‐42 . ">HALL 1998</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>373</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002229-bbs2-0019" title="VickersMR , MacLacLennanA , LawtonB , FordD , MartinJ , MeredithS , et al. WISDOM group. Main morbidities recorded in the women's international study of long duration estrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ2007;335(7613):239. VickersMR , MartinJ , MeadeTW , WISDOM study team. The Women’s international study of long‐duration of estrogen after menopause (WISDOM): a randomised controlled trial. BMC Women's Health2007;7:2. WeltonAJ , VickersMR , KimJ , FordD , LawtonBA , MacLennanAH , et al. WISDOM team. Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ2008;337:a1190. ">WISDOM 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4385</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002229-bbs2-0007" title="The ESPRIT Team. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet2002;360:2001‐8. ">ESPRIT 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002229-bbs2-0011" title="Bibbins‐DomingoK , LinF , VittinghoffE , Barrett‐ConnorE , HulleyS , GradyD , et al. Effect of hormone therapy on mortality rates among women with heart failure and coronary artery disease. American Journal of Cardiology2005;95(2):289‐91. GiddingsL . Oestrogen plus progestin increased venous thromboembolic disease in postmenopausal women with coronary artery disease. Evidence Based Nursing2000;3(4):123. GradyD , ApplegateW , BushT , FurbergC , RiggsB , HulleyS , et al. Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics. Controlled Clinical Trials1998;19(4):314‐35. GradyD , HerringtonD , BittnerV , DavidsonM , HlatkyM , HsiaJ , et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study Follow‐up (HERS II). JAMA2002;288(1):49‐57. GradyD , WengerN , HerringtonD , KhanS , FurbergC , Hunninghake , et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. Annals of Internal Medicine2000;132:689‐96. HlatkyM , BoothroydD , VittinghoffE , SharpP , WhooleyMA . Quality‐of life and depressive symptoms in postmenopausal women after receiving hormone therapy. Results from the Heart and Estrogen/Progestin Replacement Study (HERS) Trial. JAMA2002;287(5):591‐7. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA1998;280(7):605‐13. HulleyS , GradyD , BushT , FurbergC , HerringtonD , RiggsB , et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Obstetrical and Gynecological Survey1999;54(1):41‐2. KhanM , HlatkyM , LiuM , LinF , RogersW , ShlipakM . Effect of postmenopausal hormone therapy on coronary heart disease events after percutaneous transluminal coronary angioplasty. The American Journal of Cardiology2003;91(8):989‐91, A7. ShlipakM , SimonJ , VittinghoffE , LinF , Barrett‐ConnorE , KnoppR . Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA2000;283(14):1845‐52. SimonJA , HsiaJ , CauleyJA , RichardsC , HarrisF , FongJ , et al. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen‐progestin Replacement Study (HERS). Circulation2001;103(5):638‐42. SimonJA , LinF , VittinghoffE , BittnerV , Heart and Estrogen‐Progestin Replacement Study (HERS) Research Group. The relation of postmenopausal hormone therapy to serum uric acid and the risk of coronary heart disease events: The heart and estrogen‐progestin replacement study (HERS). Annals of Epidemiology2006;16(2):138‐45. SperoffL . The heart and estrogen/progestin replacement study (HERS). Maturitas1998;31(1):9‐14. ">HERS I 1998</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2763</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002229-bbs2-0014" title="HodisHN , MackWJ , AzenSP , LoboRA , ShoupeD , MahrerPR , et al. Hormone therapy and the progression of coronary‐artery atherosclerosis in postmenopausal women. New England Journal of Medicine2003;349(6):535‐45. ">WELL‐HART 2003</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>226</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002229-bbs2-0018" title="CollinsP , FlatherM , LeesB , MisterR , ProudlerA , StevensonJC , WHISP (Women's Hormone Intervention Secondary Prevention Study) Pilot Study Investigators. Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study. European Heart Journal2006;27(17):2046‐53. ">WHISP 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002229-bbs2-0005" title="HerringtonDM , ReboussinDM , Bridget BrosnihanK , SharpPC , ShumakerSA , SnyderTE , et al. Effects of estrogen replacement on the progression of coronary‐artery atherosclerosis. New England Journal of Medicine2000;343(8):522‐9. HerringtonDM , ReboussinDM , KleinKP , SharpPC , ShumakerSA , SnyderTE , et al. The estrogen replacement and atherosclerosis (ERA) study: study design and baseline characteristics of the cohort. Controlled Clinical Trials2000;21(3):257‐85. NairG , HerringtonD . The ERA trial: findings and implications for the future. Climacteric2000;3:227‐32. ">ERA 2000</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>309</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002229-bbs2-0015" title="KernanWN , BrassLM , ViscoliCM , SarrellPM , MakuchR , HorwitzRI . Estrogen after ischemic stroke: clinical basis and design of the Womens Estrogen for Stroke Trial. Journal of Stroke and Cerebrovascular Diseases1998;7(1):85‐95. ViscoliC , BrassL , Kernan , SarrelP , SuissaS , HorwitzR . Estrogen therapy and risk of cognitive decline: Results from the Women's Estrogen for Stroke Trial (WEST). American Journal of Obstetrics and Gynecology2005;192(2):387‐93. ViscoliCM , BrassLM , KernanWN , SarrelPM , SuissaS , HorwitzRI . A clinical trial of estrogen‐replacement therapy after ischemic stroke. New England Journal of Medicine2001;345(17):1243‐9. ">WEST 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>664</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002229-bbs2-0003" title="HodisH , MackW , LoboR , MahrerP , LiuC R , LiuC H . Estrogen replacement therapy effects on the progression of subclinical atherosclerosis are mediated by lipids but not by carbohydrate metabolic factors: results from the Estrogen in the Prevention of Athersclerosis Trial (EPAT). Circulation2002;106(19 Suppl II):II‐744. HodisHN , MackWJ , LoboRA , ShoupeD , SevanianA , MahrerPR , et al. Estrogen in the prevention of atherosclerosis. A randomized, double‐blind, placebo‐controlled trial. Annals of Internal Medicine2001;135(11):939‐53. ">EPAT 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>222</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NK<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62.2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002229-bbs2-0002" title="Ouyang P , TardifJ , HerringtonD , StewartK , ThompsonP , WalshM , et al. Randomized trial of hormone therapy in women after coronary bypass surgery: Evidence of differential effect of hormone therapy on angiographic progression of disease in saphenous vein grafts and native coronary arteries. Atherosclerosis2006;189(2):375‐86. ">EAGAR 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NK<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002229-bbs2-0013" title="HsiaJ , AldermanEL , VerterJI , RogersWJ , ThompsonP , HowardBV , et al. Women’s angiographic vitamin and estrogen trial: design and methods. Controlled Clinical Trials2002;23:708‐27. WatersD , AldermanE , HsiaJ , HowardB , CobbF , RogersW , et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women. JAMA2001;288(19):2432‐40. ">WAVE 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>423</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NK<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002229-bbs2-0012" title="GallagherJ , RapuriB , HaynatzkiG , DetterR . Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. The Journal of Clinical Endocrinology and Metabolism2002;87(11):4914‐23. GallagherJC , FowlerSE , DetterJR , ShermanSS . Combination treatment with estrogen and calcitriol in the prevention of age‐related bone loss. The Journal of Clinical Endocrinology and Metabolism2001;86(8):3618‐28. RapuriP , GallagherJ , KnezeticJ , HaynatzkaV . Estrogen receptor alpha gene polymorphisms are associated with changes in bone remodeling markers and treatment response to estrogen. Maturitas2006;53(4):371‐9. SaiA , GallagherJ , FangX . Effect of hormone therapy and calcitriol on serum lipid profile in postmenopausal older women: association with estrogen receptor‐alpha genotypes. Menopause2011;18(10):1101‐12. YalamanchiliV , GallagherJ . Treatment with hormone therapy and calcitriol did not affect depression in older postmenopausal women: no interaction with estrogen and vitamin D receptor genotype polymorphisms. Menopause2012;19(6):697‐703. ">STOP IT 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>489</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NK<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002229-bbs2-0009" title="GreenspanSL , ResnickNM , ParkerRA . The effect of hormone replacement on physical performance in community‐dwelling elderly women. The American Journal of Medicine2005;118:1232‐9. ">Greenspan 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>489</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NK<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71.2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TOTAL</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28705</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><sup>1</sup>Author contacted but data was not collected.<br/> <sup>2</sup>Author contacted; reported data available from National Institutes of Health (NIH) (who funded trial) but data currently pending.<br/> <sup>3</sup>Author emailed, but no reply. </p> <p>NK: not known</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Trials according to number of years since menopause when treatment commenced</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/full#CD002229-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002229-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Hormone therapy versus placebo in primary prevention</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death (all‐causes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34422</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.89, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Death (cardiovascular causes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28353</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.47, 1.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Non‐fatal myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29482</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.80, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28719</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [1.12, 1.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Angina <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27347</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.74, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Venous thromboembolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33477</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.92 [1.24, 2.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Pulmonary embolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31732</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.89 [1.17, 3.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Revascularisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27569</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.85, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Hormone therapy versus placebo in primary prevention</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/references#CD002229-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002229-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Hormone therapy versus placebo in secondary prevention</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death (all‐causes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5445</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.87, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Death (cardiovascular causes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.78, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Non‐fatal myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5359</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.81, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.89, 1.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Angina <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.74, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Venous thromboembolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4399</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.02 [1.13, 3.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Pulmonary embolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3920</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.48 [0.92, 6.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Revascularisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.63, 1.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Hormone therapy versus placebo in secondary prevention</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/references#CD002229-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002229-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Hormone therapy versus placebo in both primary and secondary prevention</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death (all‐causes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39868</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.92, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Death (cardiovascular causes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33613</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.78, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Non‐fatal myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34841</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.89, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [1.10, 1.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Angina <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30502</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.79, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Venous thromboembolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.92 [1.36, 2.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Pulmonary embolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36316</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.81 [1.32, 2.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Revascularisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30724</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.85, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Death (all‐causes): by year on treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 1‐year follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27347</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [0.93, 2.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 2‐year follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.72, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 3‐year follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.81, 1.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4 4‐year follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.76, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.5 5 year follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26827</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.66, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.6 6 year follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10427</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.81, 1.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.7 7‐year follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10333</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.67, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.8 8‐year follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.45, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Death (all‐causes): cumulatively by year on treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 1‐year follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31832</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.94, 2.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 2‐year follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28287</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.80, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 3‐year follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.96, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4 4‐year follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29773</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.95, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5 5 year follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26827</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.91, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.6 6 year follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10427</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.93, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.7 7‐year follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10333</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.93, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.8 8‐year follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.90, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.9 10‐year follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1174</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.31, 0.96]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Hormone therapy versus placebo in both primary and secondary prevention</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/references#CD002229-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002229-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Subgroup analysis of timing hypothesis (&lt;10 years versus &gt;10 years since menopause)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death (all‐causes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Hormone therapy commenced &lt;10 years after menopause</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9088</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.52, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Hormone therapy commenced &gt;10 years after menopause</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27750</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.95, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Coronary heart disease (death from cardiovascular causes and non‐fatal myocardial infarction) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Hormone therapy commenced &lt;10 years after menopause</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.29, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Hormone therapy commenced &gt;10 years after menopause</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23491</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.96, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Hormone therapy commenced &lt;10 years after menopause</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.80, 2.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Hormone therapy commenced &gt;10 years after menopause</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22722</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [1.06, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Venous thromboembolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Hormone therapy commenced &lt;10 years after menopause</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9838</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.74 [1.11, 2.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Hormone therapy commenced &gt;10 years after menopause</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27475</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.96 [1.37, 2.80]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Subgroup analysis of timing hypothesis (&lt;10 years versus &gt;10 years since menopause)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002229.pub4/references#CD002229-tbl-0014">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD002229.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD002229-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD002229-note-0007">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD002229-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD002229-note-0005">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD002229-note-0004">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ru#CD002229-note-0003">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD002229-note-0006">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD002229-note-0002">繁體中文</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD002229-note-0017">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002229\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002229\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002229\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002229\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002229\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002229\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002229\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002229\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002229\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002229\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002229\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002229\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002229\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002229\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002229\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002229\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002229\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002229\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=z6k50IFd&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002229.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002229.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD002229.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD002229.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002229.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714915342"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002229.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714915346"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002229.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d7a4e5a199368',t:'MTc0MDcxNDkxNS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 